Bicyclic sulfones and sulfoxides and methods of use thereof

ABSTRACT

The invention provides novel compounds having the general formula I: 
     
       
         
         
             
             
         
       
     
     wherein R 1 , R B1 , R B2 , n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No.62/579,392 filed Oct. 31, 2017 which is hereby incorporated by referencein its entirety.

FIELD OF THE INVENTION

The present invention relates to organic compounds useful for therapyand/or prophylaxis in a mammal, and in particular to inhibitors of RIP1kinase useful for treating diseases and disorders associated withinflammation, cell death and others.

BACKGROUND OF THE INVENTION

Receptor-interacting protein-1 (“RIP1”) kinase is a serine/threonineprotein kinase. RIP1 is a regulator of cell signaling that is involved,among other things, in the mediation of programmed cell death pathways,e.g., necroptosis. The best studied form of necroptotic cell death isinitiated by TNFα (tumor necrosis factor), but necroptosis can also beinduced by other members of the TNFα death ligand family (Fas andTRAIL/Apo2L), interferons, Toll-like receptors (TLRs) signaling andviral infection via the DNA sensor DAI (DNA-dependent activator ofinterferon regulatory factor) [1-3]. Binding of TNFα to the TNFR1 (TNFreceptor 1) prompts TNFR1 trimerization and formation of anintracellular complex, Complex-I. TRADD (TNF receptor associated deathdomain protein) binds to the intracellular death domain of TNFR1 andrecruits the protein kinase RIP1 (receptor-interacting protein 1)through the death domain present in both proteins [4]. Following initialrecruitment into TNFR1-associated signaling complex, RIP1 translocatesto a secondary cytoplasmatic complex, Complex-II [5-7]. Complex-II isformed by the death domain containing protein FADD (Fas-associatedProtein), RIP1, caspase-8 and cFLIP. If caspase-8 is not fully activatedor its activity is blocked, the protein kinase RIP3 gets recruited tothe complex, forming a necrosome, which will lead to necroptotic celldeath initiation [8-10]. Once the necrosome is formed, RIP1 and RIP3engage in a series of auto and cross phosphorylation events that areessential for necroptotic cell death. Necroptosis can be completelyblocked either by the kinase inactivating mutation in any of the twokinases, or chemically by RIP1 kinase inhibitors (necrostatins), or RIP3kinase inhibitors [11-13]. Phosphorylation of RIP3 allows the bindingand phosphorylation of pseudokinase MLKL (mixed lineage kinasedomain-like), a key component of necroptotic cell death [14, 15].

Necroptosis has crucial pathophysiological relevance in myocardialinfarction, stroke, atherosclerosis, ischemia-reperfusion injury,inflammatory bowel diseases, retinal degeneration and a number of othercommon clinical disorders [16]. Therefore, selective inhibitors of RIP1kinase activity are therefore desired as a potential treatment ofdiseases mediated by this pathway and associated with inflammationand/or necroptotic cell death.

Inhibitors of RIP1 kinase have been previously described. The firstpublished inhibitor of RIP1 kinase activity was necrostatin 1 (Nec-1)[17]. This initial discovery was followed by modified versions of Nec-1with various abilities to block RIP1 kinase activity [11, 18]. Recently,additional RIP1 kinase inhibitors have been described that differstructurally from necrostatin class of compounds [19, 20, 21].

References cited above, each of which is hereby incorporated byreference in its entirety:

-   1) Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S.,    Walczak, H. and Vandenabeele, P. (2014) Regulated necrosis: the    expanding network of non-apoptotic cell death pathways. Nature    reviews. Molecular cell biology. 15, 135-147.-   2) Newton, K. (2015) RIPK1 and RIPK3: critical regulators of    inflammation and cell death. Trends in cell biology. 25, 347-353.-   3) de Almagro, M. C. and Vucic, D. (2015) Necroptosis: Pathway    diversity and characteristics. Semin Cell Dev Biol. 39, 56-62.-   4) Chen, Z. J. (2012) Ubiquitination in signaling to and activation    of IKK. Immunological reviews. 246, 95-106.-   5) O'Donnell, M. A., Legarda-Addison, D., Skountzos, P., Yeh, W. C.    and Ting, A. T. (2007) Ubiquitination of RIP1 regulates an    NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol.    17, 418-424.-   6) Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P.,    Langlais, C., Hupe, M., Cain, K., MacFarlane, M., Hacker, G. and    Leverkus, M. (2011) cIAPs block Ripoptosome formation, a    RIP1/caspase-8 containing intracellular cell death complex    differentially regulated by cFLIP isoforms. Molecular cell. 43,    449-463.-   7) Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C.,    Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B.,    Morris, S. J. and Barker, P. A. (2008) cIAP1 and cIAP2 facilitate    cancer cell survival by functioning as E3 ligases that promote RIP1    ubiquitination. Mol Cell. 30, 689-700.-   8) Wang, L., Du, F. and Wang, X. (2008) TNF-alpha induces two    distinct caspase-8 activation pathways. Cell. 133, 693-703.-   9) He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L. and    Wang, X. (2009) Receptor interacting protein kinase-3 determines    cellular necrotic response to TNF-alpha. Cell. 137, 1100-1111.-   10) Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D.,    Guildford, M. and Chan, F. K. (2009) Phosphorylation-driven assembly    of the RIP1-RIP3 complex regulates programmed necrosis and    virus-induced inflammation. Cell. 137, 1112-1123.-   11) Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I. L., Korkina,    O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G.,    Hedrick, S. M., Gerber, S. A., Lugovskoy, A. and Yuan, J. (2008)    Identification of RIP1 kinase as a specific cellular target of    necrostatins. Nat Chem Biol. 4, 313-321.-   12) Newton, K., Dugger, D. L., Wickliffe, K. E., Kapoor, N., de    Almagro, M. C., Vucic, D., Komuves, L., Ferrando, R. E., French, D.    M., Webster, J., Roose-Girma, M., Warming, S. and    Dixit, V. M. (2014) Activity of protein kinase RIPK3 determines    whether cells die by necroptosis or apoptosis. Science. 343,    1357-1360.-   13) Kaiser, W. J., Sridharan, H., Huang, C., Mandal, P., Upton, J.    W., Gough, P. J., Sehon, C. A., Marquis, R. W., Bertin, J. and    Mocarski, E. S. (2013) Toll-like receptor 3-mediated necrosis via    TRIF, RIP3, and MLKL. The Journal of biological chemistry. 288,    31268-31279.-   14) Zhao, J., Jitkaew, S., Cai, Z., Choksi, S., Li, Q., Luo, J. and    Liu, Z. G. (2012) Mixed lineage kinase domain-like is a key receptor    interacting protein 3 downstream component of TNF-induced necrosis.    Proceedings of the National Academy of Sciences of the United States    of America. 109, 5322-5327.-   15) Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang,    L., Yan, J., Liu, W., Lei, X. and Wang, X. (2012) Mixed Lineage    Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of    RIP3 Kinase. Cell. 148, 213-227.-   16) Linkermann, A. and Green, D. R. (2014) Necroptosis. The New    England journal of medicine. 370, 455-465.-   17) Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P.,    Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A. and    Yuan, J. (2005) Chemical inhibitor of nonapoptotic cell death with    therapeutic potential for ischemic brain injury. Nat Chem Biol. 1,    112-119.-   18) Takahashi, N., Duprez, L., Grootjans, S., Cauwels, A., Nerinckx,    W., DuHadaway, J. B., Goossens, V., Roelandt, R., Van Hauwermeiren,    F., Libert, C., Declercq, W., Callewaert, N., Prendergast, G. C.,    Degterev, A., Yuan, J. and Vandenabeele, P. (2012) Necrostatin-1    analogues: critical issues on the specificity, activity and in vivo    use in experimental disease models. Cell Death Dis. 3, e437.-   19) Harris, P. A., Bandyopadhyay, D., Berger, S. B., Campobasso, N.,    Capriotti, C. A., Cox, J. A., Dare, L., Finger, J. N., Hoffman, S.    J., Kahler, K. M., Lehr, R., Lich, J. D., Nagilla, R., Nolte, R. T.,    Ouellette, M. T., Pao, C. S., Schaeffer, M. C., Smallwood, A.,    Sun, H. H., Swift, B. A., Totoritis, R. D., Ward, P., Marquis, R.    W., Bertin, J. and Gough, P. J. (2013) Discovery of Small Molecule    RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated    with Necroptosis. ACS medicinal chemistry letters. 4, 1238-1243.-   20) Najjar, M., Suebsuwong, C., Ray, S. S., Thapa, R. J., Maki, J.    L., Nogusa, S., Shah, S., Saleh, D., Gough, P. J., Bertin, J., Yuan,    J., Balachandran, S., Cuny, G. D. and Degterev, A. (2015) Structure    Guided Design of Potent and Selective Ponatinib-Based Hybrid    Inhibitors for RIPK1. Cell Rep.-   21) International Patent Publication No. WO 2014/125444.-   22) International Patent Publication No. WO 2017/004500.

SUMMARY OF THE INVENTION

Provided herein are compounds of formula I:

or a pharmaceutically acceptable salt thereof, wherein

-   R¹ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆    cycloalkyl, CH₂—(C₃-C₆ cycloalkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkyl,    C₁-C₆ haloalkoxy, C₁-C₆ alkyl-N(R^(N))₂, phenyl, benzyl, 4 to 8    membered heterocyclyl and 5 to 6 membered heteroaryl; and wherein R¹    is optionally substituted by one or two substituents selected from    the group consisting of halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl,    C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆    alkyl-N(R^(N))₂, hydroxyl, C₁-C₆ hydroxyalkyl, cyano,    C₁-C₆cyanoalkyl, C(O)C₁-C₆ alkyl, phenyl, benzyl, CH₂—(C₃-C₆    cycloalkyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6 membered    heteroaryl);    n is 0, 1 or 2;    each R² is independently selected from the group consisting of C₁-C₆    alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkyl; or two    R² together with the nitrogen atom to which they are both attached    form a 4-6 membered heterocyclic ring;    the A ring and the B ring are fused to form a polycyclic ring    system, wherein    the A ring is a 5 membered heteroaromatic ring having as its only    heteroatoms, either (i) two or three nitrogen atoms, (ii) one    nitrogen atom and one oxygen atom, or (iii) one nitrogen atom and    one sulfur atom; wherein the A ring is optionally substituted at a    carbon atom by one substituent selected from the group consisting of    fluoro, chloro, methyl, and trifluoromethyl; and    the B ring is a 4 to 8 membered carbocyclic ring, or a 4 to 8    membered heterocyclic ring having 1 to 3 heteroatoms selected from    the group consisting of nitrogen, oxygen, and sulfur;    -   p is 1 or 2, and q is 0 or 1; or p is 0, and q is 1;    -   wherein when p is 1, R^(B1) is R^(3a) and when p is 2, R^(B1) is        independently R^(3a) and R^(3b) and each R^(3a) and R^(3b), when        present, is/are independently selected from the group consisting        of halogen, deutero, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl,        C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆        thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano; wherein two C₁-C₆        alkyl substituents may together form a bridged or spirocyclic        ring; and wherein if a nitrogen atom in the B ring is        substituted, the substituent is not halogen, cyano, or a C₁-C₆        alkoxy, C₁-C₆ haloalkoxy or C₁-C₆ thioalkyl having an oxygen or        sulfur atom directly bonded to the nitrogen atom; and    -   wherein when q is 1, R^(B2) is R⁴ and R⁴ is selected from the        group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆        cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl,        C₁-C₆ alkyl-N(R²)₂, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl),        CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl),        CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered        heteroaryl, and CH₂-(5 to 6 membered heteroaryl);        -   wherein when R⁴ is phenyl, heteroaryl or benzyl the phenyl            or heteroaryl ring is optionally substituted by 1 to 3            substituents selected from the group consisting of halogen,            C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄            haloalkoxy, and cyano.

Also provided herein are pharmaceutical compositions comprising acompound of formula I, or a pharmaceutically acceptable salt thereof,and one or more pharmaceutically acceptable carriers or excipients.Specific embodiments include pharmaceutical compositions suitable fororal delivery.

Also provided herein are oral formulations of a compound of formula I,or a pharmaceutically acceptable salt thereof, and one or morepharmaceutically acceptable carriers or excipients suitable for oraldelivery.

Also provided herein are methods of treatment of diseases and disordersassociated with inflammation, cell death, and others related to RIP1kinase, as described further below.

Also provided herein are compounds or pharmaceutical compositions foruse as therapeutically active substances.

Also provided herein are uses of compounds or pharmaceuticalcompositions for use in the treatment of diseases and disordersassociated with inflammation, cell death, and others related to RIP1kinase, as described further below.

Also provided herein are uses of compounds or pharmaceuticalcompositions for the preparation of a medicament for the treatment ofdiseases and disorders associated with inflammation, cell death, andothers related to RIP1 kinase, as described further below.

Also provided herein are compounds or pharmaceutical compositions foruse in the treatment of diseases and disorders associated withinflammation, cell death, and others related to RIP1 kinase, asdescribed further below.

DETAILED DESCRIPTION OF THE INVENTION Definitions

As provided herein, all chemical formulae and generic chemicalstructures should be interpreted to provide proper valence andchemically stable bonds between atoms as understood by one of ordinaryskill in the art. Where appropriate, substituents may be bonded to morethan one adjacent atom (e.g., alkyl includes methylene where two bondsare present).

In the chemical formulae provided herein, “halogen” or “halo’ refers toflurorine, chlorine, and bromine (i.e., F, Cl, Br).

Alkyl, unless otherwise specifically defined, refers to an optionallysubstituted, straight-chain or branched C₁-C₁₂ alkyl group. In someembodiments, alkyl refers to a C₁-C₆ alkyl group. Exemplary alkyl groupsinclude methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl,tert-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, and n-oxtyl.Substituted alkyl groups provided herein are substituted by one or moresubstituents selected from the group consisting of halogen, cyano,trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy,C₃-C₆ cycloalkyl, phenyl, OH, CO₂H, CO₂(C₁-C₄ alkyl), NH₂, NH(C₁-C₄alkyl), N(C₁-C₄ alkyl)₂, NH(C═O)C₁-C₄ alkyl, (C═O)NH(C₁-C₄ alkyl),(C═O)N(C₁-C₄ alkyl)₂, S(C₁-C₄ alkyl), SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl),SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)₂, and NHSO₂(C₁-C₄ alkyl). In someembodiments, the substituted alkyl group has 1 or 2 substituents. Insome embodiments, the alkyl group is unsubstituted.

Cycloalkyl, unless otherwise specifically defined, refers to anoptionally substituted C₃-C₁₂ cycloalkyl group and includes fused,spirocyclic, and bridged bicyclic groups, wherein the substituents areselected from the group consisting of halogen, cyano, trifluoromethyl,methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, C₃-C₆ cycloalkyl,phenyl, OH, CO₂H, CO₂(C₁-C₄ alkyl), NH₂, NH(C₁-C₄ alkyl), N(C₁-C₄alkyl)₂, NH(C═O)C₁-C₄ alkyl, (C═O)NH(C₁-C₄ alkyl), (C═O)N(C₁-C₄ alkyl)₂,S(C₁-C₄ alkyl), SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl),SO₂N(C₁-C₄ alkyl)₂, and NHSO₂(C₁-C₄ alkyl). In some embodiments,cycloalkyl refers to a C₃-C₆ cycloalkyl group. In some embodiments, theC₃-C₆ cycloalkyl group is optionally substituted with 1 to three halogenatoms. In some embodiments, the C₃-C₆ cycloalkyl group is optionallysubstituted with 1 to three fluorine atoms. Exemplary C₃-C₆ cycloalkylgroups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.Exemplary C₃-C₁₂ cycloalkyl groups further include bicyclo[3.1.0]hexyl,bicyclo[2.1.1]hexyl, cycloheptyl, bicycle[4.1.0]heptyl,spiro[4.2]heptyl, cyclooctyl, spiro[4.3]octyl, spiro[5.2]octyl,bicyclo[2.2.1]heptanyl, bicycle[2.2.2]octanyl, adamantanyl, decalinyl,and spiro[5.4]decanyl. Where appropriate, cycloalkyl groups may be fusedto other groups such that more than one chemical bond exists between thecycloalkyl group and another ring system (e.g., the C ring of formulaI). In some embodiments, the cycloalkyl group is unsubstituted.

Haloalkyl, unless otherwise specifically defined, refers to astraight-chain or branched C₁-C₁₂ alkyl group, wherein one or morehydrogen atoms are replaced by a halogen. In some embodiments, haloalkylrefers to a C₁-C₆ haloalkyl group. In some embodiments, 1 to 3 hydrogenatoms of the haloalkyl group are replaced by a halogen. In someembodiments, every hydrogen atom of the haloalkyl group is replaced by ahalogen (e.g, trifluoromethyl). In some embodiments, the haloalkyl is asdefined herein wherein the halogen in each instance is fluorine.Exemplary haloalkyl groups include fluoromethyl, difluoromethyl,trifluromethyl, trifluoroethyl, and pentafluoroethyl.

Alkoxy, unless otherwise specifically defined, refers to astraight-chain or branched C₁-C₁₂ alkyl group, wherein one or moreoxygen atoms are present, in each instance between two carbon atoms. Insome embodiments, alkoxy refers to a C₁-C₆ alkoxy group. In someembodiments, C₁-C₆ alkoxy groups provided herein have one oxygen atom.Exemplary alkoxy groups include methoxy, ethoxy, CH₂OCH₃, CH₂CH₂OCH₃,CH₂OCH₂CH₃, CH₂CH₂OCH₂CH₃, CH₂OCH₂CH₂CH₃, CH₂CH₂CH₂OCH₃, CH₂OCH(CH₃)₂,CH₂OC(CH₃)₃, CH(CH₃)OCH₃, CH₂CH(CH₃)OCH₃, CH(CH₃)OCH₂CH₃, CH₂OCH₂OCH₃,CH₂CH₂OCH₂CH₂OCH₃, and CH₂OCH₂OCH₂OCH₃.

Cycloalkoxy, unless otherwise specifically defined, refers to a C₄-C₁₀or a C₄-C₆ alkoxy group as defined above wherein the group is cyclic andcontains one oxygen atom. Exemplary cycloalkoxy groups include oxetanyl,tetrahydrofuranyl, and tetrahydropyranyl.

Haloalkoxy, unless otherwise specifically defined, refers to a C₁-C₆haloalkyl group as defined above, wherein one or two oxygen atoms arepresent, in each instance between two carbon atoms. In some embodiments,C₁-C₆ haloalkoxy groups provided herein have one oxygen atom. Exemplaryhaloalkoxy groups include OCF₃, OCHF₂ and CH₂OCF₃.

Thioalkyl, unless otherwise specifically defined, refers to a C₁-C₁₂ ora C₁-C₆ alkoxy group as defined above wherein the oxygen atom isreplaced by a sulfur atom. In some embodiments, thioalkyl groups mayinclude sulfur atoms substituted by one or two oxygen atoms (i.e.,alkylsulfones and alkylsulfoxides). Exemplary thioalkyl groups are thoseexemplified in the definition of alkoxy above, wherein each oxygen atomis replaced by a sulfur atom in each instance.

Thiocycloalkyl, unless otherwise specifically defined, refers to aC₄-C₁₀ or a C₄-C₆ thioalkyl group as defined above wherein the group iscyclic and contains one sulfur atom. In some embodiments, the sulfuratom of the thiocycloalkyl group is substituted by one or two oxygenatoms (i.e., a cyclic sulfone or sulfoxide). Exemplary thiocycloalkylgroups include thietanyl, thiolanyl, thianyl, 1,1-dioxothiolanyl, and1,1-dioxothianyl.

Heterocyclyl, unless otherwise specifically defined, referes to a singlesaturated or partially unsaturated 4 to 8 membered ring that has atleast one atom other than carbon in the ring, wherein the atom isselected from the group consisting of oxygen, nitrogen and sulfur; theterm also includes multiple condensed ring systems that have at leastone such saturated or partially unsaturated ring, which multiplecondensed ring systems have from 7 to 12 atoms and are further describedbelow. Thus, the term includes single saturated or partially unsaturatedrings (e.g., 3, 4, 5, 6, 7 or 8 membered rings) from about 1 to 7 carbonatoms and from about 1 to 4 heteroatoms selected from the groupconsisting of oxygen, nitrogen and sulfur in the ring. The ring may beC-branched (i.e., substituted by C₁-C₄ alkyl). The ring may besubstituted with one or more (e.g., 1, 2 or 3) oxo groups and the sulfurand nitrogen atoms may also be present in their oxidized forms.Exemplary heterocycles include but are not limited to azetidinyl,tetrahydrofuranyl and piperidinyl. The rings of the multiple condensedring system can be connected to each other via fused, spiro and bridgedbonds when allowed by valency requirements. It is to be understood thatthe individual rings of the multiple condensed ring system may beconnected in any order relative to one another. It is also to beunderstood that the point of attachment of a multiple condensed ringsystem (as defined above for a heterocycle) can be at any position ofthe multiple condensed ring system. It is also to be understood that thepoint of attachment for a heterocycle or heterocycle multiple condensedring system can be at any suitable atom of the heterocyclyl groupincluding a carbon atom and a nitrogen atom. Exemplary heterocyclesinclude, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl,piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl,tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl,tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl,dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl,2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl,spiro[cyclopropane-1,1′-isoindolinyl]-3′-one, isoindolinyl-1-one,2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one N-methylpiperidine,imidazolidine, pyrazolidine, butyrolactam, valerolactam,imidazolidinone, hydantoin, dioxolane, phthalimide, 1,4-dioxane,thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, pyran,3-pyrroline, thiopyran, pyrone, tetrhydrothiophene, quinuclidine,tropane, 2-azaspiro[3.3]heptane, (1R,5S)-3-azabicyclo[3.2.1]octane, (1s,4s)-2-azabicyclo[2.2.2]octane, (1R,4R)-2-oxa-5-azabicyclo[2.2.2]octaneand pyrrolidin-2-one.

In some embodiments, the heterocyclyl is a C₄-C₁₀ heterocyclyl having 1to 3 heteroatoms selected from the group consisting of nitrogen, oxygenand sulfur. In some embodiments, the heterocyclyl group is neitherbicyclic nor spirocyclic. In some embodiments, the heterocyclyl is aC₅-C₆ heterocylcyl having 1 to 3 heteroatoms, wherein at least 2 arenitrogen if 3 heteroatoms are present.

Aryl, unless otherwise specifically defined, refers to a single allcarbon aromatic ring or a multiple condensed all carbon ring systemwherein at least one of the rings is aromatic and wherein the aryl grouphas 6 to 20 carbon atoms, 6 to 14 carbon atoms, 6 to 12 carbon atoms, or6 to 10 carbon atoms.

Aryl includes a phenyl radical. Aryl also includes multiple condensedring systems (e.g., ring systems comprising 2, 3 or 4 rings) havingabout 9 to 20 carbon atoms in which at least one ring is aromatic andwherein the other rings may be aromatic or not aromatic (i.e.,carbocycle). Such multiple condensed ring systems are optionallysubstituted with one or more (e.g., 1, 2 or 3) oxo groups on anycarbocycle portion of the multiple condensed ring system. The rings ofthe multiple condensed ring system can be connected to each other viafused, spiro and bridged bonds when allowed by valency requirements. Itis to be understood that the point of attachment of a multiple condensedring system, as defined above, can be at any position of the ring systemincluding an aromatic or a carbocycle portion of the ring. Exemplaryaryl groups include phenyl, indenyl, naphthyl, 1, 2, 3,4-tetrahydronaphthyl, anthracenyl, and the like.

Heteroaryl, unless otherwise specifically defined, refers to a 5 to 6membered aromatic ring that has at least one atom other than carbon inthe ring, wherein the atom is selected from the group consisting ofoxygen, nitrogen and sulfur; “heteroaryl” also includes multiplecondensed ring systems having 8 to 16 atoms that have at least one sucharomatic ring, which multiple condensed ring systems are furtherdescribed below. Thus, “heteroaryl” includes single aromatic rings offrom about 1 to 6 carbon atoms and about 1-4 heteroatoms selected fromthe group consisting of oxygen, nitrogen and sulfur. The sulfur andnitrogen atoms may also be present in an oxidized form provided the ringis aromatic. Exemplary heteroaryl ring systems include but are notlimited to pyridyl, pyrimidinyl, oxazolyl or furyl. “Heteroaryl” alsoincludes multiple condensed ring systems (e.g., ring systems comprising2 or 3 rings) wherein a heteroaryl group, as defined above, is condensedwith one or more rings selected from heteroaryls (to form for example anaphthyridinyl such as 1,8-naphthyridinyl), heterocycles, (to form forexample a 1, 2, 3, 4-tetrahydronaphthyridinyl such as1,2,3,4-tetrahydro-1,8-naphthyridinyl), carbocycles (to form for example5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) toform the multiple condensed ring system. Thus, a heteroaryl (a singlearomatic ring or multiple condensed ring system) has 1 to 15 carbonatoms and about 1-6 heteroatoms within the heteroaryl ring. Suchmultiple condensed ring systems may be optionally substituted with oneor more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycleportions of the condensed ring. The rings of the multiple condensed ringsystem can be connected to each other via fused, spiro and bridged bondswhen allowed by valency requirements. It is to be understood that theindividual rings of the multiple condensed ring system may be connectedin any order relative to one another. It is also to be understood thatthe point of attachment of a multiple condensed ring system (as definedabove for a heteroaryl) can be at any position of the multiple condensedring system including a heteroaryl, heterocycle, aryl or carbocycleportion of the multiple condensed ring system. It is also to beunderstood that the point of attachment for a heteroaryl or heteroarylmultiple condensed ring system can be at any suitable atom of theheteroaryl or heteroaryl multiple condensed ring system including acarbon atom and a heteroatom (e.g., a nitrogen). Exemplary heteroarylsinclude but are not limited to pyridyl, pyrrolyl, pyrazinyl,pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl,oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl,quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl,quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl,benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl,quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazole and3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclo-penta[1,2-c]pyrazole.

As used herein, the term “chiral” refers to molecules which have theproperty of non-superimposability of the mirror image partner, while theterm “achiral” refers to molecules which are superimposable on theirmirror image partner.

As used herein, the term “stereoisomers” refers to compounds which haveidentical chemical constitution, but differ with regard to thearrangement of the atoms or groups in space.

As used herein a wavy line “

” that intersects a bond in a chemical structure indicates the point ofattachment of the bond that the wavy bond intersects in the chemicalstructure to the remainder of a molecule.

As used herein, the term “C-linked” means that the group that the termdescribes is attached the remainder of the molecule through a ringcarbon atom.

As used herein, the term “N-linked” means that the group that the termdescribes is attached to the remainder of the molecule through a ringnitrogen atom.

“Diastereomer” refers to a stereoisomer with two or more centers ofchirality and whose molecules are not mirror images of one another.Diastereomers have different physical properties, e.g. melting points,boiling points, spectral properties, and reactivities. Mixtures ofdiastereomers can separate under high resolution analytical proceduressuch as electrophoresis and chromatography.

“Enantiomers” refer to two stereoisomers of a compound which arenon-superimposable mirror images of one another.

Stereochemical definitions and conventions used herein generally followS. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984)McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S.,“Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., NewYork, 1994. The compounds of the invention can contain asymmetric orchiral centers, and therefore exist in different stereoisomeric forms.It is intended that all stereoisomeric forms of the compounds of theinvention, including but not limited to, diastereomers, enantiomers andatropisomers, as well as mixtures thereof such as racemic mixtures, formpart of the present invention. Many organic compounds exist in opticallyactive forms, i.e., they have the ability to rotate the plane ofplane-polarized light. In describing an optically active compound, theprefixes D and L, or R and S, are used to denote the absoluteconfiguration of the molecule about its chiral center(s). The prefixes dand 1 or (+) and (−) are employed to designate the sign of rotation ofplane-polarized light by the compound, with (−) or 1 meaning that thecompound is levorotatory. A compound prefixed with (+) or d isdextrorotatory. For a given chemical structure, these stereoisomers areidentical except that they are mirror images of one another. A specificstereoisomer can also be referred to as an enantiomer, and a mixture ofsuch isomers is often called an enantiomeric mixture. A 50:50 mixture ofenantiomers is referred to as a racemic mixture or a racemate, which canoccur where there has been no stereoselection or stereospecificity in achemical reaction or process. The terms “racemic mixture” and “racemate”refer to an equimolar mixture of two enantiomeric species, devoid ofoptical activity.

When a bond in a compound formula herein is drawn in anon-stereochemical manner (e.g. flat), the atom to which the bond isattached includes all stereochemical possibilities. When a bond in acompound formula herein is drawn in a defined stereochemical manner(e.g. bold, bold-wedge, dashed or dashed-wedge), it is to be understoodthat the atom to which the stereochemical bond is attached is enrichedin the absolute stereoisomer depicted unless otherwise noted. In oneembodiment, the compound may be at least 51% the absolute stereoisomerdepicted. In another embodiment, the compound may be at least 80% theabsolute stereoisomer depicted. In another embodiment, the compound maybe at least 90% the absolute stereoisomer depicted. In anotherembodiment, the compound may be at least 95% the absolute stereoisomerdepicted. In another embodiment, the compound may be at least 97% theabsolute stereoisomer depicted. In another embodiment, the compound maybe at least 98% the absolute stereoisomer depicted. In anotherembodiment, the compound may be at least 99% the absolute stereoisomerdepicted.

As used herein, the term “tautomer” or “tautomeric form” refers tostructural isomers of different energies which are interconvertible viaa low energy barrier. For example, proton tautomers (also known asprototropic tautomers) include interconversions via migration of aproton, such as keto-enol and imine-enamine isomerizations. Valencetautomers include interconversions by reorganization of some of thebonding electrons.

As used herein, the term “solvate” refers to an association or complexof one or more solvent molecules and a compound of the invention.Examples of solvents that form solvates include, but are not limited to,water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid,and ethanolamine. The term “hydrate” refers to the complex where thesolvent molecule is water.

As used herein, the term “protecting group” refers to a substituent thatis commonly employed to block or protect a particular functional groupon a compound. For example, an “amino-protecting group” is a substituentattached to an amino group that blocks or protects the aminofunctionality in the compound. Suitable amino-protecting groups includeacetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ)and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a“hydroxy-protecting group” refers to a substituent of a hydroxy groupthat blocks or protects the hydroxy functionality. Suitable protectinggroups include acetyl and silyl. A “carboxy-protecting group” refers toa substituent of the carboxy group that blocks or protects the carboxyfunctionality. Common carboxy-protecting groups includephenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl,2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl,2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyland the like. For a general description of protecting groups and theiruse, see P. G. M. Wuts and T. W. Greene, Greene's Protective Groups inOrganic Synthesis 4^(th) edition, Wiley-Interscience, New York, 2006.

As used herein, the term “mammal” includes, but is not limited to,humans, mice, rats, guinea pigs, monkeys, dogs, cats, horses, cows,pigs, and sheep.

As used herein, the term “pharmaceutically acceptable salts” is meant toinclude salts of the active compounds which are prepared with relativelynontoxic acids or bases, depending on the particular substituents foundon the compounds described herein. When compounds of the presentinvention contain relatively acidic functionalities, base addition saltscan be obtained by contacting the neutral form of such compounds with asufficient amount of the desired base, either neat or in a suitableinert solvent. Examples of salts derived frompharmaceutically-acceptable inorganic bases include aluminum, ammonium,calcium, copper, ferric, ferrous, lithium, magnesium, manganic,manganous, potassium, sodium, zinc and the like. Salts derived frompharmaceutically-acceptable organic bases include salts of primary,secondary and tertiary amines, including substituted amines, cyclicamines, naturally-occurring amines and the like, such as arginine,betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine,2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine,glucosamine, histidine, hydrabamine, isopropylamine, lysine,methylglucamine, morpholine, piperazine, piperidine, polyamine resins,procaine, purines, theobromine, triethylamine, trimethylamine,tripropylamine, tromethamine and the like. When compounds of the presentinvention contain relatively basic functionalities, acid addition saltscan be obtained by contacting the neutral form of such compounds with asufficient amount of the desired acid, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable acid additionsalts include those derived from inorganic acids like hydrochloric,hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,monohydrogensulfuric, hydriodic, or phosphorous acids and the like, aswell as the salts derived from relatively nontoxic organic acids likeacetic, propionic, isobutyric, malonic, benzoic, succinic, suberic,fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric,tartaric, methanesulfonic, and the like. Also included are salts ofamino acids such as arginate and the like, and salts of organic acidslike glucuronic or galactunoric acids and the like (see, for example,Berge, S. M., et al., “Pharmaceutical Salts”, Journal of PharmaceuticalScience, 1977, 66, 1-19). Certain specific compounds of the presentinvention contain both basic and acidic functionalities that allow thecompounds to be converted into either base or acid addition salts.

The neutral forms of the compounds can be regenerated by contacting thesalt with a base or acid and isolating the parent compound in theconventional manner. The parent form of the compound differs from thevarious salt forms in certain physical properties, such as solubility inpolar solvents, but otherwise the salts are equivalent to the parentform of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compoundswhich are in a prodrug form. As used herein the term “prodrug” refers tothose compounds that readily undergo chemical changes underphysiological conditions to provide the compounds of the presentinvention. Additionally, prodrugs can be converted to the compounds ofthe present invention by chemical or biochemical methods in an ex vivoenvironment. For example, prodrugs can be slowly converted to thecompounds of the present invention when placed in a transdermal patchreservoir with a suitable enzyme or chemical reagent.

Prodrugs of the invention include compounds wherein an amino acidresidue, or a polypeptide chain of two or more (e.g., two, three orfour) amino acid residues, is covalently joined through an amide orester bond to a free amino, hydroxy or carboxylic acid group of acompound of the present invention. The amino acid residues include butare not limited to the 20 naturally occurring amino acids commonlydesignated by three letter symbols and also includes phosphoserine,phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine,demosine, isodemosine, gamma-carboxyglutamate, hippuric acid,octahydroindole-2-carboxylic acid, statine,1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine,ornithine, 3-methylhistidine, norvaline, beta-alanine,gamma-aminobutyric acid, citrulline, homocysteine, homoserine,methyl-alanine, para-benzoylphenylalanine, phenylglycine,propargylglycine, sarcosine, methionine sulfone and tert-butylglycine.

Additional types of prodrugs are also encompassed. For instance, a freecarboxyl group of a compound of the invention can be derivatized as anamide or alkyl ester. As another example, compounds of this inventioncomprising free hydroxy groups can be derivatized as prodrugs byconverting the hydroxy group into a group such as, but not limited to, aphosphate ester, hemisuccinate, dimethylaminoacetate, orphosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D. etal., (1996) Improved oral drug delivery: solubility limitations overcomeby the use of prodrugs Advanced Drug Delivery Reviews, 19:115. Carbamateprodrugs of hydroxy and amino groups are also included, as are carbonateprodrugs, sulfonate esters and sulfate esters of hydroxy groups.Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethylethers, wherein the acyl group can be an alkyl ester optionallysubstituted with groups including, but not limited to, ether, amine andcarboxylic acid functionalities, or where the acyl group is an aminoacid ester as described above, are also encompassed. Prodrugs of thistype are described in J. Med. Chem., (1996), 39:10. More specificexamples include replacement of the hydrogen atom of the alcohol groupwith a group such as (C₁₋₆)alkanoyloxymethyl,1-((C₁₋₆)alkanoyloxy)ethyl, 1-methyl-1-((C₁₋₆)alkanoyloxy)ethyl,(C₁₋₆)alkoxycarbonyloxymethyl, N—(C₁₋₆)alkoxycarbonylaminomethyl,succinoyl, (C₁₋₆)alkanoyl, alpha-amino(C₁₋₄)alkanoyl, arylacyl andalpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl, where eachalpha-aminoacyl group is independently selected from the naturallyoccurring L-amino acids, P(O)(OH)₂, —P(O)(O(C₁₋₆)alkyl)₂ or glycosyl(the radical resulting from the removal of a hydroxyl group of thehemiacetal form of a carbohydrate).

For additional examples of prodrug derivatives, see, for example, a)Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methodsin Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al.(Academic Press, 1985); b) A Textbook of Drug Design and Development,edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design andApplication of Prodrugs,” by H. Bundgaard p. 113-191 (1991); c) H.Bundgaard, Advanced Drug Delivery Reviews, 8:1-38 (1992); d) H.Bundgaard, et al., Journal of Pharmaceutical Sciences, 77:285 (1988);and e) N. Kakeya, et al., Chem. Pharm. Bull., 32:692 (1984), each ofwhich is specifically incorporated herein by reference.

Additionally, the present invention provides for metabolites ofcompounds of the invention. As used herein, a “metabolite” refers to aproduct produced through metabolism in the body of a specified compoundor salt thereof. Such products can result for example from theoxidation, reduction, hydrolysis, amidation, deamidation,esterification, deesterification, enzymatic cleavage, and the like, ofthe administered compound.

Metabolite products typically are identified by preparing aradiolabelled (e.g., ¹⁴C or ³H) isotope of a compound of the invention,administering it parenterally in a detectable dose (e.g., greater thanabout 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, orto man, allowing sufficient time for metabolism to occur (typicallyabout 30 seconds to 30 hours) and isolating its conversion products fromthe urine, blood or other biological samples. These products are easilyisolated since they are labeled (others are isolated by the use ofantibodies capable of binding epitopes surviving in the metabolite). Themetabolite structures are determined in conventional fashion, e.g., byMS, LC/MS or NMR analysis. In general, analysis of metabolites is donein the same way as conventional drug metabolism studies well known tothose skilled in the art. The metabolite products, so long as they arenot otherwise found in vivo, are useful in diagnostic assays fortherapeutic dosing of the compounds of the invention.

Certain compounds of the present invention can exist in unsolvated formsas well as solvated forms, including hydrated forms. In general, thesolvated forms are equivalent to unsolvated forms and are intended to beencompassed within the scope of the present invention. Certain compoundsof the present invention can exist in multiple crystalline or amorphousforms. In general, all physical forms are equivalent for the usescontemplated by the present invention and are intended to be within thescope of the present invention.

Certain compounds of the present invention possess asymmetric carbonatoms (optical centers) or double bonds; the racemates, diastereomers,geometric isomers, regioisomers and individual isomers (e.g., separateenantiomers) are all intended to be encompassed within the scope of thepresent invention.

The term “composition,” as used herein, is intended to encompass aproduct comprising the specified ingredients in the specified amounts,as well as any product which results, directly or indirectly, fromcombination of the specified ingredients in the specified amounts. By“pharmaceutically acceptable” it is meant the carrier, diluent orexcipient must be compatible with the other ingredients of theformulation and not deleterious to the recipient thereof.

The terms “treat” and “treatment” refer to both therapeutic treatmentand/or prophylactic treatment or preventative measures, wherein theobject is to prevent or slow down (lessen) an undesired physiologicalchange or disorder, such as, for example, the development or spread ofcancer. For purposes of this invention, beneficial or desired clinicalresults include, but are not limited to, alleviation of symptoms,diminishment of extent of disease or disorder, stabilized (i.e., notworsening) state of disease or disorder, delay or slowing of diseaseprogression, amelioration or palliation of the disease state ordisorder, and remission (whether partial or total), whether detectableor undetectable. “Treatment” can also mean prolonging survival ascompared to expected survival if not receiving treatment. Those in needof treatment include those already with the disease or disorder as wellas those prone to have the disease or disorder or those in which thedisease or disorder is to be prevented.

The phrase “therapeutically effective amount” or “effective amount”means an amount of a compound of the present invention that (i) treatsor prevents the particular disease, condition, or disorder, (ii)attenuates, ameliorates, or eliminates one or more symptoms of theparticular disease, condition, or disorder, or (iii) prevents or delaysthe onset of one or more symptoms of the particular disease, condition,or disorder described herein. For cancer therapy, efficacy can, forexample, be measured by assessing the time to disease progression (TTP)and/or determining the response rate (RR).

The term “bioavailability” refers to the systemic availability (i.e.,blood/plasma levels) of a given amount of drug administered to apatient. Bioavailability is an absolute term that indicates measurementof both the time (rate) and total amount (extent) of drug that reachesthe general circulation from an administered dosage form.

Inhibitors of RIP1 Kinase

All embodiments described herein can be combined.The present invention provides novel compounds having the generalformula I:

Provided herein are compounds of formula I:

or pharmaceutically acceptable salts thereof, whereinR¹ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆alkyl-N(R²)₂, phenyl, benzyl, difluoro(phenyl)methyl, 4 to 6 memberedheterocyclyl, 5 to 6 membered heteroaryl, and CH₂-(5 to 6 memberedheteroaryl); wherein when R¹ is phenyl, benzyl, difluoro(phenyl)methyl,5 to 6 membered heteroaryl or CH₂-(5 to 6 membered heteroaryl), thephenyl or aryl moiety of R¹ is optionally substituted by one or twosubstituents selected from the group consisting of fluoro, chloro,methyl, ethyl, hydroxyl, hydroxymethyl, methoxymethyl, cyano,trifluoromethyl, difluoromethoxy and trifluoromethoxy;n is 1 or 2;each R² is independently selected from the group consisting of C₁-C₆alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkyl; or two R²together with the nitrogen atom to which they are both attached form a4-6 membered heterocyclic ring;the A ring and the B ring are fused to form a polycyclic ring system,whereinthe A ring is a 5 membered heteroaromatic ring having as its onlyheteroatoms, either (i) two or three nitrogen atoms, (ii) one nitrogenatom and one oxygen atom, or (iii) one nitrogen atom and one sulfuratom; wherein the A ring is optionally substituted at a carbon atom byone substituent selected from the group consisting of fluoro, chloro,methyl, and trifluoromethyl; andthe B ring is a 4 to 8 membered carbocyclic ring, or a 4 to 8 memberedheterocyclic ring having 1 to 3 heteroatoms selected from the groupconsisting of nitrogen, oxygen, and sulfur;

-   -   p is 1 or 2, and q is 0 or 1; or p is 0, and q is 1;    -   each R^(B1) is independently selected from the group consisting        of halogen, deutero, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl,        C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆        thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano; wherein two C₁-C₆        alkyl substituents may together form a bridged or spirocyclic        ring; and wherein if a nitrogen atom in the B ring is        substituted, the substituent is not halogen, cyano, or a C₁-C₆        alkoxy, C₁-C₆ haloalkoxy or C₁-C₆ thioalkyl having an oxygen or        sulfur atom directly bonded to the nitrogen atom; and    -   R^(B2) is selected from the group consisting of C₁-C₆ alkyl,        C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆        haloalkoxy, C₁-C₆ thioalkyl, C₁-C₆ alkyl-N(R²)₂, phenyl, benzyl,        CH₂—(C₃-C₆ cycloalkyl), CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6        membered heterocyclyl), CH₂CH₂-(4 to 6 membered heterocyclyl), 5        to 6 membered heteroaryl, and CH₂-(5 to 6 membered heteroaryl);        wherein when R^(B2) is phenyl or benzyl the phenyl ring is        optionally substituted by 1 to 3 substituents selected from the        group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄        alkoxy, C₁-C₄ haloalkoxy, and cyano.

In some embodiments provided herein there is provided: of formula I: ora pharmaceutically acceptable salt thereof, wherein

R¹ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆alkyl-N(R^(N))₂, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6membered heteroaryl; wherein R¹ is bound to the adjacent —SO_(n)— by acarbon atom, and wherein R¹ is optionally substituted by one or twosubstituents selected from the group consisting of halogen, C₁-C₆ alkyl,C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆alkyl-N(R^(N))₂, hydroxyl, C₁-C₆ hydroxyalkyl, cyano, C₁-C₆cyanoalkyl,C(O)C₁-C₆ alkyl, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl), 5 to 6 memberedheteroaryl, and CH₂-(5 to 6 membered heteroaryl);n is 1 or 2;each R² is independently selected from the group consisting of C₁-C₆alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkyl; or two R²together with the nitrogen atom to which they are both attached form a4-6 membered heterocyclic ring;the A ring and the B ring are fused to form a polycyclic ring system,whereinthe A ring is a 5 membered heteroaromatic ring having as its onlyheteroatoms, either (i) two or three nitrogen atoms, (ii) one nitrogenatom and one oxygen atom, or (iii) one nitrogen atom and one sulfuratom; wherein the A ring is optionally substituted at a carbon atom byone substituent selected from the group consisting of fluoro, chloro,methyl, and trifluoromethyl; andthe B ring is a 4 to 8 membered carbocyclic ring, or a 4 to 8 memberedheterocyclic ring having 1 to 3 heteroatoms selected from the groupconsisting of nitrogen, oxygen, and sulfur;

-   -   p is 1 or 2, and q is 0 or 1; or p is 0, and q is 1;    -   wherein when p is 1, R^(B1) is R^(3a) and when p is 2, R^(B1) is        independently R^(3a) and R^(3b) and each R^(3a) and R^(3b), when        present, is/are independently selected from the group consisting        of halogen, deutero, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl,        C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆        thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano; wherein two C₁-C₆        alkyl substituents may together form a bridged or spirocyclic        ring; and wherein if a nitrogen atom in the B ring is        substituted, the substituent is not halogen, cyano, or a C₁-C₆        alkoxy, C₁-C₆ haloalkoxy or C₁-C₆ thioalkyl having an oxygen or        sulfur atom directly bonded to the nitrogen atom; and    -   wherein when q is 1, R^(B2) is R⁴ and R⁴ is selected from the        group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆        cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl,        C₁-C₆ alkyl-N(R²)₂, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl),        CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl),        CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered        heteroaryl, and CH₂-(5 to 6 membered heteroaryl);        -   wherein when R⁴ is phenyl, heteroaryl or benzyl the phenyl            or heteroaryl ring is optionally substituted by 1 to 3            substituents selected from the group consisting of halogen,            C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄            haloalkoxy, and cyano.

In some embodiments, provided herein is a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together (including substituents, p, q, R^(B1) and R^(B2)) areselected from the group consisting of:

whereinone of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or

-   -   each of R^(3a) and R^(3b) is independently selected from the        group consisting of deutero, fluoro, chloro, hydroxyl, cyano,        and methyl, provided that R^(3a) and R^(3b) cannot both be OH or        CN; or    -   R^(3a) and R^(3b), together with the carbon atom to which they        are both attached, form 1,1-cyclopropylene; and        R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆        haloalkyl, C₃₋₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy,        C₁-C₆ thioalkyl, phenyl, benzyl, CH₂—(C₃-C₆cycloalkyl),        CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl),        CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered        heteroaryl, and CH₂-(5 to 6 membered heteroaryl); wherein when a        phenyl ring is present it may be substituted by 1 to 3        substituents selected from the group consisting of halogen,        C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy,        and cyano.        In another embodiment R¹, R², R^(3a), R^(3b) and R⁴ are: or a        pharmaceutically acceptable salt thereof, wherein:        R¹ is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆        cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy,        C₁-C₆ hydroxyalkyl, C₁-C₆ cyanoalkyl, C₃-C₆ cycloalkyl-C₁-C₃        alkyl, C₁-C₆ alkyl-N(R²)₂, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆        haloalkoxy-C₁-C₆ alkyl, phenyl, benzyl, difluoro(phenyl)methyl,        4 to 6 membered heterocyclyl, 5 to 6 membered heteroaryl, and        CH₂-(5 to 6 membered heteroaryl); wherein:    -   when R¹ is phenyl, benzyl, difluoro(phenyl)methyl, 5 to 6        membered heteroaryl or CH₂-(5 to 6 membered heteroaryl), the        phenyl or heteroaryl moiety of R¹ is optionally substituted by        one or two substituents independently selected from the group        consisting of halogen, C₁-C₆ alkyl, hydroxyl, hydroxymethyl,        methoxymethyl, cyano, trifluoromethyl, difluoromethoxy and        trifluoromethoxy;    -   when R¹ is cycloalkyl the cycloalkyl is optionally substituted        by one, two or three substituents independently selected from        the group consisting of fluoro, C₁-C₆ alkyl, C₁-C₆ haloalkyl,        C₁-C₆ haloalkoxy, hydroxyl, C₁-C₆ hydroxyalkyl or cyano;        n is 1 or 2;        each R² is independently selected from the group consisting of        C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆        haloalkyl; or two R² together with the nitrogen atom to which        they are both attached form a 4-6 membered heterocyclic ring;        R^(3a) is hydrogen and R^(3b), when p is 2, R^(B1) is        independently R^(3a) and R^(3b) and each R^(3a) and R^(3b), when        present, is/are independently is selected from the group        consisting of halogen, deutero, hydroxyl, C₁-C₆ alkyl, C₁-C₆        haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy,        C₁-C₆ thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano; or        R^(3a) and R^(3b) are-independently is selected from the group        consisting of halogen, deutero, hydroxyl, C₁-C₆ alkyl, C₁-C₆        haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy,        C₁-C₆ thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano; or R^(3a) and        R^(3b) together with the atoms to which they are attached form a        bridged or spirocyclic ring; and        wherein when q is 1, R^(B2) is R⁴ and R⁴ is selected from the        group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆        cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl,        C₁-C₆ alkyl-N(R²)₂, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl),        CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl),        CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered        heteroaryl, and CH₂-(5 to 6 membered heteroaryl);        wherein when R⁴ is phenyl, heteroaryl or benzyl the phenyl or        heteroaryl ring is optionally substituted by 1 to 3 substituents        selected from the group consisting of halogen, C₁-C₄ alkyl,        C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.

In some embodiments, provided herein is a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together are:

whereinR^(3a) and R^(3b) are selected as follows:

one of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or

each of R^(3a) and R^(3b) is independently selected from the groupconsisting of deutero, fluoro, chloro, hydroxyl, cyano, and methyl,provided that R^(3a) and R^(3b) cannot both be OH or CN; or

R^(3a) and R^(3b), together with the carbon atom to which they are bothattached, form 1,1-cyclopropylene; and

R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆thioalkyl, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl), CH₂CH₂—(C₃-C₆cycloalkyl), CH₂-(4 to 6 membered heterocyclyl), CH₂CH₂-(4 to 6 memberedheterocyclyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6 memberedheteroaryl); wherein when a phenyl ring is present it may be substitutedby 1 to 3 substituents selected from the group consisting of halogen,C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.In another embodiment R^(3a) and R^(3b) are selected as follows:

one of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or

each of R^(3a) and R^(3b) is independently selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or, provided that R^(3a) and R^(3b) cannot both be OH or CN; or

R^(3a) and R^(3b), together with the carbon atom to which they are bothattached, form 1,1-cyclopropylene.

In yet another embodiment R^(3a) and R^(3b) are selected as follows:

one of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or

each of R^(3a) and R^(3b) is independently selected from the groupconsisting of deutero, fluoro, chloro, hydroxyl, cyano, and methyl,provided that R^(3a) and R^(3b) cannot both be OH or CN; or

R^(3a) and R^(3b), together with the carbon atom to which they are bothattached, form 1,1-cyclopropylene; and

R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆haloalkyl, phenyl or pyridinyl wherein the phenyl ring or pyridinyl ringis optionally substituted by 1 to 3 substituents selected from the groupconsisting of halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄haloalkoxy, and cyano.

In some embodiments, provided herein is a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together are selected from the group consisting of:

whereinone of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or

each of R^(3a) and R^(3b) is independently selected from the groupconsisting of deutero, fluoro, chloro, hydroxyl, cyano, and methyl,provided that R^(3a) and R^(3b) cannot both be OH or CN; or

R^(3a) and R^(3b), together with the carbon atom to which they are bothattached, form 1,1-cyclopropylene; and each R⁵ is independently selectedfrom the group consisting of H, F, Cl, C₁-C₆ alkyl, C₁-C₆ haloalkyl,C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy; and

m is 1, 2 or 3.In some embodiments the A ring and the B ring together are selected fromthe group consisting of:

whereinR^(3a) is hydrogen or fluorineeach R⁵ is selected from the group consisting of hydrogen, fluoro,chloro C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy.In s subembodiement R^(3a) is fluoro.

In some embodiments, provided herein is a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together are selected from the group consisting of:

whereineach R⁵ is selected from the group consisting of hydrogen, fluoro,chloro C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy;andm is 1, 2 or 3.

In some embodiments, provided herein is a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together are:

whereineach R⁵ is selected from the group consisting of hydrogen, fluoro,chloro C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy;andm is 1, 2 or 3.

In some embodiments R¹ is selected from the group consisting of C₁-C₆alkyl, optionally substituted C₃-C₆ cycloalkyl, C₃-C₆ spirocycloalkyl.C₁-C₆ haloalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ cyanoalkyl, C₁-C₆hydroxyalkyl, phenyl, benzyl, and difluoro(phenyl)methyl, or, R¹ isselected from the group consisting of methyl, ethyl, tert-butyl,difluoromethyl, trifluoromethyl, cyclopropyl, fluorocyclopropyl,difluorocyclopropyl, phenyl, benzyl, and difluoro(phenyl)methyl. or,alternatively, R¹ is selected from the group consisting of ethyl,difluoromethyl, trifluoromethyl, cyclopropyl, fluorocyclopropyl ordifluorocyclopropyl.

In some of the above embodiments, n is 1. In some embodiments, n is 2.

In some of the above embodiments, m is 1. In some embodiments, m is 2.In some of the above embodiments, m is 3.

In some embodiments R⁵ is halo. In some embodiments each R⁵ isindependently selected from chloro and fluoro.

In some of the above embodiments, R¹ is selected from the groupconsisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, phenyl,benzyl, and difluoro(phenyl)methyl. In some embodiments, R¹ is selectedfrom the group consisting of methyl, ethyl, tert-butyl, difluoromethyl,trifluoromethyl, cyclopropyl, phenyl, benzyl, anddifluoro(phenyl)methyl. In some embodiments, R¹ is selected from thegroup consisting of ethyl, difluoromethyl, trifluoromethyl, benzyl, anddifluoro(phenyl)methyl.

In some of the above embodiments, R^(3a) and R^(3b) are selected asfollows:

one of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or

each of R^(3a) and R^(3b) is independently selected from the groupconsisting of deutero, fluoro, chloro, hydroxyl, cyano, and methyl,provided that R^(3a) and R^(3b) cannot both be OH or CN.

In some of the above embodiments, R^(3a) and R^(3b) are eachindependently selected from the group consisting of hydrogen, deutero,fluoro, chloro, methyl and trifluoromethyl. In some embodiments, R^(3a)and R^(3b) are each independently selected from the group consisting ofhydrogen, deutero, fluoro and chloro. In some embodiments, R^(3a) andR^(3b) are each independently selected from the group consisting ofhydrogen, fluoro and chloro. In some embodiments, R^(3a) and R^(3b) areeach fluoro. In some embodiments, R^(3a) is hydrogen and R^(3b) isfluoro.

In some of the above embodiments, R⁴ is selected from the groupconsisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆alkoxy, C₁-C₆ haloalkoxy, phenyl, 5 to 6 membered heteroaryl, and CH₂-(5to 6 membered heteroaryl); wherein when a phenyl ring is present it maybe substituted by 1 to 3 substituents selected from the group consistingof halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄haloalkoxy, and cyano.

In some of the above embodiments, R⁵ is selected from the groupconsisting of H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆alkoxy, and C₁-C₆ haloalkoxy. In some of the above embodiments, R⁵ isselected from the group consisting of H, F, Cl, CH₃, CH₂CH₃, OCH₃, CF₃,OCF₃, CF₂H, and OCF₂H. In some of the above embodiments, R⁵ is selectedfrom the group consisting of H, F and Cl.

In another embodiment, provided herein is a compound selected from thecompounds of Table 1 below or a pharmaceutically acceptable saltthereof. In another embodiment, provided herein is a compound of Table 1having a K_(i) of less than 100 nM in a RIP1K biochemical or cell-basedassay, including as herein described. In another embodiment, thecompound of Table 1 has a K_(i) of less than 50 nM in a RIP1Kbiochemical or cell-based assay, including as herein described. In yetanother embodiment, the compound of Table 1 has a K of less than 25 nMin a RIP1K biochemical or cell-based assay, including as hereindescribed. In yet another embodiment, the compound of Table 1 has a K ofless than 10 nM in a RIP1K biochemical or cell-based assay, including asherein described.

In some embodiments, provided herein is a single stereoisomer of acompound of Table 1, as characterized by reference to its chiralseparation and isolation (e.g., as described in the Examples by chiralSFC).

In some embodiments, provided herein are pharmaceutical compositionscomprising a compound of formula I as described in any one of the aboveembodiments, or a pharmaceutically acceptable salt thereof, and one ormore pharmaceutically acceptable carriers or excipients. Specificembodiments include pharmaceutical compositions suitable for oraldelivery.

Also provided herein are oral formulations of a compound of formula I asdescribed in any one of the above embodiments, or a pharmaceuticallyacceptable salt thereof, and one or more pharmaceutically acceptablecarriers or excipients suitable for oral delivery.

In some embodiments, provided herein are uses of a compound of formula Ias described in any one of the above embodiments, or a pharmaceuticallyacceptable salt thereof, for the treatment of neurodegenerative diseasesand disorders. In some embodiments, the diseases and disorders to betreated are synucleopathies such as Parkinson's Disease, Lewy bodydementia, multiple system atrophy, Parkinson-plus syndromes. In someembodiments, the diseases and disorders to be treated are taupathiessuch as Alzheimer's Disease and frontotemporal dementia. In someembodiments, the diseases and disorders to be treated are demyelinationdiseases such as multiple sclerosis.

In some embodiments, the diseases and disorders to be treated are otherneurodegenerative diseases such as amyotrophic lateral sclerosis, spinalmuscular atrophy, primary lateral sclerosis, Huntington's disease,ischemia, and stroke. Additional exemplary neurodegenerative diseases tobe treated as provided herein include, but are not limited to,intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy,progressive muscular atrophy, pseudobulbar palsy, progressive bulbarpalsy, spinal muscular atrophy, inherited muscular atrophy, peripheralneuropathies, progressive supranuclear palsy, corticobasal degeneration,and demyelinating diseases.

In some embodiments, the disease or disorder to be treated isAlzheimer's disease. In some embodiments, the disease or disorder to betreated is Parkinson's disease. In some embodiments, the disease ordisorder to be treated is Huntington's disease. In some embodiments, thedisease or disorder to be treated is multiple sclerosis. In someembodiments, the disease or disorder to be treated is amyotrophiclateral sclerosis (ALS). In some embodiments, the disease or disorder tobe treated is spinal muscular atrophy (SMA).

In some embodiments, provided herein are uses of a compound of formula Ias described in any one of the above embodiments, or a pharmaceuticallyacceptable salt thereof, for the treatment of inflammatory diseases anddisorders. In some embodiments, the disease or disorder to be treated isselected from the group consisting of inflammatory bowel diseases(including Crohn's disease and ulcerative colitis), psoriasis, retinaldetachment, retinitis pigmentosa, macular degeneration, pancreatitis,atopic dermatitis, arthritis (including rheumatoid arthritis,osteoarthritis, spondylarthritis, gout, systemic onset juvenileidiopathic arthritis (SoJIA), psoriatic arthritis), systemic lupuserythematosus (SLE), Sjogren's syndrome, systemic scleroderma,anti-phospholipid syndrome (APS), vasculitis, liver damage/diseases(non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmunehepatitis autoimmune hepatobiliary diseases, primary sclerosingcholangitis (PSC), acetaminophen toxicity, hepatotoxicity), kidneydamage/injury (nephritis, renal transplant, surgery, administration ofnephrotoxic drugs e.g. cisplatin, acute kidney injury (AKI), Celiacdisease, autoimmune idiopathic thrombocytopenic purpura, transplantrejection, ischemia reperfusion injury of solid organs, sepsis, systemicinflammatory response syndrome (SIRS), cerebrovascular accident (CVA,stroke), myocardial infarction (MI), atherosclerosis, Huntington'sdisease, Alzheimer's disease, Parkinson's disease, amyotrophic lateralsclerosis (ALS), spinal muscular atrophy (SMA), allergic diseases(including asthma and atopic dermatitis), multiple sclerosis, type Idiabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet'sdisease, interleukin-1 converting enzyme (ICE, also known as caspase-1)associated fever syndrome, chronic obstructive pulmonary disease (COPD),tumor necrosis factor receptor-associated periodic syndrome (TRAPS),periodontitis, NEMO-deficiency syndrome (F-kappa-B essential modulatorgene (also known as IKK gamma or IKKG) deficiency syndrome), HOIL-1deficiency ((also known as RBCK1) heme-oxidized IRP2 ubiquitin ligase-1deficiency), linear ubiquitin chain assembly complex (LUBAC) deficiencysyndrome, hematological and solid organ malignancies, bacterialinfections and viral infections (such as tuberculosis and influenza),and Lysosomal storage diseases (particularly, Gaucher Disease, andincluding GM2, Gangliosidosis, Alpha-mannosidosis,Aspartylglucosaminuria, Cholesteryl Ester storage disease, ChronicHexosaminidase A Deficiency, Cystinosis, Danon disease, Fabry disease,Farber disease, Fucosidosis, Galactosialidosis, GM1 gangliosidosis,Mucolipidosis, Infantile Free Sialic Acid Storage Disease, JuvenileHexosaminidase A Deficiency, Krabbe disease, Lysosomal acid lipasedeficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosesdisorders, Multiple sulfatase deficiency, Niemann-Pick Disease, NeuronalCeroid Lipofuscinoses, Pompe disease, Pycnodysostosis, Sandhoff disease,Schindler disease, Sialic Acid Storage Disease, Tay-Sachs and Wolmandisease).

In some embodiments, the disease or disorder to be treated is aninflammatory bowel disease. In some embodiments, the disease or disorderto be treated is Crohn's disease. In some embodiments, the disease ordisorder to be treated is ulcerative colitis. In some embodiments, thedisease or disorder to be treated is glaucoma. In some embodiments, thedisease or disorder to be treated is psoriasis. In some embodiments, thedisease or disorder to be treated is rheumatoid arthritis. In someembodiments, the disease or disorder to be treated is spondyloarthritis.In some embodiments, the disease or disorder to be treated is juvenileidiopathic arthritis. In some embodiments, the disease or disorder to betreated is osteoarthritis.

In some embodiments, provided herein are methods for the treatment orprevention of a disease or disorder with a therapeutically effectiveamount of a compound of formula I, or a pharmaceutically acceptable saltthereof, wherein the disease or disorder is associated with inflammationand/or necroptosis. In some embodiments said disease or disorder isselected from the specific diseases and disorders recited herein.

In some embodiments, provided herein are methods of inhibiting RIP1kinase activity by contacting a cell with a compound of formula I or apharmaceutically acceptable salt thereof.

Pharmaceutical Compositions and Administration

Provided herein are pharmaceutical compositions or medicamentscontaining the compounds of the invention (or stereoisomers, geometricisomers, tautomers, solvates, metabolites, isotopes, pharmaceuticallyacceptable salts, or prodrugs thereof), and a therapeutically inertcarrier, diluent or excipient, as well as methods of using the compoundsof the invention to prepare such compositions and medicaments. In oneexample, compounds of formula I may be formulated by mixing at ambienttemperature at the appropriate pH, and at the desired degree of purity,with physiologically acceptable carriers, i.e., carriers that arenon-toxic to recipients at the dosages and concentrations employed intoa galenical administration form. The pH of the formulation dependsmainly on the particular use and the concentration of compound, butpreferably ranges anywhere from about 3 to about 8. In one example, acompound of formula I is formulated in an acetate buffer, at pH 5. Inanother embodiment, the compounds of formula I are sterile. The compoundmay be stored, for example, as a solid or amorphous composition, as alyophilized formulation or as an aqueous solution.

Compositions are formulated, dosed, and administered in a fashionconsistent with good medical practice. Factors for consideration in thiscontext include the particular disorder being treated, the particularmammal being treated, the clinical condition of the individual patient,the cause of the disorder, the site of delivery of the agent, the methodof administration, the scheduling of administration, and other factorsknown to medical practitioners. In some embodiments, the “effectiveamount” of the compound to be administered will be governed by suchconsiderations, and is the minimum amount necessary to inhibit RIP1kinase activity in order to provide a therapeutic effect in the mammalbeing treated. In addition, such an effective amount may be below theamount that is toxic to normal cells, or the mammal as a whole.

In one example, the pharmaceutically effective amount of the compound ofthe invention administered intravenously or parenterally will be in theper dose range of about 0.1 to 100 mg/kg, alternatively about 0.1 to 20mg/kg of patient body weight per day, or alternatively about 0.3 to 15mg/kg/day.

In another embodiment, oral unit dosage forms, such as tablets andcapsules, preferably contain from about 1 to about 1000 mg (e.g., 1 mg,5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 100 mg, 200 mg,250 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg) ofthe compound of the invention. The daily does is, in certainembodiments, given as a single daily dose or in divided doses two to sixtimes a day, or in sustained release form. In the case of a 70 kg adulthuman, the total daily dose will generally be from about 7 mg to about1,400 mg. This dosage regimen may be adjusted to provide the optimaltherapeutic response. The compounds may be administered on a regimen of1 to 4 times per day, preferably once or twice per day.

In some embodiments, a low dose of the compound of the invention isadministered in order to provide therapeutic benefit while minimizing orpreventing adverse effects.

The compounds of the invention may be administered by any suitablemeans, including oral, topical (including buccal and sublingual),rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal,intrapulmonary, intradermal, intrathecal and epidural and intranasal,and, if desired for local treatment, intralesional administration.Parenteral infusions include intramuscular, intravenous, intraarterial,intraperitoneal, or subcutaneous administration. In specificembodiments, the compound of formula I is administered orally. In otherspecific embodiments, the compound of formula I is administeredintravenously.

The compounds of the present invention may be administered in anyconvenient administrative form, e.g., tablets, powders, capsules,solutions, dispersions, suspensions, syrups, sprays, suppositories,gels, emulsions, patches, etc. Such compositions may contain componentsconventional in pharmaceutical preparations, e.g., diluents, carriers,pH modifiers, sweeteners, bulking agents, and further active agents.

A typical formulation is prepared by mixing a compound of the presentinvention and a carrier or excipient. Suitable carriers and excipientsare well known to those skilled in the art and are described in detailin, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Formsand Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins,2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice ofPharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe,Raymond C. Handbook of Pharmaceutical Excipients. Chicago,Pharmaceutical Press, 2005. The formulations may also include one ormore buffers, stabilizing agents, surfactants, wetting agents,lubricating agents, emulsifiers, suspending agents, preservatives,antioxidants, opaquing agents, glidants, processing aids, colorants,sweeteners, perfuming agents, flavoring agents, diluents and other knownadditives to provide an elegant presentation of the drug (i.e., acompound of the present invention or pharmaceutical composition thereof)or aid in the manufacturing of the pharmaceutical product (i.e.,medicament).

Suitable carriers, diluents and excipients are well known to thoseskilled in the art and include materials such as carbohydrates, waxes,water soluble and/or swellable polymers, hydrophilic or hydrophobicmaterials, gelatin, oils, solvents, water and the like. The particularcarrier, diluent or excipient used will depend upon the means andpurpose for which a compound of the present invention is being applied.Solvents are generally selected based on solvents recognized by personsskilled in the art as safe (GRAS) to be administered to a mammal. Ingeneral, safe solvents are non-toxic aqueous solvents such as water andother non-toxic solvents that are soluble or miscible in water. Suitableaqueous solvents include water, ethanol, propylene glycol, polyethyleneglycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof. Theformulations can also include one or more buffers, stabilizing agents,surfactants, wetting agents, lubricating agents, emulsifiers, suspendingagents, preservatives, antioxidants, opaquing agents, glidants,processing aids, colorants, sweeteners, perfuming agents, flavoringagents and other known additives to provide an elegant presentation ofthe drug (i.e., a compound of the present invention or pharmaceuticalcomposition thereof) or aid in the manufacturing of the pharmaceuticalproduct (i.e., medicament).

Acceptable diluents, carriers, excipients and stabilizers are nontoxicto recipients at the dosages and concentrations employed, and includebuffers such as phosphate, citrate and other organic acids; antioxidantsincluding ascorbic acid and methionine; preservatives (such asoctadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride, benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; monosaccharides,disaccharides and other carbohydrates including glucose, mannose, ordextrins; chelating agents such as EDTA; sugars such as sucrose,mannitol, trehalose or sorbitol; salt-forming counter-ions such assodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionicsurfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). Aactive pharmaceutical ingredient of the invention (e.g., compound offormula I or an embodiment thereof) can also be entrapped inmicrocapsules prepared, for example, by coacervation techniques or byinterfacial polymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington: The Science and Practice of Pharmacy: Remington the Scienceand Practice of Pharmacy (2005) 21^(st) Edition, Lippincott Williams &Wilkins, Philadelphia, Pa.

Sustained-release preparations of a compound of the invention (e.g.,compound of formula I or an embodiment thereof) can be prepared.Suitable examples of sustained-release preparations includesemipermeable matrices of solid hydrophobic polymers containing acompound of formula I or an embodiment thereof, which matrices are inthe form of shaped articles, e.g., films, or microcapsules. Examples ofsustained-release matrices include polyesters, hydrogels (for example,poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides(U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid andgamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547, 1983),non-degradable ethylene-vinyl acetate (Langer et al., J. Biomed. Mater.Res. 15:167, 1981), degradable lactic acid-glycolic acid copolymers suchas the LUPRON DEPOT™ (injectable microspheres composed of lacticacid-glycolic acid copolymer and leuprolide acetate) andpoly-D-(−)-3-hydroxybutyric acid (EP 133,988A). Sustained releasecompositions also include liposomally entrapped compounds, which can beprepared by methods known per se (Epstein et al., Proc. Natl. Acad. Sci.U.S.A. 82:3688, 1985; Hwang et al., Proc. Natl. Acad. Sci. U.S.A.77:4030, 1980; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324A).Ordinarily, the liposomes are of the small (about 200-800 Angstroms)unilamelar type in which the lipid content is greater than about 30 mol% cholesterol, the selected proportion being adjusted for the optimaltherapy.

In one example, compounds of formula I or an embodiment thereof may beformulated by mixing at ambient temperature at the appropriate pH, andat the desired degree of purity, with physiologically acceptablecarriers, i.e., carriers that are non-toxic to recipients at the dosagesand concentrations employed into a galenical administration form. The pHof the formulation depends mainly on the particular use and theconcentration of compound, but preferably ranges anywhere from about 3to about 8. In one example, a compound of formula I (or an embodimentthereof) is formulated in an acetate buffer, at pH 5. In anotherembodiment, the compounds of formula I or an embodiment thereof aresterile. The compound may be stored, for example, as a solid oramorphous composition, as a lyophilized formulation or as an aqueoussolution.

An example of a suitable oral dosage form provided herein is a tabletcontaining about 1 to about 500 mg (e.g., about 1 mg, 5 mg, 10 mg, 25mg, 30 mg, 50 mg, 80 mg, 100 mg, 150 mg, 250 mg, 300 mg and 500 mg) ofthe compound of the invention compounded with suitable amounts ofanhydrous lactose, sodium croscarmellose, polyvinylpyrrolidone (PVP)K30, and magnesium stearate. The powdered ingredients are first mixedtogether and then mixed with a solution of the PVP. The resultingcomposition can be dried, granulated, mixed with the magnesium stearateand compressed to tablet form using conventional equipment.

Formulations of a compound of the invention (e.g., compound of formula Ior an embodiment thereof) can be in the form of a sterile injectablepreparation, such as a sterile injectable aqueous or oleaginoussuspension. This suspension can be formulated according to the known artusing those suitable dispersing or wetting agents and suspending agentswhich have been mentioned above. The sterile injectable preparation canalso be a sterile injectable solution or suspension in a non-toxicparenterally acceptable diluent or solvent, such as a solution in1,3-butanediol or prepared as a lyophilized powder. Among the acceptablevehicles and solvents that can be employed are water, Ringer's solutionand isotonic sodium chloride solution. In addition, sterile fixed oilscan conventionally be employed as a solvent or suspending medium. Forthis purpose any bland fixed oil can be employed including syntheticmono- or diglycerides. In addition, fatty acids such as oleic acid canlikewise be used in the preparation of injectables.

The amount of active ingredient that can be combined with the carriermaterial to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration. For example, atime-release formulation intended for oral administration to humans cancontain approximately 1 to 1000 mg of active material compounded with anappropriate and convenient amount of carrier material which can varyfrom about 5 to about 95% of the total compositions (weight:weight). Thepharmaceutical composition can be prepared to provide easily measurableamounts for administration. For example, an aqueous solution intendedfor intravenous infusion can contain from about 3 to 500 μg of theactive ingredient per milliliter of solution in order that infusion of asuitable volume at a rate of about 30 mL/hr can occur.

Formulations suitable for parenteral administration include aqueous andnon-aqueous sterile injection solutions which can contain anti-oxidants,buffers, bacteriostats and solutes which render the formulation isotonicwith the blood of the intended recipient; and aqueous and non-aqueoussterile suspensions which can include suspending agents and thickeningagents.

The formulations can be packaged in unit-dose or multi-dose containers,for example sealed ampoules and vials, and can be stored in afreeze-dried (lyophilized) condition requiring only the addition of thesterile liquid carrier, for example water, for injection immediatelyprior to use. Extemporaneous injection solutions and suspensions areprepared from sterile powders, granules and tablets of the kindpreviously described.

An embodiment, therefore, includes a pharmaceutical compositioncomprising a compound of formula I, or pharmaceutically acceptable saltthereof. In a further embodiment includes a pharmaceutical compositioncomprising a compound of formula I, or a pharmaceutically acceptablesalt thereof, together with a pharmaceutically acceptable carrier orexcipient.

When the binding target is located in the brain, certain embodiments ofthe invention provide for a compound of formula I (or an embodimentthereof) to traverse the blood-brain barrier. In these embodiments, thecompounds provided herein exhibit sufficient brain penetration aspotential therapeutics in neurological diseases. In some embodiments,brain penetration is assessed by evaluating free brain/plasma ratio(B_(u)/P_(u)) as measured in vivo pharmacokinetic studies in rodents orby other methods known to persons skilled in the art (see, e.g., Liu, X.et al., J. Pharmacol. Exp. Therap., 325:349-56, 2008).

Certain neurological diseases are associated with an increase inpermeability of the blood-brain barrier, such that a compound of formulaI (or an embodiment thereof) can be readily introduced to the brain.When the blood-brain barrier remains intact, several art-knownapproaches exist for transporting molecules across it, including, butnot limited to, physical methods, lipid-based methods, and receptor andchannel-based methods. Physical methods of transporting a compound offormula I (or an embodiment thereof) across the blood-brain barrierinclude, but are not limited to, circumventing the blood-brain barrierentirely, or by creating openings in the blood-brain barrier.

Circumvention methods include, but are not limited to, direct injectioninto the brain (see, e.g., Papanastassiou et al., Gene Therapy9:398-406, 2002), interstitial infusion/convection-enhanced delivery(see, e.g., Bobo et al., Proc. Natl. Acad. Sci. U.S.A. 91:2076-2080,1994), and implanting a delivery device in the brain (see, e.g., Gill etal., Nature Med. 9:589-595, 2003; and Gliadel Wafers™, Guildford.

Methods of creating openings in the barrier include, but are not limitedto, ultrasound (see, e.g., U.S. Patent Publication No. 2002/0038086),osmotic pressure (e.g., by administration of hypertonic mannitol(Neuwelt, E. A., Implication of the Blood-Brain Barrier and itsManipulation, Volumes 1 and 2, Plenum Press, N.Y., 1989)), andpermeabilization by, e.g., bradykinin or permeabilizer A-7 (see, e.g.,U.S. Pat. Nos. 5,112,596, 5,268,164, 5,506,206, and 5,686,416).

Lipid-based methods of transporting a compound of formula I (or anembodiment thereof) across the blood-brain barrier include, but are notlimited to, encapsulating the a compound of formula I or I-I (or anembodiment thereof) in liposomes that are coupled to antibody bindingfragments that bind to receptors on the vascular endothelium of theblood-brain barrier (see, e.g., U.S. Patent Publication No.2002/0025313), and coating a compound of formula I (or an embodimentthereof) in low-density lipoprotein particles (see, e.g., U.S. PatentPublication No. 2004/0204354) or apolipoprotein E (see, e.g., U.S.Patent Publication No. 2004/0131692).

Receptor and channel-based methods of transporting a compound of formulaI (or an embodiment thereof) across the blood-brain barrier include, butare not limited to, using glucocorticoid blockers to increasepermeability of the blood-brain barrier (see, e.g., U.S. PatentPublication Nos. 2002/0065259, 2003/0162695, and 2005/0124533);activating potassium channels (see, e.g., U.S. Patent Publication No.2005/0089473), inhibiting ABC drug transporters (see, e.g., U.S. PatentPublication No. 2003/0073713); coating a compound of formula I or I-I(or an embodiment thereof) with a transferrin and modulating activity ofthe one or more transferrin receptors (see, e.g., U.S. PatentPublication No. 2003/0129186), and cationizing the antibodies (see,e.g., U.S. Pat. No. 5,004,697).

For intracerebral use, in certain embodiments, the compounds can beadministered continuously by infusion into the fluid reservoirs of theCNS, although bolus injection may be acceptable. The inhibitors can beadministered into the ventricles of the brain or otherwise introducedinto the CNS or spinal fluid. Administration can be performed by use ofan indwelling catheter and a continuous administration means such as apump, or it can be administered by implantation, e.g., intracerebralimplantation of a sustained-release vehicle. More specifically, theinhibitors can be injected through chronically implanted cannulas orchronically infused with the help of osmotic minipumps. Subcutaneouspumps are available that deliver proteins through a small tubing to thecerebral ventricles. Highly sophisticated pumps can be refilled throughthe skin and their delivery rate can be set without surgicalintervention. Examples of suitable administration protocols and deliverysystems involving a subcutaneous pump device or continuousintracerebroventricular infusion through a totally implanted drugdelivery system are those used for the administration of dopamine,dopamine agonists, and cholinergic agonists to Alzheimer's diseasepatients and animal models for Parkinson's disease, as described byHarbaugh, J. Neural Transm. Suppl. 24:271, 1987; and DeYebenes et al.,Mov. Disord. 2: 143, 1987.

Indications and Methods of Treatment

The compounds of the invention inhibit RIP1 kinase activity.Accordingly, the compounds of the invention are useful for the treatmentof diseases and disorders mediated by this pathway and associated withinflammation and/or necroptotic cell death.

In some embodiments, the disease or disorder to be treated is aneurodegenerative disease or disorder. In some embodiments, the diseasesand disorders to be treated are synucleopathies such as Parkinson'sDisease, Lewy body dementia, multiple system atrophy, Parkinson-plussyndromes. In some embodiments, the diseases and disorders to be treatedare taupathies such as Alzheimer's Disease and frontotemporal dementia.In some embodiments, the diseases and disorders to be treated aredemyelination diseases such as multiple sclerosis.

In some embodiments, the diseases and disorders to be treated are otherneurodegenerative diseases such as amyotrophic lateral sclerosis, spinalmuscular atrophy, primary lateral sclerosis, Huntington's disease,ischemia, and stroke. Additional exemplary neurodegenerative diseases tobe treated as provided herein include, but are not limited to,intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy,progressive muscular atrophy, pseudobulbar palsy, progressive bulbarpalsy, spinal muscular atrophy, inherited muscular atrophy, peripheralneuropathies, progressive supranuclear palsy, corticobasal degeneration,and demyelinating diseases.

In some embodiments, the disease or disorder to be treated isAlzheimer's disease. In some embodiments, the disease or disorder to betreated is Parkinson's disease. In some embodiments, the disease ordisorder to be treated is Huntington's disease. In some embodiments, thedisease or disorder to be treated is multiple sclerosis. In someembodiments, the disease or disorder to be treated is amyotrophiclateral sclerosis (ALS). In some embodiments, the disease or disorder tobe treated is spinal muscular atrophy (SMA).

In some embodiments, the disease or disorder to be treated is aninflammatory disease or disorder. In some embodiments, the disease ordisorder to be treated is selected from the group consisting ofinflammatory bowel diseases (including Crohn's disease and ulcerativecolitis), psoriasis, retinal detachment, retinitis pigmentosa, maculardegeneration, pancreatitis, atopic dermatitis, arthritis (includingrheumatoid arthritis, osteoarthritis, spondylarthritis, gout, systemiconset juvenile idiopathic arthritis (SoJIA), psoriatic arthritis),systemic lupus erythematosus (SLE), Sjogren's syndrome, systemicscleroderma, anti-phospholipid syndrome (APS), vasculitis, liverdamage/diseases (non-alcohol steatohepatitis, alcohol steatohepatitis,autoimmune hepatitis autoimmune hepatobiliary diseases, primarysclerosing cholangitis (PSC), acetaminophen toxicity, hepatotoxicity),kidney damage/injury (nephritis, renal transplant, surgery,administration of nephrotoxic drugs e.g. cisplatin, acute kidney injury(AKI), Celiac disease, autoimmune idiopathic thrombocytopenic purpura,transplant rejection, ischemia reperfusion injury of solid organs,sepsis, systemic inflammatory response syndrome (SIRS), cerebrovascularaccident (CVA, stroke), myocardial infarction (MI), atherosclerosis,Huntington's disease, Alzheimer's disease, Parkinson's disease,amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA),allergic diseases (including asthma and atopic dermatitis), multiplesclerosis, type I diabetes, Wegener's granulomatosis, pulmonarysarcoidosis, Behcet's disease, interleukin-1 converting enzyme (ICE,also known as caspase-1) associated fever syndrome, chronic obstructivepulmonary disease (COPD), tumor necrosis factor receptor-associatedperiodic syndrome (TRAPS), periodontitis, NEMO-deficiency syndrome(F-kappa-B essential modulator gene (also known as IKK gamma or IKKG)deficiency syndrome), HOIL-1 deficiency ((also known as RBCK1)heme-oxidized IRP2 ubiquitin ligase-1 deficiency), linear ubiquitinchain assembly complex (LUBAC) deficiency syndrome, hematological andsolid organ malignancies, bacterial infections and viral infections(such as tuberculosis and influenza), and Lysosomal storage diseases(particularly, Gaucher Disease, and including GM2, Gangliosidosis,Alpha-mannosidosis, Aspartylglucosaminuria, Cholesteryl Ester storagedisease, Chronic Hexosaminidase A Deficiency, Cystinosis, Danon disease,Fabry disease, Farber disease, Fucosidosis, Galactosialidosis, GM1gangliosidosis, Mucolipidosis, Infantile Free Sialic Acid StorageDisease, Juvenile Hexosaminidase A Deficiency, Krabbe disease, Lysosomalacid lipase deficiency, Metachromatic Leukodystrophy,Mucopolysaccharidoses disorders, Multiple sulfatase deficiency,Niemann-Pick Disease, Neuronal Ceroid Lipofuscinoses, Pompe disease,Pycnodysostosis, Sandhoff disease, Schindler disease, Sialic AcidStorage Disease, Tay-Sachs and Wolman disease).

In some embodiments, the disease or disorder to be treated is aninflammatory bowel disease. In some embodiments, the disease or disorderto be treated is Crohn's disease. In some embodiments, the disease ordisorder to be treated is ulcerative colitis. In some embodiments, thedisease or disorder to be treated is glaucoma. In some embodiments, thedisease or disorder to be treated is psoriasis. In some embodiments, thedisease or disorder to be treated is rheumatoid arthritis. In someembodiments, the disease or disorder to be treated is spondyloarthritis.In some embodiments, the disease or disorder to be treated is juvenileidiopathic arthritis. In some embodiments, the disease or disorder to betreated is osteoarthritis.

In some embodiments, the method of treatment provided herein is thetreatment of one or more symptoms of a disease or disorder listed above.

Also provided herein is the use of a compound of the invention intherapy. In some embodiments, provided herein is the use of a compoundof the invention for the treatment or prevention of the above diseasesand disorders. Also provided herein is the use of a compound of theinvention in the manufacture of a medicament for the treatment orprevention of the above diseases and disorders. Also provided herein arecompounds of the invention for use in the treatment or prevention of theabove diseases and disorders.

Also provided herein is a method of treating a disease or disorder asprovided above in a mammal in need of such treatment, wherein the methodcomprises administering to said mammal a therapeutically effectiveamount of a compound of formula I, or a pharmaceutically acceptable saltthereof. In some embodiments, the mammal is a human.

Also provided herein is a method of treating a symptom of a disease ordisorder in a mammal in need of such treatment, said disease or disorderbeing selected from the group consisting of irritable bowel disorders(IBD), irritable bowel syndrome (IBS), Crohn's disease, ulcerativecolitis, myocardial infarction, stroke, traumatic brain injury,atherosclerosis, ischemia-reperfusion injury of kidneys, liver andlungs, cysplatin-induced kidney injury, sepsis, systemic inflammatoryresponse syndrome (SIRS), pancreatits, psoriasis, retinitis pigmentosa,retinal degeneration, chronic kidney diseases, acute respiratorydistress syndrome (ARDS), and chronic obstructive pulmonary disease(COPD), wherein the method comprises administering to said mammal atherapeutically effective amount of a compound of formula I, or apharmaceutically acceptable salt thereof.

Also provided herein is a method of treating a disease or disorder in ahuman patient in need of such treatment, said disease or disorder beingselected from those provided above, wherein the method comprises orallyadministering a therapeutically effective amount of a compound offormula I, or a pharmaceutically acceptable salt thereof, as an orallyacceptable pharmaceutical composition.

Combination Therapy

Compounds of the invention may be combined with one or more othercompounds of the invention or one or more other therapeutic agent as anycombination thereof, in the treatment of the diseases and disordersprovided herein. For example, a compound of the invention may beadministered simultaneously, sequentially or separately in combinationwith other therapeutic agents known to be useful for the treatment of adisease or disorder selected from those recited above.

As used herein “combination” refers to any mixture or permutation of oneor more compounds of the invention and one or more other compounds ofthe invention or one or more additional therapeutic agent. Unless thecontext makes clear otherwise, “combination” may include simultaneous orsequentially delivery of a compound of the invention with one or moretherapeutic agents. Unless the context makes clear otherwise,“combination” may include dosage forms of a compound of the inventionwith another therapeutic agent. Unless the context makes clearotherwise, “combination” may include routes of administration of acompound of the invention with another therapeutic agent. Unless thecontext makes clear otherwise, “combination” may include formulations ofa compound of the invention with another therapeutic agent. Dosageforms, routes of administration and pharmaceutical compositions include,but are not limited to, those described herein.

In some embodiments, a compound provided herein may be combined withanother therapeutically active agent as recited in WO 2016/027253, thecontents of which are hereby incorporated by reference in theirentirety. In such embodiments, the compound that inhibits RIP1 kinase inthe combinations recited in WO 2016/027253 is replaced by a compound offormula I of the present disclosure.

In some embodiments, a compound provided herein may be combined with aDLK inhibitor for the treatment of neurodegenerative diseases anddisorders, such as those listed elsewhere herein, and including but notlimited to the following: Parkinson's Disease, Lewy body dementia,multiple system atrophy, Parkinson-plus syndromes, Alzheimer's Disease,frontotemporal dementia, demyelination diseases such as multiplesclerosis, amyotrophic lateral sclerosis, spinal muscular atrophy,primary lateral sclerosis, Huntington's disease, ischemia, stroke,intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy,progressive muscular atrophy, pseudobulbar palsy, progressive bulbarpalsy, spinal muscular atrophy, inherited muscular atrophy, peripheralneuropathies, progressive supranuclear palsy, and corticobasaldegeneration. DLK inhibitors are described, for example, in WO2013/174780, WO 2014/177524, WO 2014/177060, WO 2014/111496, WO2015/091889 and WO 2016/142310.

Synthetic Schemes

Compounds of the present invention can be prepared as described in theExperimental Section. While the reaction schemes are varied to adapt toindividual compounds being prepared, the basic approaches areillustrated in Schemes A-D. Additional compounds are readily prepared bythe following general schemes. Details of the preparations can be foundin the experimental section which follows.

A variant of this procedure is described in Scheme B. This approachallows introduction of a variety of moieties into for the phenyl orheteroaryl moieties into the molecule.In some instances the cyclopropyl or bicyclopropyl ring is elaboratedafter the an acyclic fragment is introduced onto the sulfur atom the6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole fragment Scheme B

In some instances the cyclopropyl or bicyclopropyl ring is elaboratedafter introduction into the 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolefragment Scheme C

Alternatively a elaborated R¹ fragment can be introduced by condensationa sodium sulfinate salt with(5S,7S)-2-bromo-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleas depicted in scheme D

EXAMPLES

The invention will be more fully understood by reference to thefollowing examples. They should not, however, be construed as limitingthe scope of the invention.

These examples serve to provide guidance to a skilled artisan to prepareand use the compounds, compositions and methods of the invention. Whileparticular embodiment of the present invention are described, theskilled artisan will appreciate that various changes and modificationscan be made without departing from the spirit and scope of theinventions.

The chemical reactions in the examples described can be readily adaptedto prepare a number of other compounds of the invention, and alternativemethods for preparing the compounds of this invention are deemed to bewithin the scope of this invention. For example, the synthesis ofnon-exemplified compounds according to the invention can be successfullyperformed by modifications apparent to those skilled in the art, forexample, by appropriately protecting interfering group, by utilizingother suitable reagents known in the art, for example, by appropriatelyprotecting interfering groups by utilizing other suitable reagents knownin the art other than those described, and/or by making routinemodifications of reaction conditions.

In the examples below, unless otherwise indicated all temperatures areset forth in degrees Celsius. Commercially available reagents werepurchased from suppliers such as Aldrich Chemical Company, Lancaster,TCI or Maybridge and were used without further purification unlessotherwise indicated. The reactions set forth below were done generallyunder a positive pressure of nitrogen or argon or with a drying tube(unless otherwise stated) in anhydrous solvents, and the reaction flaskswere typically fitted with rubber septa for the introduction ofsubstrates and reagents via syringe. Glassware was oven dried and/orheat dried. ¹H NMR spectra were obtained in deuterated CDCl₃, d₆-DMSO,CH₃OD or d₆-acetone solvent solutions (reported in ppm) using ortrimethylsilane (TMS) or residual non-deuterated solvent peaks as thereference standard. When peak multiplicities are reported, the followingabbreviates are used: s (singlet), d (doublet), t (triplet), q(quartet), m (multiplet, br (broadened), dd (doublet of doublets), dt(doublet of triplets). Coupling constants, when given, ar reported in Hz(Hertz).

All abbreviations used to describe reagents, reaction conditions orequipment are intended to be consistent with the definitions set forthin the following list of Abbreviations. The chemical names of discretecompounds of the invention were typically obtained using the structurenaming feature of ChemDraw naming program.

Abbreviations ACN Acetonitrile

Boc tert-ButoxycarbonylDAST Diethylaminosulfur trifluorideDCE 1,2-dichloroethane

DCM Dichloromethane DMF N,N-Dimethylformamide

DMSO Dimethyl sulfoxideDPPH 2,2-Diphenyl-1-picrylhydrazyl

HPLC High Pressure Liquid Chromatography LCMS Liquid Chromatography MassSpectrometry

PCC Pyridinium chlorochromateRP Reverse phaseRT or R_(T) Retention time

SEM 2-(Trimethylsilyl)ethoxymethyl SFC Supercritical FluidChromatography

TFA Trifluoroacetic acid

THF Tetrahydrofuran Example 1: Synthetic Method 1

Step 1: tert-butyl N-(2-oxo-5-phenyl-pyrrolidin-1-yl)carbamate

To a solution of methyl 4-oxo-4-phenyl-butanoate (25000 mg, 130 mmol,1.0 equiv) in tetrahydrofuran (200 mL) and acetic acid (100 mL) wasadded tert-butyl hydrazinecarboxylate (34379 mg, 260 mmol, 2.0 equiv).The resulting mixture was heated to 60° C. for 16 h. After this time,the mixture was cooled to 0° C. and to it was added sodiumcyanoborohydride (24520 mg, 390 mmol, 3.0 equiv). The resulting mixturewas stirred at 0° C. for 1 h, then at 70° C. for 6 h. After this time,the mixture was concentrated to a viscous oil, then neutralized with 3MNaOH (200 mL) and extracted with isopropyl acetate (3×100 mL). Thecombined organics were washed with saturated sodium bicarbonate (150mL), water (150 mL), and brine (150 mL), dried over sodium sulfate andconcentrated. The residue was purified by column chromatography (silicagel, 100-200 mesh, 0 to 100% isopropyl acetate in heptane) to affordtert-butyl N-(2-oxo-5-phenyl-pyrrolidin-1-yl)carbamate (26500 mg, 74%yield) as a white solid.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.51 min, ESI+ found [M+H]=277.

Step 2: 1-amino-5-phenyl-pyrrolidin-2-one

Acetyl chloride (28.5 mL, 31400 mg, 400 mmol, 4.17 equiv) was addedslowly to methanol (100 mL) at 0° C. The mixture was stirred 15 mins at0° C., then to it was added a solution of tert-butylN-(2-oxo-5-phenyl-pyrrolidin-1-yl)carbamate (26500 mg, 95.9 mmol, 1.00equiv) in methanol (100 mL) at 0° C. The mixture was allowed to warm toRT slowly and stir 16 h. After this time, the mixture was concentratedto dryness, then partitioned between saturated sodium carbonate (300 mL)and isopropyl acetate (75 mL). The layers were separated, and theaqueous was extracted four more times with isopropyl acetate. Thecombined organics were dried over sodium sulfate and concentrated toafford 1-amino-5-phenyl-pyrrolidin-2-one (16500 mg, 98% yield) as ayellow oil which was used without further purification.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.26 min, ESI+ found [M+H]=177.

Step 3: 1-tert-butyl-3-(2-oxo-5-phenyl-pyrrolidin-1-yl)thiourea

To a solution of 1-amino-5-phenyl-pyrrolidin-2-one (8000 mg, 45.4 mmol,1.0 equiv) in 1,4-dioxane (80 mL) was added tert-butyl isothiocyanate(17.1 mL, 15689 mg, 136.2 mmol, 3.0 equiv). The resulting mixture washeated to 95° C. for 72 h and then concentrated. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 100%isopropyl acetate in heptane) to afford1-tert-butyl-3-(2-oxo-5-phenyl-pyrrolidin-1-yl)thiourea (2600 mg, 20%yield) as a white solid.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.48 min, ESI+ found [M+H]=292.

Step 4: 5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

A solution of 1-tert-butyl-3-(2-oxo-5-phenyl-pyrrolidin-1-yl)thiourea(2600 mg, 8.9 mmol, 1.0 equiv) in concentrated (˜37%) hydrochloric acid(20 mL) was heated to 90° C. for 16 hr. After this time the mixture wasconcentrated, and the residue was purified by column chromatography(silica gel, 100-200 mesh, 0 to 20% methanol in dichloromethane) toafford 5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(1600 mg, 83% yield) as a white solid.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.02 min, ESI+ found [M+H]=218.

Step 5:2-(difluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol (1400 mg,6.4 mmol, 1.0 equiv) in N,N-dimethylformamide (10 mL) was added cesiumcarbonate (5200 mg, 16 mmol, 2.5 equiv) and sodium chlorodifluoroacetate(1200 mg, 8.1 mmol, 1.3 equiv). The resulting mixture was heated to 100°C. for 16 h, then was filtered through Celite and concentrated. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 10% methanol in dichloromethane) to afford a mixture of2-(difluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(540 mg, 31% yield) as a brown oil.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.48 min, ESI+ found [M+H]=268 (difluoromethylatedproduct) and retention time 1.30 min, ESI+ found [M+H]=232 (methylatedproduct)

Step 6:2-(difluoromethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-(difluoromethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of2-(difluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(mixture from the previous step) in dichloromethane (10 ml) was added3-chloroperoxybenzoic acid (904 mg, 4.04 mmol, 2.0 equiv). The resultingmixture was stirred 16 h at RT. After this time, the mixture was dilutedwith DCM (100 mL) and quenched with a 1:1 mixture of saturated aqueoussodium thiosulfate (50 mL) and saturated aqueous sodium bicarbonate (50mL). The dichloromethane layer was washed with water and brine, driedover sodium sulfate and concentrated. The residue was partially purifiedby column chromatography (silica gel, 100-200 mesh, 0 to 15% methanol indichloromethane) to afford two fractions: one containing2-(difluoromethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(500 mg) and another fraction containing pure2-(difluoromethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(12.9 mg, 2% yield) as a white solid. The fraction containing a mixtureof two compounds was further purified by reverse phase HPLC (Gemini-NXC18, 50×30 mm column; solvent A: 0.1% ammonium hydroxide in water;solvent B: acetonitrile; gradient of 10-60% B) to afford pure2-(difluoromethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(292 mg, 51% yield) and2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(33 mg, 6% yield) as white solids.

2-(difluoromethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:¹H NMR (400 MHz, DMSO-d6) δ 7.50-7.19 (m, 6H), 5.68 (dd, J=8.1, 6.2 Hz,1H), 3.30-3.02 (m, 3H), 2.69-2.52 (m, 1H). LC-MS RT=3.96 min, m/z=284.0(M+H)⁺.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 3.96 min, ESI+ found [M+H]=284.0.

2-(difluoromethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:¹H NMR (400 MHz, DMSO-d6) δ 7.62-7.22 (m, 6H), 5.77-5.70 (m, 1H),3.30-3.03 (m, 3H), 2.78-2.54 (m, 1H). LC-MS RT=4.46 min, m/z=300.1(M+H)⁺.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.46 min, ESI+ found [M+H]=300.1.

2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:¹H NMR (400 MHz, DMSO-d6) δ 7.50-7.22 (m, 5H), 5.70-5.55 (m, 1H), 3.30(s, 3H), 3.27-2.98 (m, 3H), 2.70-2.55 (m, 1H). LC-MS RT=3.53 min,m/z=264.1 (M+H)⁺.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 3.53 min, ESI+ found [M+H]=264.1.

Step 7:(5S)-2-[(R)-difluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S)-2-[(S)-difluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

2-(difluoromethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(292 mg) was further purified by chiral SFC to afford arbitrarilyassigned:(5S)-2-[(R)-difluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 3, SFC analytical retention time=1.12 min, Chiralpak AD, isocratic10% MeOH+0.1% NH₄OH, 2.5 min method) (58.4 mg, 20%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 7.52-7.16 (m, 6H), 5.71-5.64 (m, 1H), 3.27-3.02(m, 3H), 2.69-2.56 (m, 1H). LC-MS RT=3.94 min, m/z=284.1 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 3.94 min, ESI+ found [M+H]=284.1.

(5S)-2-[(S)-difluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 4, SFC analytical retention time=1.38 min, Chiralpak AD, isocratic10% MeOH+0.1% NH₄OH, 2.5 min method) (52.1 mg, 18%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 7.51-7.16 (m, 6H), 5.72-5.64 (m, 1H), 3.28-3.01(m, 3H), 2.70-2.55 (m, 1H). LC-MS RT=3.98 min, m/z=284.1 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 3.98 min, ESI+ found [M+H]=284.1.

SFC condition (prep): Performed in two stages: First column: ChiralpakAD 250×21.2 mm, 5 am, Mobile phase: A: CO2 B: 0.1% ammonium hydroxide inmethanol, Isocratic 15% B, Flow rate: 70 mL/min, column temp 40° C.Second column: Whelk 0-1 (S,S) 150×21.2 mm, 5 m, Mobile phase: A: CO2 B:0.1% ammonium hydroxide in methanol, Isocratic 30% B, Flow rate: 70mL/min, column temp 40° C.

Example 2: Method 2

2-ethylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:2-ethylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol (300 mg,1.38 mmol, 1.0 equiv, as prepared in Method 1) in N,N-dimethylformamide(4 mL) was added cesium carbonate (900 mg, 2.76 mmol, 2.0 equiv) andiodoethane (0.332 mL, 646.0 mg, 4.14 mmol, 3.0 equiv). The mixture wasstirred at RT for 16 h. After this time, the mixture was filteredthrough Celite and concentrated. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 10% methanol indichloromethane) to afford2-ethylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(100 mg, 29% yield) as a yellow oil.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.40 min, ESI+ found [M+H]=246.

Step 2:2-ethylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of2-ethylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(100 mg, 0.41 mmol, 1.0 equiv) in acetonitrile (5 mL) was added3-chloroperoxybenzoic acid (352 mg, 2.04 mmol, 5.0 equiv). The resultingmixture was stirred 16 h at RT. LCMS looks good. Quenched with saturatedaqueous sodium thiosulfate (20 mL) and saturated aqueous sodiumbicarbonate (20 mL), then extracted with isopropyl acetate (3×50 mL).The combined organics were washed with water and brine, dried oversodium sulfate and concentrated. The residue was partially purified bycolumn chromatography (silica gel, 100-200 mesh, 0 to 15% methanol indichloromethane) and further purified by achiral SFC (Torus 1-AA column,5 to 60% 0.1% ammonium hydroxide in methanol gradient in CO2) to afford2-ethylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(38.3 mg, 34% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ7.47-7.33 (m, 3H), 7.32-7.24 (m, 2H), 5.65 (dd, J=8.1, 6.2 Hz, 1H),3.45-2.99 (m, 5H), 2.67-2.52 (m, 1H), 1.17 (t, J=7.4 Hz, 3H). LC-MSRT=3.80 min, m/z=278.1 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 3.80 min, ESI+ found [M+H]=278.1.

Example 3: Method 3

(5S)-2-[(S)-ethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of2-ethylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(90 mg, 0.37 mmol, 1.0 equiv) in acetonitrile (2 mL) cooled to 0° C. wasadded a solution of Oxone (113 mg, 0.18 mmol, 0.5 equiv) in water (1mL). The reaction mixture was slowly warmed to RT and stirred 2 h. Afterthis time, the mixture was diluted with water (50 mL) and extracted withisopropyl acetate (3×50 mL). The combined organics were washed withwater and brine, dried over sodium sulfate and concentrated. The residuewas partially purified by column chromatography (silica gel, 100-200mesh, 0 to 15% methanol in dichloromethane) to afford2-ethylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40 mg, 42% yield) as a white solid. The mixture of diastereomers wasfurther purified by chiral SFC to afford arbitrarily assigned(5S)-2-[(S)-ethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(3.6 mg, 4% yield) as a white solid. (Peak 3, SFC analytical retentiontime=0.94 min, Whelk 0-1 (S,S), isocratic 35% MeOH+0.1% NH₄OH, 2.5 minmethod) (50.8 mg, 9%) as a white solid. LC-MS RT=3.37 min, m/z=262.0(M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 3.37 min, ESI+ found [M+H]=262.0.

SFC condition (prep): Performed in two stages: First column: Whelk 0-1(S,S) 150×21.2 mm, 5 m, Mobile phase: A: CO2 B: 0.1% ammonium hydroxidein methanol, Isocratic 35% B, Flow rate: 70 mL/min, column temp 40° C.Second column: Chiralpak IC 250×21.2 mm, 5 μm, Mobile phase: A: CO2 B:0.1% ammonium hydroxide in methanol, Isocratic 40% B, Flow rate: 70mL/min, column temp 25° C.

Examples 4 and 5: Method 4

2-[difluoro(phenyl)methyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-difluoro(phenyl)methyl]sulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:2-[difluoro(phenyl)methyl]sulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol (450 mg,2.07 mmol, 1.0 equiv) in N,N-dimethylformamide (4 mL) was added cesiumcarbonate (1349 mg, 4.14 mmol, 2.0 equiv) and(bromodifluoromethyl)benzene (903 mg, 4.14 mmol, 2.0 equiv). Theresulting mixture was stirred at RT for 16 h. After this time, themixture was filtered through Celite and concentrated. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 10%methanol in dichloromethane) to afford2-[difluoro(phenyl)methyl]sulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(440 mg, 62% yield) as an orange oil.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.69 min, ESI+ found [M+H]=344.

Step 2:2-[difluoro(phenyl)methyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand2-[difluoro(phenyl)methyl]sulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of2-[difluoro(phenyl)methyl]sulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(220 mg, 0.64 mmol, 1.0 equiv) in 1,2-dichloroethane (5 mL) was added3-chloroperoxybenzoic acid (415 mg, 1.85 mmol, 2.89 equiv) and stirred16 h. The reaction was quenched with saturated aqueous sodiumthiosulfate (25 mL) and saturated aqueous sodium bicarbonate (25 mL),extracted with dichloromethane (3×50 mL). The combined organics werewashed with saturated sodium bicarbonate, water and brine, dried oversodium sulfate and concentrated. The residue was purified by reversephase HPLC (Gemini-NX C18, 50×30 mm column; solvent A: 0.1% formic acidin water; solvent B: acetonitrile; gradient of 20-70% B) to afford2-[difluoro(phenyl)methyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(47.1 mg, 16%) and2-[difluoro(phenyl)methyl]sulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(104.9 mg, 46%) as white solids. Analytical data for2-[difluoro(phenyl)methyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:1H NMR (400 MHz, DMSO-d6) δ 7.78-7.68 (m, 1H), 7.65-7.56 (m, 4H),7.48-7.35 (m, 3H), 7.30-7.23 (m, 2H), 5.72 (dd, J=8.6, 6.5 Hz, 1H),3.33-3.05 (m, 3H), 2.73-2.57 (m, 1H). LC-MS RT=5.46 min, m/z=376.1(M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 5.46 min, ESI+ found [M+H]=376.1.

Analytical data for2-[difluoro(phenyl)methyl]sulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:1H NMR (400 MHz, DMSO-d6) δ 7.60 (dt, J=7.7, 4.0 Hz, 1H), 7.54-7.19 (m,8H), 7.19-7.05 (m, 1H), 6.99 (dd, J=7.4, 2.1 Hz, 1H), 5.54 (dd, J=8.5,6.1 Hz, 1H), 3.23-2.89 (m, 3H).

LC-MS RT=4.90 min, m/z=360.1 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.90 min, ESI+ found [M+H]=360.1.

Example 6

The compound of Example 6 was prepared in Example 1 using Method 1above.

Example 7: Method 5

(S)-5-(2-fluorophenyl)-2-methylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(S)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine

To a mixture of(S)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxylicacid (1.79 g, 7.24 mmol), 4 A molecular sieve (1.0 g), triethylamine(3.03 mL, 21.72 mmol) in 1,4-dioxane (100 mL) was added azido diphenylphosphate (4.13 mL, 18.10 mmol) via syringe under nitrogen atmosphere.The mixture was stirred at 20° C. for 2 h, and then added to a mixtureof 1,4-dioxane (100 mL) and water (33 mL) at 95° C. under nitrogenatmosphere. The resulting mixture was heated at 95° C. for 18 h andquenched by addition of saturated aqueous sodium bicarbonate (4 mL). Themixture was concentrated under reduced pressure and the residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 5%methanol in dichloromethane) to afford(5S)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine(1.10 g, 70%) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 7.41-7.33(m, 1H), 7.27-7.15 (m, 2H), 7.12-7.04 (m, 1H), 5.46-5.42 (m, 1H), 5.29(s, 2H), 3.11-3.00 (m, 1H), 2.91-2.73 (m, 2H), 2.41-2.31 (m, 1H).

Step 2:(S)-2-bromo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine(600 mg, 2.75 mmol), copper(II) bromide (368 mg, 1.65 mmol) andtert-butyl nitrite (567 mg, 5.50 mmol) in acetonitrile (30 mL) washeated at 75° C. for 2 h and then quenched by addition of saturatedaqueous ammonium chloride (20 mL). The mixture was extracted withdichloromethane (2×20 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 20%ethyl acetate in petroleum ether) to afford(5S)-2-bromo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(620 mg, 80%) as a yellow solid. LCMS R_(T)=0.716 min, m/z=282.0 [M+H]+.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time 0.716 min, ESI+ found [M+H]=282.0.

Step 3:(S)-5-(2-fluorophenyl)-2-methylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S)-2-bromo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 0.11 mmol), sodium methanesulfinate (18 mg, 0.17 mmol),(1R,2R)—N¹,N²-dimethylcyclohexane-1,2-diamine (6 mg, 0.04 mmol) andbis((trifluoromethylsulfonyl)oxy) copper(II) (7 mg, 0.02 mmol) indimethyl sulfoxide (2 mL) was heated to 110° C. for 12 h. After cooledthe mixture was diluted with water (5 mL) and extracted with ethylacetate (3×10 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 25-55%/0.05% hydrochloride in water)to afford arbitrarily assigned(S)-5-(2-fluorophenyl)-2-methylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(8.8 mg, 29%, 85% ee) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ7.43-7.40 (m, 1H), 7.22-7.19 (m, 3H), 5.84-5.79 (m, 1H), 3.34-3.33 (m,1H), 3.24 (s, 3H), 3.24-3.14 (m, 2H), 2.78-2.71 (m, 1H). LCMSR_(T)=0.638 min, m/z=282.0 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time 0.638 min, ESI+ found [M+H]=282.0.

Example 8: Method 6

(S)-2-ethylsulfonyl-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(S)-5-(2-fluorophenyl)-2-iodo-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(S)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine(60 mg, 0.27 mmol), diiodomethane (368 mg, 1.37 mmol) and tert-butylnitrite (56.7 mg, 0.55 mmol) in acetonitrile (5 mL) was heated at 75° C.for 2 h and then quenched by addition of saturated aqueous ammoniumchloride (20 mL). The mixture was extracted with dichloromethane (2×20mL). The combined organics were dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetate inpetroleum ether) to afford(5S)-5-(2-fluorophenyl)-2-iodo-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(65 mg, 72%) as a light yellow solid. LCMS R_(T)=0.703 min, m/z=329.8[M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time 0.703 min, ESI+ found [M+H]=329.8.

Step 2:(S)-2-ethylsulfonyl-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(S)-2-iodo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 0.09 mmol), sodium methanesulfinate (53 mg, 0.46 mmol),(1R,2R)—N¹,N²-dimethylcyclohexane-1,2-diamine (1 mg, 0.01 mmol) andbis((trifluoromethylsulfonyl)oxy) copper(II) (4 mg, 0.01 mmol) indimethyl sulfoxide (2.5 mL) was heated to 120° C. for 2 h undermicrowave conditions. After cooled the mixture was diluted with water(10 mL) and extracted with ethyl acetate (3×10 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile20-50%/0.225% formic acid in water) to afford arbitrarily assigned(S)-2-ethylsulfonyl-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(8.3 mg, 31%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.41-7.38 (m,1H), 7.21-7.17 (m, 3H), 5.83-5.79 (m, 1H), 3.37-3.25 (m, 3H), 3.25-3.08(m, 2H), 2.75-2.70 (m, 1H), 1.25 (t, J=7.6 Hz, 3H). LCMS R_(T)=0.784min, m/z=295.9 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time 0.784 min, ESI+ found [M+H]=295.9.

Example 9

The compound of Example 6 was prepared in Example 1 using Method 1above.

Example 10: Method 7

5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:5-phenyl-2-(trifluoromethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol (500 mg,2.3 mmol, 1.0 equiv) in N,N-dimethylformamide (5 mL) was added cesiumcarbonate (750 mg, 2.3 mmol, 1.0 equiv) and3,3-dimethyl-1-(trifluoromethyl)-1,2-benziodoxole (880 mg, 2.53 mmol,1.1 equiv). The resulting mixture was stirred at RT for 72 h. After thistime, the mixture was filtered through Celite and concentrated. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 10% methanol in dichloromethane) to afford5-phenyl-2-(trifluoromethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(130 mg, 20% yield) as a yellow oil.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 2.5 mins)retention time 1.59 min, ESI+ found [M+H]=286.

Step 2:5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of5-phenyl-2-(trifluoromethylsulfanyl)-6,7-dihydro-H-pyrrolo[1,2-b][1,2,4]triazole(130 mg, 0.456 mmol, 1.0 equiv) in 1,2-dichloroethane (10 mL) was added3-chloroperoxybenzoic acid (818 mg, 3.64 mmol, 8.0 equiv). The resultingmixture was heated to 50° C. and stirred 16 h. After this time, themixture was diluted with dichloromethane (100 mL), washed with saturatedsodium bicarbonate (3×50 mL), water, and brine, dried over sodiumsulfate and concentrated. The residue was purified by reverse phase HPLC(Gemini-NX C18, 50×30 mm column; solvent A: 0.1% ammonium hydroxide inwater; solvent B: acetonitrile; gradient of 20-60% B) to afford5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(27.7 mg, 20% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ7.47-7.33 (m, 3H), 7.33-7.21 (m, 2H), 5.71 (dd, J=8.1, 6.1 Hz, 1H),3.39-3.04 (m, 3H), 2.69-2.56 (m, 1H). LC-MS RT=4.49 min, m/z=302.1(M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.49 min, ESI+ found [M+H]=302.1.

Examples 11 and 12

Compounds of Examples 11 and 12 were isolated from the mixture ofExample 1 as provided in Method 1 above.

Example 13: Method 8

Rac-(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1Rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

A mixture of 4-methoxybenzyl mercaptan (437 mg, 2.84 mmol),rac-(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(400 mg, 1.42 mmol), tris(dibenzylideneacetone)dipalladium(0) (1299 mg,1.42 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (820 mg,1.42 mmol) and triethylamine (430 mg, 4.25 mmol) in 1,4-dioxane (12 mL)was heated at 100° C. for 15 h under nitrogen atmosphere andconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 30% ethyl acetate inpetroleum ether) to affordrac-(5S,7S)-7-fluoro-2-[(4-methoxyphenyl)methylsulfanyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(500 mg, 99%) as a light yellow solid. ¹H NMR (400 MHz, CDCl₃) δ7.38-7.35 (m, 3H), 7.28-7.25 (m, 2H), 7.19-7.17 (m, 2H), 6.80-6.78 (m,2H), 6.0-5.98 (m, 0.5H), 5.86-5.84 (m, 0.5H), 5.39-5.34 (m, 1H),4.35-4.29 (m, 2H), 3.59-3.49 (m, 1H), 2.87-2.76 (m, 1H).

A solution ofrac-(5S,7S)-7-fluoro-2-[(4-methoxyphenyl)methylsulfanyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(400 mg, 1.13 mmol) in 2,2,2-trifluoroacetic acid (7 mL) was heated at90° C. for 16 h and then concentrated under reduced pressure to givecruderac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(290 mg, 100%) as a light yellow solid. LCMS R_(T)=0.785 min, m/z=236.1[M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 2mins) retention time 0.785 min, ESI+ found [M+H]=236.1

Step 2rac-(5S,7S)-2-((difluoromethyl)thio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture ofrac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(270 mg, 1.15 mmol), (2-chloro-2,2-difluoro-acetyl)oxy sodium (219 mg,1.43 mmol) and cesium carbonate (1122 mg, 3.44 mmol) in1-methyl-2-pyrrolidinone (15 mL) was heated at 100° C. for 3 h anddiluted with water (15 mL). The resulting mixture was extracted withethyl acetate (3×15 mL). The combined organic layers were washed withbrine (10 mL), dried over anhydrous sodium sulfate and concentratedunder reduced pressure. The residue was purified by RP-HPLC(acetonitrile 20-45%/0.05% HCl in water) to giverac-(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(42 mg, 13%) as a white solid. LCMS R_(T)=1.108 min, m/z=286.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 2mins) retention time 1.108 min, ESI+ found [M+H]=286.1.

Step 3rac-(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture ofrac-(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(35 mg, 0.12 mmol) and 3-chloroperoxybenzoic acid (27 mg, 0.13 mmol) indichloromethane (4 mL) was stirred at 0° C. for 3 h and quenched byaddition of saturated aqueous sodium bicarbonate (15 mL). The resultingmixture was extracted with ethyl acetate (3×15 mL). The combined organiclayers were washed with brine (15 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 25-55%/0.05% ammonia hydroxide in water) to affordarbitrarily assignedrac-(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(18 mg, 48%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38 (m,3H), 7.24-7.22 (m, 2H), 6.95-6.68 (m, 1H), 6.12-6.09 (m, 0.5H),5.95-5.90 (m, 0.5H), 5.76-5.70 (m, 0.5H), 5.53-5.51 (m, 0.5H), 3.70-3.61(m, 0.5H), 3.45-3.35 (m, 0.5H), 3.03-2.96 (m, 1H). LCMS R_(T)=0.989 min,m/z=302.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 2mins) retention time 0.989 min, ESI+ found [M+H]=302.1.

Example 14: Method 9

(5R,7R)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of arbitrarily assigned(5R,7R)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 0.28 mmol), sodium cyclopropanesulfinate (182 mg, 1.42 mmol),(1R,2R)—N¹,N²-dimethylcyclohexane-1,2-diamine (20 mg, 0.14 mmol) andpotassium carbonate (47 mg, 0.34 mmol) in dimethyl sulfoxide (5 mL) washeated at 110° C. for 2 h under microwave conditions and diluted withwater (10 mL). The mixture was extracted with ethyl acetate (3×10 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 36-66%/0.05% ammonia hydroxide in water) to affordarbitrarily assigned(5R,7R)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40.3 mg, 46%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.37 (m,3H), 7.29-7.26 (m, 2H), 6.21-6.18 (m, 0.5H), 6.07-6.04 (m, 0.5H),5.70-5.62 (m, 1H), 3.84-3.69 (m, 1H), 2.91-2.78 (m, 2H), 1.33-1.28 (m,2H), 1.19-1.11 (m, 2H). LCMS R_(T)=0.695 min, m/z=308.1 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time 0.695 min, ESI+ found [M+H]=308.1.

Examples 15 and 16

(5R)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleb][1,2,4]triazole and(5S)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5R)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to Method 1 starting from methyl4-(2-chlorophenyl)-4-oxobutanoate (Rieke Metals). Analytical data forarbitrarily assigned(5R)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:(Peak 1, SFC analytical retention time=0.74 min, Chiralpak IC, isocratic15% MeOH+0.1% NH₄OH, 2.5 min method) (52.0 mg, 9%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 7.60-7.53 (m, 1H), 7.48-7.29 (m, 3H), 7.16 (dd,J=7.5, 1.9 Hz, 1H), 6.05 (dd, J=8.6, 6.4 Hz, 1H), 3.43-3.10 (m, 3H),2.70-2.56 (m, 1H). LC-MS RT=4.86 min, m/z=334.0 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.86 min, ESI+ found [M+H]=334.0.

Analytical data for arbitrarily assigned(5S)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:(Peak 2, SFC analytical retention time=1.09 min, Chiralpak IC, isocratic15% MeOH+0.1% NH₄OH, 2.5 min method) (52.2 mg, 9%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 7.61-7.52 (m, 1H), 7.51-7.28 (m, 3H), 7.16 (dd,J=7.5, 1.9 Hz, 1H), 6.05 (dd, J=8.6, 6.4 Hz, 1H), 3.31-3.08 (m, 3H),2.70-2.57 (m, 1H). LC-MS RT=4.86 min, m/z=334.0 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.86 min, ESI+ found [M+H]=334.0.

SFC condition (prep): Chiralpak IC 250×21.2 mm, 5 μm, Mobile phase: A:CO2 B: 0.1% ammonium hydroxide in methanol, Isocratic 15% B, Flow rate:70 mL/min, column temp 40° C.

Examples 17 and 18

(5S)-5-(2-chlorophenyl)-2-[(S)-difluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S)-5-(2-chlorophenyl)-2-[(R)-difluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to Method 1 starting from methyl4-(2-chlorophenyl)-4-oxobutanoate (Rieke Metals). Analytical data for(5S)-5-(2-chlorophenyl)-2-[(S)-difluoromethylsulfinyl]-6,7-dihydro-H-pyrrolo[1,2-b][1,2,4]triazole:(Peak 2, SFC analytical retention time=0.96 min, Chiralpak IC, isocratic15% MeOH+0.1% NH₄OH, 2.5 min method) (45.3 mg, 8%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 7.56 (dd, J=7.8, 1.5 Hz, 1H), 7.53-7.18 (m,3H), 7.06 (dd, J=7.5, 1.9 Hz, 1H), 5.99 (dd, J=8.6, 6.0 Hz, 1H),3.35-3.22 (m, 1H), 3.20-3.08 (m, 2H), 2.59 (ddt, J=12.8, 8.8, 6.3 Hz,1H). LC-MS RT=4.44 min, m/z=318.0 (M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.44 min, ESI+ found [M+H]=318.0.

Analytical data for(5S)-5-(2-chlorophenyl)-2-[(R)-difluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:(Peak 3, SFC analytical retention time=1.02 min, Chiralpak IC, isocratic15% MeOH+0.1% NH₄OH, 2.5 min method) (50.8 mg, 9%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 7.61-7.52 (m, 1H), 7.52-7.20 (m, 3H), 7.08 (dd,J=7.5, 1.9 Hz, 1H), 5.99 (dd, J=8.6, 5.9 Hz, 1H), 3.34-3.25 (m, 1H),3.19-3.07 (m, 2H), 2.66-2.53 (m, 1H). LC-MS RT=4.43 min, m/z=318.0(M+H)+.

LCMS (5 to 95% acetonitrile in water+0.1% formic acid over 10 mins)retention time 4.43 min, ESI+ found [M+H]=318.0.

SFC condition (prep): Chiralpak IC 250×21.2 mm, 5 m, Mobile phase: A:CO2 B: 0.1% ammonium hydroxide in methanol, Isocratic 15% B, Flow rate:70 mL/min, column temp 25° C.

Example 19: Method 10

(5S,7S)-2-benzylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-benzylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40 mg, 0.12 mmol) in dichloromethane (3 mL) was added3-chloroperoxybenzoic acid (63 mg, 0.37 mmol). The result mixture wasstirred at 25° C. for 12 h and diluted with dichloromethane (20 mL). Themixture was washed with aqueous sodium bicarbonate (2×10 mL), brine (10mL), dried over sodium sulfate and concentrated under reduced pressure.The residue was purified by RP-HPLC (acetonitrile 40-70%/0.05% ammoniahydroxide in water) to afford arbitrarily assigned(5S,7S)-2-benzylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(13.8 mg, 30%). ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.38 (m, 5H), 7.32-7.25(m, 3H), 7.13-7.11 (m, 2H), 6.10-5.94 (m, 1H), 5.49-5.45 (m, 1H),4.65-4.57 (m, 2H), 3.69-3.58 (m, 1H), 3.01-2.90 (m, 1H). LCMSR_(T)=1.910 min, m/z=358.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 3mins) retention time 1.910 min, ESI+ found [M+H]=358.1.

Example 20: Method 11

(5S,7S)-2-benzylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-2-benzylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(10 mg, 0.35 mmol), benzyl mercaptan (100 mg, 0.81 mmol),2-(dicyclohexylphosphino)-2′,4′,6′-triisopropylbiphenyl (169 mg, 0.35mmol), triethylamine (108 mg, 1.06 mmol) andtris(dibenzylideneacetone)dipalladium(0) (325 mg, 0.35 mmol) in1,4-dioxane (12 mL) was heated at 100° C. for 15 h under nitrogenatmosphere and concentrated under reduced pressure. The residue waspurified by preparative TLC (35% ethyl acetate in petroleum ether,R_(f)=0.2) to afford arbitrarily assigned(5S,7S)-2-benzylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 69%) as a yellow solid. LCMS R_(T)=0.831 min, m/z=326.1 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time 0.831 min, ESI+ found [M+H]=326.1.

Step 2(5S,7S)-2-benzylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-benzylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(25 mg, 0.08 mmol) in dichloromethane (2 mL) was added3-chloroperoxybenzoic acid (13 mg, 0.08 mmol). The result mixture wasstirred at 0° C. for 2 h and diluted with dichloromethane (20 mL). Themixture was washed with aqueous sodium bicarbonate (2×10 mL), brine (10mL), dried over anhydrous sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile 40-70%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-benzylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(8.49 mg, 32%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.36(m, 3H), 7.28-7.26 (m, 3H), 7.21-7.15 (m, 3H), 7.12-7.09 (m, 1H),6.12-5.96 (m, 1H), 5.47-5.43 (m, 1H), 4.56-4.39 (m, 2H), 3.67-3.59 (m,1H), 3.00-2.89 (m, 1H). LCMS R_(T)=1.734 min, m/z=342.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 3mins) retention time 1.734 min, ESI+ found [M+H]=342.1.

Examples 21 and 22: Method 12

(5S,7S)-2-[(S)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

A mixture of triisopropylsilanethiol (1.02 g, 5.32 mmol),(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(1.00 g, 3.54 mmol), sodium tert-butoxide (1.02 g, 10.63 mmol) andRockphos-Pd-G3 (297 mg, 0.35 mmol) in 1,4-dioxane (10 mL) was heated at90° C. for 16 h and concentrated under reduced pressure. The residue wasdiluted with ethyl acetate (40 mL) and filtered. The filtrate wasconcentrated under reduced pressure to give crude(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(1.6 g, 100%) as a light yellow solid.

Step 2(5S,7S)-2-((difluoromethyl)thio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(800 mg, 3.40 mmol), (2-chloro-2,2-difluoro-acetyl)oxy sodium (648 mg,4.25 mmol) and cesium carbonate (2769 mg, 8.50 mmol) in1-methyl-2-pyrrolidinone (20 mL) was heated at 100° C. for 3 h and thendiluted with water (15 mL). The resulting mixture was extracted withethyl acetate (3×15 mL). The combined organic layers were washed withbrine (10 mL), dried over anhydrous sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetate inpetroleum ether) to give(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(200 mg, 21%) as a white solid. LCMS R_(T)=1.230 min, m/z=286.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 2mins) retention time 1.230 min, ESI+ found [M+H]=286.1.

Step 3(5S,7S)-2-[(S)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(200 mg, 0.70 mmol) in dichloromethane (15 mL) was added3-chloroperoxybenzoic acid (213 mg, 1.05 mmol). The reaction was stirredat 0° C. for 16 h, and then diluted with dichloromethane (20 mL). Themixture washed with saturated aqueous sodium bicarbonate (2×10 mL),brine (10 mL), dried over anhydrous sodium sulfate and concentratedunder reduced pressure. The residue was purified by RP-HPLC(acetonitrile 20-45%/0.225% HCl in water) to afford arbitrarily assigned(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(90 mg, 43%) as a colorless oil. LCMS R_(T)=1.116 min, m/z=302.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 2mins) retention time 1.116 min, ESI+ found [M+H]=302.1.

This racemic material (90 mg, 0.30 mmol) was further separated by chiralSFC to afford arbitrarily assigned:

(5S,7S)-2-[(S)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.977 min) (39.0 mg, 43%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.42-7.40 (m, 3H), 7.40-7.26 (m, 2H), 7.09-6.95(m, 1H), 6.23-6.20 (m, 0.5H), 6.08-6.06 (m, 0.5H), 5.71-5.69 (m, 1H),3.83-3.73 (m, 1H), 2.91-2.80 (m, 1H). LCMS R_(T)=1.630 min, m/z=302.0[M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.1% ammonia water over 3.0 mins)retention time 1.630 min, ESI+ found [M+H]=302.0.

(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.832 min) (40.0 mg, 43%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.43-7.41 (m, 3H), 7.30-7.22 (m, 2H), 7.09-6.95(m, 1H), 6.23-6.21 (m, 0.5H), 6.09-6.07 (m, 0.5H), 5.70-5.69 (m, 1H),3.84-3.73 (m, 1H), 2.85-2.81 (m, 1H). LCMS R_(T)=1.602 min, m/z=302.0[M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.1% ammonia water over 3.0 mins)retention time 1.602 min, ESI+ found [M+H]=302.0.

SFC condition: Column: Chiralcel AD-3 150×4.6 mm I.D., 3 um Mobilephase: A: CO₂ B: iso-propanol (0.05% DEA) Gradient: from 5% to 40% of Bin 5 min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate:2.5 mL/min Column temp. 35 OC.

Examples 23: Method 13

(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(200 mg, 0.70 mmol) in dichloromethane (15 mL) was added3-chloroperoxybenzoic acid (214 mg, 1.05 mmol). The reaction was stirredat 25° C. for 16 h and quenched by addition of saturated aqueous sodiumbicarbonate (15 mL). The resulting mixture was extracted with ethylacetate (3×15 mL). The combined organic layers were washed with brine(15 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile20-45%/0.225% HCl in water) to afford arbitrarily assigned(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(21.1 mg, 9%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.42 (m,3H), 7.30-7.27 (m, 2H), 7.08-6.95 (m, 1H), 6.24-6.22 (m, 0.5H),6.10-6.08 (m, 0.5H), 5.74-5.72 (m, 1H), 3.84-3.74 (m, 1H), 2.93-2.82 (m,1H). LCMS R_(T)=1.823 min, m/z=318.0 [M+H]+.

LCMS (10 to 80% acetonitrile in water+0.1% ammonia water over 3.0 mins)retention time 1.823 min, ESI+ found [M+H]=318.0.

Example 24: Method 14

(5S,7S)-2-(tert-butylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1(5S,7S)-2-(tert-butylthio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(200 mg, 0.71 mmol), 2-methyl-2-propanethiol (0.51 mL, 4.55 mmol),tris(dibenzylideneacetone) dipalladium(0) (629 mg, 0.69 mmol),triethylamine (215 mg, 2.13 mmol) and4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (416 mg, 0.72 mmol) in1,4-dioxane (8 mL) was heated at 100° C. for 16 h under nitrogenatmosphere. Then the mixture was added sodium hypochlorite (2 mL) andstirred for 0.5 h. Then the mixture was diluted with water (15 mL) andextracted with ethyl acetate (3×15 mL). The combined organic layers werewashed with brine (2×15 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetate inpetroleum ether) to give(5S,7S)-2-tert-butylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(160 mg, 47%, 60% purity) as a brown solid. LCMS R_(T)=0.839 min,m/z=292.1 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time: 0.839 min, ESI+ found [M+H]=292.1

Step 2(5S,7S)-2-(tert-butylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-tert-butylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 0.16 mmol) and 3-chloroperoxybenzoic acid (31 mg, 0.18 mmol) indichloromethane (2 mL) was stirred at 0° C. for 1 h and quenched byaddition of saturated aqueous sodium sulfite (2 mL). The resultingmixture was extracted with ethyl acetate (3×15 mL). The combined organiclayers were washed with brine, dried over anhydrous sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 26-56%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-tert-butylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(25.8 mg, 50%) as a colorless oil. ¹H NMR (400 MHz, CD₃OD) δ 7.40-7.38(m, 3H), 7.25-7.22 (m, 2H), 6.19-6.16 (m, 0.5H), 6.05-6.02 (m, 0.5H),5.64-5.62 (m, 1H), 3.80-3.70 (m, 1H), 2.86-2.78 (m, 1H), 1.70 (s, 9H).LCMS R_(T)=0.726 min, m/z=308.1 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time: 0.726 min, ESI+ found [M+H]=308.1.

Example 25: Method 15

(5S,7S)-2-(tert-butylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-tert-butylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 0.16 mmol) and 3-chloroperoxybenzoicacid (84 mg, 0.41 mmol) indichloromethane (2 mL) was stirred at 0° C. for 1 h and quenched byaddition of saturated aqueous sodium sulfite (2 mL). The resultingmixture was extracted with ethyl acetate (3×15 mL). The combined organiclayers were washed with brine, dried over anhydrous sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 32-62%/0.05% ammonia hydroxide in water) to affordarbitrarily assigned(5S,7S)-2-tert-butylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(32.9 mg, 61%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.38 (m,3H), 7.27-7.25 (m, 2H), 6.22-6.20 (m, 0.5H), 6.08-6.06 (m, 0.5H),5.69-5.68 (m, 1H), 3.83-3.75 (m, 1H), 2.86-2.79 (m, 1H), 1.36 (s, 9H).LCMS R_(T)=0.612 min, m/z=324.1 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoacetic acid over 1.5mins) retention time: 0.612 min, ESI+ found [M+H]=324.1.

Example 26: Method 16

(5S,7S)-2-(benzenesulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1(5S,7S)-7-fluoro-5-phenyl-2-(phenylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(0.1 mL, 0.64 mmol), phenylboronic acid (0.22 mL, 1.91 mmol),2,2′-bipyridine (33 mg, 0.21 mmol), copper(I) thiophene-2-carboxylate(41 mg, 0.21 mmol), sodium carbonate (203 mg, 1.91 mmol) in1,2-dichloroethane (3 mL) was stirred at 70° C. for 5 h. The mixture wasquenched by addition of saturated aqueous ammonium chloride (20 mL). Theresulting mixture was extracted with ethyl acetate (3×15 mL). Thecombined organic layers were concentrated under reduce pressure and theresidue was purified by preparative TLC (50% ethyl acetate in petroleumether) to afford(5S,7S)-7-fluoro-5-phenyl-2-phenylsulfanyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(60 mg, 30%) as a colorless oil. LCMS R_(T)=1.309 min, m/z=312.1 [M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoacetic acid over 2mins) retention time 1.309 min, ESI+ found [M+H]=312.1.

Step 2(5S,7S)-2-(benzenesulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-7-fluoro-5-phenyl-2-phenylsulfanyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 0.10 mmol) and 3-chloroperoxybenzoic acid (83 mg, 0.48 mmol) indichloromethane (3 mL) was stirred at 0° C. for 2 h and then dilutedwith dichloromethane (20 mL). The mixture was washed with saturatedaqueous sodium bicarbonate (2×10 mL), brine (10 mL), dried overanhydrous sodium sulfate and concentrated under reduced pressure. Theresidue was purified by RP-HPLC (acetonitrile 40-70%/0.05% ammoniahydroxide in water) to afford arbitrarily assigned(5S,7S)-2-(benzenesulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(10.8 mg, 32%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d,J=7.2 Hz, 2H), 7.73-7.62 (m, 1H), 7.61-7.53 (m, 2H), 7.40-7.38 (m, 3H),7.22-7.20 (m, 2H), 6.04-5.88 (m, 1H), 5.49-5.46 (m, 1H), 3.67-3.54 (m,1H), 2.99-2.89 (m, 1H). LCMS R_(T)=0.879 min, m/z=343.9 [M+H]⁺.

Example 27, 28 and 29: Method 43(5S,7S)-2-cyclopropylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-[(R)-cyclopropylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-[(S)-cyclopropylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1: 2-ethylhexyl3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)propanoate

A mixture of tris(dibenzylideneacetone)dipalladium(0) (1.95 g, 2.13mmol),(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(3.0 g, 10.6 mmol), 3-mercaptopropionic acid 2-ethylhexylester (3.0 g,1.89 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (6.1 g, 10.6mmol) and triethylamine (3.2 g, 31.9 mmol) in 1,4-dioxane (60 mL) wasstirred at 110° C. for 15 h under nitrogen atmosphere. The mixture wasdiluted with water (100 mL) and extracted with ethyl acetate (3×50 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 30% ethyl acetate inpetroleum ether) to afford 2-ethylhexyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(2.7 g, 61%) as a light yellow oil. LCMS R_(T)=1.355 min, m/z=420.3[M+H]⁺.

LCMS (10 to 80% acetonitrile in water+0.03% trifluoroacetic acid over2.0 mins) retention time 1.355 min, ESI+ found [M+H]=420.3.

Step 2:(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

To a solution of 1-ethylhexyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(2.7 g, 6.44 mmol) in ethanol (50 mL) was added sodium ethoxide (1.31 g,19.31 mmol). The mixture was stirred at 25° C. for 1 h and concentratedunder reduced pressure. The residue was diluted with water (30 mL),washed with ethyl acetate (20 mL) and adjusted to pH=6 by addition ofcitric acid. The resulting mixture was extracted with ethyl acetate(3×20 mL). The combined organic layers were dried over sodium sulfateand concentrated under reduced pressure to afford crude(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(2.1 g, 100%) as a yellow solid. LCMS R_(T)=0.454 min, m/z=236.1 [M+H]⁺.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoroacetic acid over 1.5mins) retention time 0.454 min, ESI+ found [M+H]=236.1.

Step 3:(5S,7S)-2-(cyclopropylthio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a mixture of 2,2′-bipyridine (22 mg, 0.14 mmol),(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(100 mg, 0.43 mmol), cyclopropylboronic acid (109 mg, 1.7 mmol),copper(I) thiophene-2-carboxylate (27 mg, 0.14 mmol) and sodiumcarbonate (135 mg, 1.27 mmol) in 1,2-dichloroethane (5 mL) was stirredat 70° C. for 5 h and concentrated under reduced pressure. The residuewas purified by preparative TLC (50% ethyl acetate in petroleum ether,R_(f)=0.5) to afford(5S,7S)-2-(cyclopropylthio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 17%) as a yellow oil. LCMS R_(T)=0.638 min, m/z=276.1 [M+H]⁺.

Step 4

To a solution of(5S,7S)-2-cyclopropylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20 mg, 0.07 mmol) in dichloromethane (1 mL) was added3-chloroperoxybenzoic acid (85%, 15 mg, 0.07 mmol). The resultingmixture was stirred at 0° C. for 2 h and quenched by addition ofsaturated aqueous sodium bicarbonate (10 mL). The mixture was extractedwith dichloromethane (2×20 mL). The combined organic layers were driedover sodium sulfate and concentrated under reduced pressure. The residuewas purified by RP-HPLC (acetonitrile 40-70%/0.05% ammonia hydroxide inwater) to give(5S,7S)-2-cyclopropylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(13.1 mg, 61%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.17(m, 3H), 7.13-7.06 (m, 2H), 6.05-5.76 (m, 1H), 5.37-5.21 (m, 1H),3.59-3.48 (m, 1H), 2.96-2.74 (m, 1H), 2.73-2.52 (m, 1H), 1.28-1.15 (m,1H), 1.01-0.85 (m, 3H). LC-MS R_(T)=0.795 min, m/z=291.9 [M+H]⁺.

(5S,7S)-2-[(R)-cyclopropylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2 on SFC, retention time=4.926 min) (20.8 mg, 13%) as a pinksolid. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38 (m, 3H), 7.27-7.24 (m, 2H),6.15-5.95 (m, 1H), 5.53-5.48 (m, 1H), 3.71-3.62 (m, 1H), 3.03-2.97 (m,1H), 2.82-2.77 (m, 1H), 1.37-1.35 (m, 1H), 1.11-1.02 (m, 3H). LC-MSR_(T)=0.779 min, m/z=292.0 [M+H]+.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoroacetic acid over 1.5mins) retention time 0.779 min, ESI⁺ found [M+H]=292.0.

(5S,7S)-2-[(S)-cyclopropylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1 on SFC, retention time=4.304 min) (25 mg, 15%) as a pink solid.¹H NMR (400 MHz, CDCl₃) δ 7.43-7.37 (m, 3H), 7.27-7.22 (m, 2H),6.12-5.95 (m, 1H), 5.52-5.48 (m, 1H), 3.71-3.62 (m, 1H), 3.02-2.95 (m,1H), 2.79-2.75 (m, 1H), 1.35-1.33 (m, 1H), 1.10-1.01 (m, 3H). LC-MSR_(T)=0.769 min, m/z=291.9 [M+H]+.

LCMS (5 to 95% acetonitrile in water+0.03% trifluoroacetic acid over 1.5mins) retention time 0.769 min, ESI⁺ found [M+H]=291.9.

Analytical SFC conditions: Column: ChiralPak AD-3 150×4.6 mm I.D., 3 μm;Mobile phase: A: CO2 B: Ethanol (0.05% DEA); Gradient: from 5% to 40% ofB in 5.5 min and hold 40%; for 3 min, then 5% of B for 1.5 min; Flowrate: 2.5 mL/min Column temperature: 40° C.

Example 30: Method 17(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 0.18 mmol), sodium cyclopropanesulfinate (113 mg, 0.89 mmol),copper(I) iodide (8 mg, 0.04 mmol),(1R,2R)—N1,N2-dimethyl-1,2-cyclohexanediamine (13 mg, 0.09 mmol) andpotassium carbonate (29 mg, 0.21 mmol) in dimethyl sulfoxide (5 mL) washeated at 110° C. under microwave conditions for 1 h. The mixture wasdiluted with water (5 mL) and extracted with ethyl acetate (2×10 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 33-63%/0.05% ammonia hydroxide in water) to afford(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(26 mg, 47%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.39 (m,3H), 7.26-7.24 (m, 2H), 6.11 (dd, J=1.6, 7.6 Hz, 0.5H), 5.99 (d, J=5.6Hz, 0.5H), 5.56-5.49 (m, 1H), 3.70-3.61 (m, 1H), 3.06-2.92 (m, 1H),2.78-2.71 (m, 1H), 1.52-1.43 (m, 2H), 1.16-1.11 (m, 2H). LC-MSR_(T)=0.736 min, m/z=308.1 [M+H]⁺.

Example 31: Method 1(4S,6S)-2-cyclopropylsulfonyl-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole

(4S,6S)-2-cyclopropylsulfonyl-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolewas prepared according to Method 3 starting fromcis-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-thiol. Thefinal compound was purified by chiral SFC to give(4S,6S)-2-cyclopropylsulfonyl-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole(Peak 2, Retention time=3.894 min) (24 mg, 43%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.40-7.35 (m, 3H), 7.22-7.20 (m, 2H), 6.89 (s, 1H),6.10 (d, J=6.4 Hz, 0.5H), 5.95 (d, J=6.4 Hz, 0.5H), 5.55-5.52 (m, 1H),3.56-3.48 (m, 1H), 2.92-2.82 (m, 1H), 2.65-2.61 (m, 1H), 1.38-1.36 (m,2H), 1.05-1.03 (m, 2H). LC-MS R_(T)=0.835 min, m/z=306.9 [M+H]⁺.

SFC condition: Column: OJ-H (250 mm×30 mm, 5 μm); Mobile phase: A: CO₂B: 0.1% NH₃H₂O EtOH; Gradient: from 30% to 30% of B; Flow rate: 50mL/min Column temperature: 40° C.

Example 32: Method 18(5S,7S)-5-(2-chlorophenyl)-2-(cyclopropylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2-chlorophenyl)-2-(cyclopropylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to Method 18 starting from(5S,7S)-7-fluoro-5-(2-chlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from 2-chlorobenzaldehyde).The final compound was purified by RP-HPLC (acetonitrile 40-70%/0.05%ammonia hydroxide in water) to give(5S,7S)-5-(2-chlorophenyl)-2-(cyclopropylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(42.8 mg, 64%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.47-7.44 (m,1H), 7.36-7.22 (m, 3H), 6.75 (dd, J=1.2, 7.6 Hz, 1H), 6.12-5.93 (m, 2H),3.80-3.65 (m, 1H), 2.94-2.81 (m, 1H), 2.80-2.76 (m, 1H), 1.55-1.48 (m,2H), 1.20-1.13 (m, 2H). LC-MS R_(T)=0.798 min, m/z=342.1 [M+H]⁺.

Example 33: Method 18(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from 2-fluorobenzaldehyde).The final compound was purified by RP-HPLC (acetonitrile 44-74%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 53%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.37 (m,1H), 7.19-7.15 (m, 2H), 7.12-6.99 (m, 1H), 6.14-5.98 (m, 1H), 5.88-5.84(m, 1H), 3.77-3.71 (m, 1H), 3.00-2.90 (m, 1H), 2.79-2.75 (m, 1H),1.52-1.48 (m, 2H), 1.19-1.15 (m, 2H). LCMS R_(T)=0.831 min, m/z=325.9[M+H]⁺.

Example 34(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to methos 18 starting from(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from 4-fluorobenzaldehyde).The final compound was purified by RP-HPLC (acetonitrile 28-58%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(33 mg, 43%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.41-7.29 (m,2H), 7.19-7.15 (m, 2H), 6.24-6.02 (m, 1H), 5.68 (s, 1H), 3.83-3.69 (m,1H), 2.94-2.76 (m, 2H), 1.38-1.30 (m, 2H), 1.22-1.08 (m, 2H). LCMSRT=0.961 min, m/z=326.2 [M+H]⁺.

Example 35(5S,7S)-2-cyclopropylsulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from2,6-difluorobenzaldehyde). The final compound was purified by RP-HPLC(acetonitrile 30-60/0.05% ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfanyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(24 mg, 28%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.57-7.44 (m,1H), 7.11-7.07 (m, 2H), 6.26-6.07 (m, 1H), 6.03-5.95 (m, 1H), 3.93-3.79(m, 1H), 3.03-2.88 (m, 1H), 2.88-2.79 (m, 1H), 1.36-1.25 (m, 2H),1.20-1.11 (m, 2H). LCMS R_(T)=0.973 min, m/z=344.1 [M+H]⁺.

Example 36(5R,7R)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5R,7R)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5R,7R)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from2,3-difluorobenzaldehyde). The final compound was purified by RP-HPLC(acetonitrile 35-65%/0.225% formic acid in water) to give(5R,7R)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(51 mg, 56%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.17 (m,1H), 7.16-7.08 (m, 1H), 6.81-6.68 (m, 1H), 6.13 (dd, J=2.0, 7.6 Hz,0.5H), 5.99 (J=5.2 Hz, 0.5H), 5.91-5.81 (m, 1H), 3.78-3.70 (m, 1H),3.03-2.89 (m, 1H), 2.79-2.69 (m, 1H), 1.51-1.48 (m, 2H), 1.18-1.14 (m,2H). LCMS R_(T)=0.641 min, m/z=344.1 [M+H]⁺.

Example 37(5S,7S)-2-(cyclopropylsulfonyl)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from2,5-difluorobenzaldehyde). The final compound was purified by RP-HPLC(acetonitrile 30-60/0.05% ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(22 mg, 36%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.17-7.04 (m,2H), 6.70-6.64 (m, 1H), 6.14-5.95 (m, 1H), 5.85-5.77 (m, 1H), 3.84-3.59(m, 1H), 3.07-2.87 (m, 1H), 2.84-2.70 (m, 1H), 1.53-1.50 (m, 2H),1.19-1.15 (m, 2H). LCMS R_(T)=1.001 min, m/z=344.1 [M+H]⁺.

Example 38(5S,7S)-2-(cyclopropylsulfonyl)-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,36-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(2,3,6-trifluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from2,3,6-trifluorobenzaldehyde). The final compound was purified by RP-HPLC(acetonitrile 40-50%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(19.1 mg, 19%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.46-7.43 (m,1H), 7.12-7.09 (m, 1H), 6.26 (dd, J=4.0, 8.0 Hz, 0.5H), 6.11 (d, J=7.6Hz, 0.5H), 6.09-6.00 (m, 1H), 3.92-3.85 (m, 1H), 2.98-2.86 (m, 1H),2.85-2.82 (m, 1H), 1.32-1.28 (m, 2H), 1.17-1.15 (m, 2H). LCMSR_(T)=0.988 min, m/z=362.1 [M+H]⁺.

Example 39(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(2,3,5-trifluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from2,3,5-trifluorobenzaldehyde). The final compound was purified by RP-HPLC(acetonitrile 39-69%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(9.5 mg, 9%) as a brown solid. ¹H NMR (400 MHz, CD₃OD) δ 7.32-7.25 (m,1H), 6.81-6.78 (m, 1H), 6.24-6.08 (m, 1H), 5.97-5.92 (m, 1H), 3.90-3.77(m, 1H), 2.98-2.85 (m, 2H), 1.36-1.29 (m, 2H), 1.20-1.14 (m, 2H). LCMSR_(T)=1.025 min, m/z=362.1 [M+H]⁺.

Example 40(5S,7S)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 21 starting from2,3-difluorobenzaldehyde). The final compound was purified by RP-HPLC(acetonitrile 35-65%/0.225% formic acid in water) to give(5S,7S)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(45 mg, 53%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.28 (m,1H), 7.25-7.17 (m, 1H), 6.97-6.91 (m, 1H), 6.21-6.19 (m, 0.5H),6.07-6.05 (m, 0.5H), 5.97-5.89 (m, 1H), 3.89-3.74 (m, 1H), 2.95-2.80 (m,2H), 1.34-1.25 (m, 2H), 1.16-1.13 (m, 2H). LCMS R_(T)=0.641 min,m/z=344.1 [M+H]+.

Example 41: Method 19(5S,7S)-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:tert-butyl-[(2-cyclopropylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)oxy]-dimethyl-silane

A mixture of 2,2′-bipyridine (315 mg, 2.0 mmol),7-[tert-butyl(dimethyl)silyl]oxy-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(3.5 g, 10.0 mmol) sodium carbonate (3.2 g, 30.2 mmol) and copper(I)thiophene-2-carboxylate (1.9 g, 10.1 mmol) in 1,2-dichloroethane (100mL) was stirred at 50° C. for 3 h and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 40% ethyl acetate in petroleum ether) to affordtert-butyl-[(2-cyclopropylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)oxy]-dimethyl-silane(2.5 g, 64%) as a brown solid.

Step 2:tert-butyl-[(2-cyclopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)oxy]-dimethyl-silane

A mixture oftert-butyl-[(2-cyclopropylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)oxy]-dimethyl-silane(2.5 g, 6.45 mmol) and 3-chloroperoxybenzoic acid (3.3 g, 19.4 mmol) indichloromethane (20 mL) was stirred at 20° C. for 16 h and diluted withwater (20 mL). The mixture was extracted with ethyl acetate (3×20 mL).The combined organic layers were washed with brine (20 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 50%ethyl acetate in petroleum ether) to affordtert-butyl-(2-cyclopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)oxy]-dimethyl-silane(2.0 g, 74%) as a white solid. LCMS R_(T)=0.858 min, m/z=420.0 [M+H]⁺.

Step 3:2-cyclopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol

To a solution oftert-butyl-[(2-cyclopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)oxy]-dimethyl-silane(2.0 g, 4.77 mmol) was added hydrochloric acid (4.0 M in 1,4-dioxane, 20mL, 80.0 mmol). The mixture was stirred at 25° C. for 6 h andconcentrated under reduced pressure. The residue was diluted with ethylacetate (50 mL) and washed with brine (2×20 mL), dried over sodiumsulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 60%ethyl acetate in petroleum ether) to afford2-cyclopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol(1.4 g, 96%) as a white solid.

Step 4:2-cyclopropylsulfonyl-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-7-one

To a solution of2-cyclopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol(1.38 g, 4.5 mmol) in 1,2-dichloroethane (20 mL) was added manganesedioxide (1.9 g, 22.6 mmol). The mixture was stirred at 60° C. for 4 hand diluted with water (20 mL). The resulting mixture was extracted withethyl acetate (3×20 mL). The combined organic layers were washed withbrine (2×20 mL), dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography(silica gel, 100-200 mesh, 0 to 30% ethyl acetate in petroleum ether) toafford2-cyclopropylsulfonyl-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-7-one(1.0 g, 73%) as a white solid. LCMS R_(T)=0.583 min, m/z=304.1 [M+H]⁺.

Step 5:cis-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-7-ol

To a mixture of2-cyclopropylsulfonyl-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-7-one(0.95 g, 3.1 mmol) in methanol (10 mL) was added sodium borodeuteride(393 mg, 9.4 mmol). The mixture was stirred at 20° C. for 1 h andconcentrated under reduced pressure. The residue was diluted with water(50 mL) and extracted with ethyl acetate (3×30 mL). The combined organiclayers were washed with brine (40 mL), dried over sodium sulfate andconcentrated to afford crudecis-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-7-ol(0.5 g, 52%) as a yellow solid. LCMS R_(T)=0.566 min, m/z=307.1 [M+H]⁺.

Step 6:trans-7-chloro-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazole

To a mixture ofcis-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazol-7-ol(50 mg, 0.16 mmol) in dichloromethane (10 mL) was added sulfurylchloride (66 mg, 0.49 mmol). The mixture was stirred at 20° C. for 1 hand concentrated under reduced pressure. The residue was diluted withwater (20 mL) and extracted with ethyl acetate (3×20 mL). The combinedorganic layers were washed with brine (30 mL), dried over sodium sulfateand concentrated to afford crudetrans-7-chloro-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazole(30 mg, 57%) as a yellow solid. LCMS R_(T)=0.889 min, m/z=325.0 [M+H]⁺.

Step 7:(5S,7S)-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture oftrans-7-chloro-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazole(120 mg, 0.37 mmol) and Raney Nickle (108 mg, 1.85 mmol) in methanol (15mL) was hydrogenated (15 psi) at 25° C. for 2 h and filtered. Thefiltrate was concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 50%ethyl acetate in petroleum ether) to affordcis-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 47%) as a white solid. LCMS R_(T)=0.609 min, m/z=291.1 [M+H]⁺.

The cis mixture was further separated by chiral SFC to give arbitrarilyassigned:

(5R,7R)-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.083 min) (2.5 mg, 5%) as a white solid. ¹H NMR(400 MHz, CD₃OD) δ 7.41-7.34 (m, 3H), 7.26-7.21 (m, 2H), 5.61-5.56 (m,1H), 3.27-3.19 (m, 1H), 3.12-3.06 (m, 1H), 2.86-2.74 (m, 1H), 2.74-2.62(m, 1H), 1.29-1.23 (m, 2H), 1.15-1.10 (m, 2H). LCMS R_(T)=1.455 min,m/z=291.1 [M+H]⁺.

(5S,7S)-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.591 min) (11.4 mg, 22%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.42-7.30 (m, 3H), 7.27-7.22 (m, 2H), 5.60-5.55(m, 1H), 3.27-3.19 (m, 1H), 3.13-3.06 (m, 1H), 2.85-2.72 (m, 1H),2.76-2.60 (m, 1H), 1.30-1.24 (m, 2H), 1.16-1.11 (m, 2H). LCMSR_(T)=1.453 min, m/z=291.1 [M+H]⁺.

SFC condition: Column: Chiralpak IC 100*4.6 mm I.D., 3 μm Mobile phase:40% of ethanol (0.05% DEA) in CO₂ Flow rate: 3 mL/min Column temp: 40°C.

Example 42(5S,7S)-2-(cyclopropylsulfonyl)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(cyclopropylsulfonyl)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 23 starting from 3,5-difluorobenzoicacid). The final compound was purified by RP-HPLC (acetonitrile44-74%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(21.5 mg, 60%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 6.89-6.77 (m,3H), 6.14-5.95 (m, 1H), 5.53-5.48 (m, 1H), 3.76-3.59 (m, 1H), 3.04-2.91(m, 1H), 2.78-2.74 (m, 1H), 1.53-1.47 (m, 2H), 1.17-1.15 (m, 2H). LC-MSR_(T)=0.972 min, m/z=344.1 [M+H]

Example 43(5S,7S)-5-(3-chlorophenyl)-2-(cyclopropylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-7-fluoro-5-(3-chlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 23 starting from ethyl 3-chlorobenzoate).The final compound was purified by RP-HPLC (acetonitrile 35-65%/0.225%formic acid in water) to give(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(85 mg, 59%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.31 (m,2H), 7.26-7.24 (m, 1H), 7.16-7.10 (m, 1H), 6.14-5.95 (m, 1H), 5.56-5.45(m, 1H), 3.78-3.57 (m, 1H), 3.06-2.87 (m, 1H), 2.80-2.70 (m, 1H),1.52-1.39 (m, 2H), 1.22-1.07 (m, 2H). LCMS R_(T)=0.918 min, m/z=341.9[M+H]⁺.

Example 44(5S,7S)-2-cyclopropylsulfonyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-2-cyclopropylsulfanyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of 2,2′-bipyridine (17 mg, 0.11 mmol),(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(150 mg, 0.55 mmol), cyclopropylboronic acid (143 mg, 0.55 mmol),copper(I)thiophene-2-carboxylate (105 mg, 0.55 mmol) and sodiumcarbonate (176 mg, 1.66 mmol) in 1,2-dichloroethane (7.5 mL) was stirredat 50° C. for 3 h and concentrated under reduced pressure. The residuewas purified by preparative TLC (50% ethyl acetate in petroleum ether,R_(f)=0.5) to afford (5S,7S)-2-cyclopropylsulfanyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 47%) as a yellow solid. LCMS R_(T)=0.868 min, m/z=312.0 [M+H]⁺.

Step 2:(5S,7S)-2-cyclopropylsulfonyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of ruthenium(III) chloride (5 mg, 0.03 mmol), sodium periodate(220 mg, 1.03 mmol) and(5S,7S)-2-cyclopropylsulfanyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 0.26 mmol) in acetonitrile (2.5 mL)/water (2.5 mL)/ethyl acetate(2.5 mL) was stirred at 30° C. for 1 h and filtered. The filtrate wasdiluted with water (10 mL) and extracted with ethyl acetate (3×10 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduce pressure. The residue was purified by RP-HPLC(acetonitrile 35-65%/0.05% ammonia hydroxide in water) to afford(5S,7S)-2-cyclopropylsulfonyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(67.7 mg, 87%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.18 (m,1H), 7.14-7.12 (m, 1H), 7.11-7.05 (m, 1H), 6.15-5.97 (m, 1H), 5.55-5.45(m, 1H), 3.73-3.59 (m, 1H), 3.03-2.86 (m, 1H), 2.81-2.70 (m, 1H),1.52-1.46 (m, 2H), 1.20-1.13 (m, 2H). LCMS R_(T)=0.902 min, m/z=343.9[M+H]⁺.

Example 45(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(2-chloro-3-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 23 starting from 2-chloro-3-fluorobenzoicacid). The final compound was purified by chiral SFC to give(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(10.1 mg, 22% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ7.40-7.32 (m, 2H), 6.78-6.75 (m, 1H), 6.23-6.06 (m, 2H), 3.92-3.81 (m,1H), 2.92-2.78 (m, 2H), 1.36-1.32 (m, 2H), 1.21-1.17 (m, 2H). LC-MSR_(T)=0.914 min, m/z=360.0 [M+H]⁺.

SFC condition (prep): Column: DAICEL CHIRALCEL OJ-H (250 mm×30 mm, 5μm); Mobile phase: A: CO₂ B: 0.1% NH₃H₂O EtOH; Gradient: from 25% to 25%of B; Flow rate: 50 mL/min Column temperature: 40° C.

Example 46(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(3-chloro-2-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 23 starting from 3-chloro-2-fluorobenzoicacid). The final compound was purified by RP-HPLC (acetonitrile40-70%/0.05% hydrochloric acid in water) to give(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(41.2 mg, 26%) as white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.58-7.53 (m,1H), 7.23 (t, J=8.0 Hz, 1H), 7.13-7.08 (m, 1H), 6.24-6.07 (m, 1H),5.96-5.91 (m, 1H), 3.90-3.76 (m, 1H), 2.95-2.83 (m, 2H), 1.36-1.30 (m,2H), 1.20-1.14 (m, 2H). LCMS R_(T)=0.923 min, m/z=359.9 [M+H]⁺.

Example 47(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-(cyclopropylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(5-chloro-2-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 23 starting from 5-chloro-2-fluorobenzoicacid). The final compound was purified by RP-HPLC (acetonitrile45-75/0.225% formic acid in water) to give(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40 mg, 46%) as a white solid. ¹H NMR (400 MHz, CDCl₃) 7.38-7.31 (m,1H), 7.17-7.04 (m, 1H), 6.98-6.94 (m, 1H), 6.17-5.96 (m, 1H), 5.81-5.76(m, 1H), 3.77-3.69 (m, 1H), 3.00-2.89 (m, 1H), 2.83-2.73 (m, 1H),1.55-1.45 (m, 2H), 1.23-1.12 (m, 2H). LCMS R_(T)=0.995 min, m/z=360.1[M+H]⁺.

Example 48

(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo5-[1,2-b][1,2,4]triazole

(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to Method 23 starting from 3-fluorobenzaldehyde).The final compound was purified by RP-HPLC (acetonitrile 30-60%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(37 mg, 47%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.48-7.43 (m,1H), 7.15-7.04 (m, 3H), 6.25-6.02 (m, 1H), 5.77-5.65 (m, 1H), 3.82-3.75(m, 1H), 2.91-2.80 (m, 2H), 1.38-1.25 (m, 2H), 1.21-1.07 (m, 2H). LCMSR_(T)=1.005 min, m/z=326.1 [M+H]⁺.

Example 49(5S,7S)-2-(3,3-difluorocyclobutyl)sulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-(3,3-difluorocyclobutyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 0.09 mmol) in dichloromethane (2 mL) was added3-chloroperoxybenzoic acid (85%, 19 mg, 0.09 mmol). The mixture wasstirred at 0° C. for 2 h and quenched by addition of saturated aqueoussodium bicarbonate (10 mL). The resulting mixture was extracted withethyl acetate (3×15 mL). The combined organic layers were washed withbrine (30 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile 25-55%/0.05%ammonia hydroxide in water) to afford(5S,7S)-2-(3,3-difluorocyclobutyl)sulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(16.4 mg, 51%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.25-7.22 (m, 2H), 6.10-5.94 (m, 1H), 5.52-5.47 (m, 1H), 3.78-3.72(m, 1H), 3.71-3.58 (m, 1H), 3.46-3.26 (m, 1H), 3.02-2.92 (m, 2H),2.91-2.80 (m, 1H), 2.78-2.65 (m, 1H). LCMS R_(T)=0.997 min, m/z=342.1[M+H]⁺.

Example 50: Method 20(5S,7S)-2-(3,3-difluorocyclobutyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanone

A mixture of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(400 mg, 1.70 mmol) and 3-bromocyclobutanone (329 mg, 2.21 mmol) inN,N-dimethylformamide (10 mL) was added sodium hydride (60%, 102 mg,2.55 mmol) at 0° C. under nitrogen atmosphere. The mixture was stirredat 20° C. for 16 h and quenched by addition of water (20 mL). Theresulting mixture was extracted with ethyl acetate (3×20 mL). Thecombined organic layers were dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 30% ethyl acetate inpetroleum ether) to afford3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanone(300 mg, 58%) as a yellow oil. LCMS R_(T)=1.660 min, m/z=304.1 [M+H]⁺.

Step 2:(5S,7S)-2-(3,3-difluorocyclobutyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanone(120 mg, 0.40 mmol) in dichloromethane (2 mL) was addeddiethylaminosulfur trifluoride (0.5 mL, 1.98 mmol). The mixture wasstirred at 25° C. for 2 h and diluted with dichloromethane (20 mL). Theseparated organic layer was washed with saturated aqueous sodiumbicarbonate (2×15 mL), brine (20 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified bypreparative TLC (30% ethyl acetate in petroleum ether) to afford(5S,7S)-2-(3,3-difluorocyclobutyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(60 mg, 47%) as a brown oil. LCMS R_(T)=0.721 min, m/z=326.1 [M+H]⁺.

Step 3:(5S,7S)-2-(3,3-difluorocyclobutyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-(3,3-difluorocyclobutyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(60 mg, 0.18 mmol) in dichloromethane (1.0 mL) was added3-chloroperoxybenzoic acid (85%, 112 mg, 0.55 mmol). The mixture wasstirred at 25° C. for 2 h and quenched by addition of saturated aqueoussodium bicarbonate (10 mL). The resulting mixture was extracted withethyl acetate (3×15 mL). The combined organic layers were washed withbrine (30 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile 35-65%/0.05%ammonia hydroxide in water) to afford(5S,7S)-2-(3,3-difluorocyclobutyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(28 mg, 42%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.41 (m,3H), 7.27-7.23 (m, 2H), 6.13-6.11 (m, 0.5H), 6.00-5.97 (m, 0.5H),5.55-5.52 (m, 1H), 4.00-3.96 (m, 1H), 3.72-3.65 (m, 1H), 3.26-3.22 (m,2H), 3.07-2.90 (m, 3H). LCMS R_(T)=1.064 min, m/z=358.1 [M+H]⁺.

Example 51, 52 and 53: Method 21(5S,7S)-2-((S)-(difluoromethyl)sulfinyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(51),(5S,7S)-2-((R)-(difluoromethyl)sulfinyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(52) and(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(53)

Step 1: 1-(2-fluorophenyl)but-3-en-1-ol

To a solution of 2-fluorobenzaldehyde (15.0 g, 120.86 mmol) intetrahydrofuran (250 mL) was added allylmagnesium bromide (1.0 M intetrahydrofuran, 150.0 mL, 150.0 mmol) at 0° C. under nitrogenatmosphere. After addition, the mixture was allowed to warm to 25° C.and stirred for 2 h before quenched by addition of saturated aqueousammonium chloride (100 mL). The resulting mixture was extracted withethyl acetate (2×100 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduce pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 5%ethyl acetate in petroleum ether) to afford1-(2-fluorophenyl)but-3-en-1-ol (6.0 g, 24%) as a yellow oil. ¹H NMR(400 MHz, CDCl₃) δ 7.49-7.27 (m, 1H), 7.29-7.12 (m, 2H), 7.05-7.00 (m,1H), 5.89-5.80 (m, 1H), 5.20-5.13 (m, 2H), 5.15-5.07 (m, 1H), 2.66-2.55(m, 1H), 2.57-5.48 (m, 1H).

Step 2: tert-butyl((1-(2-fluorophenyl)but-3-en-1-yl)oxy)dimethylsilane

To a solution of 1-(2-fluorophenyl)but-3-en-1-ol (6.0 g, 36.1 mmol) indichloromethane (50 mL) was added imidazole (4.9 g, 72.2 mmol) andtert-butyldimethylchlorosilane (7.1 g, 146.9 mmol). The reaction mixturewas stirred at 25° C. for 16 h and quenched by addition of water (100mL). The mixture was extracted with dichloromethane (2×100 mL). Thecombined organic layers were washed with brine (100 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 100%petroleum ether) to affordtert-butyl-[1-(2-fluorophenyl)but-3-enoxy]-dimethyl-silane (8.5 g, 84%)as a light oil. ¹H NMR (400 MHz, CDCl₃) δ 7.60-7.36 (m, 1H), 7.34-7.18(m, 2H), 7.13-7.02 (m, 1H), 5.97-5.85 (m, 1H), 5.21-5.07 (m, 3H),2.60-2.48 (m, 2H), 0.99 (s, 9H), 0.15 (s, 3H), 0.00 (s, 3H).

Step 3: 3-((tert-butyldimethylsilyl)oxy)-3-(2-fluorophenyl)propanal

To a solution oftert-butyl-[1-(2-fluorophenyl)but-3-enoxy]-dimethyl-silane (8.50 g, 30.3mmol) in water (100 mL) and tetrahydrofuran (100 mL) was added osmiumtetroxide (0.15 g, 0.6 mmol). After stirred for 30 min at 25° C., sodiumperiodate (25.90 g, 121.2 mmol) was added in small portions over 2 h.The resulting mixture was stirred for 2 h at 25° C. and quenched byaddition of cold saturated aqueous sodium thiosulfate (100 mL). Themixture was stirred for 30 min and then extracted with ethyl acetate(3×200 mL). The combined organic layers were washed with water (50 mL),brine (50 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 5% ethyl acetate in petroleum ether) to afford3-[tert-butyl(dimethyl)silyl]oxy-3-(2-fluorophenyl)propanal (5.5 g, 64%)as a black oil. ¹H NMR (400 MHz, CDCl₃) δ 9.84-9.77 (m, 1H), 7.53-7.51(m, 1H), 7.31-7.24 (m, 1H), 7.21-7.13 (m, 1H), 7.09-6.98 (m, 1H),5.58-5.55 (m, 1H), 2.85-2.80 (m, 1H), 2.74-2.64 (m, 1H), 0.92-0.85 (m,9H), 0.09 (s, 3H), −0.09 (s, 3H).

Step4:1-(3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-5-yl)-3-((tert-butyldimethylsilyl)oxy)-3-(2-fluorophenyl)propan-1-ol

To a cooled (−78° C.) solution of3,5-dibromo-1-tetrahydropyran-2-yl-1,2,4-triazole (6.3 g, 20.1 mmol) intetrahydrofuran (50 mL) was added n-butyllithium (2.5 M in hexanes, 8.6mL, 21.4 mmol) under nitrogen atmosphere. The mixture was stirred at−78° C. for 30 min, then a solution of3-[tert-butyl(dimethyl)silyl]oxy-3-(2-fluorophenyl)propanal (5.5 g, 19.5mmol) in tetrahydrofuran (25 mL) was added dropwise. After addition, themixture was stirred at −78° C. for 1.5 h and then quenched by additionof saturated aqueous ammonium chloride (50 mL). The resulting mixturewas extracted with ethyl acetate (2×100 mL). The combined organic layerswere dried over sodium sulfate and concentrated under reduce pressure.The residue was purified by column chromatography (silica gel, 100-200mesh, 0 to 10% ethyl acetate in petroleum ether) to afford1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-tert-butyl(dimethyl)silyl]oxy-3-(2-fluorophenyl)propan-1-ol (8.0 g, 80%) as a yellow oil.

Step 5:2-bromo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol

A mixture of1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(2-fluorophenyl)propan-1-ol (8.0 g, 15.55 mmol)and trifluoroacetic acid (30.0 mL) in dichloromethane (3.0 mL) wasstirred at 50° C. for 5 h and concentrated under reduced pressure. Theresidue was adjusted to pH=9 by addition of saturated aqueous sodiumbicarbonate and extracted with dichloromethane (2×50 mL). The combinedorganic layers were washed with water (50 mL), brine (50 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 30%ethyl acetate in petroleum ether) to afford2-bromo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol(2.0 g, 43%) as a light yellow solid. LCMS R_(T)=0.505 min, m/z=298.1[M+H]⁺.

Step 6:(5S,7S)-2-bromo-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of2-bromo-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol(750 mg, 2.52 mmol) in toluene (20 mL) was added diethylaminosulfurtrifluoride (1.62 g, 10.0 6 mmol) at 0° C. The reaction mixture wasstirred at 0° C. for 1 h and then slowly added into ice water (20 mL) at0° C. The mixture was extracted with dichloromethane (2×50 mL). Thecombined organic layers were washed with water (50 mL), brine (50 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 15% ethyl acetate in petroleum ether) to affordrac-(5S,7S)-2-bromo-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(250 mg, 33%) as a light yellow solid. ¹H NMR (400 MHz, CDCl₃) δ7.40-7.27 (q, J=6.6 Hz, 1H), 7.20-7.10 (m, 2H), 7.01-6.97 (m, 1H),6.10-5.89 (m, 1H), 5.84-5.75 (m, 1H), 3.70-3.53 (m, 1H), 2.96-2.75 (m,1H). LCMS R_(T)=1.112 min, m/z=300.0 [M+H]⁺.

This cis mixture was further separated by chiral SFC to give:

(5S,7S)-2-bromo-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.408 min) (100 mg, 40%) as a white solid. (The5R,7R-isomer was also collected (Peak 1, retention time=3.139 min) (100mg, 40%)).

SFC condition: Column: ChiralPak AD-3 150×4.6 mm I.D., 3 um mobilephase: A: CO2 B: ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate: 2.5mL/min Column temp.: 35° C.

Step 7:(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

A mixture of(5S,7S)-2-bromo-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(500 mg, 1.67 mmol), N,N-diisopropylethylamine (0.89 mL, 5.00 mmol),tris(dibenzylideneacetone)dipalladium (305 mg, 0.33 mmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (964 mg, 1.67 mmol) and3-mercaptopropionic acid-2-ethylhexylester (582 mg, 2.67 mmol) in1,4-dioxane (30 mL) was stirred at 110° C. for 16 h and diluted withwater (10 mL). The mixture was extracted with ethyl acetate (2×20 mL).The combined organic layers were concentrated under reduced pressure andthe residue was purified by column chromatography (silica gel, 100-200mesh, 0-20% ethyl acetate in petroleum ether) to give crude 2-ethylhexyl3-[[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(530 mg, 73%) as a light yellow solid.

A mixture of the above crude (480 mg, 1.1 mmol) and sodium ethoxide (224mg, 3.29 mmol) in ethanol (10 mL) was stirred at 20° C. for 30 min andconcentrated under reduced pressure. The residue was diluted with water(20 mL) and washed with ethyl acetate (20 mL). The aqueous phase wasadjusted to pH=6 by addition of citric acid and extracted with ethylacetate (3×20 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure to give crude(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(300 mg, 100%, two batches combined) as a yellow solid.

Step 8:(5S,7S)-2-((difluoromethyl)thio)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of sodium (2-chloro-2,2-difluoro-acetyl)oxide (113 mg, 0.74mmol),(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(150 mg, 0.59 mmol) and cesium carbonate (482 mg, 1.48 mmol) in1-methyl-2-pyrrolidinone (5 mL) was stirred at 100° C. for 3 h. Thereaction was diluted with water (20 mL) and extracted with ethyl acetate(3×25 mL). The combined organic layers were concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0-20% ethyl acetate in petroleum ether) to give(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(43 mg, 24%) as a white solid.

Step 9:(5S,7S)-2-((S)-(difluoromethyl)sulfinyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-((R)-(difluoromethyl)sulfinyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(70 mg, 0.23 mmol) and 3-chloroperoxybenzoic acid (70 mg, 0.35 mmol) indichloromethane (15 mL) was stirred at 25° C. for 16 h and quenched byaddition of saturated aqueous sodium bicarbonate (15 mL). The resultingmixture was extracted with ethyl acetate (3×20 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile20-45%/0.225% HCl in water) to give(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(65 mg, 88%) as a white solid. This racemic material was furtherseparated by chiral SFC to give:5S,7S)-2-(S)-difluoromethylsulfinyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.437 min) (22.6 mg, 48%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.44-7.24 (m, 1H), 7.22-6.96 (m, 4H), 6.24 (dd,J=2.4, 7.2 Hz, 0.5H), 6.10 (d, J=4.8 Hz, 0.5H), 5.98-5.90 (m, 1H),3.88-3.78 (m, 1H), 2.94-2.86 (m, 1H). LC-MS R_(T)=1.671 min, m/z=320.1[M+H]⁺.

(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.071 min) (17.9 mg, 39%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.48-7.45 (m, 1H), 7.24-6.96 (m, 4H), 6.23 (dd,J=3.2, 7.2 Hz, 0.5H), 6.10 (d, J=7.6 Hz, 0.5H), 5.98-5.90 (m, 1H),3.87-3.78 (m, 1H), 2.95-2.84 (m, 1H). LC-MS R_(T)=1.651 min, m/z=320.1[M+H].

SFC condition: Column: ChiralPak AD-3 150×4.6 mm I.D., 3 um Mobilephase: A: C02 B: Ethanol (0.05% DEA); Gradient: from 5% to 40% of B in5.5 min and hold 40% for 3 min, Flow rate: 2.5 mL/min Columntemperature: 30° C.

Step 10:(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20 mg, 0.06 mmol) and 3-chloroperoxybenzoic acid (85%, 25 mg, 0.13mmol) in dichloromethane (6 mL) was stirred at 40° C. for 16 h anddiluted with water (20 mL). The mixture was extracted with ethyl acetate(3×30 mL). The combined organic layers were washed with brine (3×20 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by RP-HPLC (acetonitrile 20-45%/0.225% HCl inwater) to give(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(14.9 mg, 70%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.49-7.46 (m,1H), 7.26-7.17 (m, 3H), 7.97 (t, J=52.4 Hz, 1H), 6.24 (dd, J=2.8, 8.0Hz, 0.5H), 6.10 (d, J=2.4 Hz, 0.5H), 6.00-5.94 (m, 1H), 3.88-3.79 (m,1H), 2.96-2.88 (m, 1H). LC-MS R_(T)=1.847 min, m/z=336.0 [M+H]⁺

Example 54 and 55(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(54) and(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(55)

(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 21 starting from 3-fluorobenzaldehyde.(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(38.0 mg, 18%, white solid) was purified by RP-HPLC (acetonitrile15-45%/0.05% ammonia hydroxide in water). ¹H NMR (400 MHz, CD₃OD) δ7.44-7.42 (m, 1H), 7.22-6.95 (m, 4H), 6.21-6.05 (m, 1H), 5.72-5.70 (m,1H), 3.82-3.70 (m, 1H), 2.91-2.80 (m, 1H). LC-MS R_(T)=0.955 min,m/z=320.1 [M+H]⁺.

(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40.0 mg, 18%, white solid) was purified by RP-HPLC (acetonitrile40-50%/0.05% ammonia hydroxide in water). ¹H NMR (400 MHz, CD₃OD) δ7.46-7.44 (m, 1H), 7.15-6.83 (m, 4H), 6.23-6.07 (m, 1H), 5.75-5.74 (m,1H), 3.83-3.73 (m, 1H), 2.93-2.82 (m, 1H). LC-MS R_(T)=1.027 min,m/z=336.1 [M+H]⁺.

Example 55 and 56(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 21 starting from 4-fluorobenzaldehyde.(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(17.3 mg, 10%, colorless oil) was purified by RP-HPLC (acetonitrile36-66%/0.05% ammonia hydroxide in water). ¹H NMR (400 MHz, CD₃OD) δ7.34-7.31 (m, 2H), 7.19-6.94 (m, 3H), 6.22 (dd, J=2.4, 7.2 Hz, 0.5H),6.07 (d, J=7.2H, 0.5H), 5.71-5.70 (m, 1H), 3.82-3.72 (m, 1H), 2.91-2.81(m, 1H). LCMS R_(T)=0.979 min, m/z=320.1 [M+H]⁺.

Example 57(4R,6R)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoleand(4S,6S)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole

Step 1: 2-ethylhexyl3-[cis-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]sulfanyl]propanoate

A mixture of N,N-diisopropylethylamine (0.6 mL, 3.2 mmol),cis-2-bromo-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole (300mg, 1.1 mmol), tris(dibenzylideneacetone)dipalladium(0) (200 mg, 0.2mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (600 mg, 1.1mmol) and 3-mercaptopropionic acid 2-ethylhexylester (300 mg, 1.4 mmol)in 1,4-dioxane (150 mL) was stirred at 115° C. for 15 h and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 30% ethyl acetate inpetroleum ether) to afford 2-ethylhexyl3-[[cis-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]sulfanyl]propanoate(300 mg, 67%) as a light yellow oil. LCMS R_(T)=0.919 min, m/z=419.2[M+H]⁺.

Step 2:cis-2-(difluoromethylsulfanyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole

A solution of 2-ethylhexyl3-[[cis-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]sulfanyl]propanoate(200 mg, 0.48 mmol) in N,N-dimethylformamide (1 mL) was added sodiumethoxide (2.0 M in ethanol, 0.38 mL, 0.76 mmol). The mixture was stirredat 0° C. for 0.5 h and sodium (2-chloro-2,2-difluoro-acetyl)oxide (109mg, 0.72 mmol) and potassium carbonate (99 mg, 0.72 mmol) were added.The resulting mixture was stirred at 80° C. for 1 h and diluted. Themixture was extracted with ethyl acetate (3×20 mL). The combined organiclayers were washed with brine (3×15 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified bypreparative TLC (eluting with 30% ethyl acetate in petroleum ether) togivecis-2-(difluoromethylsulfanyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole(25 mg, 18%) as a colorless oil. LCMS R_(T)=0.747 min, m/z=285.1

[M+H]⁺.

Step 3:(4R,6R)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoleand(4S,6S)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole

To a mixture of ruthenium(III) chloride (2 mg, 0.01 mmol) andcis-2-(difluoromethylsulfanyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole(24 mg, 0.08 mmol) in ethyl acetate (2 mL), acetonitrile (2 mL) andwater (2 mL) was added sodium periodate (90 mg, 0.42 mmol). The mixturewas stirred at 25° C. for 2 h and diluted with water (30 mL). Themixture was extracted with ethyl acetate (3×30 mL). The combined organiclayers were washed with brine (20 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified bypreparative TLC to give a crude, which was further separated by chiralSFC to afford (stereochemistry arbitrarily assigned):

(4R,6R)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole(Peak 1, Retention time=3.877 min) (6.9 mg, 26%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.42-7.36 (m, 3H), 7.20-7.18 (m, 2H), 7.09 (d,J=2.4 Hz, 1H), 6.26 (t, J=53.2 Hz, 1H), 6.13 (d, J=4.4 Hz, 0.5H), 5.99(d, J=6.8 Hz, 0.5H), 5.61-5.55 (m, 1H), 3.60-3.50 (m, 1H), 2.97-2.87 (m,1H). LC-MS R_(T)=0.863 min, m/z=316.8 [M+H]⁺.

(4S,6S)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole(Peak 2, Retention time=6.030 min) (8.5 mg, 31%) as a white solid. ¹HNMR (400 MHz, CDCl3) δ 7.39-7.36 (m, 3H), 7.20-7.18 (m, 2H), 7.09 (d,J=2.4 Hz, 1H), 6.40-6.14 (m, 1H), 6.13 (s, 0.5H), 5.99 (d, J=6.8 Hz,0.5H), 5.60-5.58 (m, 1H), 3.60-3.52 (m, 1H), 2.97-2.87 (m, 1H). LC-MSR_(T)=0.711 min, m/z=317.1 [M+H]+.

SFC condition (prep): Phenomenex-Cellulose-2 (250 mm*30 mm, 5 μm);Mobile phase: A: CO₂ B: 0.1% NH₃H₂O EtOH; Gradient: from 45% to 45% ofB; Flow rate: 60 mL/min Column temperature: 40° C.

Example 58(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 21 starting from2,6-difluorobenzaldehyde. The final compound was purified by RP-HPLC(acetonitrile 35-65%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(33 mg, 34%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.48-7.38 (m,1H), 6.99 (t, J=8.4 Hz, 2H), 6.43 (t, J=52.8 Hz, 1H), 6.25-6.04 (m, 1H),6.00-5.90 (m, 1H), 3.91-3.74 (m, 1H), 3.18-3.01 (m, 1H). LCMSR_(T)=1.033 min, m/z=354.1 [M+H]⁺.

Example 59(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 21 starting from2,3,6-trifluorobenzaldehyde. The final compound was purified by RP-HPLC(acetonitrile 40-50%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(11.7 mg, 15%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.47-7.44 (m,1H), 7.11-6.83 (m, 2H), 6.28-6.13 (m, 1H), 6.07-6.03 (m, 1H), 3.94-3.87(m, 1H), 3.06-2.95 (m, 1H). LCMS R_(T)=1.841 min, m/z=372.0 [M+H]⁺.

Example 60(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 21 starting from2,3,5-trifluorobenzaldehyde. The final compound was purified by RP-HPLC(acetonitrile 40-70%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(18.8 mg, 26%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.33-7.26 (m,1H), 6.99 (t, J=52.4 Hz, 1H), 6.86-6.78 (m, 1H), 6.27-6.11 (m, 1H),6.02-5.97 (m, 1H), 3.92-3.79 (m, 1H), 3.01-2.89 (m, 1H). LCMSR_(T)=1.081 min, m/z=372.1 [M+H]⁺.

Example 61(5S,7S)-5-(3-chlorophenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chlorophenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 16 starting from ethyl3-chlorobenzoate. The final compound was purified by RP-HPLC(acetonitrile 50-80%/0.05% ammonia hydroxide in water) to give(5S,7S)-5-(3-chlorophenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(350 mg, 79%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.33 (m,2H), 7.33-7.27 (m, 1H), 7.13-7.11 (m, 1H), 6.68-6.27 (m, 1H), 6.26-5.98(m, 1H), 5.62-5.50 (m, 1H), 3.85-3.56 (m, 1H), 3.12-2.86 (m, 1H). LC-MSR_(T)=1.962 min, m/z=352.0 [M+H]⁺.

Example 62: Method 242-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile

Step 1: 2-ethylhexyl3-(((5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)propanoate

A mixture of(5S,7S)-2-bromo-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(1.0 g, 3.2 mmol), N,N-diisopropylethylamine (1.69 mL, 9.5 mmol),tris(dibenzylideneacetone)dipalladium(0) (579 mg, 0.63 mmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.8 g, 3.2 mmol) and3-mercaptopropionicacid 2-ethylhexylester (1.0 g, 4.7 mmol) in1,4-dioxane (50 mL) was stirred at 110° C. for 15 h and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 15 to 20% ethyl acetate inpetroleum ether) to afford 2-ethylhexyl3-[[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(1.0 g, 70%) as a light yellow oil. LC-MS R_(T)=0.955 min, m/z=454.2[M+H]⁺.

Step 2: 2-ethylhexyl3-(((5S,7S)-5-(2-cyanophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)propanoate

A mixture of 2-ethylhexyl3-[[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(500 mg, 1.1 mmol), potassium hexacyanoferrate(II) trihydrate (465 mg,1.1 mmol), potassium acetate (14 mg, 0.14 mmol), t-BuXPhos Phospalladium(II) biphenyl-2-amine mesylate (88 mg, 0.11 mmol) and2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (47 mg, 0.11mmol) in 1,4-dioxane (5 mL) and water (15 mL) was stirred at 100° C. for18 h and filtered. The filtrate was diluted with water (10 mL) andextracted with ethyl acetate (3×10 mL). The combined organic layers weredried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 50% ethyl acetate in petroleum ether) to afford 2-ethylhexyl3-[[(5S,7S)-5-(2-cyanophenyl)-7-fluoro-6,7-dihydro5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate (74 mg, 15%) aslight brown oil. LC-MS R_(T)=0.899 min, m/z=445.3 [M+H]⁺.

Step 3:2-((5S,7S)-7-fluoro-2-mercapto-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl)benzonitrile

A mixture of sodium ethoxide (2.0 M in ethanol, 0.17 mL, 0.34 mmol),2-ethylhexyl3-[[(5S,7S)-5-(2-cyanophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(74 mg, 0.17 mmol) in ethanol (0.4 mL) was stirred at 10° C. for 2 h andconcentrated under reduced pressure. The residue was diluted with water(20 mL) and washed with ethyl acetate (20 mL). The aqueous phase wasadjusted to pH=6 by addition of hydrochloric acid (1.0 M) and extractedwith ethyl acetate (3×20 mL). The combined organic layers were driedover sodium sulfate and concentrated under reduced pressure to affordcrude2-[(5S,7S)-7-fluoro-2-sulfanyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile(43 mg, 99%) as a red solid. LC-MS R_(T)=0.590 min, m/z=261.1 [M+H].

Step 4:2-((5S,7S)-2-((difluoromethyl)thio)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl)benzonitrile

A mixture of sodium (2-chloro-2,2-difluoro-acetyl)oxide (32 mg, 0.21mmol),2-[(5S,7S)-7-fluoro-2-sulfanyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile(43 mg, 0.17 mmol) and potassium carbonate (57 mg, 0.41 mmol) inN,N-dimethylacetamide (3.6 mL) was stirred at 90° C. for 10 min andquenched by addition of water (10 mL). The resulting mixture wasextracted with ethyl acetate (3×10 mL). The combined organic layers werewashed with brine (3×5 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetate inpetroleum ether) to give2-[(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile(27 mg, 53%) as a light yellow oil. LC-MS R_(T)=0.682 min, m/z=311.1[M+H]⁺

Step 5:2-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile

A mixture of ruthenium(III) chloride (2 mg, 0.01 mmol),2-[(5S,7S)-2-(difluoromethylsulfanyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile(27 mg, 0.09 mmol) and sodium periodate (19 mg, 0.09 mmol) in ethylacetate (0.3 mL)/acetonitrile (0.3 mL)/water (0.3 mL) was stirred at 25°C. for 10 min. The resulting mixture was diluted with water (10 mL) andextracted with ethyl acetate (3×10 mL). The combined organic layers werewashed with brine (3×5 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by RP-HPLC(acetonitrile 45-75%/0.05% ammonia hydroxide in water) to afford2-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile(5.3 mg, 18%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.85-7.77 (m,1H), 7.68-7.63 (m, 1H), 7.57-7.52 (m, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.45(t, J=52.8 Hz, 1H), 6.20-6.03 (m, 2H), 3.96-3.81 (m, 1H), 3.02-2.92 (m,1H). LC-MS R_(T)=0.919 min, m/z=343.1 [M+H]+.

Example 63: Method 23(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-H-pyrrolo[1,2-b][1,2,4]triazole

Step 1: methyl 3,4-difluorobenzoate

To a solution of 3,4-difluorobenzoic acid (50.0 g, 316.3 mmol) inmethanol (150 mL) was added concentrated sulfuric acid (26.0 mL, 478.4mmol). After addition, the mixture was stirred at 80° C. for 15 h andcooled to room temperature. The mixture was extracted withdichloromethane (3×200 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure to afford crudemethyl 3,4-difluorobenzoate (54.0 g, 99%) as a yellow oil.

Step 2: ethyl 3-(3,4-difluorophenyl)-3-oxo-propanoate

To a solution of ethyl acetate (31.0 mL, 278.9 mmol) in tetrahydrofuran(300 mL) was added lithium bis(trimethylsilyl)amide (1.0 M intetrahydrofuran, 349.0 mL, 349.0 mmol) at −78° C. under nitrogenatmosphere, followed by methyl 3,4-difluorobenzoate (40.0 g, 232.4mmol). After addition, the mixture was stirred at −78° C. for 2 h andquenched by addition of saturated aqueous ammonium chloride (100 mL).The resulting mixture was extracted with ethyl acetate (3×200 mL). Thecombined organic layers were dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetate inpetroleum ether) to give ethyl 3-(3,4-difluorophenyl)-3-oxo-propanoate(27.0 g, 51%) as a brown oil. ¹H NMR (400 MHz, CDCl₃) δ 7.86-7.66 (m,1H), 7.23 (s, 2H), 4.19-4.01 (m, 2H), 3.05-2.81 (m, 2H), 1.34-1.20 (m,3H).

Step 3: methyl (3R)-3-(3,4-difluorophenyl)-3-hydroxy-propanoate

To a mixture of potassium formate (99.50 g, 1.2 mol) and[[(1R,2R)-2-amino-1,2-diphenyl-ethyl]-(p-tolylsulfonyl)amino]-chloro-ruthenium;1-isopropyl-4-methyl-benzene (0.75 g, 1.18 mmol) in methanol (250 mL)was added ethyl 3-(3,4-difluorophenyl)-3-oxo-propanoate (27.00 g, 118.3mmol) under nitrogen atmosphere and stirred at 40° C. for 18 h. Theresulting mixture was diluted with water (200 mL) and extracted withethyl acetate (3×300 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 15%ethyl acetate in petroleum ether) to afford methyl(3R)-3-(3,4-difluorophenyl)-3-hydroxy-propanoate (25.0 g, 98%) as a redoil. ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.25 (m, 1H), 7.24-7.16 (m, 1H),7.07-7.02 (m, 1H), 5.10-4.98 (m, 1H), 3.78 (s, 3H), 2.77-2.72 (m, 2H).

Step 4: methyl(3R)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propanoate

To a solution of methyl (3R)-3-(3,4-difluorophenyl)-3-hydroxy-propanoate(25.0 g, 115.6 mmol) in dichloromethane (200 mL) was added imidazole(15.8 g, 231.3 mmol) and tert-butyldimethylchlorosilane (22.7 g, 150.3mmol). After addition, the mixture was stirred at 25° C. for 16 h andquenched by addition of water (100 mL). The resulting mixture wasextracted with dichloromethane (3×300 mL). The combined organic layerswere dried over sodium sulfate and concentrated under reduced pressure.The residue was purified by column chromatography (silica gel, 100-200mesh, 0 to 5% ethyl acetate in petroleum ether) to afford methyl(3R)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propanoate(24.0 g, 63%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.19-7.18(m, 1H), 7.13-7.02 (m, 2H), 5.11-5.09 (m, 1H), 3.68 (s, 3H), 2.69-2.66(m, 1H), 2.53-2.50 (m, 1H), 0.86-0.84 (m, 9H), 0.10 (s, 3H), 0.03 (s,3H).

Step 5:(3R)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)-N-methoxy-N-methyl-propanamide

To a solution of methyl(3R)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl) propanoate(24.0 g, 72.6 mmol) and N,O-dimethylhydroxylamine hydrochloride (14.2 g,145.3 mmol) in tetrahydrofuran (250 mL) was added isopropylmagnesiumchloride (2.0 M in tetrahydrofuran, 109.0 mL, 218.0 mmol) at −78° C.under nitrogen atmosphere. After addition, the mixture was allowed towarm to 15° C. and stirred for 16 h. The mixture was then quenched byaddition of saturated aqueous ammonium chloride (200 mL) and extractedwith ethyl acetate (2×500 mL). The combined organic layers were driedover sodium sulfate and concentrated under reduced pressure. The residuewas purified by column chromatography (silica gel, 100-200 mesh, 0 to20% ethyl acetate in petroleum ether) to afford(3R)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)-N-methoxy-N-methyl-propanamide(18.0 g, 69%) as a colorless oil. LC-MS R_(T)=1.156 min, m/z=360.0[M+H]⁺.

Step 6:(3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propan-1-one

To a cooled (−78 OC) solution of(3R)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)-N-methoxy-N-methyl-propanamide(17.0 g, 47.3 mmol) and3,5-dibromo-1-tetrahydropyran-2-yl-1,2,4-triazole (14.7 g, 47.3 mmol) intetrahydrofuran (200 mL) was added isopropylmagnesium chloride (2.0 M intetrahydrofuran, 28.0 mL, 56.0 mmol) under nitrogen atmosphere. Afteraddition, the mixture was stirred at 15° C. for 16 h and then quenchedby addition of saturated aqueous ammonium chloride (200 mL). Theresulting mixture was extracted with ethyl acetate (2×500 mL). Thecombined organic layers were dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 10% ethyl acetate inpetroleum ether) to afford(3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propan-1-one(19.0 g, 76%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.19 (m,1H), 7.15-7.07 (m, 2H), 6.24-6.22 (m, 1H), 5.31-5.27 (m, 1H), 4.10-4.02(m, 1H), 3.75-3.65 (m, 1H), 3.56-3.53 (m, 1H), 3.27-3.23 (m, 1H),2.35-2.23 (m, 1H), 1.99-1.90 (m, 1H), 1.79-1.67 (m, 2H), 1.30-1.22 (m,2H), 0.79 (d, J=2.0 Hz, 9H), −0.04 (d, J=7.6 Hz, 3H), −0.18 (d, J=8.0Hz, 3H). LCMS R_(T)=1.282 min, m/z=552.1 [M+Na]⁺.

Step 7:(1R,3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propan-1-ol

To a mixture of triethylamine (50.0 mL, 358.2 mmol), formic acid (7.0mL, 179.1 mmol) and[[(1R,2R)-2-amino-1,2-diphenyl-ethyl]-(p-tolylsulfonyl)amino]-chloro-ruthenium;1-isopropyl-4-methyl-benzene (230 mg, 0.4 mmol) in methanol (150 mL) wasadded(3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propan-1-one (19.0 g, 35.8mmol) under nitrogen atmosphere. After addition, the mixture was stirredat 30° C. for 16 h and diluted with water (200 mL). The resultingmixture was extracted with ethyl acetate (3×200 mL). The combinedorganic layers were dried over sodium sulfate and concentrated underreduced pressure. The resulting residue was purified by s columnchromatography (silica gel, 100-200 mesh, 0 to 15% ethyl acetate inpetroleum ether) to afford(1R,3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propan-1-ol(17.0 g, 89%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.22-7.08(m, 2H), 7.06 (s, 1H), 5.64-5.49 (m, 1H), 5.15-5.12 (m, 1H), 5.12-5.08(m, 1H), 5.07-5.03 (m, 1H), 4.07-3.99 (m, 1H), 3.69-3.63 (m, 1H),2.34-2.23 (m, 2H), 2.14-2.07 (m, 1H), 1.70-1.62 (m, 4H), 1.26 (t, J=7.2Hz, 2H), 0.93 (d, J=4.4 Hz, 9H), 0.10 (d, J=1.2 Hz, 3H), −0.09 (d, J=5.6Hz, 3H).

Step 8:[(1R,3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propyl]2,2-dimethylpropanoate

To a solution of triethylamine (12.0 mL, 84.5 mmol),4-dimethylaminopyridine (3.4 g, 28.2 mmol) and(1R,3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propan-1-ol(15.0 g, 28.2 mmol) in dichloromethane (200 mL) was added pivaloylchloride (5.0 g, 41.5 mmol) under nitrogen atmosphere. After addition,the mixture was stirred at 15° C. for 1.5 h and diluted with water (300mL). The mixture was extracted with dichloromethane (3×200 mL). Thecombined organic layers were dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 15% ethyl acetate inpetroleum ether) to give[(1R,3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propyl]2,2-dimethylpropanoate(16.0 g, 92%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.16-7.05(m, 2H), 6.99-6.97 (m, 1H), 6.18-6.17 (m, 0.5H), 5.95-5.70 (m, 1H),5.57-5.48 (m, 0.5H), 4.85-4.70 (m, 1H), 4.12-3.95 (m, 1H), 3.77-3.60 (m,1H), 2.49-2.24 (m, 2H), 2.15-2.00 (m, 2H), 1.99-1.88 (m, 1H), 1.77-1.60(m, 3H), 1.24 (d, J=3.2 Hz, 9H), 0.91 (d, J=3.6 Hz, 9H), 0.03 (d, J=11.2Hz, 3H), −0.21 (s, 3H).

Step 9:[(1R,3R)-1-(3-bromo-1H-1,2,4-triazol-5-yl)-3-(3,4-difluorophenyl)-3-hydroxy-propyl]2,2-dimethylpropanoate

A mixture of[(1R,3R)-1-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(3,4-difluorophenyl)propyl]2,2-dimethylpropanoate(16.0 g, 25.9 mmol) in hydrochloric acid (4.0 M in methanol, 60 mL,240.0 mmol) was stirred at 15° C. for 1.5 h and concentrated underreduced pressure. The residue was adjusted to pH=7 by addition ofsaturated aqueous sodium carbonate and then extracted with ethyl acetate(3×100 mL). The combined organic layers were washed with brine (50 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 15% ethyl acetate in petroleum ether) to give[(1R,3R)-1-(3-bromo-1H-1,2,4-triazol-5-yl)-3-(3,4-difluorophenyl)-3-hydroxy-propyl]2,2-dimethylpropanoate(9.0 g, 83%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.10 (m,2H), 7.08 (s, 1H), 6.13-6.11 (m, 1H), 4.84-4.82 (m, 1H), 2.63-2.26 (m,2H), 1.29-1.21 (m, 9H).

Step 10:[(5S,7R)-2-bromo-5-(3,4-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2,2-b][1,2,4]triazol-7-yl]2,2-dimethylpropanoate

To a solution of[(1R,3R)-1-(3-bromo-1H-1,2,4-triazol-5-yl)-3-(3,4-difluorophenyl)-3-hydroxy-propyl]2,2-dimethylpropanoate(9.0 g, 21.5 mmol), triphenylphosphine (6.8 g, 25.8 mmol) intetrahydrofuran (135 mL) was added diisopropyl azodicarboxylate (5.2 g,25.8 mmol) under nitrogen atmosphere. After addition, the mixture wasstirred at 25° C. for 1.5 h and diluted with water (100 mL). Theresulting mixture was extracted with ethyl acetate (3×100 mL). Thecombined organic layers were dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetate inpetroleum ether) to afford[(5S,7R)-2-bromo-5-(3,4-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl]2,2-dimethylpropanoate(4.0 g, 46%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.16 (m,1H), 7.03-6.96 (m, 1H), 6.93-6.91 (m, 1H), 6.16 (t, J=5.2 Hz, 1H), 5.58(t, J=6.4 Hz, 1H), 3.03 (t, J=6.0 Hz, 2H), 1.24 (s, 9H).

Step 11:(5S,7R)-2-bromo-5-(3,4-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol

To a solution of[(5S,7R)-2-bromo-5-(3,4-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl]2,2-dimethylpropanoate(2.0 g, 5 mmol) in methanol (15 mL) was added sodium hydroxide (600 mg,14.99 mmol) in water (15 mL). After addition, the mixture was stirred at15° C. for 16 h and diluted with water (20 mL). The mixture wasextracted with ethyl acetate (3×30 mL). The combined organic layers werewashed with brine (30 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 50% ethyl acetate inpetroleum ether) to afford(5S,7R)-2-bromo-5-(3,4-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol(1.3 g, 82%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.30-7.31 (m,1H), 7.25-7.22 (m, 1H), 7.20-7.07 (m, 1H), 5.69 (t, J=6.8 Hz, 1H),5.31-5.29 (m, 1H), 3.04-2.86 (m, 2H).

Step 12:(5S,7S)-2-bromo-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a cooled (−30° C.) solution of(5S,7R)-2-bromo-5-(3,4-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-ol(2.2 g, 7.0 mmol) in toluene (20 mL) was added a solution ofdiethylaminosulfur trifluoride (4 mL, 27.8 mmol) in toluene (10 mL)under nitrogen atmosphere. After addition, the mixture was stirred at 0°C. for 1 h and diluted with ethyl acetate (50 mL). The resulting mixturewas poured into saturated aqueous sodium bicarbonate (50 mL) andextracted with ethyl acetate (3×40 mL). The combined organic layers weredried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0-20% ethyl acetate in petroleum ether) to afford(5S,7S)-2-bromo-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(1.0 g, 45%) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.17 (m,1H), 7.14-7.06 (m, 1H), 7.06-6.99 (m, 1H), 6.11-5.88 (m, 1H), 5.49-5.36(m, 1H), 3.67-3.49 (m, 1H), 2.96-2.77 (m, 1H).

Step 13: 2-ethylhexyl3-[[(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate

A mixture of tris(dibenzylideneacetone)dipalladium(0) (432 mg, 0.47mmol),(5S,7S)-2-bromo-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(500 mg, 1.57 mmol), N,N-diisopropylethylamine (0.8 mL, 4.72 mmol),3-mercaptopropionic acid 2-ethylhexylester (412 mg, 1.89 mmol) and4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (910 mg, 1.57 mmol) in1,4-dioxane (10 mL) was stirred at 110° C. for 15 h under nitrogenatmosphere. The mixture was diluted with water (30 mL) and extractedwith ethyl acetate (3×30 mL). The combined organic layers were driedover sodium sulfate and concentrated under reduced pressure. The residuewas purified by column chromatography (silica gel, 100-200 mesh, 0 to20% ethyl acetate in petroleum ether) to afford 2-ethylhexyl3-[[(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(500 mg, 31%) as a light yellow oil. LCMS R_(T)=1.05 min, m/z=456.1[M+H]⁺.

Step 14:(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

To a solution of 2-ethylhexyl3-[[(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]propanoate(500 mg, 1.10 mmol) in ethanol (7 mL) was added sodium ethoxide (224 mg,3.29 mmol). The mixture was stirred at 25° C. for 1 h and concentratedunder reduced pressure. The residue was diluted with water (20 mL),washed with ethyl acetate (20 mL) and adjusted to pH=6 by addition ofcitric acid. The resulting mixture was extracted with ethyl acetate(3×20 mL). The combined organic layers were dried over sodium sulfateand concentrated under reduced pressure to afford crude(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(100 mg, 34%) as a yellow solid. LCMS R_(T)=0.692 min, m/z=272.0 [M+H]⁺.

Step 15:(5S,7S)-2-(difluoromethylsulfanyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of sodium (2-chloro-2,2-difluoro-acetyl)oxide (70 mg, 0.46mmol),(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(100 mg, 0.37 mmol) and potassium carbonate (127 mg, 0.92 mmol) inN,N-dimethylformamide (5 mL) was stirred at 90° C. for 10 min undernitrogen atmosphere. The mixture was diluted with water (10 mL) andextracted with ethyl acetate (3×15 mL). The combined organic layers weredried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by preparative TLC (50% ethyl acetate in petroleumether, R_(f)=0.5) to afford(5S,7S)-2-(difluoromethylsulfanyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 47%) as a light yellow oil. LCMS R_(T)=0.874 min, m/z=322.0[M+H]⁺.

Step 16:(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of ruthenium(III) chloride (3 mg, 0.16 mmol), sodium periodate(133 mg, 0.62 mmol) and(5S,7S)-2-(difluoromethylsulfanyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 0.16 mmol) in acetonitrile (1 mL), water (1 mL) and ethylacetate (1 mL) was stirred at 30° C. for 1 h under nitrogen atmosphereand filtered. The filtrate was diluted with water (10 mL) and extractedwith ethyl acetate (3×10 mL). The combined organic layers were driedover sodium sulfate and concentrated under reduced pressure. The residuewas purified by RP-HPLC (acetonitrile 45-75%/0.05% ammonia hydroxide inwater) to afford(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(14.2 mg, 32%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.19 (m,1H), 7.12-7.11 (m, 1H), 7.05-7.04 (m, 1H), 6.44 (t, J=53.2 Hz, 1H),6.20-5.99 (m, 1H), 5.58-5.57 (m, 1H), 3.81-3.62 (m, 1H), 3.09-2.93 (m,1H). LCMS R_(T)=1.025 min, m/z=354.1 [M+H]⁺.

Example 64(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 23 starting from2-chloro-3-fluorobenzoic acid. The final compound was purified chiralSFC to give(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(12.8 mg, 23%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.40-7.35 (m,2H), 7.00 (t, J=52.4 Hz, 1H), 6.77-6.75 (m, 1H), 6.26-6.10 (m, 2H),3.95-3.81 (m, 1H), 2.92-2.81 (m, 1H). LC-MS R_(T)=0.957 min, m/z=371.4[M+H]⁺.

SFC condition (prep): Column: DAICEL CHIRALCEL OJ-H (250 mm*30 mm, 5μm); Mobile phase: A: CO₂ B: 0.1% NH₃H₂O EtOH; Gradient: from 25% to 25%of B; Flow rate: 50 mL/min Column temperature: 40° C.

Example 63(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 23 starting from3-chloro-2-fluorobenzoic acid. The final compound was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 30% ethyl acetate inpetroleum ether) to give(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(21.0 mg, 23%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.59-7.54 (m,1H), 7.24 (t, J=8.0 Hz, 1H), 7.13-7.08 (m, 1H), 6.99 (t, J=52.4 Hz, 1H),6.27-6.10 (m, 1H), 6.01-5.95 (m, 1H), 3.90-3.80 (m, 1H), 2.99-2.85 (m,1H). LCMS R_(T)=0.953 min, m/z=369.9 [M+H]⁺.

Example 66(5S,7S)-5-(5-chloro-2-fluorophenyl)-2-((difluoromethyl)sulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 23 starting from5-chloro-2-fluorobenzoic acid. The final compound was purified byRP-HPLC (acetonitrile 48-78%/0.225 formic acid in water) to give(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(34 mg, 44%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.35 (m,1H), 7.12 (t, J=9.2 Hz, 1H), 6.97-6.93 (m, 1H), 6.45 (t, J=52.8 Hz, 1H),6.15-6.02 (m, 1H), 5.87-5.80 (m, 1H), 3.85-3.65 (m, 1H), 3.07-2.94 (m,1H). LCMS R_(T)=1.051 min, m/z=370.1 [M+H]⁺.

Example 67(5S,7S)-2-((difluoromethyl)sulfonyl)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 21 starting from2,5-difluorobenzaldehyde. The final compound was purified by RP-HPLC(acetonitrile 35-65%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(90 mg, 51%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.06 (m,2H), 6.71-6.64 (m, 1H), 6.44 (t, J=52.4 Hz, 1H), 6.19-6.00 (m, 1H),5.95-5.88 (m, 1H), 3.82-3.65 (m, 1H), 3.05-2.95 (m, 1H). LCMSR_(T)=1.059 min, m/z=354.1 [M+H]⁺.

Example 68(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 21 starting from2,3-difluorobenzaldehyde. The final compound was purified by RP-HPLC(acetonitrile 35-65%/0.225% formic acid in water) to give(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(26.1 mg, 37%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.21 (m,1H), 7.13-7.11 (m, 1H), 6.71-6.69 (m, 1H), 6.43 (t, J=53.2 Hz, 1H), 6.14(d, J=5.6 Hz, 0.5H), 6.00 (d, J=5.2 Hz, 0.5H), 5.98-5.92 (m, 1H),3.80-3.70 (m, 1H), 3.05-2.94 (m, 1H). LCMS R_(T)=0.839 min, m/z=354.0[M+H]⁺.

Example 69(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 23 starting from 3,5-difluorobenzoicacid. The final compound was purified first by RP-HPLC (acetonitrile43-73%/0.04% ammonia hydroxide+10 mM NH₄HCO₃ in water), and then by SFCto give(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 50%, white solid): ¹H NMR (400 MHz, CDCl₃) δ 6.92-6.85 (m, 1H),6.84-6.77 (m, 2H), 6.44 (t, J=53.2 Hz, 1H), 6.17-6.01 (m, 1H), 5.59-5.57(m, 1H), 3.77-3.69 (m, 1H), 3.07-2.97 (m, 1H). LC-MS R_(T)=1.030 min,m/z=354.1 [M+H]⁺.

SFC condition (prep): column: chiralcel OD-3 150×4.6 mm I.D., 3 μm;mobile phase: A: CO₂ B: ethanol (0.05% DEA); gradient: from 5% to 40% ofB in 5 min and from 40% to 5% of B in 0.5 min, hold 5% of B for 1.5 min;flow rate: 2.5 mL/min; column temp.: 35° C.

Example 70(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-((difluoromethyl)sulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 17 starting from 3-fluorobenzaldehyde.

(5S,7S)-2-((difluoromethyl)sulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(38.0 mg, 18%, white solid) was purified by RP-HPLC (acetonitrile15-45%/0.05% ammonia hydroxide in water). ¹H NMR (400 MHz, CD₃OD) δ7.44-7.42 (m, 1H), 7.22-6.95 (m, 4H), 6.21-6.05 (m, 1H), 5.72-5.70 (m,1H), 3.82-3.70 (m, 1H), 2.91-2.80 (m, 1H). LC-MS R_(T)=0.955 min,m/z=320.1 [M+H]⁺.

(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40.0 mg, 18%, white solid) was purified by RP-HPLC (acetonitrile40-50%/0.05% ammonia hydroxide in water). ¹H NMR (400 MHz, CD₃OD) δ7.46-7.44 (m, 1H), 7.15-6.83 (m, 4H), 6.23-6.07 (m, 1H), 5.75-5.74 (m,1H), 3.83-3.73 (m, 1H), 2.93-2.82 (m, 1H). LC-MS R_(T)=1.027 min,m/z=336.1 [M+H]⁺.

Example 71: Method 25(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-7-fluoro-2-(fluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a cooled (0° C.) solution of(5S,7S)-7-fluoro-2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(149 mg, 0.60 mmol) in acetonitrile (4 mL) was added1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate) (222 mg, 0.63 mmol). The mixture was stirred at 0°C. for 2 h and concentrated under reduced pressure. The residue waspurified by preparative TLC (50% ethyl acetate in petroleum ether,R_(f)=0.4) to give(5S,7S)-7-fluoro-2-(fluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(65 mg, 41%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.34 (m,3H), 7.25-7.22 (m, 2H), 6.14-6.06 (m, 1H), 6.06-6.03 (m, 0.5H),6.01-5.93 (m, 1H), 5.92-5.88 (m, 0.5H), 5.47-5.36 (m, 1H), 3.67-3.48 (m,1H), 2.97-2.79 (m, 1H).

Step 2:(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a cooled (0° C.) solution of(5S,7S)-7-fluoro-2-(fluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(65 mg, 0.24 mmol) in dichloromethane (2 mL) was added3-chloroperoxybenzoic acid (85%, 42 mg, 0.24 mmol). The mixture wasstirred at 0° C. for 2 h and diluted with dichloromethane (20 mL). Themixture was washed with saturated aqueous sodium bicarbonate (2×10 mL),brine (2×10 mL), dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by preparative TLC (47% ethylacetate and 6% ethanol in petroleum ether, R_(f)=0.4, 0.3) to afford twoisomers:

(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1 on SFC, retention time=3.597 min) (14.1 mg, 20%) as a whitesolid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m, 3H), 7.26-7.21 (m, 2H),6.14-5.96 (m, 1H), 5.72-5.66 (m, 1H), 5.61-5.55 (m, 1H), 5.54-5.48 (m,1H), 3.72-3.61 (m, 1H), 3.05-2.94 (m, 1H). LC-MS R_(T)=0.701 min,m/z=284.1 [M+H]⁺.

(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2 on SFC, retention time=3.947 min) (15.7 mg, 21%) as a whitesolid. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38 (m, 3H), 7.26-7.22 (m, 2H),6.13-5.96 (m, 1H), 5.73-5.62 (m, 1H), 5.61-5.48 (m, 2H), 3.74-3.59 (m,1H), 3.06-2.93 (m, 1H). LC-MS R_(T)=0.692 min, m/z=284.1 [M+H]⁺.

Analytical SFC conditions: SFC condition: Column: ChiralPak AD-3 Mobilephase: A: C02 B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in5.5 min and hold 40% for 3 min, then 5% of B for 1.5 min Flow rate: 2.5mL/min Column temperature: 40° C.

Example 72(5S,7S)-7-fluoro-2-((fluoromethyl)sulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-7-fluoro-2-(fluoromethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(60 mg, 0.22 mmol) in dichloromethane (10 mL) was added3-chloroperoxybenzoic acid (85%, 91 mg, 0.45 mmol). The reaction mixturewas stirred at 20° C. for 16 h and diluted with dichloromethane (20 mL).The mixture was washed with saturated aqueous sodium bicarbonate (2×10mL), dried over sodium sulfate and concentrated under reduced pressure.The residue was purified by RP-HPLC (acetonitrile 22-52%/0.05%hydrochloric acid in water) to give(5S,7S)-7-fluoro-2-(fluoromethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(23 mg, 34%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m,3H), 7.26-7.23 (m, 2H), 6.14-5.98 (m, 1H), 5.59-5.53 (m, 1H), 5.49 (s,1H), 5.37 (s, 1H), 3.74-3.63 (m, 1H), 3.07-2.96 (m, 1H). LCMSR_(T)=0.932 min, m/z=300.1 [M+H]⁺.

Examples 74 and 75(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 25 starting from(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by preparative TLC (50% ethyl acetatein petroleum ether, R_(f)=0.4, 0.3) to give:(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1 on SFC, Retention time=3.300 min) (10.4 mg, 15%) as a whitesolid. ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.43 (m, 1H), 7.34-6.98 (m, 3H),6.22-6.06 (m, 1H), 6.06-5.91 (m, 1H), 5.87-5.77 (m, 1H), 5.75-5.64 (m,1H), 3.88-3.73 (m, 1H), 2.93-2.80 (m, 1H). LC-MS R_(T)=0.828 min,m/z=301.9 [M+H]⁺.

(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2 on SFC, Retention time=3.476 min) (21.6 mg, 23%) as a whitesolid. ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.23 (m, 1H), 7.22-7.13 (m, 3H),6.21 (d, J=1.6 Hz, 0.5H), 6.07 (d, J=1.6 Hz, 0.5H), 5.80-5.78 (m, 1H),5.77-5.75 (m, 1H), 5.74-5.64 (m, 1H), 3.87-3.74 (m, 1H), 2.93-2.81 (m,1H). LC-MS R_(T)=0.828 min, m/z=302.1 [M+H]⁺.

Analytical SFC conditions: SFC condition: Column: ChiralPak AD-3 Mobilephase: A: C02 B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate: 2.5mL/min Column temperature: 35° C.

Examples 76 and 77(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 25 starting from(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by chiral SFC to give:

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.277 min) (31.9 mg, 26%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.35-7.33 (m, 1H), 7.21-7.20 (m, 1H), 6.96-6.94(m, 1H), 6.23-6.07 (m, 1H), 5.96-5.94 (m, 1H), 5.84-5.78 (m, 1H),5.74-5.66 (m, 1H), 3.88-3.78 (m, 1H), 2.95-2.84 (m, 1H). LC-MSR_(T)=0.720 min, m/z=320.1 [M+H]⁺.

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(R)-fluoromethysulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.552 min) (36.4 mg, 30%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.37-7.33 (m, 1H), 7.22-7.20 (m, 1H), 6.96-6.94(m, 1H), 6.23-6.07 (m, 1H), 5.96-5.94 (m, 1H), 5.84-5.78 (m, 1H),5.74-5.66 (m, 1H), 3.87-3.78 (m, 1H), 2.95-2.85 (m, 1H). LC-MSR_(T)=0.712 min, m/z=320.1 [M+H]⁺.

SFC condition: Chiralcel OD-3 150×4.6 mm I.D., 3 μm Mobile phase: A: C02B: ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5 min and hold40% for 2.5 min, then 5% of B for 1.5 min Flow rate: 2.5 mL/min Columntemperature.: 40° C.

Examples 78 and 79(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 25 starting from(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by preparative TLC ((50% ethyl acetatein petroleum ether, Rf=0.2) to give:(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1 on SFC, retention time=2.985 min) (14.5 mg, 18%) as a whitesolid. ¹H NMR (400 MHz, CD₃OD) δ 7.26-7.19 (m, 2H), 6.97-6.91 (m, 1H),6.22-6.06 (m, 1H), 5.89-5.67 (m, 3H), 3.88-3.74 (m, 1H), 2.93-2.82 (m,1H). LC-MS R_(T)=0.869 min, m/z=320.1 [M+H]⁺.

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2 on SFC, retention time=3.221 min) (20 mg, 25%) as a white solid.¹H NMR (400 MHz, CD₃OD) δ 7.26-7.19 (m, 2H), 7.18-6.91 (m, 1H),6.20-6.06 (m, 1H), 5.89-5.65 (m, 3H), 3.87-3.74 (m, 1H), 2.93-2.82 (m,1H). LC-MS R_(T)=0.853 min, m/z=320.1 [M+H]⁺.

Analytical SFC conditions: SFC condition: Column: ChiralPak AD-3 Mobilephase: A: C02 B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate: 2.5mL/min Column temperature: 35 OC.

Examples 80 and 81(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 25 starting from(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified by RP-HPLC (acetonitrile 30-60%/0.05%HCl in water) to give:(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1 on SFC, retention time=3.157 min) (9.7 mg, 13%) as a whitesolid. ¹H NMR (400 MHz, CD₃OD) δ 7.52-7.46 (m, 1H), 7.10-7.05 (m, 2H),6.23-6.08 (m, 1H), 6.00-5.98 (m, 1H), 5.80-5.75 (m, 1H), 5.74-5.65 (m,1H), 3.89-3.82 (m, 1H), 3.01-2.99 (m, 1H). LC-MS R_(T)=0.836 min,m/z=320.1 [M+H]⁺.

(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2 on SFC, retention time=3.53 min) (2.7 mg, 4%) as a white solid.¹H NMR (400 MHz, CDCl₃) δ 7.43-7.39 (m, 1H), 7.00-6.95 (m, 2H),6.03-5.87 (m, 1H), 5.63-5.61 (m, 1H), 5.60-5.49 (m, 2H), 3.85-3.75 (m,1H), 3.14-3.02 (m, 1H). LC-MS R_(T)=0.585 min, m/z=320.1 [M+H]⁺.

Analytical SFC conditions: SFC condition: Column: ChiralPak AD-3 Mobilephase: A: C02 B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate: 2.5mL/min Column temperature: 35° C.

Examples 82 and 83(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by chiral SFC to give:

(5S,7S)-7-fluoro-2-[(S)-fluoromethysulfinyl]-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.305 min) (22.6 mg, 22%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.39-7.37 (m, 1H), 7.17-7.00 (m, 2H), 6.95 (d,J=9.2 Hz, 1H), 6.12-5.95 (m, 1H), 5.70-5.68 (m, 1H), 5.63-5.52 (m, 2H),3.73-3.60 (m, 1H), 3.02-2.92 (m, 1H). LC-MS R_(T)=0.857 min, m/z=302.1[M+H]⁺.

(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.695 min) (24.7 mg, 25%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.40-7.38 (m, 1H), 7.10-7.09 (m, 2H), 6.97-6.95(m, 1H), 6.12-5.96 (m, 1H), 5.72-5.60 (m, 2H), 5.58-5.51 (m, 1H),3.73-3.63 (m, 1H), 3.03-2.92 (m, 1H). LC-MS R_(T)=0.837 min, m/z=302.1[M+H].

SFC condition: Column: AD (250 mm*30 mm, 5 μm); Mobile phase: A: CO₂ B:0.1% NH₃H₂O MeOH; Gradient: from 25% to 25% of B; Flow rate: 50 mL/minColumn temperature: 35° C.

Examples 84 and 85(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

The title compounds were prepared according to method 25 starting from(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by chiral SFC to give:

(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.932 min) (7.4 mg, 21%). ¹H NMR (400 MHz,CD₃OD) δ 7.00-6.98 (m, 1H), 6.95-6.91 (m, 2H), 6.20-6.18 (m, 1H),5.87-5.67 (m, 3H), 3.80-3.72 (m, 1H), 2.91-2.80 (m, 1H). LC-MSR_(T)=0.625 min, m/z=320.1 [M+H]⁺.

(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(peak 2, retention time=3.144 min) (5.4 mg, 15%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.01-6.98 (m, 1H), 6.95-6.91 (m, 2H), 6.20-6.06(m, 1H), 5.86-5.65 (m, 3H), 3.82-3.74 (m, 1H), 2.91-2.81 (m, 1H). LC-MSR_(T)=0.617 min, m/z=320.1 [M+H]⁺.

SFC condition: Column: Phenomenex-Amylose-1 (250 mm*30 mm, 5 μm)., 3 umMobile phase: A: C02 B: 0.1% NH₃.H₂O-MeOH Gradient: from 20% to 20% ofB, Flow rate: 50 mL/min Column temperature.: 40° C.

Examples 86 and 87(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-((S)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand (5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-((R)-(fluoromethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole wereprepared according to Method 10 starting from(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-(methylthio)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by preparative TLC (50% ethyl acetatein petroleum ether, R_(f)=0.2) to give:(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1 on SFC, retention time=3.763 min) (35 mg, 25%) as a white solid¹H NMR (400 MHz, CD₃OD) δ 7.54-7.52 (m, 1H), 7.41-7.30 (m, 2H),6.91-6.89 (m, 1H), 6.21-6.18 (m, 0.5H), 6.08-6.05 (m, 1.5H), 5.86-5.68(m, 2H), 3.91-3.79 (m, 1H), 2.84-2.74 (m, 1H). LC-MS R_(T)=0.929 min,m/z=318.1 [M+H]⁺.

(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2 on SFC, retention time=3.971 min) (20 mg, 14%) as a white solid.¹H NMR (400 MHz, CD₃OD) δ 7.54-7.52 (m, 1H), 7.41-7.33 (m, 2H),6.91-6.89 (m, 1H), 6.21-6.18 (m, 0.5H), 6.08-6.05 (m, 1.5H), 5.87-5.69(m, 2H), 3.90-3.77 (m, 1H), 2.85-2.74 (m, 1H). LC-MS R_(T)=1.536 min,m/z=318.0 [M+H]⁺.

Analytical SFC conditions: SFC condition: Column: ChiralPak AD-3 Mobilephase: A: C02 B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate: 2.5mL/min Column temperature: 35° C.

Examples 88, 89 and 102

2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetonitrile(89),2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(102) and2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetonitrile(88)

2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetonitrile,2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrileand2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetonitrilewas prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloroacetonitrile.

2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetonitrilewas purified by RP-HPLC (acetonitrile 30-60%/0.05% ammonia hydroxide inwater) (250 mg, 85%) as light yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ7.43-7.36 (m, 3H), 7.25-7.21 (m, 2H), 6.26-6.09 (m, 1H), 5.65-5.62 (m,1H), 4.29-4.19 (m, 2H), 3.73-3.64 (m, 1H), 2.69-2.56 (m, 1H). LCMSR_(T)=0.825 min, m/z=274.9 [M+H]⁺.

2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrilewas purified by RP-HPLC (acetonitrile 45-75%/0.05% ammonia hydroxide inwater) (20.8 mg, 39%) as a yellow oil. H NMR (400 MHz, CDCl₃) δ7.43-7.40 (m, 3H), 7.30-7.25 (m, 2H), 6.16-5.99 (m, 1H), 5.63-5.54 (m,1H), 4.41-4.31 (m, 1H), 4.15-4.06 (m, 1H), 3.72-3.66 (m, 1H), 3.08-2.95(m, 1H). LC-MS R_(T)=0.847 min, m/z=291.1 [M+H]⁺.

2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetonitrilewas purified by RP-HPLC (acetonitrile 40-70%/0.05% ammonia hydroxide inwater) (16.7 mg, 37%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ7.51-7.35 (m, 4H), 7.33-7.15 (m, 1H), 6.17-6.00 (m, 1H), 5.65-5.57 (m,1H), 4.52-4.39 (m, 2H), 3.79-3.64 (m, 1H), 3.10-2.99 (m, 1H). LCMSR_(T)=0.956 min, m/z=307.1 [M+H]⁺.

Example 902-(((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfonyl)acetonitrile

2-(((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfonyl)acetonitrile was prepared according to method 26 starting from(4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-thioland chloroacetonitrile. The final compound was purified by RP-HPLC(acetonitrile 32-62%/0.1% bicarbonate in water) to give2-(((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfonyl)acetonitrile(14 mg, 40%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m,3H), 7.23-7.21 (m, 2H), 7.11 (d, J=2.8 Hz, 1H), 6.14 (d, J=6.8 Hz,0.5H), 5.99 (d, J=6.4 Hz, 0.5H), 5.70-5.55 (m, 1H), 4.27-4.17 (m, 2H),3.65-3.50 (m, 1H), 2.97-2.87 (m, 1H). LC-MS R_(T)=0.787 min, m/z=306.1[M+H]⁺.

Examples 91 and 922-((S)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrile(92) and2-((R)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrile(91)

2-((S)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrileand2-((R)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrilewere prepared according to Method 11 starting from(4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-thioland chloroacetonitrile. The final compounds were purified by chiral SFCto give:2-((S)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrile (Peak 1, Retention time=3.727 min) (7 mg, 12%) as a whitesolid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.35 (m, 3H), 7.27-7.21 (m, 2H),7.08 (s, 1H), 6.13 (d, J=6.8 Hz, 0.5H), 5.99 (d, J=6.4 Hz, 0.5H),5.55-5.50 (m, 1H), 4.09 (d, J=15.6 Hz, 1H), 3.84 (d, J=16.0 Hz, 1H),3.62-3.49 (m, 1H), 2.93-2.83 (m, 1H). LC-MS R_(T)=0.718 min, m/z=290.1[M+H]+.

2-((R)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl) acetonitrile (Peak 2, Retention time=3.964 min) (6 mg, 11%) asa white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.36 (m, 3H), 7.21-7.19(m, 2H), 7.07 (s, 1H), 6.13 (d, J=6.8 Hz, 0.5H), 5.98 (d, J=6.8 Hz,0.5H), 5.55-5.50 (m, 1H), 4.10 (d, J=15.6 Hz, 1H), 3.81 (d, J=15.6 Hz,1H), 3.61-3.50 (m, 1H), 2.93-2.83 (m, 1H). LC-MS R_(T)=0.711 min,m/z=290.1 [M+H]⁺.

SFC condition: Phenomenex-Amylose-1 (250 mm*30 mm, 5 μm); Mobile phase:A: CO₂ B: 0.1% NH₃H₂O EtOH; Gradient: from 20% to 20% of B; Flow rate:50 mL/min Column temperature: 40° C.

Examples 93 and 942-[(S)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrileand2-[(R)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile

2-[(S)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrileand2-[(R)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrilewere prepared according to method 26 starting from(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloroacetonitrile. The final compounds were purified by chiral SFCto give:

2-[(S)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 1, retention time=4.505 min) (22 mg, 29%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.46 (dd, J=1.2, 8.4 Hz, 1H), 7.36-7.30 (m, 1H),7.29-7.27 (m, 0.5H), 7.25-7.23 (m, 0.5H), 6.75 (dd, J=1.2, 7.6 Hz, 1H),6.12 (d, J=5.6 Hz, 0.5H), 6.05-5.96 (m, 1.5H), 4.37 (d, J=15.6 Hz, 1H),4.14 (d, J=15.6 Hz, 1H), 3.83-3.67 (m, 1H), 2.98-2.84 (m, 1H). LC-MSR_(T)=0.956 min, m/z=325.1 [M+H]⁺.

2-[(R)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 2, retention time=5.032 min) (17 mg, 20%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.46 (dd, J=1.2, 8.8 Hz, 1H), 7.37-7.27 (m, 2H), 6.77(d, J=9.2 Hz, 1H), 6.11 (d, J=5.2 Hz, 0.5H), 6.06-5.95 (m, 1.5H), 4.40(d, J=15.6 Hz, 1H), 4.10 (d, J=15.6 Hz, 1H), 3.83-3.68 (m, 1H),2.99-2.84 (m, 1H). LC-MS R_(T)=0.949 min, m/z=325.1 [M+H]⁺.

SFC condition: column: chiralpak AD-3 150×4.6 mm I.D., 3 μm mobilephase: A: CO₂ B: ethanol (0.05% DEA) gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min; flow rate: 2.5mL/min; column temp.: 35° C.

Examples 95 and 962-[(S)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(95) and2-[(R)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(96)

2-[(S)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrileand2-[(R)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrilewere prepared according to Method 11 starting from(5S,7S)-5-(2-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloroacetonitrile. The final compounds were purified by chiral SFCto give:

2-[(S)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 1, Retention time=3.929 min) (33 mg, 33%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.40-7.38 (m, 1H), 7.18-7.13 (m, 2H), 7.10-6.99 (m,1H), 6.15-6.00 (m, 1H), 5.90-5.88 (m, 1H), 4.34 (d, J=15.6 Hz, 1H), 4.14(d, J=15.6 Hz, 1H), 3.79-3.67 (m, 1H), 3.02-2.91 (m, 1H). LCMSR_(T)=0.775 min, m/z=308.9 [M+H]⁺.

2-[(R)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 2, Retention time=4.366 min) (33 mg, 33%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.41-7.39 (m, 1H), 7.20-7.14 (m, 2H), 7.01-6.98 (m,1H), 6.15-6.00 (m, 1H), 5.99-5.89 (m, 1H), 4.40 (d, J=15.6 Hz, 1H), 4.10(d, J=15.6 Hz, 1H), 3.79-3.67 (m, 1H), 3.03-2.93 (m, 1H). LCMSR_(T)=0.762 min, m/z=308.9 [M+H]⁺.

SFC condition: Column: Chiral Amylose-C (250 mm*30 mm, 5 m); Condition:0.10% NH₃H₂O EtOH; Begin B 30% End B 30%; Flow Rate (60 mL/min), Columntemperature 40° C.

Examples 97 and 982-[(S)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(97) and2-[(R)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(98)

2-[(S)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrileand2-[(R)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrilewere prepared according to method 26 starting from(5S,7S)-5-(3-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloroacetonitrile. The final compounds were purified by chiral SFCto give:

2-[(S)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 1, retention time=3.324 min) (20 mg, 23%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.40-7.35 (m, 1H), 7.16-6.89 (m, 3H), 6.18-5.95 (m,1H), 5.68-5.58 (m, 1H), 4.31-4.10 (m, 2H), 3.78-3.68 (m, 1H), 3.00-2.88(m, 1H). LCMS R_(T)=0.914 min, m/z=309.1 [M+H]⁺.

2-[(R)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 2, retention time=3.948 min) (17 mg, 20%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.43-7.37 (m, 1H), 7.17-6.92 (m, 3H), 6.18-5.96 (m,1H), 5.58-5.54 (m, 1H), 4.44-4.03 (m, 2H), 3.81-3.62 (m, 1H), 3.04-2.89(m, 1H). LCMS R_(T)=0.894 min, m/z=309.1 [M+H]⁺.

SFC condition: Column: Chiralpak IC-3 100×4.6 mm I.D., 3 μm Mobilephase: A: CO2 B: ethanol (0.05% DEA) Gradient: from 5% to 40% of B in3.5 min and hold 40% for 2.5 min, then 5% of B for 1.5 min, Flow rate: 3mL/min Column temp: 40° C.

Examples 99 and 1002-[(S)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(99) and2-[(R)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(100)

2-[(S)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrileand2-[(R)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrilewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloroacetonitrile. The final compounds were purified by chiral SFCto give:

2-[(S)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 1, retention time=3.293 min) (189 mg, 22%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.37-7.25 (m, 2H), 7.12-7.08 (m, 2H), 6.14-5.98(m, 1H), 5.62-5.58 (m, 1H), 4.37-4.07 (m, 2H), 3.74-3.68 (m, 1H),3.00-2.89 (m, 1H). LCMS R_(T)=0.907 min, m/z=309.1 [M+H]⁺.

2-[(R)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 2, retention time=3.964 min) (22 mg, 26%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.27-7.22 (m, 2H), 7.14-7.10 (m, 2H), 6.19-5.96 (m,1H), 5.70-5.55 (m, 1H), 4.39-4.06 (m, 2H), 3.79-3.61 (m, 1H), 3.02-2.92(m, 1H). LCMS R_(T)=0.899 min, m/z=309.1 [M+H]⁺

SFC condition: Chiralpak IC-3 100×4.6 mm I.D., 3 μm; Mobile phase: A:CO2 B: ethanol (0.05% DEA); Gradient: from 5% to 40% of B in 3.5 min andhold 40% for 2.5 min, then 5% of B for 1.5 min; Flow rate: 3 mL/min;Column temp: 40° C.

Example 1012-[(S)-[(5R,7R)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile

Arbitrary assigned2-[(S)-[(5R,7R)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrilewas prepared according to method 26 starting from(5R,7R)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloroacetonitrile. The final compound was purified by chiral SFC togive:

2-[(S)-[(5R,7R)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(Peak 1, retention time=5.070 min) (11 mg, 17%) as a arbitrarilyassigned white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.53 (d, J=8.4 Hz, 1H),7.41-7.35 (m, 1H), 7.34-7.28 (m, 1H), 6.89 (d, J=7.6 Hz, 1H), 6.21 (d,J=5.2 Hz, 0.5H), 6.12-6.05 (m, 1.5H), 3.90-3.76 (m, 1H), 3.38-3.31 (m,2H), 2.87-2.72 (m, 1H). LC-MS R_(T)=0.741 min, m/z=325.0 [M+H]⁺.

SFC condition: column: chiralpak AD-3 150×4.6 mm I.D. 3 μm; mobilephase: A: CO₂ B: ethanol (0.05% DEA); gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min flow rate: 2.5mL/min column temp.: 35° C.

Example 103: Method 272-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]-2-methyl-propanenitrile

To a solution of2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile(40 mg, 0.14 mmol) (prepared sing the general procedure of method 16) intetrahydrofuran (2 mL) was added sodium hydride (60%, 22 mg, 0.55 mmol).After stirred at 20° C. for 5 min, the reaction mixture was addediodomethane (2.0 g, 14.1 mmol). The resulting mixture was stirred at 20°C. for another 2 h and quenched by addition of saturated aqueousammonium chloride (10 mL). The resulting mixture was extracted withethyl acetate (2×10 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 25-55%/0.05% ammonia hydroxide inwater) to afford2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]-2-methyl-propanenitrile(14.3 mg, 29%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38(m, 3H), 7.27-7.21 (m, 2H), 6.14-6.11 (m, 0.5H), 5.99-5.97 (m, 0.5H),5.59-5.54 (m, 1H), 3.74-3.62 (m, 1H), 3.03-2.92 (m, 1H), 1.79-1.77 (m,6H). LC-MS R_(T)=0.796 min, m/z=340.9 [M+Na]⁺.

Example 1042-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)-2-methylpropanenitrile

2-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)-2-methylpropanenitrilewas prepared according to Method 24 starting from2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetonitrile.The final compound was purified by RP-HPLC (40-70/0.04% NH₃H₂O+10 mMNH₄HCO₃ in water) to give2-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)-2-methylpropanenitrile(13.6 mg, 40%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.27-7.22 (m, 2H), 6.17-6.00 (m, 1H), 5.64-5.61 (m, 1H), 3.76-3.66(m, 1H), 3.08-2.97 (m, 1H), 1.89-1.87 (m, 6H). LCMS R_(T)=1.794 min,m/z=335.1 [M+H]⁺.

Example 105: Method 26(5S,7S)-7-fluoro-2-methylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-7-fluoro-2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a mixture of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(200 mg, 0.85 mmol) and potassium carbonate (352 mg, 2.55 mmol) inacetonitrile (3 mL) was added iodomethane (1.2 g, 8.45 mmol). Themixture was stirred at 25° C. for 1 h and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bycolumn chromatography (silica gel, 100-200 mesh, 0 to 20% ethyl acetatein petroleum ether) to afford(5S,7S)-7-fluoro-2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(190 mg, 90%) as a light brown solid.

Step 2:(5S,7S)-7-fluoro-2-methylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-7-fluoro-2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40 mg, 0.16 mmol) in dichloromethane (5 mL) was added3-chloroperoxybenzoic acid (85%, 33 mg, 0.16 mmol). The resultingmixture was stirred at 0° C. for 2 h and diluted with dichloromethane(20 mL). The mixture was washed with saturated aqueous sodiumbicarbonate (2×10 mL), brine (2×10 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 40-70%/0.05% ammonia hydroxide in water) to give(5S,7S)-7-fluoro-2-methylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(23.4 mg, 54%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.51-7.34 (m,3H), 7.27-7.26 (m, 2H), 6.18-5.91 (m, 1H), 5.51-5.50 (m, 1H), 3.79-3.52(m, 1H), 3.08-3.05 (m, 3H), 3.02-2.90 (m, 1H). LCMS R_(T)=1.218 & 1.256min, m/z=266.1 [M+H]⁺.

Example 106(5S,7S)-7-fluoro-2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-7-fluoro-2-methylsulfanyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(70 mg, 0.28 mmol) in dichloromethane (5 mL) was added3-chloroperoxybenzoic acid (85%, 285 mg, 1.40 mmol). The mixture wasstirred at 25° C. for 2 h and diluted with dichloromethane (20 mL). Themixture was washed with saturated aqueous sodium bicarbonate (2×10 mL),brine (2×10 mL), dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by RP-HPLC (acetonitrile40-70%/0.05% ammonia hydroxide in water) to give(5S,7S)-7-fluoro-2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(75.0 mg, 91%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.35 (m,3H), 7.30-7.27 (m, 2H), 6.16-5.95 (m, 1H), 5.53-5.46 (m, 1H), 3.75-3.63(m, 1H), 3.28-3.20 (m, 3H), 3.05-2.95 (m, 1H). LC-MS R_(T)=1.471 min,m/z=282.1 [M+H]⁺.

Examples 107 and Example 108(5S,7S)-2-ethylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-ethylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-ethylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-ethylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland iodoethane.(5S,7S)-2-ethylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 25-55%/0.05% ammonia hydroxide inwater) (16.7 mg, 52%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ7.44-7.35 (m, 3H), 7.26-7.24 (m, 2H), 6.12-5.95 (m, 1H), 5.53-5.48 (m,1H), 3.73-3.58 (m, 1H), 3.30-3.22 (m, 2H), 3.02-2.92 (m, 1H), 1.33 (t,J=7.6 Hz, 3H). LCMS R_(T)=0.756 min, m/z=280.1 [M+H]⁺.

(5S,7S)-2-ethylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 30-60%/0.05% ammonia hydroxide inwater) (13.3 mg, 39%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ7.44-7.40 (m, 3H), 7.26-7.24 (m, 2H), 6.14-5.97 (m, 1H), 5.56-5.51 (m,1H), 3.75-3.60 (m, 1H), 3.43-3.36 (m, 2H), 3.06-2.95 (m, 1H), 1.39 (t,J=7.6 Hz, 3H). LCMS R_(T)=0.799 min, m/z=295.9 [M+H]⁺.

Example 109 and Example 110(5S,7S)-7-fluoro-2-isopropylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-isopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-isopropylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-isopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 2-bromopropane.

(5S,7S)-7-fluoro-2-isopropylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 50-80%/0.05% ammonia hydroxide inwater) (21.2 mg, 44%) as a yellow oil. 1H NMR (400 MHz, CDCl₃) δ7.28-7.25 (m, 3H), 7.16-7.09 (m, 2H), 6.00-5.84 (m, 1H), 5.41-5.37 (m,1H), 3.58-3.46 (m, 1H), 3.41-3.21 (m, 1H), 2.96-2.71 (m, 1H), 1.23-1.09(m, 6H). LCMS R_(T)=0.785 min, m/z=293.9 [M+H]⁺.

(5S,7S)-7-fluoro-2-isopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 40-70%/0.05% ammonia hydroxide inwater) (23.4 mg, 49%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ7.47-7.30 (m, 3H), 7.28-7.14 (m, 2H), 6.22-5.89 (m, 1H), 5.59-5.53 (m,1H), 3.75-3.58 (m, 1H), 3.57-3.45 (m, 1H), 3.08-2.90 (m, 1H), 1.40-1.25(m, 6H). LCMS R_(T)=0.826 min, m/z=309.9 [M+H]⁺.

Example 111 and Example 112(5S,7S)-2-(cyclopropylmethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-(cyclopropylmethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(cyclopropylmethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-(cyclopropylmethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland cyclopropylmethyl bromide.

(5S,7S)-2-(cyclopropylmethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 40-70%/0.05% ammonia hydroxide inwater) (13.7 mg, 28%) as a yellow oil. H NMR (400 MHz, CDCl₃) δ7.38-7.24 (m, 3H), 7.19-7.02 (m, 2H), 5.99-5.85 (m, 1H), 5.41-5.35 (m,1H), 3.61-3.48 (m, 1H), 3.18-2.83 (m, 3H), 1.05-0.98 (m, 1H), 0.60-0.45(m, 2H), 0.25-0.16 (m, 2H). LCMS R_(T)=0.811 min, m/z=305.9 [M+H]⁺.

(5S,7S)-2-(cyclopropylmethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 30-70%/0.05% ammonia hydroxide inwater) (14.7 mg, 29%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ7.41-7.32 (m, 3H), 7.27-7.16 (m, 2H), 6.14-5.98 (m, 1H), 5.57-5.53 (m,1H), 3.82-3.58 (m, 1H), 3.35-3.23 (m, 2H), 3.12-2.95 (m, 1H), 1.27-1.13(m, 1H), 0.69-0.48 (m, 2H), 0.31-0.11 (m, 2H). LC-MS R_(T)=0.831 min,m/z=321.9 [M+H]⁺.

Example 113 and Example 114(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand (5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 2-iodo-1,1,1-trifluoroethane.(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by preparative TLC (50% ethyl acetate in petroleum ether)(10 mg, 35.3%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.46-7.39(m, 3H), 7.27-7.22 (m, 2H), 6.15-5.97 (m, 1H), 5.55-5.50 (m, 1H),4.20-4.09 (m, 1H), 4.04-3.95 (m, 1H), 3.76-3.61 (m, 1H), 3.06-2.93 (m,1H). LCMS R_(T)=0.837 min, m/z=333.9 [M+H]⁺.

(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by preparative TLC (50% ethyl acetate in petroleum ether)(19 mg, 30%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.38 (m,3H), 7.25-7.18 (m, 2H), 6.19-5.97 (m, 1H), 5.63-5.53 (m, 1H), 4.26-4.19(m, 2H), 3.75-3.63 (m, 1H), 3.07-3.06 (m, 1H). LCMS R_(T)=0.674 min,m/z=350.1 [M+H]⁺.

Example 115 and Example 116(5S,7S)-7-fluoro-2-(methoxymethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-(methoxymethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-(methoxymethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-(methoxymethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland chloro(methoxy)methane.

(5S,7S)-7-fluoro-2-(methoxymethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 40-50%/0.05% ammonia hydroxide inwater) (49.4 mg, 44%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ7.48-7.40 (m, 3H), 7.27-7.22 (m, 2H), 6.16-5.96 (m, 1H), 5.57-5.51 (m,1H), 5.01-4.85 (m, 2H), 3.70-3.68 (m, 3H), 3.69-3.55 (m, 1H), 3.03-2.82(m, 1H). LC-MS RT=0.761 min, m/z=295.9 [M+H]⁺.

(5S,7S)-7-fluoro-2-(methoxymethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 30-65%/0.05% ammonia hydroxide inwater) (22.6 mg, 20%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ7.52-7.40 (m, 3H), 7.27-7.19 (m, 2H), 6.15-5.99 (m, 1H), 5.58-5.55 (m,1H), 4.86-4.77 (m, 2H), 3.79-3.61 (m, 4H), 3.06-2.94 (m, 1H). LC-MSR_(T)=1.580 min, m/z=312.1 [M+H]⁺.

Example 117: Method 43

(5S,7S)-2-((2,2-difluorocyclopropyl)sulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-(2,2-difluorocyclopropyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 0.16 mmol) (made analogously to example 16) and3-chloroperoxybenzoic acid (85%, 49 mg, 0.24 mmol) in dichloromethane (6mL) was stirred at 25° C. for 16 h and quenched by addition of saturatedaqueous sodium bicarbonate (20 mL). The mixture was extracted withdichloromethane (3×20 mL). The combined organic layers were washed withbrine (20 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile 40-50%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-(2,2-difluorocyclopropyl)sulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(2 mg, 3%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.38 (m,3H), 7.29-7.25 (m, 2H), 6.21-6.19 (m, 0.5H), 6.07-6.04 (m, 0.5H),5.69-5.65 (m, 1H), 3.87-3.72 (m, 2H), 2.90-2.82 (m, 1H), 2.45-2.37 (m,1H), 2.25-2.10 (m, 1H). LC-MS RT=1.571 & 1.619 min, m/z=328.1 [M+H]⁺.

Example 118, Example 119 and Example 120(5S,7S)-2-((2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-(((S)-2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-2-(((R)-2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-((2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 28 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol).The final compound was purified by RP-HPLC (acetonitrile 40-50% o/0.05%ammonia hydroxide in water) to give(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(2 mg, 3%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.39 (m,3H), 7.29-7.25 (m, 2H), 6.22-6.06 (m, 1H), 5.75-5.66 (m, 1H), 3.90-3.22(m, 2H), 2.91-2.84 (m, 1H), 2.50-2.40 (m, 1H), 2.38-2.25 (m, 1H). LC-MSR_(T)=1.727 & 1.782 min, m/z=344.1 [M+H]⁺.

A batch of the racemic material was further separated by chiral SFC togive:

(5S,7S)-2-(((S)-2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, Retention time=3.214 min) (117 mg, 28%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.44-7.37 (m, 3H), 7.29-7.27 (m, 2H), 6.22-6.06(m, 1H), 5.71-5.66 (m, 1H), 3.89-3.76 (m, 2H), 2.91-2.83 (m, 1H),2.42-2.38 (m, 1H), 2.29-2.25 (m, 1H). LC-MS R_(T)=1.771 min, m/z=344.0[M+H]⁺.

(5S,7S)-2-(((R)-2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, Retention time=4.159 min) (139 mg, 35%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.45-7.38 (m, 3H), 7.30-7.27 (m, 2H), 6.22-6.06(m, 1H), 5.71-5.67 (m, 1H), 3.88-3.74 (m, 2H), 2.90-2.82 (m, 1H),2.42-2.38 (m, 1H), 2.30-2.26 (m, 1H). LC-MS R_(T)=1.770 min, m/z=344.1[M+H]⁺.

SFC condition: Column: ChiralPak AD-3 Mobile phase: A: CO2 B: Ethanol(0.05% DEA) Gradient: from 5% to 40% of B in 5.5 min and hold 40% for 3min, then 5% of B for 1.5 min Flow rate: 2.5 mL/min Column temperature:40° C.

Example 119 and Example 124: Method 28(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1: vinyl 4-methylbenzenesulfonate

A solution of n-butyllithium (2.5 M in hexanes, 40.0 mL, 100.0 mmol) intetrahydrofuran (110 mL) was stirred at 35° C. for 4 h under nitrogenatmosphere and then cooled to −78° C. A solution of p-toluenesulfonylchloride (15.3 g, 80.3 mmol) in tetrahydrofuran (40 mL) was addeddropwise over 30 min. The resulting mixture was stirred at −78° C. for 1h and at 25° C. for 1 h, and then poured into water (250 mL). Thesolution was extracted with ethyl acetate (2×100 mL). The combinedorganic layers were washed with brine (100 mL), dried over sodiumsulfate and then concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 10%ethyl acetate in petroleum ether) to give vinyl 4-methylbenzenesulfonate(12.0 g, 75%) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.87-7.73 (m,2H), 7.50-7.29 (m, 2H), 6.65-6.51 (m, 1H), 4.92-4.80 (m, 1H), 4.74-4.51(m, 1H), 2.51-2.36 (m, 3H).

Step 2: 2,2-difluorocyclopropyl 4-methylbenzenesulfonate

To a solution of vinyl 4-methylbenzenesulfonate (10.0 g, 50 mmol) andsodium fluoride (0.21 g, 5.05 mmol) in o-xylene (10 mL) was addedtrimethylsilyl 2,2-difluoro-2-(fluorosulfonyl)acetate (59.64 mL, 303mmol) dropwise at 120° C. The resulting mixture was stirred at 120° C.for 2 h and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 10%ethyl acetate in petroleum ether) to afford (2,2-difluorocyclopropyl)4-methylbenzenesulfonate (8.0 g, 64%) as a light yellow solid. ¹H NMR(400 MHz, CDCl₃) δ 7.82-7.80 (m, 2H), 7.37-7.24 (m, 2H), 4.25-4.19 (m,1H), 2.46 (s, 3H), 1.70-1.53 (m, 2H).

Step 3:(5S,7S)-2-(2,2-difluorocyclopropyl)sulfanyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a mixture of(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(170 mg, 0.67 mmol) and cesium carbonate (656 mg, 2.01 mmol) inN,N-dimethylformamide (50 mL) was added (2,2-difluorocyclopropyl)4-methylbenzenesulfonate (833 mg, 3.36 mmol). The mixture was stirred at50° C. for 16 h and quenched by addition of water (50 mL). The resultingmixture was extracted with ethyl acetate (2×100 mL). The combinedorganic layers were dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography(silica gel, 100-200 mesh, 0 to 5% ethyl acetate in petroleum ether) toafford(5S,7S)-2-(2,2-difluorocyclopropyl)sulfanyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(170 mg, 77%) as a yellow oil. LC-MS R_(T)=0.734 min, m/z=330.1 [M+H]⁺.

Step 4:(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of ruthenium(III) chloride (10 mg, 0.05 mmol), sodiumperiodate (441 mg, 2.06 mmol) and(5S,7S)-2-(2,2-difluorocyclopropyl)sulfanyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(170 mg, 0.52 mmol) in acetonitrile (10 mL)/water (10 mL)/ethyl acetate(10 mL) was stirred at 30° C. for 16 h and extracted with ethyl acetate(2×50 mL). The combined organic layers were washed with brine (50 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by RP-HPLC (acetonitrile 40-70%/0.05% ammoniahydroxide in water) to afford(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 43%) as a white solid. The racemic mixture was further separatedby chiral SFC to arbitrarily afford:

(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.766 min) (5 mg, 6%) as a white solid. ¹H NMR(400 MHz, CD₃OD) δ 7.50-7.41 (m, 1H), 7.27-7.11 (m, 3H), 6.26-6.06 (m,1H), 5.96-5.87 (m, 1H), 3.92-3.74 (m, 2H), 2.96-2.80 (m, 1H), 2.46-2.41(m, 1H), 2.30-2.27 (m, 1H). LC-MS R_(T)=1.010 min, m/z=362.1 [M+H]⁺.

(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.151 min) (11 mg, 13%) as a white solid. ¹H NMR(400 MHz, CD₃OD) δ 7.50-7.41 (m, 1H), 7.26-7.10 (m, 3H), 6.26-6.06 (m,1H), 5.95-5.88 (m, 1H), 3.95-3.72 (m, 2H), 2.99-2.77 (m, 1H), 2.49-2.36(m, 1H), 2.34-2.22 (m, 1H). LC-MS R_(T)=1.009 min, m/z=362.1 [M+H]⁺.

SFC condition: column: chiralpak AD-3 150×4.6 mm I.D., 3 μm; mobilephase: A: CO₂ B: methanol (0.05% DEA); gradient: from 5% to 40% of B in5.5 min, then 5% of B for 1.5 min flow rate: 2.5 mL/min columntemperature: 40° C.

Example 120 and Example 125(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 28 starting from(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compounds were purified first by RP-HPLC (acetonitrile15-45%/0.05% ammonia hydroxide in water) then chiral SFC to give:

(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.228 min) (27 mg, 32%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.48 (d, J=8.0 Hz, 1H), 7.38-7.28 (m, 2H), 6.79-6.71(m, 1H), 6.16-6.10 (m, 0.5H), 6.08-6.01 (m, 1H), 6.00-5.96 (m, 0.5H),3.80-3.68 (m, 1H), 3.58-3.47 (m, 1H), 2.98-2.87 (m, 1H), 2.65-2.57 (m,1H), 2.22-2.14 (m, 1H). LC-MS R_(T)=1.061 min, m/z=378.1 [M+H]⁺.

(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.615 min) (26 mg, 31%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.47 (d, J=7.6 Hz, 1H), 7.38-7.28 (m, 2H), 6.75 (d,J=7.6 Hz, 1H), 6.13 (d, J=6.8 Hz, 0.5H), 6.07-6.01 (m, 1H), 5.99 (d,J=7.2 Hz, 0.5H), 3.84-3.67 (m, 1H), 3.56-3.45 (m, 1H), 3.00-2.85 (m,1H), 2.69-2.49 (m, 1H), 2.23-2.09 (m, 1H). LC-MS R_(T)=1.062 min,m/z=378.1 [M+H]⁺.

SFC condition: column: chiralpak AD-3 150×4.6 mm I.D., 3 μm; mobilephase: A: CO₂ B: methanol (0.05% DEA); gradient: from 5% to 40% of B in5.5 min, then 5% of B for 1.5 min flow rate: 2.5 mL/min columntemperature: 40° C.

Example 121, Example 128 and Example 129(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 40-70%/0.05%ammonia hydroxide in water) to give (5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(72.4 mg, 44%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22 (m,1H), 7.15-7.10 (m, 1H), 6.77-6.70 (m, 1H), 6.16-6.00 (m, 1H), 5.95-5.85(m, 1H), 3.80-3.68 (m, 1H), 3.52-3.47 (m, 1H), 3.05-2.92 (m, 1H),2.70-2.52 (m, 1H), 2.20-2.10 (m, 1H). LC-MS R_(T)=1.823 min, m/z=380.0[M+H]⁺.

The racemic material was further separated by chiral SFC to give:

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.263 min) (26.6 mg, 38%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.27-7.22 (m, 1H), 7.20-7.10 (m, 1H), 6.77-6.72(m, 1H), 6.16-6.00 (m, 1H), 5.95-5.85 (m, 1H), 3.83-3.73 (m, 1H),3.55-3.46 (m, 1H), 3.03-2.95 (m, 1H), 2.59-2.54 (m, 1H), 2.16-2.12 (m,1H). LC-MS R_(T)=1.830 min, m/z=380.0 [M+H]⁺.

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=2.606 min)) (26 mg, 37% yield) as a white solid.¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22 (m, 1H), 7.20-7.08 (m, 1H),6.77-6.72 (m, 1H), 6.16-6.00 (m, 1H), 5.98-5.85 (m, 1H), 3.80-3.72 (m,1H), 3.52-3.44 (m, 1H), 3.05-2.88 (m, 1H), 2.75-2.55 (m, 1H), 2.17-2.13(m, 1H). LC-MS R_(T)=1.826 min, m/z=380.0 [M+H]⁺.

SFC condition Column: Chiralpak AS (150 mm*4.6 mm, 3 μm), Mobile phase:A: CO₂ B: ethanol (0.05% DEA), Gradient: from 5% to 40% of B in 5 minand hold 40% for 2.5 min, then 5% of B for 2.5 min, Flow rate: 2.5mL/min, Column temperature: 35° C.

Example 122, Example 126 and Example 127(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 28 starting from(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 40-70%/0.05%ammonia hydroxide in water) to give (5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(12 mg, 22%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.18-7.09 (m,2H), 6.75-6.68 (m, 1H), 6.15-5.99 (m, 1H), 5.90-5.85 (m, 1H), 3.79-3.68(m, 1H), 3.53-3.47 (m, 1H), 3.03-2.92 (m, 1H), 2.65-2.55 (m, 1H),2.25-2.15 (m, 1H). LC-MS R_(T)=1.024 min, m/z=380.1 [M+H]⁺.

Another batch of the racemic material was further separated by chiralSFC to give:

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.668 min) (5 mg, 10%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.20-7.05 (m, 2H), 6.75-6.68 (m, 1H), 6.16-6.00 (m,1H), 5.95-5.85 (m, 1H), 3.80-3.68 (m, 1H), 3.60-3.47 (m, 1H), 3.03-2.98(m, 1H), 2.70-2.52 (m, 1H), 2.20-2.15 (m, 1H). LCMS R_(T)=1.808 min,m/z=380.0 [M+H]⁺.

(5S,7S)-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=2.945 min) (4.9 mg, 10%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.20-7.05 (m, 2H), 6.75-6.68 (m, 1H), 6.16-5.95(m, 1H), 5.90-5.80 (m, 1H), 3.82-3.65 (m, 1H), 3.62-3.40 (m, 1H),3.07-2.92 (m, 1H), 2.62-2.55 (m, 1H), 2.20-2.12 (m, 1H). LCMSR_(T)=1.808 min, m/z=380.1 [M+H]⁺.

SFC condition: Column: Chiralpak AD-3 150×4.6 mm I.D., 3 μm Mobilephase: A: CO₂ B: ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5min and hold 40% for 2.5 min, then 5% of B for 2.5 min Flow rate: 2.5mL/min Column temp.: 35° C.

Example 123(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 28 starting from(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 36-66%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(19 mg, 25%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38 (m,1H), 6.99-6.94 (m, 2H), 6.20-6.03 (m, 1H), 5.91-5.87 (m, 1H), 3.84-3.76(m, 1H), 3.49-3.43 (m, 1H), 3.15-3.00 (m, 1H), 2.70-2.53 (m, 1H),2.14-2.08 (m, 1H). LCMS R_(T)=1.004 min, m/z=380.1 [M+H]⁺.

Example 132: Method 29(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.To a solution of(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(65 mg, 0.21 mmol) in chloroform (6 mL) was added 3-chloroperoxybenzoicacid (85%, 131 mg, 0.64 mmol). The reaction mixture was stirred at 60°C. for 16 h and quenched by addition of saturated aqueous sodiumthiosulfate (15 mL). The resulting mixture was extracted with ethylacetate (3×15 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 40-70%/0.05% ammonia hydroxide inwater) to afford(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(24.8 mg, 36%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m,3H), 7.27-7.24 (m, 2H), 6.17-6.13 (m, 0.5H), 6.03-6.00 (m, 0.5H),5.58-5.55 (m, 1H), 3.75-3.65 (m, 1H), 3.07-2.96 (m, 1H). LCMSR_(T)=0.862 min, m/z=319.9 [M+H]⁺.

Example 135(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of 3,3-dimethyl-1-(trifluoromethyl)-1,2-benziodoxole (72mg, 0.22 mmol) in dichloromethane (2 mL) was added(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(50 mg, 0.20 mmol) at −78° C. The mixture was stirred at −78° C. for 3.5h and concentrated under reduced pressure. The residue was purified bypreparative TLC (30% ethyl acetate in petroleum ether) to afford(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40 mg, 63%) as a colorless oil. LCMS R_(T)=0.761 min, m/z=322.1 [M+H]⁺.

Step 2:(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of ruthenium(III) chloride (2 mg, 0.01 mmol), sodium periodate(80 mg, 0.37 mmol) and(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 0.09 mmol) in acetonitrile (1 mL), water (1 mL) and ethylacetate (1 mL) was stirred at 30° C. for 20 min and filtered. Thefiltrate was diluted with water (10 mL) and extracted with ethyl acetate(3×10 mL). The combined organic layers were dried over sodium sulfateand concentrated under reduced pressure. The residue was purified bypreparative TLC (30% ethyl acetate in petroleum ether, R_(f)=0.4) togive(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(18 mg, 50%) as a faint yellow solid. ¹H NMR (400 MHz, CD₃OD) δ7.48-7.44 (m, 1H), 7.17-7.06 (m, 3H), 6.26-6.10 (m, 1H), 5.79-5.76 (m,1H), 3.86-3.75 (m, 1H), 2.96-2.85 (m, 1H). LCMS R_(T)=1.135 min,m/z=354.1 [M+H]⁺.

Example 133(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 47-77%/0.05%ammonia hydroxide in water) to give(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(37 mg, 41%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.41 (m,1H), 7.21-7.14 (m, 2H), 6.99-6.95 (m, 1H), 6.18 (d, J=7.2 Hz, 0.5H),6.05 (d, J=7.2 Hz, 0.5H), 5.96-5.93 (m, 1H), 3.84-3.70 (m, 1H),3.08-2.92 (m, 1H). LC-MS R_(T)=0.929 min, m/z=353.8 [M+H]⁺.

Example 134(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 50-80/o/0.05%ammonia hydroxide in water) to give(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(98 mg, 74%) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, J=7.6 Hz,1H), 7.40-7.27 (m, 2H), 6.70 (d, J=7.6 Hz, 1H), 6.17 (d, J=7.2 Hz,0.5H), 6.13-6.07 (m, 1H), 6.02 (d, J=5.2 Hz, 0.5H), 3.87-3.71 (m, 1H),3.03-2.92 (m, 1H). LC-MS R_(T)=0.900 min, m/z=370.0 [M+H]⁺.

Example 136(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 40-70%/0.05%ammonia hydroxide in water) to give(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(48 mg, 43%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22 (m,1H), 7.20-7.14 (m, 1H), 6.74-6.70 (m, 1H), 6.20-6.04 (m, 1H), 5.96-5.94(m, 1H), 3.86-3.72 (m, 1H), 3.09-2.98 (m, 1H). LC-MS R_(T)=2.022 min,m/z=372.0 [M+H]⁺.

Example 137(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 43-63%/0.05%ammonium bicarbonate in water) to give(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20 mg, 28%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.42 (m,3H), 7.27-7.24 (m, 2H), 6.19-6.05 (m, 1H), 5.64-5.60 (m, 1H), 3.79-3.65(m, 1H), 3.12-3.01 (m, 1H). LCMS R_(T)=1.123 min, m/z=336.1 [M+H]⁺.

Example 138(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 50-80%/0.05%ammonia hydroxide in water) to give(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(17 mg, 31%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.17-7.12 (m,2H), 6.70-6.67 (m, 1H), 6.19-6.03 (m, 1H), 5.90-5.89 (m, 1H), 3.84-3.70(m, 1H), 3.08-2.97 (m, 1H). LC-MS R_(T)=1.134 min, m/z=372.1 [M+H]⁺.

Example 139(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-(trifuoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo-[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by column chromatography (silica gel,100-200 mesh, 0 to 20% ethyl acetate in petroleum ether) to give(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(15 mg, 28%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.55-7.51 (m,1H), 7.13-7.08 (m, 2H), 6.29-6.13 (m, 1H), 6.08-6.06 (m, 1H), 3.95-3.83(m, 1H), 3.04-2.92 (m, 1H). LCMS R_(T)=1.124 min, m/z=372.1 [M+H]⁺

Example 140(5R,7R)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Arbitrarily assigned(5R,7R)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 29 starting from(5R,7R)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 50-80%/0.05%ammonia hydroxide in water) to give arbitrarily assigned(5R,7R)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(60 mg, 32%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.24 (m,1H), 7.23-7.14 (m, 1H), 6.75-6.71 (m, 1H), 6.21-6.05 (m, 1H), 6.02-5.95(m, 1H), 3.88-3.75 (m, 1H), 3.08-2.97 (m, 1H). LC-MS R_(T)=2.031 min,m/z=372.0 [M+H]⁺.

Example 141 and Example 142: Method 30(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1: Trans-2-fluorocyclopropanecarbonyl Chloride

A mixture of trans-2-fluorocyclopropanecarboxylic acid (25.0 g, 240mmol) and N,N-dimethylformamide (1.8 g, 24 mmol) in dichloromethane (227mL) was added oxalyl chloride (30.5 mL, 360 mmol) at 0° C. The mixturewas stirred at 20° C. for 16 h and concentrated under reduced pressureto give crude trans-2-fluorocyclopropanecarbonyl chloride (29.4 g, 99%).

Step 2: 2-[trans-2-fluorocyclopropyl]sulfanylpyridine

A cooled (0° C.) solution of trans-2-fluorocyclopropanecarbonyl chloride(29.4 g, 240.2 mol) in dichloromethane (454 mL) was added4-dimethylaminopyridine (2.9 g, 24 mmol) and sodium1-oxidopyridine-2-thione (53.7 g, 360 mmol) portionwise under dark.After addition, the mixture was stirred for 2 h and quenched by additionof water (200 mL). The separated organic layer was filtered through ashort pad of Celite and washed with dichloromethane (2×100 mL). Thecombined organic layers were concentrated under reduced pressure(without heating). The residue was dissolved in ethyl acetate (300 mL)and irradiated with a 600 W halogen lamp until complete consumption ofthe Barton ester. The crude was then used directly into the next stepwithout further purification.

Step 3: 2-[trans-2-fluorocyclopropyl]sulfonylpyridine

To a cooled (0° C.) mixture of crude2-[trans-2-fluorocyclopropyl]sulfanylpyridine in ethyl acetate (300 mL)and water (300 mL) was added ruthenium(III) chloride (249 mg, 1.2 mmol)and sodium periodate (205.3 g, 959.7 mmol). The reaction was stirred for16 h at 20° C. and extracted with ethyl acetate (3×100 mL). The combinedorganic layers were washed with brine (200 mL), dried over magnesiumsulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 30%ethyl acetate in petroleum ether) to afford2-[trans-2-fluorocyclopropyl]sulfonylpyridine (13.5 g, 28%) as acolorless oil. ¹H NMR (400 MHz, DMSO-d₆) δ 8.85-8.84 (m, 1H), 8.21-8.17(m, 1H), 8.08-8.06 (m, 1H), 7.81-7.80 (m, 1H), 5.30-5.27 (m, 0.5H),5.13-5.12 (m, 0.5H), 3.68-3.63 (m, 1H), 1.94-1.87 (m, 1H), 1.64-1.59 (m,1H).

Step 4: Sodium trans-2-fluorocyclopropanesulfinate

To a mixture of 2-[trans-2-fluorocyclopropyl]sulfonylpyridine (7.5 g,37.3 mmol) in tetrahydrofuran (150 mL) was added sodium ethanethiolate(3.8 g, 44.7 mmol) at 0° C. After addition, the mixture was stirred at18° C. for 16 h and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 30%methanol in dichloromethane) to give the sodiumtrans-2-fluorocyclopropanesulfinate (4.5 g, 83%) as a white solid. ¹HNMR (400 MHz, DMSO-d₆) δ 4.55-4.52 (m, 0.5H), 4.38-4.36 (m, 0.5H),2.15-2.08 (m, 1H), 1.02-0.89 (m, 2H).

Step 5(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-bromo-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(300 mg, 1.00 mmol), sodium trans-2-fluorocyclopropanesulfinate (292 mg,2.00 mmol), copper(I) trifluoromethanesulfonate benzene complex (100 mg,0.20 mmol), potassium iodide (83 mg, 0.50 mmol) and(1R,2R)—N˜1˜,N˜2˜-dimethyl-1,2-cyclohexanediamine (71 mg, 0.50 mmol) indimethyl sulfoxide (10 mL) was heated at 100° C. for 2 h under microwaveconditions. After cooled, the reaction mixture was extracted with ethylacetate (2×50 mL). The combined organic layers were washed with brine(50 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile 31-61%/0.05%ammonia hydroxide in water) to afford(5S,7S)-7-fluoro-2-[trans-2-fluorocyclopropyl]sulfonyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(75 mg, 22%) as a white solid. This trans mixture was further separatedby chiral SFC to give:

(5S,7S)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=4.035 min) (6 mg, 7%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.45-7.37 (m, 1H), 7.15-7.09 (m, 1H), 7.08-7.04 (m,1H), 7.02-6.95 (m, 1H), 6.16-5.98 (m, 1H), 5.58-5.51 (m, 1H), 5.24-5.04(m, 1H), 3.77-3.62 (m, 1H), 3.23-3.12 (m, 1H), 3.08-2.95 (m, 1H),1.90-1.75 (m, 2H). LC-MS R_(T)=0.974 min, m/z=344.1 [M+H]⁺.

(5S,7S)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.600 min) (15 mg, 20%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.45-7.37 (m, 1H), 7.15-7.09 (m, 1H), 7.08-7.04 (m,1H), 7.02-6.96 (m, 1H), 6.14-5.98 (m, 1H), 5.59-5.49 (m, 1H), 5.22-5.06(m, 1H), 3.80-3.64 (m, 1H), 3.24-3.10 (m, 1H), 3.08-2.94 (m, 1H),1.93-1.75 (m, 2H). LC-MS R_(T)=0.974 min, m/z=344.1 [M+H]⁺.

SFC condition: column: chiralpak AY 150×4.6 mm I.D., 3 μm, mobile phase:A: CO₂ B: ethanol (0.05% DEA), gradient: from 5% to 40% of B in 5 minand hold 40% for 2.5 min, then 5% of B for 2.5 min, flow rate: 2.5mL/min, column temp.: 35° C.

Example 126 and Example 127(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 29 starting from(5S,7S)-2-bromo-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by chiral SFC to give arbitrarilyassigned:

(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, Retention time=3.495 min) (15 mg, 5%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.27-7.21 (m, 1H), 7.20-7.10 (m, 1H), 7.06-7.03 (m,1H), 6.14 (d, J=8.4 Hz, 0.5H), 6.00 (d, J=8.0 Hz, 0.5H), 5.53-5.21 (m,1H), 5.15-5.10 (m, 0.5H), 5.06-3.02 (m, 0.5H), 3.73-3.64 (m, 1H),3.16-3.12 (m, 1H), 3.03-2.92 (m, 1H), 1.89-1.80 (m, 2H). LC-MSR_(T)=0.972 min, m/z=362.1 [M+H]⁺.

(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, Retention time=3.709 min) (17 mg, 6%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.27-7.22 (m, 1H), 7.16-7.10 (m, 1H), 7.07-7.03 (m,1H), 6.13 (d, J=6.8 Hz, 0.5H), 6.00 (d, J=8.4 Hz, 0.5H), 5.54-5.21 (m,1H), 5.15-5.10 (m, 0.5H), 5.06-5.02 (m, 0.5H), 3.73-3.64 (m, 1H),3.19-3.12 (m, 1H), 3.04-2.93 (m, 1H), 1.88-1.78 (m, 2H). LC-MSR_(T)=0.792 min, m/z=362.1 [M+H]⁺.

SFC condition: AY-H (250 mm×30 mm, 5 μm); Mobile phase: A: CO₂ B: 0.1%NH₃H₂O EtOH; Gradient: from 25% to 25% of B; Flow rate: 50 mL/min Columntemperature: 40° C.

Example 145 and Example 146(5S,7S)-7-fluoro-5-phenyl-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand (5S,7S)-7-fluoro-5-phenyl-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole wereprepared according to method 20 starting from(5S,7S)-2-bromo-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compounds were purified by chiral SFC to give arbitrarilyassigned:

(5S,7S)-7-fluoro-5-phenyl-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=4.973 min) (2.5 mg, 2%) as a white solid. ¹H NMR(400 MHz, CD₃OD) δ 7.47-7.41 (m, 3H), 7.32-7.30 (m, 2H), 6.24-6.08 (m,1H), 5.71-5.69 (m, 1H), 5.22-5.06 (m, 1H), 3.83-3.76 (m, 1H), 3.41-3.32(m, 1H), 2.95-2.86 (m, 1H), 1.89-1.84 (m, 1H), 1.75-1.70 (m, 1H). LCMSR_(T)=0.669 min, m/z=326.1 [M+H]⁺.

(5S,7S)-7-fluoro-5-phenyl-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=5.569 min) (2.7 mg, 2%) as a white solid. ¹H NMR(400 MHz, CD₃OD) δ 7.47-7.41 (m, 3H), 7.31-7.29 (m, 2H), 6.24-6.08 (m,1H), 5.71-5.69 (m, 1H), 5.22-5.05 (m, 1H), 3.83-3.76 (m, 1H), 3.41-3.33(m, 1H), 2.95-2.86 (m, 1H), 1.90-1.74 (m, 2H). LCMS R_(T)=0.670 min,m/z=326.1 [M+H]⁺.

SFC condition: Column: ChiralPak AY-3 150×4.6 mm I.D., 3 um Mobilephase: A: C02 B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in5.5 min and hold 40% for 3 min, then 5% of B for 1.5 min Flow rate: 2.5mL/min Column temperature: 40° C.

Example 147(5S,7S)-7-fluoro-5-phenyl-2-((pyridin-2-ylmethyl)sulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-(2-pyridylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 2-(chloromethyl)pyridine hydrochloride. The final compound waspurified by column chromatography (silica gel, 0-65% ethyl acetate inpetroleum ether) to give(5S,7S)-7-fluoro-5-phenyl-2-(2-pyridylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20 mg, 62%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.49-8.46 (m,1H), 7.77-7.74 (m, 1H), 7.42-7.32 (m, 5H), 7.26-7.25 (m, 1H), 7.18-7.15(m, 1H), 6.19-6.03 (m, 1H), 5.64-5.60 (m, 1H), 4.76-4.71 (m, 2H),3.80-3.70 (m, 1H), 2.88-2.74 (m, 1H). LC-MS R_(T)=1.428 min, m/z=343.1[M+H]⁺.

Example 148(5S,7S)-2-(2,2-difluoroethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(2,2-difluoroethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 2-iodo-1,1-difluoroethane. The final compound was purified bypreparative TLC (40% ethyl acetate in petroleum ether, R_(f)=0.2) togive(5S,7S)-2-(2,2-difluoroethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(23.1 mg, 43%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.40 (m,3H), 7.27-7.24 (m, 2H), 6.31-6.15 (m, 1H), 6.13-5.97 (m, 1H), 5.54-5.50(m, 1H), 3.93-3.75 (m, 1H), 3.73-3.62 (m, 2H), 3.05-2.98 (m, 1H). LC-MSR_(T)=0.806 min, m/z=315.9 [M+H]⁺.

Example 149: Method 31(5S,7S)-2-(1,1-difluoroethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-2-(1,1-difluoroethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 31 starting from 2,2-difluoropropanoicacid. The final compound was purified by RP-HPLC (acetonitrile35-65%/0.05% ammonia hydroxide in water) to give(5S,7S)-2-(1,1-difluoroethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(2 mg, 18%) as yellow solid. ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.41 (m,3H), 7.28-7.25 (m, 2H), 6.24-6.08 (m, 1H), 5.75-5.70 (m, 1H), 3.86-3.72(m, 1H), 2.93-2.82 (m, 1H), 2.06 (t, J=6.8 Hz, 3H). LCMS R_(T)=1.081min, m/z=332.1 [M+H]⁺.

Example 150

(5S,7S)-7-fluoro-2-(1-methylcyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-(1-methylcyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 31 starting from1-methylcyclopropanecarboxylic acid. The final compound was purified byRP-HPLC (acetonitrile 38-68/0.05% ammonia hydroxide in water) to give(5S,7S)-7-fluoro-2-(1-methylcyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(2 mg, 28%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m,3H), 7.27-7.23 (m, 2H), 6.13-6.11 (m, 0.5H), 6.00-5.97 (m, 0.5H),5.56-5.53 (m, 1H), 3.71-3.62 (m, 1H), 3.05-2.94 (m, 1H), 1.75-1.68 (m,2H), 1.52 (s, 3H), 0.94-0.87 (m, 2H). LCMS R_(T)=0.831 min, m/z=321.9[M+H]⁺.

Example 151 and Example 152(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 1-(bromomethyl)pyrazole.

(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by preparative TLC (66% ethyl acetate in petroleum ether)(16 mg, 41%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.56-7.53 (m,2H), 7.41-7.39 (m, 3H), 7.26-7.22 (m, 2H), 6.27 (s, 1H), 6.15-5.98 (m,1H), 5.69-5.55 (m, 2H), 5.53-5.47 (m, 1H), 3.69-3.60 (m, 1H), 3.02-2.92(m, 1H). LC-MS R_(T)=0.876 min, m/z=332.2 [M+H]⁺.

(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 35-65%/0.05% ammonia hydroxide inwater) (15 mg, 38%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s,1H), 7.45-7.35 (m, 3H), 7.34-7.30 (m, 1H), 7.21-7.19 (m, 2H), 6.28-6.27(m, 1H), 6.10-5.96 (m, 1H), 5.75-5.65 (m, 2H), 5.55-5.48 (m, 1H),3.75-3.60 (m, 1H), 3.05-2.92 (m, 1H). LC-MS R_(T)=0.905 min, m/z=348.1[M+H]⁺.

Example 153 and Example 154(5S,7S)-7-fluoro-2-(1,1,2,2,2,-pentafluoroethysulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand (5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland pentafluoroethyl iodide.(5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 40-50%/0.05% ammonia hydroxide inwater) (6.7 mg, 4%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ7.43-7.40 (m, 3H), 7.29-7.25 (m, 2H), 6.25-6.22 (m, 0.5H), 6.11-6.08 (m,0.5H), 5.73-5.70 (m, 1H), 3.85-3.75 (m, 1H), 2.91-2.80 (m, 1H). LCMSR_(T)=1.959 min, m/z=370.0 [M+H]⁺.

(5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas purified by RP-HPLC (acetonitrile 40-50%/0.05% ammonia hydroxide inwater) (30.4 mg, 23%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ7.46-7.41 (m, 3H), 7.29-7.26 (m, 2H), 6.27-6.24 (m, 0.5H), 6.13-6.10 (m,0.5H), 5.77-5.75 (m, 1H), 3.85-3.75 (m, 1H), 2.95-2.84 (m, 1H). LCMSR_(T)=2.113 min, m/z=386.0 [M+H]⁺.

Example 155: Method 17(5S,7S)-2-[1-(difluoromethyl)cyclopropyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1: methyl4-bromo-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]butanoate

To a solution of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(500 mg, 2.13 mmol) in acetonitrile (10 mL) was added potassiumcarbonate (441 mg, 3.19 mmol) and methyl 2,4-dibromobutanoate (829 mg,3.19 mmol). The mixture was stirred at 20° C. for 3 h and filtered. Thefiltrate was concentrated under reduced pressure. The residue waspurified by preparative TLC (50% ethyl acetate in petroleum ether,R_(f)=0.5) to give methyl4-bromo-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]butanoate(520 mg, 59%) as a colorless oil.

Step 2:1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylicacid

To a solution of methyl4-bromo-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]butanoate(520 mg, 1.26 mmol) in acetonitrile (2 mL) was added sodiumtert-butoxide (1.0 M in tetrahydrofuran, 2.51 mL, 2.51 mmol). Themixture was stirred at 25° C. for 3 h and quenched by addition of water(20 mL). The resulting was adjusted to pH=4 by addition of aqueoushydrochloric acid (1.0 M) and extracted with ethyl acetate (2×15 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure to afford crude1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylicacid (380 mg, 95%) as a brown solid.

Step 3:1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarboxylicacid

A mixture of1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylicacid (200 mg, 0.63 mmol), sodium periodate (536 mg, 2.51 mmol) andruthenium(III) chloride (1.3 mg, 0.01 mmol) in water (1 mL)/ethylacetate (1 mL)/acetonitrile (1 mL) was stirred at 20° C. for 2 h anddiluted with ethyl acetate (50 mL). The mixture was washed with brine(30 mL). The separated organic layer was dried over sodium sulfate andconcentrated under reduced pressure to afford crude1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarboxylicacid (120 mg, 55%) as a dark brown solid.

Step 4:[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropyl]methanol

To a cooled (0° C.) solution of1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarboxylicacid (120 mg, 0.34 mmol) and triethylamine (0.06 mL, 0.44 mmol) intetrahydrofuran (3 mL) was added isobutyl chloroformate (0.06 mL, 0.44mmol) under nitrogen atmosphere. The mixture was stirred at 20° C. for30 min and filtered. The filtrate was added sodium borohydride (26 mg,0.68 mmol) in water (0.40 mL) at 0° C. and stirred at 20° C. for 2 h.The mixture was quenched by the addition of saturated aqueous ammoniumchloride (10 mL) and extracted with ethyl acetate (2×10 mL). Thecombined organic layers were washed with saturated aqueous sodiumbicarbonate (10 mL), brine (10 mL), dried over sodium sulfate andconcentrated under reduced pressure to give crude[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropyl]methanol(110 mg, 96%) as a light brown oil.

Step 5:1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbaldehyde

To a solution of[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropyl]methanol(100 mg, 0.30 mmol) in dichloromethane (2 mL) was added pyridiniumchlorochromate (96 mg, 0.44 mmol). The mixture was stirred at 20° C. for18 h and another batch of pyridinium chlorochromate (192 mg, 0.88 mmol)was added. The resulting mixture was stirred for 48 h and concentratedunder reduced pressure. The residue was purified by preparative TLC (50%ethyl acetate in petroleum ether, Rf=0.4) to afford1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbaldehyde(70 mg, 70%) as a light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 10.21 (s,1H), 7.46-7.37 (m, 3H), 7.25-7.21 (m, 2H), 6.14-5.92 (m, 1H), 5.60-5.46(m, 1H) 3.76-3.54 (m, 1H), 3.12-2.89 (m, 1H), 2.06-2.01 (m, 2H),1.84-1.71 (m, 2H).

Step 6:(5S,7S)-2-[1-(difluoromethyl)cyclopropyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbaldehyde(60 mg, 0.18 mmol) and diethylaminosulfur trifluoride (2.0 mL, 0.18mmol) was heated at 40° C. for 1 h. The mixture was diluted withdichloromethane (20 mL) and poured into ice cooled saturated aqueoussodium bicarbonate. The aqueous layer was extracted with dichloromethane(2×10 mL). The combined organic layers were washed with water (10 mL),brine (20 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by RP-HPLC (acetonitrile 43-73%/0.05%ammonia hydroxide in water) to give(5S,7S)-2-[1-(difluoromethyl)cyclopropyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(28.8 mg, 44%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.37 (m,3H), 7.26-7.18 (m, 2H), 6.57 (t, J=56.8 Hz, 1H), 6.12-5.96 (m, 1H),5.56-5.53 (m, 1H), 3.74-3.60 (m, 1H), 3.02-2.92 (m, 1H), 1.90-1.84 (m,2H), 1.50-1.44 (m, 2H). LCMS R_(T)=1.043 min, m/z=358.1 [M+H]⁺.

Example 156: Method 182,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol

Step 1: ethyl2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetate

A mixture of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(300 mg, 1.28 mmol), ethyl bromodifluoroacetate (388 mg, 1.91 mmol) andcesium carbonate (831 mg, 2.55 mmol) in N,N-dimethylformamide (5 mL) wasstirred at 10° C. for 3 h under nitrogen atmosphere and diluted withethyl acetate (50 mL). The mixture was washed with water (50 mL), brine(50 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 20% ethyl acetate in petroleum ether) to afford ethyl2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetate(280 mg, 61%) as a yellow oil. LCMS R_(T)=0.892 min, m/z=358.0 [M+H]⁺.

Step 2: ethyl2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetate

A mixture of ruthenium(III) chloride (15 mg, 0.07 mmol), sodiumperiodate (748 mg, 3.5 mmol) and ethyl2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetate(250 mg, 0.70 mmol) in ethyl acetate (4 mL), water (4 mL) andacetonitrile (4 mL) was stirred at 35° C. for 5 h and quenched byaddition of saturated aqueous sodium sulfite (10 mL). The mixture wasextracted with ethyl acetate (3×30 mL). The combined organic layers werewashed with water (20 mL), brine (20 mL) and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 40% ethyl acetate in petroleum ether) to afford ethyl2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetate(120 mg, 44%) as a yellow solid.

Step 3:2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol

To a mixture of ethyl2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetate(90 mg, 0.23 mmol) in methanol (4 mL) was added sodium borohydride (26mg, 0.69 mmol). After addition, the mixture was stirred at 10° C. for 2h and quenched by addition of saturated aqueous ammonium chloride (10mL). The mixture was diluted with water (20 mL) and extracted with ethylacetate (3×30 mL). The combined organic layers were washed with brine(20 mL) and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 36-66%/0.05% ammonia hydroxide inwater) to afford2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol(30 mg, 36%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.40 (m,3H), 7.28-7.25 (m, 2H), 6.24-6.08 (m, 1H), 5.73-5.71 (m, 1H), 4.19 (t,J=14.4 Hz, 2H), 3.84-3.73 (m, 1H), 2.91-2.80 (m, 1H). LCMS R_(T)=0.972min, m/z=348.1 [M+H]⁺.

Example 157: Method 191-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile

Step 1:1-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclopropanecarboxamide

A mixture of1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylicacid (150 mg, 0.47 mmol), ammonium chloride (75 mg, 1.41 mmol),1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxid hexafluorophosphate (196 mg, 0.52 mmol) andN,N-diisopropylethylamine (182 mg, 1.41 mmol) in N,N-dimethylformamide(2 mL) was stirred at 20° C. for 2 h and diluted with water (10 mL). Theresulting mixture was extracted ethyl acetate (3×10 mL). The combinedorganic layers were washed with water (10 mL), brine (10 mL), dried oversodium sulfate and concentrated under reduced pressure to afford crude1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxamide(160 mg, 100%) as a brown solid. LC-MS R_(T)=0.617 min, m/z=319.1[M+H]⁺.

Step 2:1-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclopropanecarbonitrile

To a solution of1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxamide(160 mg, 0.50 mmol) in 1,4-dioxane (3 mL) was added triethylamine (153mg, 1.51 mmol) and trifluoroacetic anhydride (211 mg, 1.01 mmol)dropwise. The reaction mixture was stirred at 25° C. for 2 h andquenched by addition of water (10 mL). The mixture was extracted withethyl acetate (3×20 mL). The combined organic layers were washed withsaturated aqueous sodium bicarbonate (20 mL), dried over sodium sulfateand concentrated under reduced pressure. The residue was purified bypreparative TLC (50% ethyl acetate in petroleum ether, R_(f)=0.4) togive1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarbonitrile(150 mg, 99%) as a white solid. LC-MS R_(T)=0.687 min, m/z=301.2 [M+H]⁺.

Step 3:1-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclopropanecarbonitrile

A mixture of1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarbonitrile(150 mg, 0.50 mmol) and 3-chloroperoxybenzoic acid (85%, 406 mg, 2 mmol)in 1,2-dichloroethane (10 mL) was stirred at 30° C. for 5 h and quenchedby addition of saturated aqueous sodium bicarbonate (10 mL). Theresulting mixture was extracted with ethyl acetate (3×10 mL). Thecombined organic layers were washed with brine (3×10 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 40-70%/0.05% ammonia hydroxide inwater) to give1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile(32.4 mg, 32%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.52-7.40 (m,2H), 7.38-7.25 (m, 3H), 6.16-6.00 (m, 1H), 5.67-5.59 (m, 1H), 3.78-3.64(m, 1H), 3.08-2.96 (m, 1H), 2.20-2.09 (m, 2H), 1.95-1.80 (m, 2H). LC-MSR_(T)=0.842 min, m/z=354.9 [M+Na]⁺.

Example 158, Example 159 and Example 160: Method 20(5S,7S)-7-fluoro-2-(1-fluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-[(1S)-1-fluoroethyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-1-fluoroethyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-2-ethylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(100 mg, 0.43 mmol) in acetonitrile (10 mL) was added potassiumcarbonate (1.3 mL, 1.28 mmol) and iodoethane (133 mg, 0.85 mmol). Thereaction was stirred at 20° C. for 1 h and diluted with water (10 mL).The mixture was extracted with ethyl acetate (3×20 mL). The combinedorganic layers were dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by column chromatography(silica gel, 100-200 mesh, 0 to 30% ethyl acetate in petroleum ether) toafford(5S,7S)-2-ethylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(110 mg, 98%) as a yellow solid. LC-MS R_(T)=0.700 min, m/z=264.1[M+H]⁺.

Step 2:(5S,7S)-7-fluoro-2-(1-fluoroethylsulfanyl)-5-phenyl-6,7-dihydro-H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-ethylsulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(110 mg, 0.42 mmol) in acetonitrile (8 mL) was added triethylamine (63mg, 0.63 mmol) and1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate)(222 mg, 0.63 mmol). The reaction was stirred at 0° C. for 1 h anddiluted with water (20 mL). The resulting mixture was extracted withethyl acetate (3×20 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 30%ethyl acetate in petroleum ether) to afford(5S,7S)-7-fluoro-2-(1-fluoroethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(80 mg, 68%) as a yellow solid. LC-MS R_(T)=0.696 min, m/z=282.1 [M+H]+.

Step 3:(5S,7S)-7-fluoro-2-(1-fluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-[(1S)-1-fluoroethyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-1-fluoroethyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-7-fluoro-2-(1-fluoroethylsulfanyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(30 mg, 0.11 mmol) and 3-chloroperoxybenzoic acid (85%, 300 mg, 1.48mmol) in dichloromethane (10 mL) was stirred at 40° C. for 16 h. Themixture was diluted with water (20 mL) and extracted with ethyl acetate(3×20 mL). The combined organic layers were washed with saturatedaqueous ammonium chloride (20 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 30-60%/0.05% ammonia hydroxide in water) to afford(5S,7S)-7-fluoro-2-(1-fluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(17 mg, 46%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.27-7.23 (m, 2H), 6.15-5.98 (m, 1H), 5.74-5.56 (m, 2H), 3.76-3.66(m, 1H), 3.07-2.96 (m, 1H), 1.88-1.80 (m, 3H). LC-MS R_(T)=1.692 min,m/z=314.1 [M+H]⁺.

A batch of the racemic material was further separated by chiral SFC togive:(5S,7S)-7-fluoro-2-[(1S)-1-fluoroethyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.814 min) (11.2 mg, 32%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.45-7.40 (m, 3H), 7.27-7.23 (m, 2H), 6.14-5.98(m, 1H), 5.74-5.72 (m, 0.5H), 5.62-5.57 (m, 1.5H), 3.74-3.64 (m, 1H),3.06-2.96 (m, 1H), 1.88-1.80 (m, 3H). LCMS R_(T)=1.705 min, m/z=314.1[M+H]⁺.

(5S,7S)-7-fluoro-2-[(1R)-1-fluoroethyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=3.979 min) (9.4 mg, 27%) as a white solid ¹H NMR(400 MHz, CDCl₃) δ 7.43-7.40 (m, 3H), 7.27-7.23 (m, 2H), 6.15-5.98 (m,1H), 5.74-5.71 (m, 0.5H), 5.62-5.56 (m, 1.5H), 3.74-3.63 (m, 1H),3.07-2.96 (m, 1H), 1.88-1.79 (m, 3H). LCMS R_(T)=1.704 min, m/z=314.1[M+H]⁺.

SFC condition: Column: ChiralPak OD_3_EtOH_DEA_5_40_25 mL_7 min; Mobilephase: A: CO₂ B: Ethanol (0.05% DEA); Gradient: from 5% to 40% of B in5.5 min and hold 40% for 3 min, then 5% of B for 1.5 min; Flow rate: 2.5mL/min; Column temperature: 40° C.

Example 165: Method 35(5S,7S)-7-fluoro-2-(1-fluoro-1-methyl-ethyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-7-fluoro-2-(1-fluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(50 mg, 0.16 mmol) in tetrahydrofuran (9 mL) was added lithiumbis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 0.4 mL, 0.4 mmol)and iodomethane (1.2 g, 8.44 mmol). The reaction was stirred at −78° C.for 1 h and quenched by addition of water (10 mL). The reaction mixturewas extracted with ethyl acetate (3×10 mL). The combined organic layerswere dried over sodium sulfate and concentrated under reduced pressure.The residue was purified by preparative TLC (40% ethyl acetate inpetroleum ether, R_(f)=0.3) to afford(5S,7S)-7-fluoro-2-(1-fluoro-1-methyl-ethyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(3.1 mg, 6%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.40 (m,3H), 7.28-7.26 (m, 2H), 6.24-6.21 (m, 0.5H), 6.09-6.07 (m, 0.5H),5.72-5.69 (m, 1H), 3.82-3.73 (m, 1H), 2.91-2.81 (m, 1H), 1.87-1.69 (m,6H). LCMS R_(T)=1.745 min, m/z=328.1 [M+H]⁺.

Example 161(5S,7S)-7-fluoro-5-phenyl-2-(propylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-(propylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 1-bromopropane. The final compound was purified by RP-HPLC(acetonitrile 39-69%/0.05% ammonia hydroxide) to give(5S,7S)-7-fluoro-5-phenyl-2-(propylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(63.8 mg, 63%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m,3H), 7.27-7.24 (m, 2H), 6.13-6.11 (m, 0.5H), 5.99-5.97 (m, 0.5H),5.54-5.52 (m, 1H), 3.71-3.65 (m, 1H), 3.36-3.32 (m, 2H), 3.04-2.94 (m,1H), 1.92-1.82 (m, 2H), 1.05 (t, J=7.2 Hz, 3H). LCMS R_(T)=0.847 min,m/z=309.9 [M+H]⁺.

Example 162(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2S)-2-methylcyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2S)-2-methylcyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland trans-2-methylcyclopropyl]boronic acid. The final compound waspurified by RP-HPLC (acetonitrile 36-66%/0.225% Formic acid in water) togive(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2S)-2-methylcyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(1.5 mg, 5%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m,3H), 7.25-7.22 (m, 2H), 6.12-6.10 (m, 0.5H), 5.99-5.97 (m, 0.5H),5.54-5.51 (m, 1H), 3.74-3.63 (m, 1H), 3.05-2.94 (m, 1H), 2.48-2.44 (m,1H), 1.89-1.86 (m, 1H), 1.63-1.61 (m, 1H), 1.16 (t, J=5.6 Hz, 3H),0.97-0.95 (m, 1H). LCMS R_(T)=0.689 min, m/z=322.1 [M+H]⁺.

Example 163(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2R)-2-(trifluoromethyl)cyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2R)-2-(trifluoromethyl)cyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland trans-2-(trifluoromethyl)cyclopropyl]boronic acid. The finalcompound was purified by preparative TLC (30% ethyl acetate in petroleumether, R_(f)=0.4) to give(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2R)-2-(trifluoromethyl)cyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole (11mg, 25.1%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m,3H), 7.27-7.23 (m, 2H), 6.14-6.12 (m, 0.5H), 6.00-5.98 (m, 0.5H),5.57-5.53 (m, 1H), 3.72-3.66 (m, 1H), 3.13-2.96 (m, 2H), 2.57-2.51 (m,1H), 1.92-1.88 (m, 1H), 1.60-1.55 (m, 1H). LCMS R_(T)=0.846 min,m/z=376.1 [M+H]⁺.

Example 164: Method 7a(5S,7S)-7-fluoro-2-(((1R,3S)-3-fluorocyclobutyl)sulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol

To a mixture of3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanone(300 mg, 0.99 mmol) in methanol (10 mL) was added sodium borohydride(112 mg, 2.97 mmol). The mixture was stirred at 20° C. for 1 h andconcentrated under reduced pressure. The residue was diluted with water(50 mL) and extracted with ethyl acetate (3×50 mL). The combined organiclayers were washed with brine (50 mL), dried over sodium sulfate andconcentrated under reduced pressure to afford(1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol(300 mg, 99%) as a yellow solid. LCMS R_(T)=0.616 min, m/z=306.1 [M+H]⁺.

Step 2:(5S,7S)-7-fluoro-2-(((1R,3S)-3-fluorocyclobutyl)thio)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a cooled solution (−50° C.) of(1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol(300 mg, 0.98 mmol) in toluene (10 mL) was added diethylaminosulfurtrifluoride (633 mg, 3.93 mmol). The mixture was stirred at −50° C. for1 h and quenched by addition of saturated aqueous sodium bicarbonate (50mL). The resulting mixture was extracted with ethyl acetate (3×50 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure to afford(5S,7S)-7-fluoro-2-(((1R,3S)-3-fluorocyclobutyl)thio)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(150 mg, 50%) as a white solid. LCMS R_(T)=3.205 min, m/z=307.9 [M+H]⁺.

Step 3:(5S,7S)-7-fluoro-2-(((1R,3S)-3-fluorocyclobutyl)sulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of ruthenium(III) chloride (10 mg, 0.05 mmol), sodiumperiodate (418 mg, 1.95 mmol) and(5S,7S)-7-fluoro-2-(((1R,3S)-3-fluorocyclobutyl)thio)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(150 mg, 0.49 mmol) in acetonitrile (5 mL), water (5 mL) and ethylacetate (5 mL) was stirred at 30° C. for 4 h. The mixture was dilutedwith water (10 mL) and extracted with ethyl acetate (3×10 mL). Thecombined organics were washed with brine, dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 40-70%/ammonia hydroxide in water) to afford(5S,7S)-7-fluoro-2-(((1R,3S)-3-fluorocyclobutyl)sulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(24 mg, 14%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m,3H), 7.27-7.23 (m, 2H), 6.12-5.96 (m, 1H), 5.55-5.50 (m, 1H), 5.40-5.24(m, 1H), 4.15-4.11 (m, 1H), 3.71-3.66 (m, 1H), 3.06-2.99 (m, 3H),2.67-2.64 (m, 2H). LCMS R_(T)=0.679 min, m/z=340.1 [M+H]⁺.

Example 166(5S,7S)-7-fluoro-5-phenyl-2-tetrahydrofuran-3-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-tetrahydrofuran-3-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 3-bromotetrahydrofuran. The final compound was purified by RP-HPLC(acetonitrile 26-56%/0.225% acetate acid in water) to give(5S,7S)-7-fluoro-5-phenyl-2-tetrahydrofuran-3-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(26.2 mg, 13%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.39 (m,3H), 7.26-7.21 (m, 2H), 6.13-5.96 (m, 1H), 5.56-5.53 (m, 1H), 4.33-4.30(m, 1H), 4.20-4.02 (m, 2H), 4.00-3.77 (m, 2H), 3.75-3.60 (m, 1H),3.03-2.95 (m, 1H), 2.60-2.54 (m, 1H), 2.30-2.22 (m, 1H). LC-MSR_(T)=0.905 min, m/z=338.1 [M+H]⁺.

Example 167: Method 16(5S,7S)-2-((2,2-difluoro-1-methylcyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-2-((2,2-difluoro-1-methylcyclopropyl)thio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(400 mg, 1.7 mmol), 2,2-difluoro-1-methyl-cyclopropanecarboxylic acid(694 mg, 5.1 mmol), silver nitrate (577 mg, 3.4 mmol) and ammoniumpersulfate (776 mg, 3.4 mmol) in acetonitrile (12 mL) and water (4 mL)was stirred at 80° C. for 3 h. The reaction was diluted with water (35mL) and extracted with ethyl acetate (3×35 mL). The combined organiclayers were washed with brine (2×35 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was first purified bycolumn chromatography (silica gel, 100-200 mesh, 0 to 24% ethyl acetatein petroleum ether), then by preparative TLC (35% ethyl acetate inpetroleum ether, R_(f)=0.4) to give(5S,7S)-2-(2,2-difluoro-1-methyl-cyclopropyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(18 mg, 3%) as a colorless oil. LC-MS RT=0.740 min, m/z=326.1 [M+H]⁺.

Step 2:(5S,7S)-2-((2,2-difluoro-1-methylcyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of ruthenium(III) chloride (0.8 mg), sodium periodate (33 mg,0.15 mmol) and(5S,7S)-2-(2,2-difluoro-1-methyl-cyclopropyl)sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(16 mg, 0.04 mmol) in acetonitrile (0.4 mL), water (0.4 mL) and ethylacetate (0.4 mL) was stirred at 25° C. for 1 h and diluted with ethylacetate (8 mL). The solution was washed with brine (2×8 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 45-75%/0.05% hydrochloric acid inwater) to give(5S,7S)-2-(2,2-difluoro-1-methyl-cyclopropyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(4.8 mg, 34%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.40 (m,3H), 7.28-7.25 (m, 2H), 6.22-6.06 (m, 1H), 5.77-5.65 (m, 1H), 3.83-3.75(m, 1H), 2.90-2.83 (m, 1H), 2.62-2.57 (m, 1H), 1.96-1.93 (m, 1H),1.61-1.57 (m, 3H). LC-MS R_(T)=0.708 min, m/z=358.1 [M+H]⁺.

Example 168: Method 36((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol

Step 1: methyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]thio]cyclobutanecarboxylate

To a solution of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(500 mg, 2.13 mmol) in N,N-dimethylformamide (10 mL) was added methyl3-bromocyclobutanecarboxylate (820 mg, 4.25 mmol) and potassiumcarbonate (881 mg, 6.38 mmol). The reaction mixture was stirred at 25°C. for 2 h and poured into water (15 mL). The mixture was extracted withethyl acetate (3×15 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 50%ethyl acetate in petroleum ether) to afford methyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanecarboxylate(610 mg, 83%) as a colorless oil.

Step 2: methyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarboxylate

To a solution of methyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanecarboxylate(590 mg, 1.70 mmol) in dichloromethane (20 mL) was added3-chloroperoxybenzoic acid (85%, 1700 mg, 8.49 mmol). The mixture wasstirred at 25° C. for 2 h and quenched by addition of saturated aqueoussodium carbonate (20 mL). The resulting mixture was extracted withdichloromethane (3×20 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 40%ethyl acetate in petroleum ether) to give methyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarboxylate(540 mg, 84%) as a white solid.

Step 3:((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol

To a solution of methyl3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarboxylate(470 mg, 1.24 mmol) in tetrahydrofuran (10 mL) was added lithiumborohydride (54 mg, 2.48 mmol) at 25° C. The mixture was stirred at 25°C. for 2 h and quenched by addition of water (20 mL). The resultingmixture was extracted with ethyl acetate (3×20 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was first purified by column chromatography(silica gel, 100-200 mesh, 0 to 80% ethyl acetate in petroleum ether),then by chiral SFC to give((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol(LHS stereochemistry arbitrarily assigned) (150 mg, 38%) as a colorlessoil. ¹¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38 (m, 3H), 7.26-7.21 (m, 2H),6.11-5.95 (m, 1H), 5.53-5.49 (m, 1H), 4.10-4.05 (m, 1H), 3.70-3.61 (m,3H), 2.99-2.95 (m, 1H), 2.60-2.56 (m, 1H), 2.50-2.34 (m, 4H). LC-MSR_(T)=0.862 min, m/z=352.1 [M+H]⁺.

SFC condition: Column: ChiralPak AD-3 150×4.6 mm I.D., 3 um Mobilephase: A: C02 B: Ethanol (0.05% DEA), Gradient: from 5% to 40% of B in5.5 min, then 5% of B for 1.5 min, Flow rate: 2.5 mL/min, Column temp.:40° C.

Example 169((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol

To a solution of((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol(129 mg, 0.28 mmol) in toluene (8 mL) was added diethylaminosulfurtrifluoride (0.15 mL, 1.14 mmol) at 0° C. The mixture was stirred at 0°C. for 1 h and quenched by addition of saturated sodium bicarbonate (20mL). The resulting mixture was extracted with ethyl acetate (3×20 mL).The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure. The resulting residue was purifiedby RP-HPLC (acetonitrile 42-72%/0.225% formic acid in water) to afford((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol(9.9 mg, 10%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.38 (m,3H), 7.26-7.21 (m, 2H), 6.12-5.95 (m, 1H), 5.55-5.50 (m, 1H), 5.43-4.29(m, 2H), 4.15-4.06 (m, 1H), 3.70-3.64 (m, 1H), 3.01-2.91 (m, 1H),2.75-2.65 (m, 1H), 2.57-2.47 (m, 2H), 2.46-2.36 (m, 2H). LC-MSR_(T)=0.976 min, m/z=354.1 [M+H]⁺.

Example 170: Method 23(5S,7S)-7-fluoro-5-phenyl-2-spiro[2.2]pentan-2-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1: ethyl 1-(methylsulfonyloxymethyl)cyclopropanecarboxylate

To a solution of ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (5.0g, 34.7 mmol) in dichloromethane (40 mL) and triethylamine (10.5 g, 104mmol) was added methanesulfonyl chloride (3.66 mL, 47 mmol). The mixturewas stirred at 0° C. for 2 h and diluted with dichloromethane (50 mL).The solution was then washed with citric acid (2×40 mL), brine (15 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 20% ethyl acetate in petroleum ether) to give ethyl1-(methylsulfonyloxymethyl)cyclopropanecarboxylate (3.0 g, 39%) as awhite solid. ¹H NMR (400 MHz, CDCl₃) δ 4.34-4.30 (m, 2H), 4.20-4.13 (m,2H), 3.08 (s, 3H), 1.45-1.41 (m, 2H), 1.29-1.24 (m, 3H), 1.07-1.03 (m,2H).

Step 2: ethyl1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanylmethyl]cyclopropanecarboxylate

To a solution of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(1.0 g, 4.3 mmol) and 1-(methylsulfonyloxymethyl)cyclopropanecarboxylate (945 mg, 4.25 mmol) in N,N-dimethylformamide (40 mL) wasadded sodium hydride (60%, 450 mg, 11.2 mmol). After addition, themixture was stirred at 0° C. for 4 h and quenched by addition ofsaturated aqueous ammonium chloride (40 mL). The resulting solution wasextracted with ethyl acetate (2×40 mL). The combined organic layers werewashed with water (20 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 50% ethyl acetate inpetroleum ether) to give ethyl1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanylmethyl]cyclopropanecarboxylate(1.2 g, 79%) as a yellow solid.

Step 3: ethyl1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropanecarboxylate

To a solution of ethyl1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanylmethyl]cyclopropanecarboxylate(1.0 g, 2.77 mmol) in dichloromethane (20 mL) was added3-chloroperoxybenzoic acid (85%, 1.7 g, 8.3 mmol). The mixture wasstirred at 25° C. for 2 h and quenched by addition of saturated aqueoussodium bicarbonate (20 mL). The resulting mixture was extracted withethyl acetate (3×30 mL). The combined the organics were washed withbrine (30 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 100% ethyl acetate in petroleum ether) to give ethyl1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropanecarboxylate(1.0 g, 92%) as a yellow oil. LCMS R_(T)=1.063 min, m/z=394 [M+H]⁺.

Step 4:[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropyl]methanol

To a solution of ethyl1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropanecarboxylate(1.0 g, 2.54 mmol) in dichloromethane (20 mL) was addeddiisobutylaluminum hydride (1.0 M in dichloromethane, 12.7 mL, 12.7mmol) under nitrogen atmosphere. The mixture was stirred at 20° C. for16 h and quenched by slow addition of sodium sulfate decahydrate (1.0g). The precipitate was filtered and the filtrate was concentrated underreduced pressure to give crude[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropyl]methanol(740 mg, 83%) as a yellow oil. LCMS R_(T)=0.886 min, m/z=352.2 [M+H]⁺.

Step 5:[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropyl]methylmethanesulfonate

To a solution of[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropyl]methanol(740 mg, 2.11 mmol) and triethylamine (1.2 g, 11.86 mmol) indichloromethane (20 mL) was added methanesulfonyl chloride (840 mg, 7.33mmol). The mixture was stirred at 0° C. for 2 h and diluted withdichloromethane (50 mL). The solution was washed with water (2×30 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 100% ethyl acetate in petroleum ether) to give[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropyl]methylmethanesulfonate (450 mg, 50%) as a white solid.

Step 6:(5S,7S)-7-fluoro-5-phenyl-2-spiro[2.2]pentan-2-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of[1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonylmethyl]cyclopropyl]methylmethanesulfonate (150 mg, 0.35 mmol) in tetrahydrofuran (8 mL) was addedlithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 1.05 mL,1.05 mmol) at −70° C. under nitrogen protection. The mixture was stirredat −70° C. for 2 h and quenched by addition of saturated aqueousammonium chloride (20 mL). The resulting mixture was extracted withethyl acetate (2×20 mL). The combined organic layers were washed withwater (2×10 mL), brine (10 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 25-60%/0.05% ammonia hydroxide in water) to afford(5S,7S)-7-fluoro-5-phenyl-2-spiro[2.2]pentan-2-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(7.3 mg, 6%) as a white solid. 1H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.27-7.22 (m, 2H), 6.12-5.95 (m, 1H), 5.53-5.50 (m, 1H), 3.75-3.67(m, 1H), 3.09-2.98 (m, 2H), 1.97-1.94 (m, 1H), 1.61-1.57 (m, 1H),1.28-1.24 (m, 1H), 1.18-1.12 (m, 1H), 0.98-0.85 (m, 2H). LCMSR_(T)=1.768 min, m/z=334.1[M+H]⁺.

Example 171 and Example 172(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-phenyl-2-[(1S)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand (5S,7S)-7-fluoro-5-phenyl-2-[(1S)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole wereprepared according to method 20 starting from 2-bromocyclobutanone. Thefinal compound was purified by chiral SFC to give:(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.129 min) (12.2 mg, 22%, 68% ee) as a yellowsolid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m, 3H), 7.26-7.20 (m, 2H),6.12-5.96 (m, 1H), 5.55-5.50 (m, 1H), 4.62-4.56 (m, 1H), 3.71-3.62 (m,1H), 2.99-2.90 (m, 1H), 2.88-2.77 (m, 1H), 2.57-2.50 (m, 2H), 2.30-2.22(m, 1H). LC-MS RT=0.918 min, m/z=358.0 [M+H]⁺.

(5S,7S)-7-fluoro-5-phenyl-2-[(1S)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.512 min) (8.5 mg, 15%, 63% ee) as a whitesolid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38 (m, 3H), 7.26-7.20 (m, 2H),6.13-5.96 (m, 1H), 5.56-5.50 (m, 1H), 4.64-4.56 (m, 1H), 3.73-3.64 (m,1H), 3.03-2.93 (m, 1H), 2.88-2.78 (m, 1H), 2.70-2.55 (m, 2H), 2.30-2.27(m, 1H). LC-MS RT=0.915 min, m/z=357.9 [M+H]⁺.

SFC condition (prep): Column: AD-H (250 mm×30 mm, 5 um); Mobile phase:A: CO₂ B: 0.1% NH₃H₂O MeOH; Gradient: hold 25% of B; Flow rate: 50mL/min Column temperature: 40° C.

Example 173 and Example 174: Method 1(5S)-2-[(S)-difluoromethylsulfinyl]-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S)-2-[(R)-difluoromethylsulfinyl]-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

The diastereomeric mixture of2-(difluoromethylsulfinyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas separated by chiral SFC. Analytical data for arbitrarily assigned:

(5S)-2-[(S)-difluoromethylsulfinyl]-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:(Peak 2, SFC analytical retention time=0.73 min, Whelk 0-1 (S,S),isocratic 15% MeOH+0.1% NH₄OH, 2.5 min method) (5.5 mg, 1%) as a whitesolid. 1H NMR (400 MHz, DMSO-d6) δ 7.53-7.19 (m, 2H), 7.15-7.04 (m, 2H),5.72 (dd, J=8.2, 6.3 Hz, 1H), 3.27-3.12 (m, 2H), 3.07 (ddd, J=16.1, 9.7,6.1 Hz, 1H), 2.70-2.52 (m, 1H).

LC-MS RT=4.30 min, m/z=320.0 (M+H)+.

(5S)-2-[(R)-difluoromethylsulfinyl]-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole:(Peak 4, SFC analytical retention time=1.13 min, Whelk 0-1 (S,S),isocratic 15% MeOH+0.1% NH₄OH, 2.5 min method) (8.7 mg, 2%) as a whitesolid. 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.20 (m, 2H), 7.17-7.04 (m, 2H),5.72 (dd, J=8.2, 6.3 Hz, 1H), 3.29-3.14 (m, 2H), 3.13-3.02 (m, 1H),2.70-2.57 (m, 1H). LC-MS RT=4.26 min, m/z=320.0 (M+H)+.

SFC condition (prep): Whelk 0-1 (S,S) 250×21.2 mm, 5 um, Mobile phase:A: CO2 B: 0.1% ammonium hydroxide in methanol, Isocratic 18% B, Flowrate: 80 mL/min, column temp 30° C.

Example 175: Method 382-(Difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of2-(difluoromethylsulfinyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(70 mg, 0.22 mmol, 1.0 equiv) in dichloromethane (5 mL) was added3-chloroperoxybenzoic acid (393 mg, 1.75 mmol, 8.0 equiv). The mixturewas stirred at RT for 16 h. After this time, the reaction was quenchedwith saturated aqueous sodium thiosulfate (25 mL) and saturated sodiumbicarbonate (25 mL). The layers were separated, and the aqueous wasextracted three more times with dichloromethane (3×50 mL). The combinedorganics were washed with water and brine, dried over sodium sulfate andconcentrated. The residue was purified by reverse phase HPLC (Gemini-NXC18, 50×30 mm column; solvent A: 0.1% formic acid in water; solvent B:acetonitrile; gradient of 20-60% B) to afford2-(difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(24 mg, 33%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.59-7.24 (m,2H), 7.22-7.10 (m, 2H), 5.82-5.70 (m, 1H), 3.26-3.01 (m, 3H), 2.71-2.60(m, 1H). LC-MS RT=4.73 min, m/z=336.0 (M+H)+.

Example 1762-(Difluoromethylsulfinyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Prepared according to method 1 starting from ethyl4-(3,5-difluorophenyl)-4-oxo-butanoate (Rieke Metals) (140 mg, 26% yieldfor the final step). 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.19 (m, 2H),7.18-7.00 (m, 2H), 5.77-5.67 (m, 1H), 3.28-3.14 (m, 2H), 3.07 (ddd,J=16.3, 9.8, 6.2 Hz, 1H), 2.71-2.57 (m, 1H). LC-MS RT=4.35 min,m/z=320.0 (M+H)+.

Example 177: Method 395-Phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:5-phenyl-2-(2,2,2-trifluoroethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,22-b][1,2,4]triazole

To a solution of5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol (800 mg,3.68 mmol, 1.0 equiv) in N,N-dimethylformamide (10 mL) was added cesiumcarbonate (3600 mg, 11.0 mmol, 3.0 equiv) and 2,2,2-trifluoroethyltrifluoromethanesulfonate (2.19 mL, 3520 mg, 14.7 mmol, 4.0 equiv). Theresulting heterogeneous mixture was stirred at RT for 16 h. After thistime, the mixture was filtered through Celite and concentrated. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 10% methanol in dichloromethane) to afford5-phenyl-2-(2,2,2-trifluoroethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(270 mg, 25%) as a yellow oil.

Step 2:5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of5-phenyl-2-(2,2,2-trifluoroethylsulfanyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(270 mg, 0.90 mmol, 1.0 equiv) in 1,2-dichloroethane (5 mL) was added3-chloroperoxybenzoic acid (303 mg, 1.35 mmol, 1.5 equiv). The resultingmixture was stirred at RT for 16 h. After this time, the reaction wasquenched with saturated aqueous sodium thiosulfate (50 mL) and saturatedsodium bicarbonate (50 mL). The layers were separated, and the aqueouswas extracted three more times with dichloromethane (3×50 mL). Thecombined organics were washed with water and brine, dried over sodiumsulfate and concentrated. The residue was purified by reverse phase HPLC(Gemini-NX C18, 50×30 mm column; solvent A: 0.1% formic acid in water;solvent B: acetonitrile; gradient of 20-60% B) to afford5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(111 mg, 39%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.46-7.33(m, 3H), 7.31-7.20 (m, 2H), 5.66 (q, J=7.2 Hz, 1H), 4.52-4.38 (m, 2H),3.29-2.98 (m, 3H), 2.69-2.56 (m, 1H). LC-MS RT=4.33 min, m/z=316.0(M+H)+.

Example 178: Method 40(5S,7S)-7-Fluoro-2-(1-fluorocyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(1000 mg, 3.25 mmol, 1.0 equiv) in tetrahydrofuran (15 mL) cooled to−78° C. was added a solution of 2,2,6,6-tetramethylpiperidinyl magnesiumchloride-lithium chloride complex (Sigma-Aldrich, 1M intetrahydrofuran/toluene, 3.9 mL, 1.2 equiv). The resulting mixture wasstirred for 30 mins at −78° C., then to it was addedN-fluorobenzenesulfonimide as a solid (1230 mg, 3.9 mmol, 1.2 equiv).The resulting mixture was stirred at −78° C. for 30 mins, then wasquenched with 5% aqueous citric acid (100 mL). The mixture was extractedwith isopropyl acetate (3×75 mL). The combined organics were washed withsaturated aqueous sodium bicarbonate, water and brine, dried over sodiumsulfate and concentrated. The residue was partially purified by columnchromatography (silica gel, 100-200 mesh, 0 to 90% isopropyl acetate inheptane), then was further purified by reverse phase HPLC (Gemini-NXC18, 50×30 mm column; solvent A: 0.1% formic acid in water; solvent B:acetonitrile; gradient of 20-60% B) to afford(5S,7S)-7-fluoro-2-(1-fluorocyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(27 mg, 3% yield) as a colorless residue. 1H NMR (400 MHz, DMSO-d6) δ7.52-7.36 (m, 3H), 7.34-7.24 (m, 2H), 6.31 (ddd, J=56.1, 7.3, 2.2 Hz,1H), 5.82 (ddd, J=8.4, 6.5, 3.4 Hz, 1H), 3.79 (dddd, J=25.0, 15.5, 8.5,7.3 Hz, 1H), 2.77 (dddd, J=27.1, 15.1, 3.4, 2.1 Hz, 1H), 1.86-1.63 (m,4H). LC-MS RT=4.89 min, m/z=326.0 (M+H)+.

TABLE II Chiral Separations Conditions (CPCT) - Instrument: PIC 200Chiral - Solvent: A CO₂ - Detector Wavelength 215 nm - Column Dimension150 × 21.2 mm 5 μm % B Sample number Amount/yield Solvent B InitialFinal Solvent Column Flow Rate Run Time (min) 179 7.1 mg/33% 0.1% NH4OH20 20 MeOH Chiralpak AD 70 9 in MeOH 180 6.1 mg/26% 0.1% NH4OH 20 20MeOH Cellulose-4 70 9 in MeOH 181 6.8 mg/30% 0.1% NH4OH 20 20 MeOHCellulose-4 70 9 in MeOH 182  7 mg/32% 0.1% NH4OH 20 20 MeOH ChiralpakAD 70 9 in MeOH 183 1.7 mg/12% 0.1% NH4OH 20 20 MeOH/ACN Whelko-01 70 30in MeOH 184 2.9 mg/26% 0.1% NH4OH 25 25 MeOH Chiralpak AD 70 40 in MeOH185 1.9 mg/13% 0.1% NH4OH 20 20 MeOH/ACN Whelko-01 70 30 in MeOH 186 2.9mg/26% 0.1% NH4OH 25 25 MeOH Chiralpak AD 70 40 in MeOH 187 4.7 mg/25%0.1% NH4OH 40 40 MeOH/ACN Chiralcel OX 70 46 in MeOH 188  4 mg/26% 0.1%NH4OH 40 40 MeOH/ACN Chiralcel OX 70 31 in MeOH 189 5.4 mg/28% 0.1%NH4OH 40 40 MeOH/ACN Chiralcel OX 70 46 in MeOH 190  2 mg/13% 0.1% NH4OH40 40 MeOH/ACN Chiralcel OX 70 31 in MeOH 191 8.8 mg/34% 0.1% NH4OH 3535 MeOH Chiralpak IG 70 24 in MeOH

Example 192: Method 413-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile

To a solution of(5S,7S)-5-(3-chlorophenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(250 mg, 0.71 mmol, made as in method 16),tris(dibenzylideneacetone)dipalladium(0) (130 mg, 0.14 mmol) and1,1-bis(diphenylphosphino)ferrocene (158 mg, 0.28 mmol) inN,N-dimethylacetamide (12 mL) was added with zinc (5 mg, 0.09 mmol) andzinc cyanide (150 mg, 1.28 mmol). The mixture was purged with nitrogenand stirred at 120° C. for 18 h. The resulting mixture was filtered. Thefiltrate was diluted water (20 mL) and extracted with ethyl acetate(3×10 mL). The combined organic layers were dried over sodium sulfateand concentrate under reduced pressure. The residue was first purifiedby RP-HPLC (acetonitrile 23-53%/0.05% ammonium bicarbonate in water),then by SFC to give3-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile(3.6 mg, 1.5%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d,J=8.0 Hz, 1H), 7.64-7.53 (m, 2H), 7.47 (d, J=8.0 Hz, 1H), 6.43 (t,J=53.2 Hz, 1H), 6.21-6.02 (m, 1H), 5.66-5.62 (m, 1H), 3.84-3.67 (m, 1H),3.10-2.96 (m, 1H). LCMS R_(T)=1.058 min, m/z=343.1 [M+H]⁺.

SFC condition: Column: Chiralcel OJ-H (150*4.6 mm, 5 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5.5 min,then 5% B for 1.5 min, Flow rate: 2.5 mL/min Column temp. 40° C.

Example 226: Method 42(5S,7S)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a cooled (−30° C.) solution ofcis-3-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanol(480 mg, 1.48 mmol) in toluene (12 mL) was added diethylaminosulfurtrifluoride (0.78 mL, 5.94 mmol) over 20 min under nitrogen atmosphere.After addition, the mixture was stirred at 0° C. for 1 h, diluted withethyl acetate (30 mL) and poured into saturated aqueous sodiumbicarbonate (20 mL). The mixture was extracted with ethyl acetate (2×20mL). The combined organic layers were dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0-20% ethyl acetate inpetroleum ether) to afford(5S,7S)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfanyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(170 mg, 35%) as a brown solid. LCMS R_(T)=0.976 min, m/z=325.9 [M+H]⁺.

To a mixture of(5S,7S)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfanyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(150 mg, 0.46 mmol), ruthenium(iii) chloride (10 mg, 0.05 mmol) andsodium periodate (395 mg, 1.84 mmol) in acetonitrile (3 mL), water (3mL) and ethyl acetate (3 mL) was stirred at 30° C. for 1 h and filtered.The filtrate was diluted with water (10 mL) and extracted with ethylacetate (3×10 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 42-72%/0.05% ammonia hydroxide inwater) to afford(5S,7S)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(92.0 mg, 91%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.39 (m,1H), 7.15-7.10 (m, 1H), 7.09-7.03 (m, 1H), 7.02-6.94 (m, 1H), 6.15-5.92(m, 1H), 5.56-5.49 (m, 1H), 5.44-5.19 (m, 1H), 4.18-4.07 (m, 1H),3.78-3.57 (m, 1H), 3.11-2.96 (m, 3H), 2.76-2.61 (m, 2H). LCMS RT=0.918min, m/z=357.9 [M+H]+.

Example 193: Method 42(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared using method 42 starting from(5S,7S)-7-fluoro-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by column chromatography (silica gel,100-200 mesh, 0 to 50% ethyl acetate in petroleum ether) to give(5S,7S)-5-(3,5-diluophenyurophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20.0 mg, 10.2%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 6.88-6.83(m, 1H), 6.79-6.77 (m, 2H), 6.12-5.95 (m, 1H), 5.53-5.51 (m, 1H),5.50-5.25 (m, 1H), 4.17-4.12 (m, 1H), 3.75-3.64 (m, 1H), 3.15-2.98 (m,3H), 2.75-2.66 (m, 2H). LCMS RT=1.142 min, m/z=376.1 [M+H]⁺.

Example 195: Method 44Cis-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol

Cis-3-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanolwas prepared according to method 44 starting from(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 28-58%/0.05%ammonia hydroxide in water) to affordcis-3-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol(20.6 mg, 21%) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.34 (m,1H), 7.14-7.06 (m, 1H), 7.05-6.99 (m, 1H), 6.98-6.89 (m, 1H), 6.16-5.94(m, 1H), 5.61-5.50 (m, 1H), 4.33-4.19 (m, 1H), 3.80-3.60 (m, 2H),3.01-2.88 (m, 1H), 2.77-2.62 (m, 2H), 2.60-2.35 (m, 3H). LCMSR_(T)=0.825 min, m/z=356.1 [M+H]⁺.

Example 225: Method 44Cis-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol

Step 1:3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutanone

To a solution of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(650 mg, 2.8 mmol) and 3-bromocyclobutanone (535 mg, 3.6 mmol) inN,N-dimethylformamide (30 mL) was added sodium hydride (60%, 165 mg, 4.1mmol) at 0° C. under nitrogen atmosphere. The solution was stirred at20° C. for 2 h and quenched by addition of water (20 mL). The resultingmixture was extracted with ethyl acetate (3×30 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by purified by column chromatography(silica gel, 100-200 mesh, 0 to 30% ethyl acetate in petroleum ether) toafford3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanone(800 mg, 96%) as yellow oil.

Step 2:cis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol

To a mixture of3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanone(200 mg, 0.66 mmol) in methanol (10 mL) was added sodium borohydride(74.8 mg, 2.0 mmol). The mixture was stirred at 20° C. for 1 h andquenched by addition of water (30 mL). The resulting mixture wasextracted with ethyl acetate (3×30 mL). The combined organic layers werewashed with brine (40 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 80% ethyl acetate inpetroleum ether) to affordcis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol(140 mg, 70%) as a light yellow solid.

Step 3:Cis-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol

A mixture of3-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanol(90 mg, 0.28 mmol) and 3-chloroperoxybenzoic acid (85%, 226 mg, 1.11mmol) in dichloromethane (9 mL) was stirred at 25° C. for 4 h. Thereaction mixture was diluted with water (30 mL) and extracted withdichloromethane (3×20 mL). The combined organic layers were washed withsaturated aqueous sodium bicarbonate (2×20 mL), brine (20 mL), driedover sodium sulfate and concentrated under reduced pressure. The residuewas purified by RP-HPLC (acetonitrile 28-58%/0.05% ammonia hydroxide inwater) to afford3-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol(20.6 mg, 21%) as colorless oil. ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.39 (m,3H), 7.27-7.25 (m, 2H), 6.20-6.18 (m, 0.5H), 6.05-6.03 (m, 0.5H),5.67-5.65 (m, 1H), 4.21-4.15 (m, 1H), 3.77-3.72 (m, 2H), 2.90-2.80 (m,1H), 2.57-2.51 (m, 2H), 2.38-2.35 (m, 2H). LCMS R_(T)=0.585 min,m/z=338.1 [M+H]⁺.

Example 196 and Example 197(5S,7S)-7-fluoro-5-(4-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(4-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-(4-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(4-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 (starting from(5S,7S)-2-bromo-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified first by flash chromatography on silica(solvent gradient: 0 to 25% ethyl acetate in petroleum ether), and thenby SFC to give:

(5S,7S)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.735 min) (14.5 mg, 13%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.30-7.26 (m, 2H), 7.14-7.07 (m, 2H), 6.17-5.94(m, 1H), 5.57-5.50 (m, 1H), 5.27-4.98 (m, 1H), 3.79-3.56 (m, 1H),3.20-3.15 (m, 1H), 3.05-2.91 (m, 1H), 1.90-1.76 (m, 2H). LCMSR_(T)=0.952 min, m/z=344.1 [M+H]⁺.

(5S,7S)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.033 min) (22.0 mg, 19.8%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.30-7.27 (m, 1H), 7.26-7.23 (m, 1H), 7.14-7.06(m, 2H), 6.20-5.92 (m, 1H), 5.57-5.49 (m, 1H), 5.27-4.98 (m, 1H),3.79-3.56 (m, 1H), 3.19-3.08 (m, 1H), 3.05-2.90 (m, 1H), 1.91-1.76 (m,2H). LCMS R_(T)=0.956 min, m/z=344.1 [M+H]⁺.

SFC condition: Column: Chiralcel AD-3 (150*4.6 mm, 3 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5.5 minand 5% of B for 1.5 min, Flow rate: 2.5 mL/min Column temp. 40° C.

Example 198: Method 45(5S,7S)-2-[2-(Difluoromethoxy)ethylsulfonyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-2-[2-(difluoromethoxy)ethylsulfanyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a mixture of2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]ethanol(200 mg, 0.72 mmol) and copper(I) iodide (30 mg, 0.2 mmol) inacetonitrile (1.0 mL) was added a solution ofdifluoro(fluorosulfonyl)acetic acid (500 mg, 2.8 mmol) in acetonitrile(0.5 mL) at 50° C. The mixture was stirred at 50° C. for 40 min andconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 50% ethyl acetate inpetroleum ether) to give(5S,7S)-2-[2-(difluoromethoxy)ethylsulfanyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(45 mg, 19%) as yellow oil. LCMS R_(T)=0.726 min, m/z=330.1 [M+H]⁺.

Step 2:(5S,7S)-2-[2-(difluoromethoxy)ethylsulfonyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of(5S,7S)-2-[2-(difluoromethoxy)ethylsulfanyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(45 mg, 0.14 mmol), ruthenium(iii) chloride (6 mg, 0.03 mmol) and sodiumperiodate (117 mg, 0.55 mmol). in acetonitrile (1.8 mL), water (1.8 mL)and ethyl acetate (1.8 mL) was stirred at 30° C. for 1 h and filtered.The filtrate was concentrated under reduced pressure and the residue waspurified by RP-HPLC (acetonitrile 25-55%/0.225% formic acid in water) toafford(5S,7S)-2-[2-(difluoromethoxy)ethylsulfonyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(5.3 mg, 10.3%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.39(m, 3H), 7.30-7.27 (m, 2H), 6.22 (t. J=74.8 Hz, 1H), 6.21-6.03 (m, 1H),5.68-5.66 (m, 1H), 4.25 (t, J=5.6 Hz, 2H), 3.82-3.74 (m, 3H), 1.31-1.28(m, 1H). LCMS R_(T)=0.943 min, m/z=362.1 [M+H]⁺.

Example 199 and Example 200(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 starting from(5S,7S)-2-bromo-5-(3-chloro-5-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(prepared according to method 23). The final compound was purified firstby RP-HPLC (acetonitrile 42-72%/0.225% formic acid in water), and thenby SFC to afford:

(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=4.266 min) (15.5 mg, 34%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.17-7.13 (m, 1H), 7.09 (s, 1H), 6.90-6.87 (m,1H), 6.14-5.98 (m, 1H), 5.52-5.47 (m, 1H), 5.25-5.05 (m, 1H), 3.76-3.61(m, 1H), 3.20-3.10 (m, 1H), 3.05-2.94 (m, 1H), 1.93-1.76 (m, 2H). LCMSR_(T)=1.030 min, m/z=378.1 [M+H]⁺.

(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.480 min) (8.6 mg, 19%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.17-7.13 (m, 1H), 7.09 (s, 1H), 6.90-6.87 (m,1H), 6.14-5.98 (m, 1H), 5.52-5.47 (m, 1H), 5.24-5.05 (m, 1H), 3.76-3.61(m, 1H), 3.22-3.13 (m, 1H), 3.05-2.94 (m, 1H), 1.89-1.75 (m, 2H). LCMSRT=0.952 min, m/z=377.9 [M+H]+.

SFC condition: Column: Chiralcel OD-3 (150*4.6 mm, 3 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5 min andhold 40% of B for 2.5 min, Flow rate: 2.5 mL/min Column temp. 35° C.

Example 201 and Example 202(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 starting from(5S,7S)-2-bromo-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified first by RP-HPLC (acetonitrile40-70%/0.05% ammonia hydroxide in water), and then by SFC to give:

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.467 min) (25.4 mg, 23%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.19-7.04 (m, 2H), 6.75-6.65 (m, 1H), 6.18-5.95(m, 1H), 5.89-5.80 (m, 1H), 5.29-5.01 (m, 1H), 3.83-3.64 (m, 1H),3.26-3.14 (m, 1H), 3.05-2.89 (m, 1H), 1.92-1.76 (m, 2H). LCMSR_(T)=0.955 min, m/z=362.1 [M+H]⁺.

(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=2.544 min) (61.4 mg, 55%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.20-7.05 (m, 2H), 6.76-6.67 (m, 1H), 6.17-5.97(m, 1H), 5.88-5.80 (m, 1H), 5.29-5.05 (m, 1H), 3.82-3.65 (m, 1H),3.23-3.11 (m, 1H), 3.05-2.90 (m, 1H), 1.94-1.77 (m, 2H). LCMS RT=0.952min, m/z=362.1 [M+H]⁺.

SFC condition: Column: Chiralcel AS-3 (150*4.6 mm, 3 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5 min andfrom 40% to 5% of B in 0.5 min, hold 5% of B for 1.5 min, Flow rate: 2.5mL/min Column temp. 35 OC.

Example 203(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(3-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2-b][1,2,4]triazole-2-thiol. The final compound was purified byRP-HPLC (acetonitrile 35-65%/0.225% formic acid in water) to afford(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(145 mg, 81%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.31 (m,2H), 7.26-7.24 (m, 1H), 7.16-7.10 (m, 1H), 6.14-5.95 (m, 1H), 5.56-5.48(m, 1H), 3.78-3.57 (m, 1H), 3.06-2.87 (m, 1H), 2.80-2.70 (m, 1H),1.52-1.39 (m, 2H), 1.22-1.07 (m, 2H). LCMS R_(T)=0.917 min, m/z=341.9[M+H]⁺.

Example 204: Method 42(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 42 starting from(5S,7S)-7-fluoro-5-(2,3-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol.The final compound was purified by RP-HPLC (acetonitrile 45-75%/0.05%ammonia hydroxide in water) to give(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole (11.9 mg, 31%) asa white solid. H NMR (400 MHz, CDCl₃) δ 7.27-7.19 (m, 1H), 7.17-7.10 (m,1H), 6.75-6.72 (m, 1H), 6.17-5.95 (m, 1H), 5.92-5.81 (m, 1H), 5.46-5.19(m, 1H), 4.24-4.08 (m, 1H), 3.85-3.64 (m, 1H), 3.14-2.91 (m, 3H),2.79-2.61 (m, 2H). LCMS RT=1.845 min, m/z=376.1 [M+H]⁺.

Example 205 and Example 206(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 starting from(5S,7S)-2-bromo-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified first by RP-HPLC (acetonitrile42-72%/0.05% ammonia hydroxide in water), and then by SFC to give:

(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=2.623 min) (37.5 mg, 31.3%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.44-7.37 (m, 1H), 7.21-7.13 (m, 2H), 6.99 (t,J=6.8 Hz, 1H), 6.16-5.98 (m, 1H), 5.89-5.87 (m, 1H), 5.27-5.04 (m, 1H),3.81-3.64 (m, 1H), 3.25-3.14 (m, 1H), 3.06-2.90 (m, 1H), 1.91-1.75 (m,2H). LCMS R_(T)=0.897 min, m/z=343.9 [M+H]⁺.

(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=2.747 min) (36.4 mg, 30%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.44-7.36 (m, 1H), 7.21-7.12 (m, 2H), 6.99 (t,J=7.2 Hz, 1H), 6.19-5.96 (m, 1H), 5.88-5.85 (m, 1H), 5.28-5.07 (m, 1H),3.83-3.63 (m, 1H), 3.18-3.16 (m, 1H), 3.06-2.90 (m, 1H), 1.94-1.74 (m,2H). LCMS R_(T)=0.896 min, m/z=343.9 [M+H]⁺.

SFC condition: Column: Chiralcel AS-3 (150*4.6 mm, 3 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5 min andfrom 40% to 5% of B in 0.5 min, hold 5% of B for 1.5 min, Flow rate: 2.5mL/min Column temp. 35 OC.

Example 207 and Example 218(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 starting from(5S,7S)-2-bromo-5-(5-chloro-2-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified first by RP-HPLC (42-72%acetonitrile/0.05% hydrochloric acid in water), and then by SFC to give:

(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=4.275 min) (10.2 mg, 10%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.40-7.32 (m, 1H), 7.12 (t, J=9.2 Hz, 1H),7.00-6.95 (m, 1H), 6.17-5.95 (m, 1H), 5.84-5.76 (m, 1H), 5.27-5.06 (m,1H), 3.80-3.63 (m, 1H), 3.22-3.12 (m, 1H), 3.03-2.91 (m, 1H), 1.93-1.81(m, 2H). LCMS R_(T)=1.018 min, m/z=378.1 [M+H]⁺.

(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.504 min) (14.1 mg, 14%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.51-7.44 (m, 1H), 7.30-7.19 (m, 2H), 6.29-6.05(m, 1H), 5.95-5.80 (m, 1H), 5.30-5.02 (m, 1H), 3.94-3.71 (m, 1H),3.50-3.38 (m, 1H), 3.01-2.81 (m, 1H), 1.94-1.81 (m, 1H), 1.78-1.67 (m,1H). LCMS R_(T)=1.010 min, m/z=378.1 [M+H]⁺.

SFC condition: Column: Chiralcel OD-3 (150×4.6 mm, 3 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5 min andfrom 40% to 5% of B in 0.5 min, hold 5% of B for 1.5 min, Flow rate: 2.5mL/min Column temp. 35° C.

Example 219 and Example 208(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 starting from(5S,7S)-2-bromo-5-(3-chloro-2-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified first by RP-HPLC (45-72%acetonitrile/0.05% hydrochloric acid in water), and then by SFC to give:

(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=4.561 min) (9.9 mg, 14%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.48-7.44 (m, 1H), 7.15-7.10 (m, 1H), 6.88-6.84(m, 1H), 6.15-5.98 (m, 1H), 5.90-5.85 (m, 1H), 5.24-5.08 (m, 1H),3.81-3.66 (m, 1H), 3.23-3.11 (m, 1H), 3.03-2.92 (m, 1H), 1.89-1.84 (m,2H). LCMS R_(T)=1.029 min, m/z=378.1 [M+H]⁺.

(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 2, retention time=4.332 min) (20.0 mg, 29%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.48-7.43 (m, 1H), 7.16-7.10 (m, 1H), 6.89-6.85(m, 1H), 6.15-5.98 (m, 1H), 5.90-5.85 (m, 1H), 5.24-5.03 (m, 1H),3.81-3.66 (m, 1H), 3.23-3.14 (m, 1H), 3.03-2.92 (m, 1H), 1.90-1.80 (m,2H). LCMS R_(T)=0.939 min, m/z=337.9 [M+H]⁺.

SFC condition: Column: Chiralcel AD-3 (150×4.6 mm, 3 um) Mobile phase:A: CO₂ B: Ethanol (0.05% DEA) Gradient: from 5% to 40% of B in 5.5 minand 5% of B for 1.5 min, Flow rate: 2.5 mL/min Column temp. 40° C.

Example 209 and Example 212: Method 46(1R,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrileand(1S,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile

Step 1: ethyltrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylateand ethylcis-2-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclopropanecarboxylate

A mixture of 2,2′-bipyridine (71 mg, 0.45 mmol),(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(535 mg, 2.3 mmol), sodium carbonate (723 mg, 6.8 mmol),(2-ethoxycarbonylcyclopropyl)boronic acid (387 mg, 2.5 mmol) andcopper(I) thiophene-2-carboxylate (445 mg, 2.3 mmol) in1,2-dichloroethane (25 mL) was stirred at 50° C. for 3 h under nitrogenatmosphere. The mixture was poured into water (10 mL) and extracted withdichloromethane (3×10 mL). The combined organic layers were washed withbrine (20 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 50% ethyl acetate in petroleum ether) to give ethyltrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylate(195 mg, 25%) and ethylcis-2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylate(210 mg, 27%), both as light yellow solids.

Step 2:trans-2-[[(5S,7S)-7-Fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylicacid

To a solution of ethyltrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylate(180 mg, 0.5 mmol) in tetrahydrofuran (10 mL) and water (2 mL) was addedlithium hydroxide hydrate (37 mg, 1.6 mmol). The reaction mixture wasstirred at 25° C. for 4 h and concentrated under reduced pressure. Theresidue was adjusted to pH=3 by addition of hydrochloric acid (4 M) andextracted with ethyl acetate (3×15 mL). The combined organic layers werewashed with brine (20 mL), dried over sodium sulfate and concentratedunder reduced pressure to afford crudetrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylic acid (150 mg, 91%) as a white solid. LCMS R_(T)=0.902 min,m/z=320.1 [M+H]⁺.

Step 3:trans-[[(5S,7S)-7-Fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxamide

To a mixture of 1-hydroxybenzotriazole (64 mg, 0.5 mmol), ammoniumchloride (50 mg, 0.94 mmol), N,N-diisopropylethylamine (182 mg, 1.4mmol) andtrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxylicacid (150 mg, 0.47 mmol) in N,N-dimethylformamide (5.0 mL) was added1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (90 mg, 0.47mmol). The mixture was stirred at 25° C. for 18 h and poured into water(30 mL). The resulting solution was extracted with ethyl acetate (3×20mL). The combined organic layers were concentrated under reducedpressure and the residue was purified by column chromatography (silicagel, 100-200 mesh, 0 to 8% methanol in ethyl acetate) to affordtrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxamide(100 mg, 67%) as a colorless oil. LCMS R_(T)=0.590 min, m/z=319.1[M+H]⁺.

Step 4:trans-2-[[(5S,7S)-7-Fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarbonitrile

To a solution oftrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarboxamide(100 mg, 0.31 mmol) in 1,4-dioxane (10 mL) was added triethylamine (158mg, 1.57 mmol) and trifluoroacetic anhydride (198 mg, 0.94 mmol). Thereaction mixture was stirred at 25° C. for 4 h and quenched by additionof water (20 mL). The mixture was extracted with ethyl acetate (3×15mL). The combined organic layers were washed with saturated aqueoussodium bicarbonate (20 mL), dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 70% ethyl acetate inpetroleum ether) to affordtrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarbonitrile (70 mg, 74%) as a white solid. LCMS R_(T)=0.811 min,m/z=301.1 [M+H]⁺.

Step 5:(1R,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrileand(1S,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile

A mixture oftrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclopropanecarbonitrile(70 mg, 0.23 mmol) and 3-chloroperoxybenzoicacid (85%, 187 mg, 0.93mmol) in dichloromethane (10 mL) was stirred at 25° C. for 4 h. Themixture was diluted with water (30 mL) and extracted withdichloromethane (3×15 mL). The combined organic layers were washed withsaturated aqueous sodium bicarbonate (20 mL), brine (15 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 80%ethyl acetate in petroleum ether) to affordtrans-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile(60 mg, 77%) as a white solid. LCMS R_(T)=0.653 min, m/z=333.1 [M+H]⁺.

The above racemic mixture (60 mg, 0.18 mmol) was further separated bychiral SFC to afford:

(1R,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile(Peak 1, retention time=2.795 min) (19.7 mg, 33%) as a white solid. 1HNMR (400 MHz, CD₃OD) δ 7.45-7.40 (m, 3H), 7.31-7.29 (m, 2H), 6.23-6.21(m, 0.5H), 6.09-6.07 (m, 0.5H), 5.70-5.69 (m, 1H), 3.85-3.69 (m, 2H),2.93-2.82 (m, 1H), 2.54-2.50 (m, 1H), 1.90-1.83 (m, 2H). LCMSR_(T)=0.655 min, m/z=333.1 [M+H]⁺.

(1S,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile(Peak 2, retention time=3.005 min) (11.4 mg, 19%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.45-7.40 (m, 3H), 7.30-7.28 (m, 2H), 6.24-6.21(m, 0.5H), 6.10-6.07 (m, 0.5H), 5.71-5.68 (m, 1H), 3.86-3.68 (m, 2H),2.55-2.52 (m, 1H), 2.51-2.50 (m, 1H), 1.91-1.84 (m, 2H). LCMSR_(T)=0.655 min, m/z=333.1 [M+H]⁺.

SFC conditions: Column: Daicel chiralpak AS-H (250 mm×30 mm, 5 um)Mobile phase: A: C02 B: 0.1% ammonium hydroxide Ethanol Gradient: from30% B to 30% B Flow rate: 65 mL/min Column temperature: 40° C.

Example 210: Method 47Cis-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile

Step 1:trans-[3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutyl]4-nitrobenzoate

To a mixture ofcis-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanol(500 mg, 1.6 mmol), 4-nitrobenzoic acid (355 mg, 2.1 mmol) andtriphenylphosphine (644 mg, 2.5 mmol) in tetrahydrofuran (15 mL) wasadded diisopropyl azodicarboxylate (497 mg, 2.5 mmol) at 0° C. undernitrogen atmosphere. The mixture was stirred at 50° C. for 16 h anddiluted with water (30 mL). The resulting mixture was extracted withethyl acetate (3×30 mL). The combined organic layers were washed withbrine (10 mL), dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 50% ethyl acetate in petroleum ether) to givetrans-[3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutyl]4-nitrobenzoate (950 mg, 43%) as a white solid. LCMS R_(T)=0.824 min,m/z=455.1 [M+H]⁺.

Step 2:trans-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanol

A mixture of potassium carbonate (175 mg, 1.3 mmol) andtrans-[3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutyl]4-nitrobenzoate (850 mg, 0.64 mmol) in methanol (15 mL) and water (5 mL)was stirred at 25° C. for 1.5 h. The reaction was diluted with water (30mL) and extracted with ethyl acetate (3×30 mL). The combined organiclayers were washed with brine (10 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified by columnchromatography (silica gel, 100-200 mesh, 0 to 50% ethyl acetate inpetroleum ether) to affordtrans-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]cyclobutanol(430 mg, 43% purity, 41%) as a white solid.

Step 3:trans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutyl4-methylbenzenesulfonate

To a mixture oftrans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol(200 mg, 43% purity, 0.28 mmol), triethylamine (71 mg, 0.7 mmol) and4-dimethylaminopyridine (7 mg, 0.06 mmol) in dichloromethane (10 mL) wasadded p-toluenesulfonyl chloride (80 mg, 0.42 mmol). The mixture wasstirred at 20° C. for 2.5 h and quenched by addition of water (20 mL).The mixture was extracted with ethyl acetate (3×20 mL). The combinedorganic layers were washed with brine (30 mL), dried over sodium sulfateand concentrated under reduced pressure. The residue was purified bycolumn chromatography (silica gel, 100-200 mesh, 0 to 50% ethyl acetatein petroleum ether) to affordtrans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutyl4-methylbenzenesulfonate (120 mg, 93%) as a white solid.

Step 4:cis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanecarbonitrile

A mixture oftrans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutyl4-methylbenzenesulfonate (90 mg, 0.2 mmol) and sodium cyanide (19 mg,0.39 mmol) in dimethyl sulfoxide (9 mL) was stirred at 100° C. for 16 hunder nitrogen atmosphere. The reaction mixture was diluted with water(10 mL) and extracted with ethyl acetate (3×10 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue purified by column chromatography (silica gel,100-200 mesh, 0 to 40% ethyl acetate in petroleum ether) to givecis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanecarbonitrile(80.0 mg, 81%) as colorless oil. LCMS R_(T)=0.685 min, m/z=315.1 [M+H]⁺.

Step 5:cis3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile

A mixture of 3-chloroperoxybenzoic acid (85%, 155 mg, 0.76 mmol) andcis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanecarbonitrile(60 mg, 0.19 mmol) in dichloromethane (4 mL) was stirred at 25° C. for 2h and quenched by addition of saturated aqueous sodium bicarbonate (10mL). The resulting mixture was extracted with dichloromethane (3×10 mL).The combined organic layers were washed with brine (10 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 28-58/0.05% hydrochloric acid inwater) to affordcis-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile(14.6 mg, 21%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.46-7.38(m, 3H), 7.28-7.26 (m, 2H), 6.35-6.18 (m, 1H), 5.77-5.73 (m, 1H),4.43-4.35 (m, 1H), 3.83-3.69 (m, 1H), 3.49-3.43 (m, 1H), 2.79-2.74 (m,1H), 2.72-2.57 (m, 4H). LCMS R_(T)=0.908 min, m/z=347.1 [M+H]⁺.

Example 211: Method 34trans-3-[[(5S,7S)-7-Fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile

Step 1:cis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutyl4-methylbenzenesulfonate

To a mixture ofcis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol(110 mg, 0.36 mmol), triethylamine (91 mg, 0.9 mmol) and4-dimethylaminopyridine (8.8 mg, 0.07 mmol) in dichloromethane (5 mL)was added p-toluenesulfonyl chloride (103 mg, 0.54 mmol). The mixturewas stirred at 20° C. for 2.5 h and quenched by addition of water (20mL). The resulting solution was extracted with ethyl acetate (3×20 mL).The combined organic layers were washed with brine (30 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 50%ethyl acetate in petroleum ether) to affordcis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutyl 4-methylbenzenesulfonate (165 mg, 99%) as a white solid.

Step 2:trans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanecarbonitrile

A mixture ofcis-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutyl4-methylbenzenesulfonate (145 mg, 0.32 mmol) and sodium cyanide (23 mg,0.47 mmol) in dimethyl sulfoxide (10 mL) was stirred at 100° C. for 16 hunder nitrogen atmosphere. The reaction mixture was diluted with water(10 mL) and extracted with ethyl acetate (3×10 mL). The combined organiclayers were dried over sodium sulfate and concentrated under reducedpressure. The residue was purified by column chromatography (silica gel,100-200 mesh, 0 to 40% ethyl acetate in petroleum ether) to givetrans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanecarbonitrile(80.0 mg, 81%) as colorless oil.

Step 3:trans-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile

A mixture of 3-chloroperoxybenzoic acid (85%, 180 mg, 0.89 mmol) andtrans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanecarbonitrile)(70 mg, 0.22 mmol) in dichloromethane (5 mL) was stirred at 25° C. for 2h and quenched by addition of saturated aqueous sodium bicarbonate (10mL). The resulting mixture was extracted with dichloromethane (3×10 mL).The combined organic layers were washed with brine (10 mL), dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 30-60/0.05% hydrochloric acid inwater) to affordtrans-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile(24.5 mg, 31%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) 7.47-7.38 (m,3H), 7.30-7.26 (m, 2H), 6.42-6.18 (m, 1H), 5.86-5.67 (m, 1H), 4.45-4.38(m, 1H), 3.92-3.60 (m, 1H), 3.53-3.43 (m, 1H), 2.83-2.71 (m, 5H). LCMSR_(T)=0.923 min, m/z=347.1 [M+H]⁺.

Example 213: Method 49(5S,7S)-2-trans-[3-(difluoromethoxy)cyclobutyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5S,7S)-2-trans-((3-(difluoromethoxy)cyclobutyl)thio)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution oftrans-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclobutanol(200 mg, 0.28 mmol) and copper(I) iodide (16 mg, 0.08 mmol) inacetonitrile (2.0 mL) was added a solution ofdifluoro(fluorosulfonyl)acetic acid (75 mg, 0.42 mmol) in acetonitrile(1.0 mL) at 50° C. The mixture was stirred at 50° C. for 40 min andquenched by addition of water (30 mL). The resulting solution wasextracted with ethyl acetate (3×30 mL). The combined organic layers weredried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by preparative TLC (40% ethyl acetate in petroleumether, R_(f)=0.4) to give(5S,7S)-2-trans-[3-(difluoromethoxy)cyclobutyl]sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(70 mg, 70%) as yellow oil. LCMS R_(T)=0.759 min, m/z=356.1 [M+H]⁺.

Step 2:(5S,7S)-2-trans-[3-(difluoromethoxy)cyclobutyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of(5S,7S)-2-trans-[3-(difluoromethoxy)cyclobutyl]sulfanyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(60 mg, 0.17 mmol) in dichloromethane (3 mL) was added3-chloroperoxybenzoic acid (85%, 137 mg, 0.68) at 25° C. The mixture wasstirred at 25° C. for 1.5 h and quenched by addition of saturatedaqueous sodium bicarbonate (10 mL). The resulting mixture was extractedwith dichloromethane (3×10 mL). The combined organic layers were wishedwith brine (10 mL), dried over sodium sulfate and concentrated underreduced pressure. The residue was purified by RP-HPLC (acetonitrile35-65/0.05% hydrochloric acid in water) to afford(5S,7S)-2-trans-[3-(difluoromethoxy)cyclobutyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(27.6 mg, 42%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.44-7.42(m, 3H), 7.27-7.26 (m, 2H), 6.68 (t, J=75.6 Hz, 1H), 6.34-6.18 (m, 1H),5.80-5.72 (m, 1H), 4.85-4.72 (m, 1H), 4.25-4.17 (m, 1H), 3.80-3.70 (m,1H), 2.85-2.73 (m, 3H), 2.70-2.61 (m, 2H). LCMS R_(T)=1.026 min,m/z=388.1 [M+H]⁺.

Example 214(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 18 starting from(5S,7S)-5-(3-chloro-5-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to method 23 starting from 3-chloro-5-fluorobenzoicacid). The final compound was purified by RP-HPLC (acetonitrile40-70%/0.05% hydrochloric acid in water) to afford(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(18.3 mg, 33%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.16-7.12 (m,1H), 7.08 (s, 1H), 6.90-6.86 (m, 1H), 6.13-5.96 (m, 1H), 5.51-5.46 (m,1H), 3.75-3.60 (m, 1H), 3.02-2.91 (m, 1H), 2.80-2.72 (m, 1H), 1.52-1.46(m, 2H), 1.20-1.13 (m, 2H). LCMS R_(T)=0.926 min, m/z=359.9 [M+H]⁺.

Example 215(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 6 starting from(5S,7S)-5-(3-chloro-5-fluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(prepared according to method 6 starting from 3-chloro-5-fluorobenzoicacid. The final compound was purified by RP-HPLC (acetonitrile45-75%/0.05% hydrochloric acid) to afford(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(40.9 mg, 62%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.18-7.14(m, 1H), 7.07 (s, 1H), 6.88-6.84 (m, 1H), 6.44 (t, J=52.8 Hz, 1H),6.17-6.00 (m, 1H), 5.58-5.53 (m, 1H), 3.79-3.64 (m, 1H), 3.07-2.96 (m,1H). LCMS R_(T)=0.972 min, m/z=369.9

[M+H]⁺.

Example 216 and Example 217(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazoleand(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewere prepared according to method 30 starting from(5S,7S)-2-bromo-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.The final compound was purified first by preparative TLC (50% ethylacetate in petroleum ether, R_(f)=0.6), and then by SFC to give:

(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(Peak 1, retention time=3.199 min) (22.5 mg, 20%) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ 7.27-7.19 (m, 1H), 7.18-7.07 (m, 1H), 6.84-6.67(m, 1H), 6.21-5.97 (m, 1H), 5.90-5.88 (m, 1H), 5.30-5.01 (m, 1H),3.79-3.73 (m, 1H), 3.25-3.16 (m, 1H), 3.08-2.86 (m, 1H), 2.01-1.75 (m,2H). LCMS R_(T)=1.817 min, m/z=362.1 [M+H]⁺.

Example 220: Method 502-(Difluoromethylsulfonyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

Step 1:(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-phenyl-methanone

To a cooled (−78° C.) solution of N-methoxy-N-methylbenzamide (4.3 g,26.0 mmol) and 3,5-dibromo-1-tetrahydropyran-2-yl-1,2,4-triazole (9.7 g,31.2 mmol) in tetrahydrofuran (45 mL) was added isopropylmagnesiumchloride (2.0 M in tetrahydrofuran, 15.6 mL, 31.2 mmol) dropwise undernitrogen atmosphere. The mixture was stirred at −78° C. for about 1 hand then at 15° C. for 16 h before quenched by addition of saturatedaqueous ammonium chloride (100 mL). The resulting mixture was extractedwith ethyl acetate (3×100 mL). The combined organic layers were driedover sodium sulfate and concentrated under reduced pressure. The residuewas purified by column chromatography (silica gel, 100-200 mesh, 0 to 8%ethyl acetate in petroleum ether) to afford(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-phenyl-methanone(7.1 g, 81%) as colorless oil. LCMS R_(T)=0.795 min, m/z=254.0 [M+H]⁺.

Step 2: ethyl(E)-3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-prop-2-enoate

To an ice-cold suspension of sodium hydride (60%, 1014 mg, 25.3 mmol) intetrahydrofuran (80 mL) was added triethyl phosphonoacetate (4.61 mL,23.2 mmol). The reaction mixture was stirred at 20° C. for 15 min and asolution of(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-phenyl-methanone(7.1 g, 21.1 mmol) in tetrahydrofuran (20 mL) was added. The mixture wasstirred at 20° C. for 1 h and quenched by addition of saturated aqueousammonium chloride (100 mL). The solution was extracted with ethylacetate (3×100 mL). The combined organic layers were dried over sodiumsulfate and concentrated under reduced pressure. The residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 10%ethyl acetate in petroleum ether) to afford ethyl(E)-3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-prop-2-enoate(8.0 g, 93%) as colorless oil. LCMS R_(T)=0.803 min, m/z=324.1[M+H-85]⁺.

Step 3: ethyl3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-propanoate

A mixture of ethyl(E)-3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-prop-2-enoate(3.5 g, 8.6 mmol) and platinum oxide (0.6 g, 2.57 mmol) in ethyl acetate(20 mL) was hydrogenated (15 psi) at 20° C. for 16 h and filtered. Thefiltrate was concentrated under reduced pressure and the residue waspurified by column chromatograph (silica gel, 100-200 mesh, 0-15% ethylacetate in petroleum ether) to afford ethyl3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-propanoate(3.5 g, 99%) as a colorless oil. LCMS R_(T)=0.940 min, m/z=326.0[M+H-85]⁺.

Step 4:3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-propan-1-ol

To a solution of lithium borohydride (1.04 g, 47.8 mmol) intetrahydrofuran (25 mL) was added ethyl3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-propanoate(6.50 g, 15.9 mmol). The mixture was stirred at 15° C. for 1 h andquenched by addition of saturated aqueous ammonium chloride (100 mL).The resulting mixture was extracted with ethyl acetate (3×100 mL). Thecombined organic layers were washed with water (100 mL), brine (100 mL),dried over sodium sulfate and concentrated under reduced pressure. Theresidue was purified by column chromatography (silica gel, 100-200 mesh,0 to 50% ethyl acetate in petroleum ether) to afford3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-propan-1-ol(5.5 g, 94%) as a colorless oil. LCMS R_(T)=0.809 min, m/z=282.0[M+H-85]⁺.

Step 5: 3-(3-bromo-1H-1,2,4-triazol-5-yl)-3-phenyl-propan-1-ol

A mixture of3-(5-bromo-2-tetrahydropyran-2-yl-1,2,4-triazol-3-yl)-3-phenyl-propan-1-ol(5.0 g, 13.7 mmol) and hydrochloric acid (4.0 M in methanol, 17.0 mL,68.0 mmol) in methanol (50 mL) was stirred at 20° C. for 1 h andquenched by addition of saturated sodium carbonate (50 mL). Theresulting solution was extracted with ethyl acetate (3×50 mL). Thecombined organic layers were dried over sodium sulfate and concentratedunder reduced pressure. The residue was purified by columnchromatography (100-200 mesh, silica gel, 50% ethyl acetate in petroleumether) to afford 3-(3-bromo-1H-1,2,4-triazol-5-yl)-3-phenyl-propan-1-ol(2.4 g, 62%) as a white solid. LCMS R_(T)=0.538 min, m/z=282.0 [M+H]⁺.

Step 6: 2-bromo-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

To a solution of 3-(3-bromo-1H-1,2,4-triazol-5-yl)-3-phenyl-propan-1-ol(2.4 g, 8.5 mmol) and triphenylphosphine (2.7 g, 10.2 mmol) intetrahydrofuran (50 mL) was added diisopropyl azodicarboxylate (2 mL,10.2 mmol) at 25° C. under nitrogen atmosphere. The reaction was stirredat 25° C. for 12 h and concentrated under reduced pressure. The residuewas purified by column chromatography (silica gel, 100-200 mesh, 0-20%ethyl acetate in petroleum ether) to afford2-bromo-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole (2.3 g,60%) as a white solid. LCMS R_(T)=0.641 min, m/z=266.0 [M+H]⁺.

Step 7: 2-ethylhexyl3-[(7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfanyl]propanoate

To a mixture of2-bromo-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole (190 mg,0.72 mmol), N,N-diisopropylethylamine (0.38 mL, 2.2 mmol) andtris(dibenzylideneacetone) dipalladium(0) (198 mg, 0.22 mmol) was added3-mercaptopropionic acid 2-ethylhexylester (189 mg, 0.86 mmol) and4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (416 mg, 0.72 mmol) in1,4-dioxane (5 mL). The mixture was stirred at 110° C. for 15 h undernitrogen atmosphere and filtered. The filtrate was concentrated underreduced pressure and the residue was purified by column chromatography(silica gel, 100-200 mesh, 0 to 15% ethyl acetate in petroleum ether) toafford 2-ethylhexyl3-[(7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfanyl]propanoate(630 mg, 22% purity, 48%) as yellow oil. LCMS R_(T)=1.106 min, m/z=402.2[M+H]⁺.

Step 8: 7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol

To a solution of 2-ethylhexyl3-[(7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfanyl]propanoate(630 mg, 1.57 mmol, crude) in ethanol (10 mL) was added sodium ethoxide(2 M in ethanol, 2.35 mL, 4.70 mmol). The reaction mixture was stirredat 25° C. for 1 h and concentrated under reduced pressure. The residuewas diluted with water (30 mL) and washed with ethyl acetate (20 mL).The aqueous phase was adjusted to pH=6 by addition of citric acid andextracted with ethyl acetate (2×50 mL). The combined organic layers weredried over sodium sulfate and concentrated under reduce pressure toafford crude7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol (200 mg,42%) as a yellow solid. LCMS R_(T)=0.412 min, m/z=218.1 [M+H]⁺.

Step 9:2-(difluoromethylsulfanyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of sodium (2-chloro-2,2-difluoro-acetyl)oxide (88 mg, 0.58mmol), 7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(100 mg, 0.46 mmol) and potassium carbonate (159 mg, 1.15 mmol) inN,N-dimethylformamide (1.5 mL) was stirred at 90° C. for 10 min undernitrogen atmosphere. After cooled, the mixture was diluted with water(20 mL) and extracted with ethyl acetate (3×20 mL). The combined organiclayers were washed with brine (20 mL), dried over sodium sulfate andconcentrated under reduced pressure. The residue was purified bypreparative TLC (30% ethyl acetate in petroleum ether, R_(f)=0.5) togive2-(difluoromethylsulfanyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20 mg, 16%) as a light oil. LCMS R_(T)=0.682 min, m/z=268.1 [M+H]⁺.

Step 10:2-(difluoromethylsulfonyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

A mixture of2-(difluoromethylsulfanyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(20 mg, 0.08 mmol), ruthenium(iii) chloride (2 mg, 0.008 mmol) andsodium periodate (64 mg, 0.30 mmol) in acetonitrile (0.5 mL), water (0.5mL) and ethyl acetate (0.5 mL) was stirred at 30° C. for 1 h andfiltered. The filtrate was diluted with water (10 mL) and extracted withethyl acetate (3×5 mL). The combined organic layers were dried oversodium sulfate and concentrated under reduced pressure. The residue waspurified by RP-HPLC (acetonitrile 37-67%/0.05% hydrochloride in water)to afford2-(difluoromethylsulfonyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(8.2 mg, 36%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.31 (m,3H), 7.24-7.21 (m, 2H), 6.42 (t, J=53.2 Hz, 1H), 4.59-4.55 (m, 1H),4.52-4.45 (m, 1H), 4.41-4.33 (m, 1H), 3.40-3.30 (m, 1H), 2.89-2.79 (m,1H).

LCMS R_(T)=0.896 min, m/z=299.9 [M+H]⁺.

Example 221 and Example 222(1S,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrileand(1R,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile

(1S,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrileand(1R,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrilewere prepared according to method 46 starting from cis-ethyl2-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)thio)cyclopropanecarboxylate. The final compounds were purified first by RP-HPLC(acetonitrile 50-80%/0.05% ammonia hydroxide in water) and then bychiral SFC to give:

(1S,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile(Peak 1, retention time=4.876 min) (20.3 mg, 31%) as a white solid. ¹HNMR (400 MHz, CD₃OD) δ 7.44-7.40 (m, 3H), 7.30-7.28 (m, 2H), 6.22-6.20(m, 0.5H), 6.09-6.06 (m, 0.5H), 5.71-5.68 (m, 1H), 3.81-3.75 (m, 1H),3.42-3.38 (m, 1H), 2.58-2.57 (m, 1H), 2.46-2.42 (m, 1H), 1.97-1.94 (m,1H), 1.82-1.78 (m, 1H). LCMS R_(T)=0.628 min, m/z=333.1 [M+H]⁺.

(1R,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile(Peak 2, retention time=5.573 min) (25.6 mg, 39%) as a white solid. 1HNMR (400 MHz, DMSO-d₆) δ 7.45-7.40 (m, 3H), 7.30-7.28 (m, 2H), 6.37-6.34(m, 0.5H), 6.23-6.21 (m, 0.5H), 5.81-5.78 (m, 1H), 3.83-3.75 (m, 1H),3.63-3.34 (m, 1H), 2.72-2.68 (m, 2H), 1.89-1.81 (m, 2H). LCMSR_(T)=0.627 min, m/z=333.1 [M+H]⁺.

SFC conditions: Column: Phenomenex-Amylose-1 (250 mm×30 mm, 5 um) Mobilephase: A: C02 B: Ethanol (0.1% ammonium hydroxide) Gradient: from 40% to40% of B Flow rate: 50 mL/min Column temperature: 35 OC.

Example 223: Method 372-[[(5S,7S)-7-Fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol

Step 1:2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]ethanol

To a solution of(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thiol(100 mg, 0.43 mmol) and 2-bromoethanol (200 mg, 1.6 mmol) inacetonitrile (3 mL) was added potassium carbonate (100 mg, 0.72 mmol) at20° C. The resulting solution was stirred for 2 h and filtered. Thefiltrate was concentrated under reduced pressure and the residue waspurified by column chromatography (silica gel, 100-200 mesh, 0 to 100%ethyl acetate in petroleum ether) to give2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]ethanol(70 mg, 59%) as a yellow oil. LCMS R_(T)=0.593 min, m/z=280.1 [M+H]⁺.

Step 2:2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol

A mixture of2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]ethanol(50 mg, 0.18 mmol), ruthenium(iii) chloride (7 mg, 0.04 mmol) and sodiumperiodate (153 mg, 0.72 mmol) in acetonitrile (2 mL), water (2 mL) andethyl acetate (2 mL) was stirred at 30° C. for 16 h and diluted withethyl acetate (30 mL). The solution was washed with water (10 mL) andconcentrated under reduced pressure. The residue was purified by RP-HPLC(acetonitrile 25-55%/0.225% formic acid in water) to give2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol(18.7 mg, 31%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.45-7.40(m, 3H), 7.40-7.24 (m, 2H), 6.34-6.17 (m, 1H), 5.77-5.73 (m, 1H),4.99-4.95 (m, 1H), 3.79-3.72 (m, 3H), 3.63-3.59 (m, 2H), 2.67-2.66 (m,1H). LCMS R_(T)=0.777 min, m/z=312.1 [M+H]⁺.

Example 224(5S,7S)-7-fluoro-2-(2-methoxyethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-(2-methoxyethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-5-phenyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland 1-bromo-2-methoxyethane. The final compound was purified by RP-HPLC(acetonitrile 32-62%/0.225% formic acid in water) to give(5S,7S)-7-fluoro-2-(2-methoxyethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(36.2 mg, 40%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.39 (m,3H), 7.29-7.26 (m, 2H), 6.21-6.04 (m, 1H), 5.70-5.67 (m, 1H), 3.79-3.64(m, 5H), 3.13 (s, 3H), 2.90-2.82 (m, 1H). LCMS R_(T)=0.865 min,m/z=326.1 [M+H]⁺.

Example 227(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(oxetan-3-ylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(oxetan-3-ylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland oxetan-3-yl 4-methylbenzenesulfonate. The final compound waspurified by RP-HPLC (acetonitrile 35-65%/0.05% ammonia hydroxide inwater) to give(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(oxetan-3-ylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(8.3 mg, 25%) as colorless oil. H NMR (400 MHz, CDCl₃) δ 7.46-7.35 (m,1H), 7.15-7.08 (m, 1H), 7.06-7.01 (m, 1H), 6.99-6.92 (m, 1H), 6.16-5.94(m, 1H), 5.59-5.50 (m, 1H), 5.12-5.04 (m, 2H), 4.97-4.89 (m, 2H),4.80-4.70 (m, 1H), 3.79-3.59 (m, 1H), 3.08-2.91 (m, 1H). LCMSR_(T)=0.883 min, m/z=342.1 [M+H]⁺.

Example 228(5S,7S)-7-fluoro-2-(oxetan-3-ylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole

(5S,7S)-7-fluoro-2-(oxetan-3-ylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolewas prepared according to method 26 starting from(5S,7S)-5-phenyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-thioland oxetan-3-yl 4-methylbenzenesulfonate. The final compound waspurified by RP-TLC (50% ethyl acetate in petroleum ether, R_(f)=0.3) toafford(5S,7S)-7-fluoro-2-(oxetan-3-ylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole(33.5 mg, 32%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m,3H), 7.25-7.12 (m, 2H), 6.14-6.12 (m, 0.5H), 6.00-5.98 (m, 0.5H),5.54-5.52 (m, 1H), 5.12-5.06 (m, 2H), 4.93-4.89 (m, 2H), 4.77-4.74 (m,1H), 3.71-3.65 (m, 1H), 3.06-2.95 (m, 1H). LCMS R_(T)=0.706 min,m/z=324.1 [M+H]⁺.

RIP1 Kinase Inhibition Assays (Biochemical Assay)

The compounds of the present invention were tested for their capacity toinhibit RIP1K activity as described below.

Enzyme Assay:

The ability of the receptor interacting protein kinase (RIPK1) tocatalyze the hydrolysis of adenosine-5′-triphosphate (ATP) is monitoredusing the Transcreener ADP (adenosine-5′-diphosphate) assay (BellBrookLabs). Purified human RIP1 kinase domain (2-375) (50 nM) derived from abaculovirus-infected insect cell expression system is incubated withtest compounds for 2 hours in 50 mM Hepes buffer (pH 7.5) containing 30mM MgCl₂, 1 mM dithiothreitol, 50 uM ATP, 0.002% Brij-35, and 0.5%dimethyl sulfoxide (DMSO). Reactions are quenched by the addition of 1×Bell Brooks Stop buffer B (20 mM Hepes (ph7.5), 40 mMethylenediaminetetraacetic acid and 0.02% Brij-35) containing anadditional 12 mM EDTA and 55 ug/mL ADP2 antibody and 4 nMADP-AlexaFluor® 633 tracer. The tracer bound to the antibody isdisplaced by the ADP generated during the RIP1K reaction, which causes adecrease in fluorescence polarization that is measured by laserexcitation at 633 nm with a FP microplate reader M1000. Fractionalactivity was plotted against test article concentration. Using GenedataScreener software (Genedata; Basel, Switzerland), the data were fit tothe tight-binding apparent inhibition constant (K_(i) ^(app)) Morrisonequation [Williams, J. W. and Morrison, J. F. (1979) The kinetics ofreversible tight-binding inhibition. Methods Enzymol 63: 437-67]. Thefollowing equation was used to calculate fractional activity and K_(i)^(app):

${{Fractional}\mspace{14mu} {activity}} = {\frac{V_{i}}{V_{o}} = {1 - \frac{( {\lbrack E\rbrack_{T} + \lbrack I\rbrack_{T} + K_{i}^{app}} ) - \sqrt{( {\lbrack E\rbrack_{T} + \lbrack I\rbrack_{T} + K_{i}^{app}} )^{2} - {{4\lbrack E\rbrack}_{T}\lbrack I\rbrack}_{T}}}{{2\lbrack E\rbrack}_{T}}}}$

where [E]_(T) and [I]_(T) are the total concentrations of active enzymeand test article, respectively.

Exemplary compounds of the present invention are provided in Table 1along with their physiochemical characterization and in vitro RIP1kinase inhibitory activity data. “Method” in the first column of eachtable refers to the synthetic method(s) used to prepare each compound asshown in the Examples above. In certain examples, chiral columnretention times (min) are provided for certain stereoisomers. Unlessotherwise specified, the stereochemistry shown in each structurerepresents relative configuration of a single stereoisomer, and absoluteconfiguration (i.e., “R” and/or “S”) is arbitrarily assigned. In someembodiments, where the Method is described to include the separation ofstereoisomers, a single stereoisomer of a compound of Table 1 isprovided.

TABLE 1 Example Synthetic Ki MS (m/z) Method Structure (μM) Stereo ¹HNMR R.T. (min)  1 Method 1

0.058 Mixture of Diastereomers ¹H NMR (400 MHz, DMSO-d6) δ 7.50-7.19 (m,6H), 5.68 (dd, J = 8.1, 6.2 Hz, 1H), 3.30-3.02 (m, 3H), 2.69-2.52 (m,1H). LC- MS RT = 3.78 min, m/z = 257.1 (M + H)⁺. 284.0   3.96  2 Method2

0.864 Mixture of Enantiomers 1H NMR (400 MHz, DMSO-d6) δ 7.47-7.33 (m,3H), 7.32-7.24 (m, 2H), 5.65 (dd, J = 8.1, 6.2 Hz, 1H), 3.45-2.99 (m,5H), 2.67-2.52 (m, 1H), 1.17 (t, J = 7.4 Hz, 3H). 278.1   3.80  3 Method3

0.162 Single Unknown Stereoisomer — 262.0   3.37  4 Method 4

0.152 Mixture of Enantiomers 1H NMR (400 MHz, DMSO-d6) δ 7.78-7.68 (m,1H), 7.65-7.56 (m, 4H), 7.48-7.35 (m, 3H), 7.30-7.23 (m, 2H), 5.72 (dd,J = 8.6, 6.5 Hz, 1H), 3.33-3.05 (m, 3H), 2.73-2.57 (m, 1H). 376.1   5.46 5 Method 4

0.548 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) δ 7.60 (dt, J =7.7, 4.0 Hz, 1H), 7.54-7.19 (m, 8H), 7.19-7.05 (m, 1H), 6.99 (dd, J =7.4, 2.1 Hz, 1H), 5.54 (dd, J = 8.5, 6.1 Hz, 1H), 3.23-2.89 (m, 3H).360.1   4.90  6 Method 1

0.101 Mixture of Enantiomers ¹H NMR (400 MHz, DMSO-d6) δ 7.62-7.22 (m,6H), 5.77-5.70 (m, 1H), 3.30-3.03 (m, 3H), 2.78-2.54 (m, 1H). 300.1  4.46  7 Method 5

0.250 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.40(m, 1H), 7.22-7.19 (m, 3H), 5.84-5.79 (m, 1H), 3.34-3.33 (m, 1H), 3.24(s, 3H), 3.24-3.14 (m, 2H), 2.78-2.71 (m, 1H) 282.0   0.638  8 Method 6

0.290 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.41-7.38(m, 1H), 7.21-7.17 (m, 3H), 5.83-5.79 (m, 1H), 3.37-3.25 (m, 3H),3.25-3.08 (m, 2H), 2.75-2.70 (m, 1H), 1.25 (t, J = 7.6 Hz, 3H) 295.9  0.784  9 Method 1

1.037 Mixture of Enantiomers ¹H NMR (400 MHz, DMSO-d6) δ 7.50-7.22 (m,5H), 5.70-5.55 (m, 1H), 3.30 (s, 3H), 3.27-2.98 (m, 3H), 2.70-2.55 (m,1H) 264.1   3.53  10 Method 7

0.089 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) δ 7.47-7.33 (m,3H), 7.33-7.21 (m, 2H), 5.71 (dd, J = 8.1, 6.1 Hz, 1H), 3.39-3.04 (m,3H), 2.69-2.56 (m, 1H). 302.1   4.49  11 Method 1

0.010 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.16(m, 6H), 5.71-5.64 (m, 1H), 3.27-3.02 (m, 3H), 2.69-2.56 (m, 1H). 284.1  3.94  12 Method 1

0.048 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.51-7.16(m, 6H), 5.72-5.64 (m, 1H), 3.28-3.01 (m, 3H), 2.70-2.55 (m, 1H). 284.1  3.98  13 Method 8

0.042 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38 (m,3H), 7.24-7.22 (m, 2H), 6.95-6.68 (m, 1H), 6.12-6.09 (m, 0.5H),5.95-5.90 (m, 0.5H), 5.76-5.70 (m, 0.5H), 5.53-5.51 (m, 0.5H), 3.70-3.61(m, 0.5H), 3.45-3.35 (m, 0.5H), 3.03-2.96 (m, 1H) 302.1   0.989  14Method 9

0.980 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.37(m, 3H), 7.29-7.26 (m, 2H), 6.21-6.18 (m, 0.5H), 6.07-6.04 (m, 0.5H),5.70-5.62 (m, 1H), 3.84-3.69 (m, 1H), 2.91-2.78 (m, 2H), 1.33-1.28 (m,2H), 1.19-1.11 (m, 2H) 308.1   0.695  15 Method 1

1.601 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.60-7.53(m, 1H), 7.48-7.29 (m, 3H), 7.16 (dd, J = 7.5, 1.9 Hz, 1H), 6.05 (dd, J= 8.6, 6.4 Hz, 1H), 3.43-3.10 (m, 3H), 2.70-2.56 (m, 1H). 334.0   4.86 16 Method 1

0.056 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.61-7.52(m, 1H), 7.51-7.28 (m, 3H), 7.16 (dd, J = 7.5, 1.9 Hz, 1H), 6.05 (dd, J= 8.6, 6.4 Hz, 1H), 3.31-3.08 (m, 3H), 2.70-2.57 (m, 1H). 334.0   4.86 17 Method 1

0.050 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.56 (dd,J = 7.8, 1.5 Hz, 1H), 7.53-7.18 (m, 3H), 7.06 (dd, J = 7.5, 1.9 Hz, 1H),5.99 (dd, J = 8.6, 6.0 Hz, 1H), 3.35-3.22 (m, 1H), 3.20-3.08 (m, 2H),2.59 (ddt, J = 12.8, 8.8, 6.3 Hz, 1H). 318.0   4.44  18 Method 1

0.008 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.61-7.52(m, 1H), 7.52-7.20 (m, 3H), 7.08 (dd, J = 7.5, 1.9 Hz, 1H), 5.99 (dd, J= 8.6, 5.9 Hz, 1H), 3.34-3.25 (m, 1H), 3.19-3.07 (m, 2H), 2.66-2.53 (m,1H). 318.0   4.43  19 Method 10

0.015 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.38(m, 5H), 7.32-7.25 (m, 3H), 7.13-7.11 (m, 2H), 6.10-5.94 (m, 1H),5.49-5.45 (m, 1H), 4.65-4.57 (m, 2H), 3.69-3.58 (m, 1H), 3.01-2.90 (m,1H) 358.1   1.910  20 Method 11

0.024 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.36 (m,3H), 7.28-7.26 (m, 3H), 7.21-7.15 (m, 3H), 7.12-7.09 (m, 1H), 6.12-5.96(m, 1H), 5.47-5.43 (m, 1H), 4.56-4.39 (m, 2H), 3.67-3.59 (m, 1H),3.00-2.89 (m, 1H) 342.1   1.734  21 Method 12

0.100 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.40(m, 3H), 7.40-7.26 (m, 2H), 7.09-6.95 (m, 1H), 6.23-6.20 (m, 0.5H),6.08-6.06 (m, 0.5H), 5.71-5.69 (m, 1H), 3.83-3.73 (m, 1H), 2.91-2.80 (m,1H) 302.0   1.630  22 Method 12

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.41(m, 3H), 7.30-7.22 (m, 2H), 7.09-6.95 (m, 1H), 6.23-6.21 (m, 0.5H),6.09-6.07 (m, 0.5H), 5.70-5.69 (m, 1H), 3.84-3.73 (m, 1H), 2.85-2.81 (m,1H) 302.0   1.602  23 Method 13

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.42(m, 3H), 7.30-7.27 (m, 2H), 7.08-6.95 (m, 1H), 6.24-6.22 (m, 0.5H),6.10-6.08 (m, 0.5H), 5.74-5.72 (m, 1H), 3.84-3.74 (m, 1H), 2.93-2.82 (m,1H) 318.0   1.823  24 Method 14

0.020 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.40-7.38 (m,3H), 7.25-7.22 (m, 2H), 6.19-6.16 (m, 0.5H), 6.05-6.02 (m, 0.5H),5.64-5.62 (m, 1H), 3.80-3.70 (m, 1H), 2.86-2.78 (m, 1H), 1.70 (s, 9H)308.1   0.726  25 Method 15

0.032 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.38(m, 3H), 7.27-7.25 (m, 2H), 6.22-6.20 (m, 0.5H), 6.08-6.06 (m, 0.5H),5.69-5.68 (m, 1H), 3.83-3.75 (m, 1H), 2.86-2.79 (m, 1H), 1.36 (s, 9H)324.1   0.612  26 Method 16

3.2 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, J =7.2 Hz, 2H), 7.73-7.62 (m, 1H), 7.61-7.53 (m, 2H), 7.40-7.38 (m, 3H),7.22-7.20 (m, 2H), 6.04-5.88 (m, 1H), 5.49-5.46 (m, 1H), 3.67-3.54 (m,1H), 2.99-2.89 (m, 1H) 343.9   0.879  27 Method 43

0.033 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.17 (m,3H, 7.13-7.06 (m, 2H, 6.05-5.76 (m, 1H, 5.37-5.21 (m, 1H, 3.59-3.48 (m,1H, 2.96-2.74 (m, 1H, 2.73-2.52 (m, 1H, 1.28-1.15 (m, 1H, 1.01-0.85 (m,3H). 291.9   0.795  28 Method 43

0.089 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38(m, 3H), 7.27-7.24 (m, 2H), 6.15-5.95 (m, 1H), 5.53-5.48 (m, 1H),3.71-3.62 (m, 1H), 3.03-2.97 (m, 1H), 2.82-2.77 (m, 1H), 1.37-1.35 (m,1H), 1.11-1.02 (m, 3H). 292.0   0.779  29 Method 43

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.37(m, 3H), 7.27-7.22 (m, 2H), 6.12-5.95 (m, 1H), 5.52-5.48 (m, 1H),3.71-3.62 (m, 1H), 3.02-2.95 (m, 1H), 2.79-2.75 (m, 1H), 1.35-1.33 (m,1H), 1.10-1.01 (m, 3H). 291.9   0.769  30 Method 17

0.004 Single Known Stereoisomer ¹H NMR (40 MHz, CDCl₃) δ 7.42-7.39 (m,3H), 7.26-7.24 (m, 2H), 6.11 (dd, J = 1.6, 7.6 Hz, 0.5H), 5.99 (d, J =5.6 Hz, 0.5H), 5.56-5.49 (m, 1H), 3.70-3.61 (m, 1H), 3.06-2.92 (m, 1H),2.78-2.71 (m, 1H), 1.52-1.43 (m, 2H), 1.16-1.11 (m, 2H). 308.1   0.736 31 Method 18

0.010 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.35(m, 3H), 7.22-7.20 (m, 2H), 6.89 (s, 1H), 6.10 (d, J = 6.4 Hz, 0.5H),5.95 (d, J = 6.4 Hz, 0.5H), 5.55-5.52 (m, 1H), 3.56-3.48 (m, 1H),2.92-2.82 (m, 1H), 2.65-2.61 (m, 1H), 1.38-1.36 (m, 2H), 1.05-1.03 (m,2H). 306.9   0.835  32 Method 18

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.47-7.44(m, 1H), 7.36-7.22 (m, 3H), 6.75 (dd, J = 1.2, 7.6 Hz, 1H), 6.12-5.93(m, 2H), 3.80-3.65 (m, 1H), 2.94-2.81 (m, 1H), 2.80-2.76 (m, 1H),1.55-1.48 (m, 2H), 1.20-1.13 (m, 2H). 342.1   0.798  33 Method 18

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.37(m, 1H), 7.19-7.15 (m, 2H), 7.12-6.99 (m, 1H), 6.14-5.98 (m, 1H),5.88-5.84 (m, 1H), 3.77-3.71 (m, 1H), 3.00-2.90 (m, 1H), 2.79-2.75 (m,1H), 1.52-1.48 (m, 2H), 1.19-1.15 (m, 2H). 325.9   0.831  34 Method 18

0.010 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.41-7.29(m, 2H, 7.19-7.15 (m, 2H, 6.24-6.02 (m, 1H), 5.68 (s, 1H), 3.83-3.69 (m,1H), 2.94-2.76 (m, 2H), 1.38-1.30 (m, 2H), 1.22-1.08 (m, 2H). 326.2  0.961  35 Method 18

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.57-7.44(m, 1H, 7.11-7.07 (m, 2H, 6.26-6.07 (m, 1H, 6.03-5.95 (m, 1H, 3.93-3.79(m, 1H, 3.03-2.88 (m, 1H, 2.88-2.79 (m, 1H, 1.36-1.25 (m, 2H, 1.20-1.11(m, 2H). 344.1   0.973  36 Method 18

0.880 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.17(m, 1H), 7.16-7.08 (m, 1H), 6.81-6.68 (m, 1H), 6.13 (dd, J = 2.0, 7.6Hz, 0.5H), 5.99 (J = 5.2 Hz, 0.5H), 5.91-5.81 (m, 1H), 3.78-3.70 (m,1H), 3.03-2.89 (m, 1H), 2.79-2.69 (m, 1H), 1.51-1.48 (m, 2H), 1.18-1.14(m, 2H). 344.1   0.641  37 Method 18

0.006 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ  7.17-7.04(m, 2H, 6.70-6.64 (m, 1H, 6.14-5.95 (m, 1H, 5.85-5.77 (m, 1H, 3.84-3.59(m, 1H, 3.07-2.87 (m, 1H, 2.84-2.70 (m, 1H, 1.53-1.50 (m, 2H, 1.19-1.15(m, 2H). 344.1   1.001  38 Method 18

0.010 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.46-7.43(m, 1H), 7.12-7.09 (m, 1H), 6.26 (dd, J = 4.0, 8.0 Hz, 0.5H), 6.11 (d, J= 7.6 Hz, 0.5H), 6.09-6.00 (m, 1H), 3.92-3.85 (m, 1H), 2.98-2.86 (m,1H), 2.85-2.82 (m, 1H), 1.32-1.28 (m, 2H), 1.17-1.15 (m, 2H). 362.1  0.988  39 Method 19

0.006 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.32-7.25(m, 1H, 6.81-6.78 (m, 1H, 6.24-6.08 (m, 1H, 5.97-5.92 (m, 1H, 3.90-3.77(m, 1H, 2.98-2.85 (m, 2H, 1.36-1.29 (m, 2H, 1.20-1.14 (m, 2H). 362.1  1.025  40 Method 18

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.28(m, 1H), 7.25-7.17 (m, 1H), 6.97-6.91 (m, 1H), 6.21-6.19 (m, 0.5H),6.07-6.05 (m, 0.5H), 5.97-5.89 (m, 1H), 3.89-3.74 (m, 1H), 2.95-2.80 (m,2H), 1.34-1.25 (m, 2H), 1.16-1.13 (m, 2H). 344.1   0.641  41 Method 19

0.140 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.30(m, 3H), 7.27-7.22 (m, 2H), 5.60-5.55 (m, 1H), 3.27-3.19 (m, 1H),3.13-3.06 (m, 1H), 2.85-2.72 (m, 1H), 2.76-2.60 (m, 1H), 1.30-1.24 (m,2H), 1.16-1.11 (m, 2H). 291.1   1.453  42 Method 18

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 6.89-6.77(m, 3H), 6.14-5.95 (m, 1H), 5.53-5.48 (m, 1H), 3.76-3.59 (m, 1H),3.04-2.91 (m, 1H), 2.78-2.74 (m, 1H), 1.53-1.47 (m, 2H), 1.17-1.15 (m,2H). 344.1   0.972  43 Method 18

0.039 Single Unknown Stereoisomer ¹H NMR (40 MHz, CDCl₃) δ 7.41-7.31 (m,2H), 7.26-7.24 (m, 1H), 7.16-7.10 (m, 1H), 6.14-5.95 (m, 1H), 5.56-5.45(m, 1H), 3.78-3.57 (m, 1H), 3.06-2.87 (m, 1H), 2.80-2.70 (m, 1H),1.52-1.39 (m, 2H), 1.22-1.07 (m, 2H). 341.9   0.918  44 Method 18

0.021 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.18(m, 1H), 7.14-7.12 (m, 1H), 7.11-7.05 (m, 1H), 6.15-5.97 (m, 1H),5.55-5.45 (m, 1H), 3.73-3 59 (m, 1H), 3.03-2.86 (m, 1H), 2.81-2.70 (m,1H), 1.52-1.46 (m, 2H), 1.20-1.13 (m, 2H). 343.9   0.902  45 Method 18

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.40-7.32(m, 2H), 6.78-6.75 (m, 1H), 6.23-6.06 (m, 2H), 3.92-3.81 (m, 1H),2.92-2.78 (m, 2H), 1.36-1.32 (m, 2H), 1.21-1.17 (m, 2H). 360.0   0.914 46 Method 19

0.020 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.58-7.53(m, 1H), 7.23 (t, J = 8.0 Hz, 1H), 7.13-7.08 (m, 1H), 6.24-6.07 (m, 1H),5.96-5.91 (m, 1H), 3.90-3.76 (m, 1H), 2.95-2.83 (m, 2H), 1.36-1.30 (m,2H), 1.20-1.14 (m, 2H). 359.9   0.923  47 Method 18

0.067 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) 7.38-7.31 (m,1H), 7.17-7.04 (m, 1H), 6.98-6.94 (m, 1H), 6.17-5.96 (m, 1H), 5.81-5.76(m, 1H), 3.77-3.69 (m, 1H), 3.00-2.89 (m, 1H), 2.83-2.73 (m, 1H),1.55-1.45 (m, 2H), 1.23-1.12 (m, 2H). 360.1   0.995  48 Method 18

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.48-7.43(m, 1H, 7.15-7.04 (m, 3H, 6.25-6.02 (m, 1H, 5.77-5.65 (m, 1H, 3.82-3.75(m, 1H, 2.91-2.80 (m, 2H, 1.38-1.25 (m, 2H, 1.21-1.07 (m, 2H). 326.1  1.005  49 Method 20

0.012 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.25-7.22 (m, 2H), 6.10-5.94 (m, 1H), 5.52-5.47 (m, 1H), 3.78-3.72(m, 1H), 3.71-3.58 (m, 1H), 3.46-3.26 (m, 1H), 3.02-2.92 (m, 2H),2.91-2.80 (m, 1H), 2.78-2.65 (m, 1H). 342.1   0.997  50 Method 20

0.017 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.41(m, 3H), 7.27-7.23 (m, 2H), 6.13-6.11 (m, 0.5H), 6.00-5.97 (m, 0.5H),5.55-5.52 (m, 1H), 4.00-3.96 (m, 1H), 3.72-3.65 (m, 1H), 3.26-3.22 (m,2H), 3.07-2.90 (m, 3H). 358.1   1.064  51 Method 21

0.140 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.24(m, 1H), 7.22-6.96 (m, 4H), 6.24 (dd, J = 2.4, 7.2 Hz, 0.5H), 6.10 (d, J= 4.8 Hz, 0.5H), 5.98-5.90 (m, 1H), 3.88-3.78 (m, 1H, 2.94-2.86 (m, 1H).320.1   1.671  52 Method 21

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.48-7.45(m, 1H), 7.24-6.96 (m, 4H), 6.23 (dd, J = 3.2, 7.2 Hz, 0.5H), 6.10 (d, J= 7.6 Hz, 0.5H), 5.98-5.90 (m, 1H, 3.87-3.78 (m, 1H, 2.95-2.84 (m, 1H).320.1   1.651  53 Method 21

0.013 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.49-7.46(m, 1H), 7.26-7.17 (m, 3H), 7.97 (t, J = 52.4 Hz, 1H), 6.24 (dd, J =2.8, 8.0 Hz, 0.5H), 6.10 (d, J = 2.4 Hz, 0.5H), 6.00-5.94 (m, 1H,3.88-3.79 (m, 1H, 2.96-2.88 (m, 1H). 336.0   1.847  54 Method 21

0.017 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.42 (m,1H), 7.22-6.95 (m, 4H), 6.21-6.05 (m, 1H), 5.72-5.70 (m, 1H), 3.82-3.70(m, 1H), 2.91-2.80 (m, 1H). 320.1   0.955  55 Method 21

0.016 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.34-7.31 (m,2H), 7.19-6.94 (m, 3H), 6.22 (dd, J = 2.4, 7.2 Hz, 0.5H), 6.07 (d, J =7.2H, 0.5H), 5.71-5.70 (m, 1H), 3.82-3.72 (m, 1H), 2.91-2.81 (m, 1H).320.1   0.979  56 Method 21

0.055 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.34(m, 2H), 7.20-7.16 (m, 2H), 6.96 (t, J = 52.4 Hz, 1H), 6.24 (dd, J =2.0, 7.2 Hz, 0.5H), 6.09 (d, J = 2.4 Hz, 0.5H), 5.80-5.75 (m, 1H),3.84-3.76 (m, 1H), 2.94-2.87 (m, 1H). 336.1   1.051  57 Method 21

0.009 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.36(m, 3H), 7.20-7.18 (m, 2H), 7.09 (d, J = 2.4 Hz, 1H), 6.26 (t, J = 53.2Hz, 1H), 6.13 (d, J = 4.4 Hz, 0.5H), 5.99 (d, J = 6.8 Hz, 0.5H),5.61-5.55 (m, 1H), 3.60-3.50 (m, 1H), 2.97-2.87 (m, 1H). 316.8   0.863 58 Method 21

0.034 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.48-7.38(m, 1H), 6.99 (t, J = 8.4 Hz, 2H), 6.43 (t, J = 52.8 Hz, 1H), 6.25-6.04(m, 1H), 6.00-5.90 (m, 1H), 3.91-3.74 (m, 1H), 3.18-3.01 (m, 1H). 354.1  1.033  59 Method 21

0.007 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.47-7.44(m, 1H), 7.11-6.83 (m, 2H), 6.28-6.13 (m, 1H), 6.07-6.03 (m, 1H),3.94-3.87 (m, 1H), 3.06-2.95 (m, 1H). 372.0   1.841  60 Method 21

0.007 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.33-7.26(m, 1H), 6.99 (t, J = 52.4 Hz, 1H), 6.86-6.78 (m, 1H), 6.27-6.11 (m,1H), 6.02-5.97 (m, 1H), 3.92-3.79 (m, 1H), 3.01-2.89 (m, 1H). 372.1  1.081  61 Method 43

0.039 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.33(m, 2H), 7.33-7.27 (m, 1H), 7.13-7.11 (m, 1H), 6.68-6.27 (m, 1H),6.26-5.98 (m, 1H), 5.62-5.50 (m, 1H), 3.85-3.56 (m, 1H), 3.12-2.86 (m,1H). 352.0   1.962  62 Method 24

0.266 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.85-7.77(m, 1H), 7.68-7.63 (m, 1H), 7.57-7.52 (m, 1H), 6.95 (d, J = 8.0 Hz, 1H),6.45 (t, J = 52.8 Hz, 1H), 6.20-6.03 (m, 2H), 3.96-3.81 (m, 1H),3.02-2.92 (m, 1H). 343.1   0.919  63 Method 23

0.034 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.19(m, 1H), 7.12-7.11 (m, 1H), 7.05-7.04 (m, 1H), 6.44 (t, J = 53.2 Hz,1H), 6.20-5.99 (m, 1H), 5.58-5.57 (m, 1H), 3.81-3.62 (m, 1H), 3.09-2.93(m, 1H). 354.1   1.025  64 Method 23

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.40-7.35(m, 2H), 7.00 (t, J = 52.4 Hz, 1H), 6.77-6.75 (m, 1H), 6.26-6.10 (m,2H), 3.95-3.81 (m, 1H), 2.92-2.81 (m, 1H). 371.4   0.957  65 Method 23

0.018 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.59-7.54(m, 1H), 7.24 (t, J = 8.0 Hz, 1H), 7.13-7.08 (m, 1H), 6.99 (t, J = 52.4Hz, 1H), 6.27-6.10 (m, 1H), 6.01-5.95 (m, 1H), 3.90-3.80 (m, 1H),2.99-2.85 (m, 1H). 369.9   0.953  66 Method 23

0.069 ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.35 (m, 1H), 7.12 (t, J = 9.2 Hz,1H), 6.97-6.93 (m, 1H), 6.45 (t, J = 52.8 Hz, 1H), 6.15-6.02 (m, 1H),5.87-5.80 (m, 1H), 3.85-3.65 (m, 1H), 3.07-2.94 (m, 1H). 370.1   1.051 67 Method 21

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.06(m, 2H), 6.71-6.64 (m, 1H), 6.44 (t, J = 52.4 Hz, 1H), 6.19-6.00 (m,1H), 5.95-5.88 (m, 1H), 3.82-3.65 (m, 1H), 3.05-2.95 (m, 1H). 354.1  1.059  68 Method 21

0.006 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.21(m, 1H), 7.13-7.11 (m, 1H), 6.71-6.69 (m, 1H), 6.43 (t, J = 53.2 Hz,1H), 6.14 (d, J = 5.6 Hz, 0.5H), 6.00 (d, J = 5.2 Hz, 0.5H), 5.98-5.92(m, 1H), 3.80-3.70 (m, 1H), 3.05-2.94 (m, 1H). 354.0   0.839  69 Method23

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 6.92-6.85(m, 1H), 6.84-6.77 (m, 2H), 6.44 (t, J = 53.2 Hz, 1H), 6.17-6.01 (m,1H), 5.59-5.57 (m, 1H), 3.77-3.69 (m, 1H), 3.07-2.97 (m, 1H). 354.1  1.030  70 Method 21

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.46-7.44(m, 1H), 7.15-6.83 (m, 4H), 6.23-6.07 (m, 1H), 5.75-5.74 (m, 1H),3.83-3.73 (m, 1H), 2.93-2.82 (m, 1H). 336.1   1.027  71 Method 25

0.090 ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m, 3H), 7.26-7.21 (m, 2H),6.14-5.96 (m, 1H), 5.61-5.55 (m, 1H), 5.54-5.48 (m, 1H), 3.72-3.61 (m,1H), 3.05-2.94 (m, 1H). 284.1   0.701  72 Method 25

0.023 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40(m, 3H), 7.26-7.23 (m, 2H), 6.14-5.98 (m, 1H), 5.59-5.53 (m, 1H), 5.49(s, 1H), 5.37 (s, 1H), 3.74-3.63 (m, 1H), 3.07-2.96 (m, 1H). 300.1  0.932  73 Method 25

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38(m, 3H), 7.26-7.22 (m, 2H), 6.13-5.96 (m, 1H), 5.73-5.62 (m, 1H),5.61-5.48 (m, 2H), 3.74-3.59 (m, 1H), 3.06-2.93 (m, 1H). 284.1   0.692 74 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.23(m, 1H), 7.22-7.13 (m, 3H), 6.21 (d, J = 1.6 Hz, 0.5H), 6.07 (d, J = 1.6Hz, 0.5H), 5.80-5.78 (m, 1H), 5.77-5.75 (m, 1H), 5.74-5.64 (m, 1H),3.87-3.74 (m, 1H), 2.93-2.81 (m, 1H). 302.1   0.828  75 Method 25

0.140 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.43(m, 1H), 7.34-6.98 (m, 3H), 6.22-6.06 (m, 1H), 6.06-5.91 (m, 1H),5.87-5.77 (m, 1H), 5.75-5.64 (m, 1H), 3.88-3.73 (m, 1H), 2.93-2.80 (m,1H). 301.9   0.828  76 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.33(m, 1H), 7.22-7.20 (m, 1H), 6.96-6.94 (m, 1H), 6.23-6.07 (m, 1H),5.96-5.94 (m, 1H), 5.84-5.78 (m, 1H), 5.74-5.66 (m, 1H), 3.87-3.78 (m,1H), 2.95-2.85 (m, 1H).  0.712 320.1   77 Method 25

0.280 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.35-7.33(m, 1H), 7.21-7.20 (m, 1H), 6.96-6.94 (m, 1H), 6.23-6.07 (m, 1H),5.96-5.94 (m, 1H), 5.84-5.78 (m, 1H), 5.74-5.66 (m, 1H), 3.88-3.78 (m,1H), 2.95-2.84 (m, 1H). 320.1   0.720  78 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.26-7.19(m, 2H), 7.18-6.91 (m, 1H), 6.20-6.06 (m, 1H), 5.89-5.65 (m, 3H),3.87-3.74 (m, 1H), 2.93-2.82 (m, 1H). 320.1   0.853  79 Method 25

0.190 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.26-7.19(m, 2H, 6.97-6.91 (m, 1H, 6.22-6.06 (m, 1H, 5.89-5.67 (m, 3H, 3.88-3.74(m, 1H, 2.93-2.82 (m, 1H). 320.1   0.869  80 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ  7.43-7.39(m, 1H, 7.00-6.95 (m, 2H, 6.03-5.87 (m, 1H, 5.63-5.61 (m, 1H, 5.60-5.49(m, 2H, 3.85-3.75 (m, 1H, 3.14-3.02 (m, 1H). 320.1   0.585  81 Method 25

0.290 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.52-7.46(m, 1H, 7.10-7.05 (m, 2H, 6.23-6.08 (m, 1H, 6.00-5.98 (m, 1H, 5.80-5.75(m, 1H, 5.74-5.65 (m, 1H, 3.89-3.82 (m, 1H, 3.01-2.99 (m, 1H). 320.1  0.836  82 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.38(m, 1H), 7.10-7.09 (m, 2H), 6.97-6.95 (m, 1H), 6.12-5.96 (m, 1H),5.72-5.60 (m, 2H), 5.58-5.51 (m, 1H), 3.73-3.63 (m, 1H), 3.03-2.92 (m,1H). 302.1   0.837  83 Method 25

0.130 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.37(m, 1H), 7.17-7.00 (m, 2H), 6.95 (d, J = 9.2 Hz, 1H), 6.12-5.95 (m, 1H),5.70-5.68 (m, 1H), 5.63-5.52 (m, 2H), 3.73-3.60 (m, 1H), 3.02-2.92 (m,1H). 302.1   0.857  84 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.01-6.98(m, 1H), 6.95-6.91 (m, 2H), 6.20-6.06 (m, 1H), 5.86-5.65 (m, 3H),3.82-3.74 (m, 1H), 2.91-2.81 (m, 1H). 320.1   0.617  85 Method 25

0.180 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.00-6.98(m, 1H), 6.95-6.91 (m, 2H), 6.20-6.18 (m, 1H), 5.87-5.67 (m, 3H),3.80-3.72 (m, 1H), 2.91-2.80 (m, 1H). 320.1   0.625  86 Method 25

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.54-7.52(m, 1H), 7.41-7.33 (m, 2H), 6.91-6.89 (m, 1H), 6.21-6.18 (m, 0.5H),6.08-6.05 (m, 1.5H), 5.87-5.69 (m, 2H), 3.90-3.77 (m, 1H), 2.85-2.74 (m,1H). 318.0   1.536  87 Method 25

0.100 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.54-7.52(m, 1H), 7.41-7.30 (m, 2H), 6.91-6.89 (m, 1H), 6.21-6.18 (m, 0.5H),6.08-6.05 (m, 1.5H), 5.86-5.68 (m, 2H), 3.91-3.79 (m, 1H), 2.84-2.74 (m,1H). 318.1   0.929  88 Method 26

0.032 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.51-7.35(m, 4H), 7.33-7.15 (m, 1H), 6.17-6.00 (m, 1H), 5.65-5.57 (m, 1H),4.52-4.39 (m, 2H), 3.79-3.64 (m, 1H), 3.10-2.99 (m, 1H). 307.1   0.956 89 Method 26

0.010 Single Unknown Stereoisomer ¹H NMR (400 MHz, DMSO-d6) δ 7.43-7.36(m, 3H), 7.25-7.21 (m, 2H), 6.26-6.09 (m, 1H), 5.65-5.62 (m, 1H),4.29-4.19 (m, 2H), 3.73-3.64 (m, 1H), 2.69-2.56 (m, 1H). 274.9   0.825 90 Method 26

0.008 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38(m, 3H, 7.23-7.21 (m, 2H), 7.11 (d, J = 2.8 Hz, 1H), 6.14 (d, J = 6.8Hz, 0.5H), 5.99 (d, J = 6.4 Hz, 0.5H), 5.70-5.55 (m, 1H), 4.27-4.17 (m,2H), 3.65-3.50 (m, 1H), 2.97-2.87 (m, 1H). 306.1   0.787  91 Method 26

0.150 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.36(m, 3H), 7.21-7.19 (m, 2H), 7.07 (s, 1H), 6.13 (d, J = 6.8 Hz, 0.5H),5.98 (d, J = 6.8 Hz, 0.5H), 5.55-5.50 (m, 1H), 4.10 (d, J = 15.6 Hz,1H), 3.81 (d, J = 15.6 Hz, 1H), 3.61-3.50 (m, 1H), 2.93-2.83 (m, 1H).290.1   0.711  92 Method 26

0.019 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.35(m, 3H), 7.27-7.21 (m, 2H), 7.08 (s, 1H), 6.13 (d, J = 6.8 Hz, 0.5H),5.99 (d, J = 6.4 Hz, 0.5H), 5.55-5.50 (m, 1H), 4.09 (d, J = 15.6 Hz,1H), 3.84 (d, J = 16.0 Hz, 1H), 3.62-3.49 (m, 1H), 2.93-2.83 (m, 1H).290.1   0.718  93 Method 24

0.092 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.46 (dd, J= 1.2, 8.4 Hz, 1H), 7.36-7.30 (m, 1H), 7.29-7.27 (m, 0.5H), 7.25-7.23(m, 0.5H), 6.75 (dd, J = 1.2, 7.6 Hz, 1H), 6.12 (d, J = 5.6 Hz, 0.5H),6.05-5.96 (m, 1.5H), 4.37 (d, J = 15.6 Hz, 1H), 4.14 (d, J = 15.6 Hz,1H), 3.83-3.67 (m, 1H), 2.98-2.84 (m, 1H). 325.1   0.956  94 Method 26

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.46 (dd, J= 1.2, 8.8 Hz, 1H), 7.37-7.27 (m, 2H), 6.77 (d, J = 9.2 Hz, 1H), 6.11(d, J = 5.2 Hz, 0.5H), 6.06-5.95 (m, 1.5H), 4.40 (d, J = 15.6 Hz, 1H),4.10 (d, J = 15.6 Hz, 1H, 3.83-3.68 (m, 1H, 2.99-2.84 (m, 1H). 325.1  0.949  95 Method 26

0.190 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.38(m, 1H), 7.18-7.13 (m, 2H), 7.10-6.99 (m, 1H), 6.15-6.00 (m, 1H),5.90-5.88 (m, 1H), 4.34 (d, J = 15.6 Hz, 1H), 4.14 (d, J = 15.6 Hz, 1H),3.79-3.67 (m, 1H), 3.02-2.91 (m, 1H). 308.9   0.775  96 Method 26

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.39(m, 1H), 7.20-7.14 (m, 2H), 7.01-6.98 (m, 1H), 6.15-6.00 (m, 1H),5.99-5.89 (m, 1H), 4.40 (d, J = 15.6 Hz, 1H), 4.10 (d, J = 15.6 Hz, 1H),3.79-3.67 (m, 1H), 3.03-2.93 (m, 1H). 308.9   0.762  97 Method 26

0.190 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.35(m, 1H), 7.16-6.89 (m, 3H), 6.18-5.95 (m, 1H), 5.68-5.58 (m, 1H),4.31-4.10 (m, 2H), 3.78-3.68 (m, 1H), 3.00-2.88 (m, 1H). 309.1   0.914 98 Method 26

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.37(m, 1H), 7.17-6.92 (m, 3H), 6.18-5.96 (m, 1H), 5.58-5.54 (m, 1H),4.44-4.03 (m, 2H), 3.81-3.62 (m, 1H), 3.04-2.89 (m, 1H). 309.1   0.894 99 Method 26

0.530 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.25(m, 2H), 7.12-7.08 (m, 2H), 6.14-5.98 (m, 1H), 5.62-5.58 (m, 1H),4.37-4.07 (m, 2H), 3.74-3.68 (m, 1H), 3.00-2.89 (m, 1H). 309.1   0.907100 Method 26

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22(m, 2H), 7.14-7.10 (m, 2H), 6.19-5.96 (m, 1H), 5.70-5.55 (m, 1H),4.39-4.06 (m, 2H), 3.79-3.61 (m, 1H), 3.02-2.92 (m, 1H). 309.1   0.899101 Method 26

0.047 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.53 (d, J =8.4 Hz, 1H), 7.41-7.35 (m, 1H), 7.34-7.28 (m, 1H), 6.89 (d, J = 7.6 Hz,1H), 6.21 (d, J = 5.2 Hz, 0.5H), 6.12-6.05 (m, 1.5H, 3.90-3.76 (m, 1H),3.38-3.31 (m, 2H), 2.87-2.72 (m, 1H). 325.0   0.741 102 Method 26

0.018 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.30-7.25 (m, 2H), 6.16-5.99 (m, 1H), 5.63-5.54 (m, 1H), 4.41-4.31(m, 1H), 4.15-4.06 (m, 1H), 3.72-3.66 (m, 1H), 3.08-2.95 (m, 1H). 291.1  0.847 103 Method 27

0.150 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m,3H), 7.27-7.21 (m, 2H), 6.14-6.11 (m, 0.5H), 5.99-5.97 (m, 0.5H),5.59-5.54 (m, 1H), 3.74-3.62 (m, 1H), 3.03-2.92 (m, 1H), 1.79-1.77 (m,6H). 340.9   0.796 104 Method 27

0.014 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40(m, 3H), 7.27-7.22 (m, 2H), 6.17-6.00 (m, 1H), 5.64-5.61 (m, 1H),3.76-3.66 (m, 1H), 3.08-2.97 (m, 1H), 1.89-1.87 (m, 6H). 335.1   1.794105 Method 26

0.046 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.51-7.34 (m,3H), 7.27-7.26 (m, 2H), 6.18-5.91 (m, 1H), 5.51-5.50 (m, 1H), 3.79-3.52(m, 1H), 3.08-3.05 (m, 3H), 3.02-2.90 (m, 1H). 266.1   1.218 &  1.256106 Method 26

0.022 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.35(m, 3H), 7.30-7.27 (m, 2H), 6.16-5.95 (m, 1H), 5.53-5.46 (m, 1H),3.75-3.63 (m, 1H), 3.28-3.20 (m, 3H), 3.05-2.95 (m, 1H). 282.1   1.471107 Method 26

0.034 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.35 (m,3H), 7.26-7.24 (m, 2H), 6.12-5.95 (m, 1H), 5.53-5.48 (m, 1H), 3.73-3.58(m, 1H), 3.30-3.22 (m, 2H), 3.02-2.92 (m, 1H), 1.33 (t, J = 7.6 Hz, 3H).280.1   0.756 108 Method 26

0.011 Single Unknown Stereoisomer ¹H NMR (40 MHz, CDCl₃) δ 7.44-7.40 (m,3H), 7.26-7.24 (m, 2H), 6.14-5.97 (m, 1H), 5.56-5.51 (m, 1H), 3.75-3.60(m, 1H), 3.43-3.36 (m, 2H), 3.06-2.95 (m, 1H), 1.39 (t, J = 7.6 Hz, 3H).295.9   0.799 109 Method 26

0.019 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.28-7.25 (m,3H), 7.16-7.09 (m, 2H), 6.00-5.84 (m, 1H), 5.41-5.37 (m, 1H), 3.58-3.46(m, 1H), 3.41-3.21 (m, 1H), 2.96-2.71 (m, 1H), 1.23-1.09 (m, 6H). 293.9  0.785 110 Method 26

0.014 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.47-7.30(m, 3H), 7.28-7.14 (m, 2H), 6.22-5.89 (m, 1H), 5.59-5.53 (m, 1H),3.75-3.58 (m, 1H), 3.57-3.45 (m, 1H), 3.08-2.90 (m, 1H), 1.40-1.25 (m,6H). 309.9   0.826 111 Method 26

0.044 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.38-7.24 (m,3H), 7.19-7.02 (m, 2H), 5.99-5.85 (m, 1H), 5.41-5.35 (m, 1H), 3.61-3.48(m, 1H), 3.18-2.83 (m, 3H), 1.05-0.98 (m, 1H), 0.60-0.45 (m, 2H),0.25-0.16 (m, 2H). 305.9   0.811 112 Method 26

0.060 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.32(m, 3H), 7.27-7.16 (m, 2H), 6.14-5.98 (m, 1H), 5.57-5.53 (m, 1H),3.82-3.58 (m, 1H), 3.35-3.23 (m, 2H), 3.12-2.95 (m, 1H), 1.27-1.13 (m,1H), 0.69-0.48 (m, 2H), 0.31-0.11 (m, 2H). 321.9   0.831 113 Method 26

0.028 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.46-7.39 (m,3H), 7.27-7.22 (m, 2H), 6.15-5.97 (m, 1H), 5.55-5.50 (m, 1H), 4.20-4.09(m, 1H), 4.04-3.95 (m, 1H), 3.76-3.61 (m, 1H), 3.06-2.93 (m, 1H). 333.9  0.837 114 Method 26

0.071 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.38(m, 3H), 7.25-7.18 (m, 2H), 6.19-5.97 (m, 1H), 5.63-5.53 (m, 1H),4.26-4.19 (m, 2H), 3.75-3.63 (m, 1H), 3.07-3.06 (m, 1H). 350.1   0.674115 Method 26

0.031 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.48-7.40 (m,3H), 7.27-7.22 (m, 2H), 6.16-5.96 (m, 1H), 5.57-5.51 (m, 1H), 5.01-4.85(m, 2H), 3.70-3.68 (m, 3H), 3.69-3.55 (m, 1H), 3.03-2.82 (m, 1H). 295.9  0.761 116 Method 26

0.170 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.52-7.40(m, 3H), 7.27-7.19 (m, 2H), 6.15-5.99 (m, 1H), 5.58-5.55 (m, 1H),4.86-4.77 (m, 2H), 3.79-3.61 (m, 4H), 3.06-2.94 (m, 1H). 312.1   1.580117 Method 16

0.012 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.38 (m,3H), 7.29-7.25 (m, 2H), 6.21-6.19 (m, 0.5H), 6.07-6.04 (m, 0.5H),5.69-5.65 (m, 1H), 3.87-3.72 (m, 2H), 2.90-2.82 (m, 1H), 2.45-2.37 (m,1H), 2.25-2.10 (m, 1H). 328.1   1.571 &  1.619 118 Method 28

0.004 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.39 (m,3H), 7.29-7.25 (m, 2H), 6.22-6.06 (m, 1H), 5.75-5.66 (m, 1H), 3.90-3.22(m, 2H), 2.91-2.84 (m, 1H), 2.50-2.40 (m, 1H), 2.38-2.25 (m, 1H) s.344.1   1.727 &  1.782 119 Method 28

0.007 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.41(m, 1H), 7.27-7.11 (m, 3H), 6.26-6.06 (m, 1H), 5.96-5.87 (m, 1H),3.92-3.74 (m, 2H), 2.96-2.80 (m, 1H), 2.46-2.41 (m, 1H), 2.30-2.27 (m,1H). 362.1   1.010 120 Method 28

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, J= 8.0 Hz, 1H), 7.38-7.28 (m, 2H), 6.79-6.71 (m, 1H), 6.16-6.10 (m,0.5H), 6.08-6.01 (m, 1H), 6.00-5.96 (m, 0.5H), 3.80-3.68 (m, 1H),3.58-3.47 (m, 1H), 2.98-2.87 (m, 1H), 2.65-2.57 (m, 1H), 2.22-2.14 (m,1H). 378.1   1.061 121 Method 28

<0.005 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22 (m,1H), 7.15-7.10 (m, 1H), 6.77-6.70 (m, 1H), 6.16-6.00 (m, 1H), 5.95-5.85(m, 1H), 3.80-3.68 (m, 1H), 3.52-3.47 (m, 1H), 3.05-2.92 (m, 1H),2.70-2.52 (m, 1H), 2.20-2.10 (m, 1H). 380.0   1.823 122 Method 28

0.012 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.18-7.09(m, 2H), 6.75-6.68 (m, 1H), 6.15-5.99 (m, 1H), 5.90-5.85 (m, 1H),3.79-3.68 (m, 1H), 3.53-3.47 (m, 1H), 3.03-2.92 (m, 1H), 2.65-2.55 (m,1H), 2.25-2.15 (m, 1H). 380.1   1.024 123 Method 28

<0.005 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.38 (m,1H), 6.99-6.94 (m, 2H), 6.20-6.03 (m, 1H), 5.91-5.87 (m, 1H), 3.84-3.76(m, 1H), 3.49-3.43 (m, 1H), 3.15-3.00 (m, 1H), 2.70-2.53 (m, 1H),2.14-2.08 (m, 1H). 380.1   1.004 124 Method 28

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.41(m, 1H), 7.26-7.10 (m, 3H), 6.26-6.06 (m, 1H), 5.95-5.88 (m, 1H),3.95-3.72 (m, 2H), 2.99-2.77 (m, 1H), 2.49-2.36 (m, 1H), 2.34-2.22 (m,1H). 362.1   1.009 125 Method 28

<0.005 Single Unknown Stereoisomer ¹H NMR (40 MHz, CDCl₃) δ 7.47 (d, J =7.6 Hz, 1H), 7.38-7.28 (m, 2H), 6.75 (d, J = 7.6 Hz, 1H), 6.13 (d, J =6.8 Hz, 0.5H), 6.07-6.01 (m, 1H), 5.99 (d, J = 7.2 Hz, 0.5H), 3.84-3.67(m, 1H), 3.56-3.45 (m, 1H), 3.00-2.85 (m, 1H), 2.69-2.49 (m, 1H),2.23-2.09 (m, 1H). 378.1   1.062 126 Method 28

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.05(m, 2H), 6.75-6.68 (m, 1H), 6.16-6.00 (m, 1H), 5.95-5.85 (m, 1H),3.80-3.68 (m, 1H), 3.60-3.47 (m, 1H), 3.03-2.98 (m, 1H), 2.70-2.52 (m,1H), 2.20-2.15 (m, 1H). 380.0   1.808 127 Method 28

0.006 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.05(m, 2H), 6.75-6.68 (m, 1H), 6.16-5.95 (m, 1H), 5.90-5.80 (m, 1H),3.82-3.65 (m, 1H), 3.62-3.40 (m, 1H), 3.07-2.92 (m, 1H), 2.62-2.55 (m,1H), 2.20-2.12 (m, 1H). 380.1   1.808 128 Method 28

0.010 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22(m, 1H), 7.20-7.08 (m, 1H), 6.77-6.72 (m, 1H), 6.16-6.00 (m, 1H),5.98-5.85 (m, 1H), 3.80-3.72 (m, 1H), 3.52-3.44 (m, 1H), 3.05-2.88 (m,1H), 2.75-2.55 (m, 1H), 2.17-2.13 (m, 1H). 380.0   1.826 129 Method 28

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22(m, 1H), 7.20-7.10 (m, 1H), 6.77-6.72 (m, 1H), 6.16-6.00 (m, 1H),5.95-5.85 (m, 1H), 3.83-3.73 (m, 1H), 3.55-3.46 (m, 1H), 3.03-2.95 (m,1H), 2.59-2.54 (m, 1H), 2.16-2.12 (m, 1H). 380.0   1.830 130 Method 28

0.003 ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.37 (m, 3H), 7.29-7.27 (m, 2H),6.22-6.06 (m, 1H), 5.71-5.66 (m, 1H), 3.89-3.76 (m, 2H), 2.91-2.83 (m,1H), 2.42-2.38 (m, 1H), 2.29-2.25 (m, 1H). 344.0   1.771 131 Method 28

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.38(m, 3H), 7.30-7.27 (m, 2H), 6.22-6.06 (m, 1H), 5.71-5.67 (m, 1H),3.88-3.74 (m, 2H), 2.90-2.82 (m, 1H), 2.42-2.38 (m, 1H), 2.30-2.26 (m,1H). 344.1   1.770 min 132 Method 29

0.011 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m,3H), 7.27-7.24 (m, 2H), 6.17-6.13 (m, 0.5H), 6.03-6.00 (m, 0.5H),5.58-5.55 (m, 1H), 3.75-3.65 (m, 1H), 3.07-2.96 (m, 1H). 319.9   0.862133 Method 29

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.41(m, 1H), 7.21-7.14 (m, 2H), 6.99-6.95 (m, 1H), 6.18 (d, J = 7.2 Hz,0.5H), 6.05 (d, J = 7.2 Hz, 0.5H), 5.96-5.93 (m, 1H), 3.84-3.70 (m, 1H),3.08-2.92 (m, 1H). 353.8   0.929 134 Method 29

0.003 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, J =7.6 Hz, 1H), 7.40-7.27 (m, 2H), 6.70 (d, J = 7.6 Hz, 1H), 6.17 (d, J =7.2 Hz, 0.5H), 6.13-6.07 (m, 1H), 6.02 (d, J = 5.2 Hz, 0.5H), 3.87-3.71(m, 1H), 3.03-2.92 (m, 1H). 370.0   0.900 135 Method 29

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.48-7.44(m, 1H), 7.17-7.06 (m, 3H), 6.26-6.10 (m, 1H), 5.79-5.76 (m, 1H),3.86-3.75 (m, 1H), 2.96-2.85 (m, 1H). 354.1   1.135 136 Method 29

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22(m, 1H), 7.20-7.14 (m, 1H), 6.74-6.70 (m, 1H), 6.20-6.04 (m, 1H),5.96-5.94 (m, 1H), 3.86-3.72 (m, 1H), 3.09-2.98 (m, 1H). 372.0   2.022137 Method 29

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.42(m, 2H), 6.19-6.05 (m, 1H), 5.64-5.60 (m, 1H), 3.79-3.65 (m, 1H),3.12-3.01 (m, 1H). 336.1   1.123 138 Method 29

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.17-7.12(m, 2H), 6.70-6.67 (m, 1H), 6.19-6.03 (m, 1H), 5.90-5.89 (m, 1H),3.84-3.70 (m, 1H), 3.08-2.97 (m, 1H). 372.1   1.134 139 Method 29

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.55-7.51(m, 1H), 7.13-7.08 (m, 2H), 6.29-6.13 (m, 1H), 6.08-6.06 (m, 1H),3.95-3.83 (m, 1H), 3.04-2.92 (m, 1H). 372.1   1.124 140 Method 29

0.540 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.24(m, 1H), 7.23-7.14 (m, 1H), 6.75-6.71 (m, 1H), 6.21-6.05 (m, 1H),6.02-5.95 (m, 1H), 3.88-3.75 (m, 1H), 3.08-2.97 (m, 1H). 373.2   2.031141 Method 30

<0.005 Single Unknown Stereoisomer ¹H NMR (40 MHz, CDCl₃) δ 7.45-7.37(m, 1H), 7.15-7.09 (m, 1H), 7.08-7.04 (m, 1H), 7.02-6.95 (m, 1H),6.16-5.98 (m, 1H), 5.58-5.51 (m, 1H), 5.24-5.04 (m, 1H), 3.77-3.62 (m,1H), 3.23-3.12 (m, 1H), 3.08-2.95 (m, 1H), 1.90-1.75 (m, 2H). 344.1  0.974 142 Method 30

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.37(m, 1H), 7.15-7.09 (m, 1H), 7.08-7.04 (m, 1H), 7.02-6.96 (m, 1H),6.14-5.98 (m, 1H), 5.59-5.49 (m, 1H), 5.22-5.06 (m, 1H), 3.80-3.64 (m,1H), 3.24-3.10 (m, 1H), 3.08-2.94 (m, 1H), 1.93-1.75 (m, 2H). 344.1  0.974 143 Method 29

0.031 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.21(m, 1H), 7.20-7.10 (m, 1H), 7.06-7.03 (m, 1H), 6.14 (d, J = 8.4 Hz,0.5H), 6.00 (d, J = 8.0 Hz, 0.5H), 5.53-5.21 (m, 1H), 5.15-5.10 (m,0.5H), 5.06-3.02 (m, 0.5H), 3.73-3.64 (m, 1H), 3.16-3.12 (m, 1H),3.03-2.92 (m, 1H), 1.89-1.80 (m, 2H). 362.1   0.972 144 Method 29

0.009 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.22(m, 1H), 7.16-7.10 (m, 1H), 7.07-7.03 (m, 1H), 6.13 (d, J = 6.8 Hz,0.5H), 6.00 (d, J = 8.4 Hz, 0.5H), 5.54-5.21 (m, 1H), 5.15-5.10 (m,0.5H), 5.06-5.02 (m, 0.5H), 3.73-3.64 (m, 1H), 3.19-3.12 (m, 1H),3.04-2.93 (m, 1H), 1.88-1.78 (m, 2H). 362.1   0.792 145 Method 20

0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.47-7.41(m, 3H), 7.31-7.29 (m, 1H), 5.71-5.69 (m, 1H), 5.22-5.05 (m, 1H),3.83-3.76 (m, 1H), 3.41-3.33 (m, 1H), 2.95-2.86 (m, 1H), 1.90-1.74 (m,2H). 326.1   0.670 146 Method 20

0.004 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.47-7.41(m, 3H), 7.32-7.30 (m, 2H), 6.24-6.08 (m, 1H), 5.71-5.69 (m, 1H),5.22-5.06 (m, 1H), 3.83-3.76 (m, 1H), 3.41-3.32 (m, 1H), 2.95-2.86 (m,1H), 1.89-1.84 (m, 1H), 1.75-1.70 (m, 1H). 326.1   0.669 147 Method 26

0.140 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 8.49-8.46 (m,1H), 7.77-7.74 (m, 1H), 7.42-7.32 (m, 5H), 7.26-7.25 (m, 1H), 7.18-7.15(m, 1H), 6.19-6.03 (m, 1H), 5.64-5.60 (m, 1H), 4.76-4.71 (m, 2H),3.80-3.70 (m, 1H), 2.88-2.74 (m, 1H). 343.1   1.428 148 Method 26

0.007 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.40 (m,3H), 7.27-7.24 (m, 2H), 6.31-6.15 (m, 1H), 6.13-5.97 (m, 1H), 5.54-5.50(m, 1H), 3.93-3.75 (m, 1H), 3.73-3.62 (m, 2H), 3.05-2.98 (m, 1H). 315.9  0.806 149 Method 31

0.016 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.41(m, 3H), 7.28-7.25 (m, 2H), 6.24-6.08 (m, 1H), 5.75-5.70 (m, 1H),3.86-3.72 (m, 1H), 2.93-2.82 (m, 1H), 2.06 (t, J = 6.8 Hz, 3H). 332.1  1.081 150 Method 31

0.021 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38(m, 3H), 7.27-7.23 (m, 2H), 6.13-6.11 (m, 0.5H), 6.00-5.97 (m, 0.5H),5.56-5.53 (m, 1H), 3.71-3.62 (m, 1H), 3.05-2.94 (m, 1H), 1.75-1.68 (m,2H), 1.52 (s, 3H), 0.94-0.87 (m, 2H). 321.9   0.831 151 Method 26

0.730 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s,1H), 7.45-7.35 (m, 3H), 7.34-7.30 (m, 1H), 7.21-7.19 (m, 2H), 6.28-6.27(m, 1H), 6.10-5.96 (m, 1H), 5.75-5.65 (m, 2H), 5.55-5.48 (m, 1H),3.75-3.60 (m, 1H), 3.05-2.92 (m, 1H). 348.1   0.905 152 Method 26

0.030 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.56-7.53 (m,2H), 7.41-7.39 (m, 3H), 7.26-7.22 (m, 2H), 6.27 (s, 1H), 6.15-5.98 (m,1H), 5.69-5.55 (m, 2H), 5.53-5.47 (m, 1H), 3.69-3.60 (m, 1H), 3.02-2.92(m, 1H). 332.2   0.876 153 Method 26

0.010 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.46-7.41(m, 3H), 7.29-7.26 (m, 2H), 6.27-6.24 (m, 0.5H), 6.13-6.10 (m, 0.5H),5.77-5.75 (m, 1H), 3.85-3.75 (m, 1H), 2.95-2.84 (m, 1H). 386.0   2.113154 Method 26

0.007 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.40 (m,3H), 7.29-7.25 (m, 2H), 6.25-6.22 (m, 0.5H), 6.11-6.08 (m, 0.5H),5.73-5.70 (m, 1H), 3.85-3.75 (m, 1H), 2.91-2.80 (m, 1H). 370.0   1.959155 Method 32

0.0048 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.37(m, 3H), 7.26-7.18 (m, 2H), 6.57 (t, J = 56.8 Hz, 1H), 6.12-5.96 (m,1H), 5.56-5.53 (m, 1H), 3.74-3.60 (m, 1H), 3.02-2.92 (m, 1H), 1.90-1.84(m, 2H), 1.50-1.44 (m, 2H). 358.1   1.043 156 Method 33

0.270 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.43-7.40(m, 3H), 7.28-7.25 (m, 2H), 6.24-6.08 (m, 1H), 5.73-5.71 (m, 1H), 4.19(t, J = 14.4 Hz, 2H), 3.84-3.73 (m, 1H), 2.91-2.80 (m, 1H). 348.1  0.972 157 Method 34

0.023 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.52-7.40(m, 2H), 7.38-7.25 (m, 3H), 6.16-6.00 (m, 1H), 5.67-5.59 (m, 1H),3.78-3.64 (m, 1H), 3.08-2.96 (m, 1H), 2.20-2.09 (m, 2H), 1.95-1.80 (m,2H). 354.9  [M + Na]⁺.  0.842 158 Method 35

0.013 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.27-7.23 (m, 2H), 6.15-5.98 (m, 1H), 5.74-5.56 (m, 2H), 3.76-3.66(m, 1H), 3.07-2.96 (m, 1H), 1.88-1.80 (m, 3H). 314.1   1.692 159 Method35

0.015 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.45-7.40(m, 3H), 7.27-7.23 (m, 2H), 6.14-5.98 (m, 1H), 5.74-5.72 (m, 0.5H),5.62-5.57 (m, 1.5H), 3.74-3.64 (m, 1H), 3.06-2.96 (m, 1H), 1.88-1.80 (m,3H). 314.1   1.705 160 Method 35

0.018 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40(m, 3H), 7.27-7.23 (m, 2H), 6.15-5.98 (m, 1H), 5.74-5.71 (m, 0.5H),5.62-5.56 (m, 1.5H), 3.74-3.63 (m, 1H), 3.07-2.96 (m, 1H), 1.88-1.79 (m,3H). 314.1   1.704 161 Method 26

0.026 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.44-7.40(m, 3H), 7.27-7.24 (m, 2H), 6.13-6.11 (m, 0.5H), 5.99-5.97 (m, 0.5H),5.54-5.52 (m, 1H), 3.71-3.65 (m, 1H), 3.36-3.32 (m, 2H), 3.04-2.94 (m,1H), 1.92-1.82 (m, 2H), 1.05 (t, J = 7.2 Hz, 3H). 309.9   0.847 162Method 18

0.014 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m,3H), 7.25-7.22 (m, 2H), 6.12-6.10 (m, 0.5H), 5.99-5.97 (m, 0.5H),5.54-5.51 (m, 1H), 3.74-3.63 (m, 1H), 3.05-2.94 (m, 1H), 2.48-2.44 (m,1H), 1.89-1.86 (m, 1H), 1.63-1.61 (m, 1H), 1.16 (t, J = 5.6 Hz, 3H),0.97-0.95 (m, 1H). 322.1   0.689 163 Method 18

0.007 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40 (m,3H), 7.27-7.23 (m, 2H), 6.14-6.12 (m, 0.5H), 6.00-5.98 (m, 0.5H),5.57-5.53 (m, 1H), 3.72-3.66 (m, 1H), 3.13-2.96 (m, 2H), 2.57-2.51 (m,1H), 1.92-1.88 (m, 1H), 1.60-1.55 (m, 1H). 376.1   0.846 164 Method 20a

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.40(m, 3H), 7.27-7.23 (m, 2H), 6.12-5.96 (m, 1H), 5.55-5.50 (m, 1H),5.40-5.24 (m, 1H), 4.15-4.11 (m, 1H), 3.71-3.66 (m, 1H), 3.06-2.99 (m,3H), 2.67-2.64 (m, 2H). 340.1   0.980 165 Method 35

0.025 Single Unknown Stereoisomer ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.40(m, 3H), 7.28-7.26 (m, 2H), 6.24-6.21 (m, 0.5H), 6.09-6.07 (m, 0.5H),5.72-5.69 (m, 1H), 3.82-3.73 (m, 1H), 2.91-2.81 (m, 1H), 1.87-1.69 (m,6H). 328.1   1.745 166 Method 26

0.043 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.39 (m,3H), 7.26-7.21 (m, 2H), 6.13-5.96 (m, 1H), 5.56-5.53 (m, 1H), 4.33-4.30(m, 1H), 4.20-4.02 (m, 2H), 4.00-3.77 (m, 2H), 3.75-3.60 (m, 1H),3.03-2.95 (m, 1H), 2.60-2.54 (m, 1H), 2.30-2.22 (m, 1H). 338.1   0.905167 Method 31

0.012 Mixture of Diastereomers ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.40 (m,3H), 7.28-7.25 (m, 2H), 6.22-6.06 (m, 1H), 5.77-5.65 (m, 1H), 3.83-3.75(m, 1H), 2.90-2.83 (m, 1H), 2.62-2.57 (m, 1H), 1.96-1.93 (m, 1H),1.61-1.57 (m, 3H). 358.1   0.708 168 Method 36

0.530 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38(m, 3H), 7.26-7.21 (m, 2H), 6.11-5.95 (m, 1H), 5.53-5.49 (m, 1H),4.10-4.05 (m, 1H), 3.70-3.61 (m, 3H), 2.99-2.95 (m, 1H), 2.60-2.56 (m,1H), 2.50-2.34 (m, 4H). 352.1   0.862 169 Method 36

0.052 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.38(m, 3H), 7.26-7.21 (m, 2H), 6.12-5.95 (m, 1H), 5.55-5.50 (m, 1H),5.43-4.29 (m, 2H), 4.15-4.06 (m, 1H), 3.70-3.64 (m, 1H), 3.01-2.91 (m,1H), 2.75-2.65 (m, 1H), 2.57-2.47 (m, 2H), 2.46-2.36 (m, 2H). 354.1  0.976 170 Method 37

<0.005 Mixture of Diastereomers ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.40 (m,3H), 7.27-7.22 (m, 2H), 6.12-5.95 (m, 1H), 5.53-5.50 (m, 1H), 3.75-3.67(m, 1H), 3.09-2.98 (m, 2H), 1.97-1.94 (m, 1H), 1.61-1.57 (m, 1H),1.28-1.24 (m, 1H), 1.18-1.12 (m, 1H), 0.98-0.85 (m, 2H). 334.1   1.768171 Method 20

<0.005 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38(m, 3H), 7.26-7.20 (m, 2H), 6.12-5.96 (m, 1H), 5.55-5.50 (m, 1H),4.62-4.56 (m, 1H), 3.71-3.62 (m, 1H), 2.99-2.90 (m, 1H), 2.88-2.77 (m,1H), 2.57-2.50 (m, 2H), 2.30-2.22 (m, 1H). 358.0   0.918 172 Method 20

0.006 Single Unknown Stereoisomer ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.38(m, 3H), 7.26-7.20 (m, 2H), 6.13-5.96 (m, 1H), 5.56-5.50 (m, 1H),4.64-4.56 (m, 1H), 3.73-3.64 (m, 1H), 3.03-2.93 (m, 1H), 2.88-2.78 (m,1H), 2.70-2.55 (m, 2H), 2.30-2.27 (m, 1H). 357.9   0.915 173 Method 43

0.019 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.20(m, 2H), 7.17-7.04 (m, 2H), 5.72 (dd, J = 8.2, 6.3 Hz, 1H, 3.29-3.14 (m,2H), 3.13-3.02 (m, 1H), 2.70-2.57 (m, 1H). 320.0   4.26 174 Method 43

0.310 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.53-7.19(m, 2H), 7.15-7.04 (m, 2H), 5.72 (dd, J = 8.2, 6.3 Hz, 1H), 3.27-3.12(m, 2H, 3.07 (ddd, J = 16.1, 9.7, 6.1 Hz, 1H), 2.70-2.52 (m, 1H). 320.0  4.30 175 Method 38

0.220 Mixture of Enantiomers 1H NMR (400 MHz, DMSO-d6) δ 7.59-7.24 (m,2H), 7.22-7.10 (m, 2H), 5.82-5.70 (m, 1H), 3.26-3.01 (m, 3H), 2.71-2.60(m, 1H). 336.0   4.73 176 Method 1

0.110 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.19 (m,2H), 7.18-7.00 (m, 2H), 5.77-5.67 (m, 1H), 3.28-3.14 (m, 2H), 3.07 (ddd,J = 16.3, 9.8, 6.2 Hz, 1H), 2.71-2.57 (m, 1H). 320.0   4.35 177 Method39

0.057 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) δ 7.46-7.33 (m,3H), 7.31-7.20 (m, 2H), 5.66 (q, J = 7.2 Hz, 1H), 4.52-4.38 (m, 2H),3.29-2.98 (m, 3H), 2.69-2.56 (m, 1H). 316.0   4.33 178 Method 40

0.006 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.52-7.36(m, 3H), 7.34-7.24 (m, 2H), 6.31 (ddd, J = 56.1, 7.3, 2.2 Hz, 1H), 5.82(ddd, J = 8.4, 6.5, 3.4 Hz, 1H, 3.79 (dddd, J = 25.0, 15.5, 8.5, 7.3 Hz,1H), 2.77 (dddd, J = 27.1, 15.1, 3.4, 2.1 Hz, 1H), 1.86-1.63 (m, 4H).326.0   4.89 179 Method 40¹

0.210 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.58-7.12(m, 5H), 6.31 (ddd, J = 56.0, 7.3, 2.0 Hz, 1H), 5.82 (ddd, J = 8.5, 6.7,3.2 Hz, 1H), 2.76 (dddd, J = 27.2, 15.3, 3.2, 2.0 Hz, 1H), 2.53 (s, 1H).320     4.89 180 Method 40¹

0.30  Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.58-7.12(m, 5H), 6.31 (ddd, J = 56.0, 7.3, 2.0 Hz, 1H), 5.82 (ddd, J = 8.5, 6.7,3.2 Hz, 1H), 2.76 (dddd, J = 27.2, 15.3, 3.2, 2.0 Hz, 1H), 2.53 (s, 1H).320     4.48 181 Method 40¹

0.004 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.65-7.37(m, 2H), 7.38-7.13 (m, 1H), 7.13 (ddt, J = 21.1, 7.7, 1.6 Hz, 2H), 6.29(ddd, J = 56.0, 7.2, 2.0 Hz, 1H, 5.83 (ddd, J = 8.7, 6.5, 3.2 Hz, 1H),2.78 (dddd, J = 26.7, 15.2, 3.3, 2.1 Hz, 1H). 320     4.41 182 Method40¹

0.006 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.58-7.11(m, 6H), 6.32 (ddd, J = 56.0, 7.3, 2.0 Hz, 1H), 5.82 (ddd, J = 8.4, 6.6,3.2 Hz, 1H), 2.76 (dddd, J = 27.1, 15.2, 3.2, 2.0 Hz, 1H). 320     4.85183 Method 40¹

0.004 Single Unknown Stereoisomer No NMR 334     4.50 184 Method 40¹

0.130 Single Unknown Stereoisomer No NMR 306.1   3.51 185 Method 40¹

0.019 Single Unknown Stereoisomer No NMR 334     4.59 186 Method 40¹

0.020 Single Unknown Stereoisomer No NMR 306.1   4.11 187 Method 40¹

0.008 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.55-7.26(m, 3H), 7.38-7.12 (m, 3H), 6.24 (ddd, J = 56.4, 7.2, 2.0 Hz, 1H), 5.72(ddd, J = 8.4, 6.8, 3.1 Hz, 1H, 3.53-3.28 (m, 2H), 2.71 (dddd, J = 26.9,15.2, 3.1, 1.9 Hz, 1H), 1.16 (dd, J = 31.2, 6.8 Hz, 6H). 294.1   3.93188 Method 40¹

0.510 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.55-7.26(m, 3H), 7.39-7.13 (m, 2H), 6.24 (ddd, J = 56.4, 7.2, 2.0 Hz, 1H), 5.73(ddd, J = 8.4, 6.8, 3.1 Hz, 1H), 3.75 (dddd, J = 25.5, 15.5, 8.4, 7.2Hz, 1H), 3.37-3.03 (m, 2H), 2.87-2.45 (m, 1H), 1.13 (t, J = 7.4 Hz, 3H).280.1   3.72 189 Method 40¹

0.760 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.55-7.26(m, 3H), 7.34-7.08 (m, 2H), 6.24 (ddd, J = 56.4, 7.2, 2.0 Hz, 1H), 5.72(ddd, J = 8.4, 6.8, 3.1 Hz, 1H, 3.51-3.28 (m, 1H), 2.70 (dddd, J = 27.0,15.2, 3.2, 2.0 Hz, 1H), 1.16 (dd, J = 32.4, 6.9 Hz, 6H). 294.1   4.00190 Method 40¹

0.008 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.55-7.27(m, 3H), 7.36-7.14 (m, 2H), 6.24 (ddd, J = 56.3, 7.2, 2.0 Hz, 1H), 5.72(ddd, J = 8.4, 6.8, 3.1 Hz, 1H), 3.75 (dddd, J = 25.7, 15.5, 8.5, 7.2Hz, 1H), 3.36-3.02 (m, 2H), 2.87-2.56 (m, 1H), 1.12 (t, J = 7.4 Hz, 3H).280.1   3.64 191 Method 40¹

0.005 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.55-7.26(m, 3H), 7.33-7.11 (m, 2H), 6.23 (ddd, J = 56.4, 7.2, 1.9 Hz, 1H), 5.71(ddd, J = 8.4, 6.8, 3.0 Hz, 1H), 2.85-2.53 (m, 1H), 1.19 (s, 9H). 308.1  4.22 192 Method 41

0.350 Single Unknown Stereoisomer 1H NMR (40 MHz, CDCl3) δ 7.73 (d, J =8.0 Hz, 1H), 7.64-7.53 (m, 2H), 7.47 (d, J = 8.0 Hz, 1H), 6.43 (t, J =53.2 Hz, 1H), 6.21-6.02 (m, 1H), 5.66-5.62 (m, 1H), 3.84-3.67 (m, 1H),3.10-2.96 (m, 1H). 343.1   1.058 193 Method 42

0.023 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 6.88-6.83(m, 1H), 6.79-6.77 (m, 2H), 6.12-5.95 (m, 1H), 5.53-5.51 (m, 1H),5.50-5.25 (m, 1H), 4.17-4.12 (m, 1H), 3.75-3.64 (m, 1H), 3.15-2.98 (m,3H), 2.75-2.66 (m, 2H). 376.1   1.142 195 Method 44

0.460 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.43-7.34(m, 1H), 7.14-7.06 (m, 1H), 7.05-6.99 (m, 1H), 6.98-6.89 (m, 1H),6.16-5.94 (m, 1H), 5.61-5.50 (m, 1H), 4.33-4.19 (m, 1H), 3.80-3.60 (m,2H), 3.01-2.88 (m, 1H), 2.77-2.62 (m, 2H), 2.60-2.35 (m, 3H). 356.1  0.825 196 Method 30

0.032 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.30-7.27(m, 1H), 7.26-7.23 (m, 1H), 7.14-7.06 (m, 2H), 6.20-5.92 (m, 1H),5.57-5.49 (m, 1H), 5.27-4.98 (m, 1H), 3.79-3.56 (m, 1H), 3.19-3.08 (m,1H), 3.05-2.90 (m, 1H), 1.91-1.76 (m, 2H). 344.1   0.956 197 Method 30

0.008 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.30-7.26(m, 2H), 7.14-7.07 (m, 2H), 6.17-5.94 (m, 1H), 5.57-5.50 (m, 1H),5.27-4.98 (m, 1H), 3.79-3.56 (m, 1H), 3.20-3.15 (m, 1H), 3.05-2.91 (m,1H), 1.90-1.76 (m, 2H). 344.1   0.952 198 Method 45

0.068 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.43-7.39(m, 3H), 7.30-7.27 (m, 2H), 6.22 (t, J = 74.8 Hz, 1H), 6.21-6.03 (m,1H), 5.68-5.66 (m, 1H), 4.25 (t, J = 5.6 Hz, 2H), 3.82-3.74 (m, 3H),1.31-1.28 (m, 1H). 362.1   0.943 199 Method 30

0.008 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.17-7.13(m, 1H), 7.09 (s, 1H), 6.90-6.87 (m, 1H), 6.14-5.98 (m, 1H), 5.52-5.47(m, 1H), 5.24-5.05 (m, 1H), 3.76-3.61 (m, 1H), 3.22-3.13 (m, 1H),3.05-2.94 (m, 1H), 1.89-1.75 (m, 2H). 377.9   0.952 200 Method 30

0.048 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.17-7.13(m, 1H), 7.09 (s, 1H), 6.90-6.87 (m, 1H), 6.14-5.98 (m, 1H), 5.52-5.47(m, 1H), 5.25-5.05 (m, 1H), 3.76-3.61 (m, 1H), 3.20-3.10 (m, 1H),3.05-2.94 (m, 1H), 1.93-1.76 (m, 2H). 378.1   1.030 201 Method 30

0.025 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.20-7.05(m, 2H), 6.76-6.67 (m, 1H), 6.17-5.97 (m, 1H), 5.88-5.80 (m, 1H),5.29-5.05 (m, 1H), 3.82-3.65 (m, 1H), 3.23-3.11 (m, 1H), 3.05-2.90 (m,1H), 1.94-1.77 (m, 2H). 362.1   0.952 202 Method 30

<0.005 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.19-7.04(m, 2H), 6.75-6.65 (m, 1H), 6.18-5.95 (m, 1H), 5.89-5.80 (m, 1H),5.29-5.01 (m, 1H), 3.83-3.64 (m, 1H), 3.26-3.14 (m, 1H), 3.05-2.89 (m,1H), 1.92-1.76 (m, 2H). 362.1   0.955 203 Method 18

0.039 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.41-7.31(m, 2H), 7.26-7.24 (m, 1H), 7.16-7.10 (m, 1H), 6.14-5.95 (m, 1H),5.56-5.48 (m, 1H), 3.78-3.57 (m, 1H), 3.06-2.87 (m, 1H), 2.80-2.70 (m,1H), 1.52-1.39 (m, 2H), 1.22-1.07 (m, 2H). 341.9   0.917 204 Method 42

0.016 Mixture of Diastereomers 1H NMR (400 MHz, CDCl3) δ 7.27-7.19 (m,1H), 7.17-7.10 (m, 1H), 6.75-6.72 (m, 1H), 6.17-5.95 (m, 1H), 5.92-5.81(m, 1H), 5.46-5.19 (m, 1H), 4.24-4.08 (m, 1H), 3.85-3.64 (m, 1H),3.14-2.91 (m, 3H), 2.79-2.61 (m, 2H). 376.1   1.845 205 Method 30

0.020 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.44-7.36(m, 1H), 7.21-7.12 (m, 2H), 6.99 (t, J = 7.2 Hz, 1H), 6.19-5.96 (m, 1H),5.88-5.85 (m, 1H), 5.28-5.07 (m, 1H), 3.83-3.63 (m, 1H), 3.18-3.16 (m,1H), 3.06-2.90 (m, 1H), 1.94-1.74 (m, 2H). 343.9   0.896 206 Method 30

0.010 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.44-7.37(m, 1H), 7.21-7.13 (m, 2H), 6.99 (t, J = 6.8 Hz, 1H), 6.16-5.98 (m, 1H),5.89-5.87 (m, 1H), 5.27-5.04 (m, 1H), 3.81-3.64 (m, 1H), 3.25-3.14 (m,1H), 3.06-2.90 (m, 1H), 1.91-1.75 (m, 2H). 343.9   0.897 207 Method 30

0.037 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.51-7.44(m, 1H), 7.30-7.19 (m, 2H), 6.29-6.05 (m, 1H), 5.95-5.80 (m, 1H),5.30-5.02 (m, 1H), 3.94-3.71 (m, 1H), 3.50-3.38 (m, 1H), 3.01-2.81 (m,1H), 1.94-1.81 (m, 1H), 1.78-1.67 (m, 1H). 378.1   1.010 208 Method 30

0.007 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.48-7.43(m, 1H), 7.16-7.10 (m, 1H), 6.89-6.85 (m, 1H), 6.15-5.98 (m, 1H),5.90-5.85 (m, 1H), 5.24-5.03 (m, 1H), 3.81-3.66 (m, 1H), 3.23-3.14 (m,1H), 3.03-2.92 (m, 1H), 1.90-1.80 (m, 2H). 377.9   0.939 209 Method 46

<0.005 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.45-7.40(m, 3H), 7.31-7.29 (m, 2H), 6.23-6.21 (m, 0.5H), 6.09-6.07 (m, 0.5H),5.70-5.69 (m, 1H), 3.85-3.69 (m, 2H), 2.93-2.82 (m, 1H), 2.54-2.50 (m,1H), 1.90-1.83 (m, 2H). 333.1   0.655 210 Method 47

0.055 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) δ 7.46-7.38 (m,3H), 7.28-7.26 (m, 2H), 6.35-6.18 (m, 1H), 5.77-5.73 (m, 1H), 4.43-4.35(m, 1H), 3.83-3.69 (m, 1H), 3.49-3.43 (m, 1H), 2.79-2.74 (m, 1H),2.72-2.57 (m, 4H). 347.1   0.908 211 Method 48

0.012 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) 7.47-7.38 (m,3H), 7.30-7.26 (m, 2H), 6.42-6.18 (m, 1H), 5.86-5.67 (m, 1H), 4.45-4.38(m, 1H), 3.92-3.60 (m, 1H), 3.53-3.43 (m, 1H), 2.83-2.71 (m, 5H). 347.1  0.923 212 Method 46

0.011 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.45-7.40(m, 3H), 7.30-7.28 (m, 2H), 6.24-6.21 (m, 0.5H), 6.10-6.07 (m, 0.5H),5.71-5.68 (m, 1H), 3.86-3.68 (m, 2H), 2.55-2.52 (m, 1H), 2.51-2.50 (m,1H), 1.91-1.84 (m, 2H). 333.1   0.655 213 Method 49

0.006 Mixture of Diastereomers 1H NMR (400 MHz, DMSO-d6) δ 7.44-7.42 (m,3H), 7.27-7.26 (m, 2H), 6.68 (t, J = 75.6 Hz, 1H), 6.34-6.18 (m, 1H),5.80-5.72 (m, 1H), 4.85-4.72 (m, 1H), 4.25-4.17 (m, 1H), 3.80-3.70 (m,1H), 2.85-2.73 (m, 3H), 2.70-2.61 (m, 2H). 388.1   1.026 214 Method 18

0.029 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.16-7.12(m, 1H), 7.08 (s, 1H), 6.90-6.86 (m, 1H), 6.13-5.96 (m, 1H), 5.51-5.46(m, 1H), 3.75-3.60 (m, 1H), 3.02-2.91 (m, 1H), 2.80-2.72 (m, 1H),1.52-1.46 (m, 2H), 1.20-1.13 (m, 2H). 359.9   0.926 215 Method 23

0.032 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.18-7.14(m, 1H), 7.07 (s, 1H), 6.88-6.84 (m, 1H), 6.44 (t, J = 52.8 Hz, 1H),6.17-6.00 (m, 1H), 5.58-5.53 (m, 1H), 3.79-3.64 (m, 1H), 3.07-2.96 (m,1H). 369.9   0.972 216 Method 30

<0.005 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.26-7.24(m, 1H), 7.14-7.10 (m, 1H), 6.77-6.75 (m, 1H), 6.21-5.97 (m, 1H),5.91-5.89 (m, 1H), 5.30-5.01 (m, 1H), 3.80-3.71 (m, 1H), 3.25-3.19 (m,1H), 3.08-2.78 (m, 1H), 1.94-1.76 (m, 2H). 362.0   1.825 217 Method 30

0.006 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.27-7.19(m, 1H), 7.18-7.07 (m, 1H), 6.84-6.67 (m, 1H), 6.21-5.97 (m, 1H),5.90-5.88 (m, 1H), 5.30-5.01 (m, 1H), 3.79-3.73 (m, 1H), 3.25-3.16 (m,1H), 3.08-2.86 (m, 1H), 2.01-1.75 (m, 2H). 362.1   1.817 218 Method 30

0.140 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.40-7.32(m, 1H), 7.12 (t, J = 9.2 Hz, 1H), 7.00-6.95 (m, 1H), 6.17-5.95 (m, 1H),5.84-5.76 (m, 1H), 5.27-5.06 (m, 1H), 3.80-3.63 (m, 1H), 3.22-3.12 (m,1H), 3.03-2.91 (m, 1H), 1.93-1.81 (m, 2H). 378.1   1.018 219 Method 30

0.025 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.48-7.44(m, 1H), 7.15-7.10 (m, 1H), 6.88-6.84 (m, 1H), 6.15-5.98 (m, 1H),5.90-5.85 (m, 1H), 5.24-5.08 (m, 1H), 3.81-3.66 (m, 1H), 3.23-3.11 (m,1H), 3.03-2.92 (m, 1H), 1.89-1.84 (m, 2H). 378.1   1.029 220 Method 50

0.100 Mixture of Enantiomers 1H NMR (400 MHz, CDCl3) δ 7.40-7.31 (m,3H), 7.24-7.21 (m, 2H), 6.42 (t, J = 53.2 Hz, 1H), 4.59-4.55 (m, 1H),4.52-4.45 (m, 1H), 4.41-4.33 (m, 1H), 3.40-3.30 (m, 1H), 2.89-2.79 (m,1H). 299.9   0.896 221 Method 46

0.018 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.45-7.40(m, 3H), 7.30-7.28 (m, 2H), 6.37-6.34 (m, 0.5H), 6.23-6.21 (m, 0.5H),5.81-5.78 (m, 1H), 3.83-3.75 (m, 1H), 3.63-3.34 (m, 1H), 2.72-2.68 (m,2H), 1.89-1.81 (m, 2H). 333.1   0.627 222 Method 46

0.061 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.44-7.40(m, 3H), 7.30-7.28 (m, 2H), 6.22-6.20 (m, 0.5H), 6.09-6.06 (m, 0.5H),5.71-5.68 (m, 1H), 3.81-3.75 (m, 1H), 3.42-3.38 (m, 1H), 2.58-2.57 (m,1H), 2.46-2.42 (m, 1H), 1.97-1.94 (m, 1H), 1.82-1.78 (m, 1H). 333.1  0.628 223 Method 51

0.190 Single Unknown Stereoisomer 1H NMR (400 MHz, DMSO-d6) δ 7.45-7.40(m, 3H), 7.40-7.24 (m, 2H), 6.34-6.17 (m, 1H), 5.77-5.73 (m, 1H),4.99-4.95 (m, 1H), 3.79-3.72 (m, 3H), 3.63-3.59 (m, 2H), 2.67-2.66 (m,1H). 312.1   0.777 224 Method 25

0.180 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.44-7.39(m, 3H), 7.29-7.26 (m, 2H), 6.21-6.04 (m, 1H), 5.70-5.67 (m, 1H),3.79-3.64 (m, 5H), 3.13 (s, 3H), 2.90-2.82 (m, 1H). 326.1   0.865 225Method 45

0.300 Single Unknown Stereoisomer 1H NMR (400 MHz, CD3OD) δ 7.44-7.39(m, 3H), 7.27-7.25 (m, 2H), 6.20-6.18 (m, 0.5H), 6.05-6.03 (m, 0.5H),5.67-5.65 (m, 1H), 4.21-4.15 (m, 1H), 3.77-3.72 (m, 2H), 2.80-2.90 (m,1H), 2.57-2.51 (m, 2H), 2.38-2.35 (m, 2H). 338.1   0.585 226 Method 42

0.0093 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.45-7.39(m, 1H), 7.15-7.10 (m, 1H), 7.09-7.03 (m, 1H), 7.02-6.94 (m, 1H),6.15-5.92 (m, 1H), 5.56-5.49 (m, 1H), 5.44-5.19 (m, 1H), 4.18-4.07 (m,1H), 3.78-3.57 (m, 1H), 3.11-2.96 (m, 3H), 2.76-2.61 (m, 2H). 357.9  0.918 227 Method 26

Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.46-7.35 (m, 1H),7.15-7.08 (m, 1H), 7.06-7.01 (m, 1H), 6.99-6.92 (m, 1H), 6.16-5.94 (m,1H), 5.59-5.50 (m, 1H), 5.12-5.04 (m, 2H), 4.97-4.89 (m, 2H), 4.80-4.70(m, 1H), 3.79-3.59 (m, 1H), 3.08-2.91 (m, 1H). 342.1   0.883 228 Method26

0.006 Single Unknown Stereoisomer 1H NMR (400 MHz, CDCl3) δ 7.42-7.38(m, 3H), 7.25-7.12 (m, 2H), 6.14-6.12 (m, 0.5H), 6.00-5.98 (m, 0.5H),5.54-5.52 (m, 1H), 5.12-5.06 (m, 2H), 4.93-4.89 (m, 2H), 4.77-4.74 (m,1H), 3.71-3.65 (m, 1H), 3.06-2.95 (m, 1H). 324.1   0.706 ¹see Table IIfor chiral chromatography conditions

All of the U.S. patents, U.S. patent application publications, U.S.patent applications, foreign patents, foreign patent applications andnon-patent publications referred to in this specification areincorporated herein by reference in their entireties.

Although the foregoing invention has been described in some detail tofacilitate understanding, it will be apparent that certain changes andmodifications may be practiced within the scope of the appended claims.Accordingly, the described embodiments are to be considered asillustrative and not restrictive, and the invention is not to be limitedto the details given herein, but may be modified within the scope andequivalents of the appended claims.

We claim:
 1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein R¹ is selectedfrom the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, CH₂—(C₃-C₆cycloalkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆alkyl-N(R^(N))₂, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6membered heteroaryl; and wherein R¹ is optionally substituted by one ortwo substituents each independently selected from the group consistingof halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆ alkyl-N(R^(N))₂, hydroxyl, C₁-C₆hydroxyalkyl, cyano, C₁-C₆cyanoalkyl, C(O)C₁-C₆ alkyl, phenyl, benzyl,CH₂—(C₃-C₆ cycloalkyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6membered heteroaryl); n is 0, 1 or 2; each R² is independently selectedfrom the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkoxy, and C₁-C₆ haloalkyl; or two R² together with the nitrogen atomto which they are both attached form a 4-6 membered heterocyclic ring;the A ring and the B ring are fused to form a polycyclic ring system,wherein the A ring is a 5 membered heteroaromatic ring having as itsonly heteroatoms, either (i) two or three nitrogen atoms, (ii) onenitrogen atom and one oxygen atom, or (iii) one nitrogen atom and onesulfur atom; wherein the A ring is optionally substituted at a carbonatom by one substituent selected from the group consisting of fluoro,chloro, methyl, and trifluoromethyl; and the B ring is a 4 to 8 memberedcarbocyclic ring, or a 4 to 8 membered heterocyclic ring having 1 to 3heteroatoms selected from the group consisting of nitrogen, oxygen, andsulfur; p is 1 or 2, and q is 0 or 1; or p is 0, and q is 1; whereinwhen p is 1, R^(B1) is R^(3a) and when p is 2, R^(B1) is independentlyR^(3a) and R^(3b) and each R^(3a) and R^(3b), when present, isindependently selected from the group consisting of halogen, deutero,hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy,C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano;wherein two C₁-C₆ alkyl substituents may together form a bridged orspirocyclic ring; and wherein if a nitrogen atom in the B ring issubstituted, the substituent is not halogen, cyano, or a C₁-C₆ alkoxy,C₁-C₆ haloalkoxy or C₁-C₆ thioalkyl having an oxygen or sulfur atomdirectly bonded to the nitrogen atom; and wherein when q is 1, R^(B2) isR⁴ and R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆thioalkyl, C₁-C₆ alkyl-N(R²)₂, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl),CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl), CH₂CH₂-(4to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6membered heteroaryl); wherein when R⁴ is phenyl, heteroaryl or benzylthe phenyl or heteroaryl ring is optionally substituted by 1 to 3substituents selected from the group consisting of halogen, C₁-C₄ alkyl,C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.
 2. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein the A ring and the B ring together are selected from the groupconsisting of:

or a pharmaceutically acceptable salt thereof, wherein: R¹ is selectedfrom the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆ hydroxyalkyl, C₁-C₆cyanoalkyl, C₃-C₆ cycloalkyl-C₁-C₃ alkyl, C₁-C₆ alkyl-N(R²)₂, C₁-C₆alkoxy-C₁-C₆ alkyl, C₁-C₆ haloalkoxy-C₁-C₆ alkyl, phenyl, benzyl,difluoro(phenyl)methyl, 4 to 6 membered heterocyclyl, 5 to 6 memberedheteroaryl, and CH₂-(5 to 6 membered heteroaryl); wherein: when R¹ isphenyl, benzyl, difluoro(phenyl)methyl, 5 to 6 membered heteroaryl orCH₂-(5 to 6 membered heteroaryl), the phenyl or heteroaryl moiety of R¹is optionally substituted by one or two substituents independentlyselected from the group consisting of halogen, C₁-C₆ alkyl, hydroxyl,hydroxymethyl, methoxymethyl, cyano, trifluoromethyl, difluoromethoxyand trifluoromethoxy; when R¹ is cycloalkyl the cycloalkyl is optionallysubstituted by one, two or three substituents independently selectedfrom the group consisting of fluoro, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆haloalkoxy, hydroxyl, C₁-C₆ hydroxyalkyl or cyano; n is 1 or 2; each R²is independently selected from the group consisting of C₁-C₆ alkyl,C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkyl; or two R² togetherwith the nitrogen atom to which they are both attached form a 4-6membered heterocyclic ring; R^(3a) is hydrogen and R^(3b), when p is 2,R^(B1) is independently R^(3a) and R^(3b) and each R^(3a) and R^(3b),when present, is/are independently is selected from the group consistingof halogen, deutero, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl, C₁-C₆alkyl-N(R²)₂, and cyano; or R^(3a) and R^(3b) are-independently isselected from the group consisting of halogen, deutero, hydroxyl, C₁-C₆alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆haloalkoxy, C₁-C₆ thioalkyl, C₁-C₆ alkyl-N(R²)₂, and cyano; or R^(3a)and R^(3b) together with the atoms to which they are attached form abridged or spirocyclic ring; and wherein when q is 1, R^(B2) is R⁴ andR⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆thioalkyl, C₁-C₆ alkyl-N(R²)₂, phenyl, benzyl, CH₂—(C₃-C₆ cycloalkyl),CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl), CH₂CH₂-(4to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6membered heteroaryl); wherein when R⁴ is phenyl, heteroaryl or benzylthe phenyl or heteroaryl ring is optionally substituted by 1 to 3substituents selected from the group consisting of halogen, C₁-C₄ alkyl,C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.
 3. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein the A ring and the B ring together are:


4. The compound of claim 1 wherein R^(3a) and R^(3b) are selected asfollows: one of R^(3a) and R^(3b) is H, and the other is selected fromthe group consisting of hydrogen, deutero, fluoro, chloro, hydroxyl,cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄haloalkoxy; or each of R^(3a) and R^(3b) is independently selected fromthe group consisting of hydrogen, deutero, fluoro, chloro, hydroxyl,cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄haloalkoxy; or, provided that R^(3a) and R^(3b) cannot both be OH or CN;or R^(3a) and R^(3b), together with the carbon atom to which they areboth attached, form 1,1-cyclopropylene; and R⁴ is selected from thegroup consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl,C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl, phenyl, benzyl,CH₂—(C₃-C₆ cycloalkyl), CH₂CH₂—(C₃-C₆ cycloalkyl), CH₂-(4 to 6 memberedheterocyclyl), CH₂CH₂-(4 to 6 membered heterocyclyl), or 5 to 6 memberedheteroaryl, and CH₂-(5 to 6 membered heteroaryl); wherein when a phenylor heteroaryl ring is present it may be substituted by 1 to 3substituents selected from the group consisting of halogen, C₁-C₄ alkyl,C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.
 5. Thecompound of claim 1 wherein: R^(3a) and R^(3b) are selected as follows:one of R^(3a) and R^(3b) is H, and the other is selected from the groupconsisting of hydrogen, deutero, fluoro, chloro, hydroxyl, cyano, C₁-C₄alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy;or each of R^(3a) and R^(3b) is independently selected from the groupconsisting of deutero, fluoro, chloro, hydroxyl, cyano, and methyl,provided that R^(3a) and R^(3b) cannot both be OH or CN; or R^(3a) andR^(3b), together with the carbon atom to which they are both attached,form 1,1-cyclopropylene; and R⁴ is selected from the group consisting ofC₁-C₆ alkyl, C₁-C₆ haloalkyl, phenyl or pyridinyl wherein the phenylring or pyridinyl ring is optionally substituted by 1 to 3 substituentsselected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.
 6. The compound ofclaim 1, or a pharmaceutically acceptable salt thereof, wherein R^(3a)and R^(3b) are independently hydrogen or fluorine and R⁴ is selectedfrom the group consisting of ethyl, isopropyl n-propyl, trifluoromethyl,1,1-difluoroethyl, 1,1-difluoropropyl, optionally substituted phenyl oroptionally substituted pyridine-2-yl.
 7. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together are selected from the group consisting of:

wherein R^(3a) is hydrogen or fluorine each R⁵ is selected from thegroup consisting of hydrogen, fluoro, chloro C₁-C₆ alkyl, C₁-C₆haloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy; and m is 1, 2 or
 3. 8.The compound of claim 1, or a pharmaceutically acceptable salt thereof,wherein the A ring and the B ring together are:

wherein each R⁵ is selected from the group consisting of hydrogen,fluoro, chloro C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, and C₁-C₆haloalkoxy; and m is 1, 2 or
 3. 9. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein R⁵ is selected fromthe group consisting of H, F, Cl, CH₃, CH₂CH₃, OCH₃, CF₃, OCF₃, CF₂H,and OCF₂H.
 10. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein R⁵ is halo.
 11. The compound of claim 1 or apharmaceutically acceptable salt thereof, wherein the A ring and the Bring together are:


12. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein R¹ is selected from the group consisting of C₁-C₆alkyl, optionally substituted C₃-C₆ cycloalkyl, C₃-C₆ spirocycloalkyl,C₁-C₆ haloalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ cyanoalkyl, C₁-C₆hydroxyalkyl, phenyl, benzyl, and difluoro(phenyl)methyl.
 13. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein R¹ is selected from the group consisting of methyl, ethyl,tert-butyl, difluoromethyl, trifluoromethyl, cyclopropyl,fluorocyclopropyl, difluorocyclopropyl, phenyl, benzyl, anddifluoro(phenyl)methyl.
 14. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein R¹ is selected fromthe group consisting of ethyl, difluoromethyl, trifluoromethyl,cyclopropyl, fluorocyclopropyl or difluorocyclopropyl.
 15. The compoundof claim 1, wherein the compound is selected from the group consistingof:2-(difluoromethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-ethylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S)-2-[(S)-ethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-[difluoro(phenyl)methyl]sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-[difluoro(phenyl)methyl]sulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-(difluoromethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(S)-5-(2-fluorophenyl)-2-methylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(S)-2-ethylsulfonyl-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S)-2-[(R)-difluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S)-2-[(S)-difluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;rac-(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5R,7R)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5R)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S)-5-(2-chlorophenyl)-2-(difluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S)-5-(2-chlorophenyl)-2-[(S)-difluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S)-5-(2-chlorophenyl)-2-[(R)-difluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-benzylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-benzylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-[(S)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-tert-butylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-tert-butylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-[(R)-cyclopropylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-[(S)-cyclopropylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(4S,6S)-2-cyclopropylsulfonyl-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;(5S,7S)-5-(2-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5R,7R)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-7-deuterio-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b]1,2,4]triazole;(5S,7S)-2-cyclopropylsulfonyl-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-(3,3-difluorocyclobutyl)sulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(3,3-difluorocyclobutyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-[(S)-difluoromethylsulfinyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfinyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(4R,6R)-2-(difluoromethylsulfonyl)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,6-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(2,3,5-trifluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chlorophenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;2-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile;(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,4-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo-[1,2-b][1,2,4]triazole;(5S,7S)-5-(2-chloro-3-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(fluoromethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrol[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrol[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(R)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(S)-fluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]acetonitrile;2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfanyl]acetonitrile;2-2-(((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfonyl)acetonitrile;2-2-((R)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrile;2-2-((S)-((4S,6S)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)sulfinyl)acetonitrile;2-[(S)-[(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(R)-[rac-(5S,7S)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(S)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(R)-[(5S,7S)-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(S)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(R)-[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(S)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(R)-[(5S,7S)-7-fluoro-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[(S)-[(5R,7R)-5-(2-chlorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]acetonitrile;2-methyl-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfinyl]propanenitrile;2-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)-2-methylpropanenitrile;(5S,7S)-7-fluoro-2-methylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-2-methylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-ethylsulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-ethylsulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-2-isopropylsulfinyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-2-isopropylsulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(cyclopropylmethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-(cyclopropylmethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(2,2,2-trifluoroethylsulfonyl)-6,7-dihydro-H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(methoxymethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(methoxymethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-(2,2-difluorocyclopropyl)sulfinyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-((2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,3-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,5-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(2,2-difluorocyclopropyl)sulfonyl-5-(2,6-difluorophenyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1R)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S)-2,2-difluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(((S)-2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(((R)-2,2-difluorocyclopropyl)sulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo-[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(2-chlorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-5-(2,6-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5R,7R)-5-(2,3-difluorophenyl)-7-fluoro-2-(trifluoromethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-[rac-(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3,4-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(2-pyridylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-(2,2-difluoroethylsulfinyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-2-(1,1-difluoroethylsulfonyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(1-methylcyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-(pyrazol-1-ylmethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(1,1,2,2,2-pentafluoroethylsulfinyl)-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-2-[1-(difluoromethyl)cyclopropyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2,2-difluoro-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol;1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile;(5S,7S)-7-fluoro-2-(1-fluoroethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[(1S)-1-fluoroethyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-1-fluoroethyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-propylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2S)-2-methylcyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[rac-(1S,2R)-2-(trifluoromethyl)cyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(3-fluorocyclobutyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(1-fluoro-1-methyl-ethyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-tetrahydrofuran-3-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-(2,2-difluoro-1-methyl-cyclopropyl)sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol;((1R,3S)-3-(((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)sulfonyl)cyclobutyl)methanol;(5S,7S)-7-fluoro-5-phenyl-2-spiro[2.2]pentan-2-ylsulfonyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S,7S)-7-fluoro-5-phenyl-2-[(1S)-2,2-difluorocyclobutyl]sulfonyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;(5S)-2-[(R)-difluoromethylsulfinyl]-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;(5S)-2-[(S)-difluoromethylsulfinyl]-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;2-(difluoromethylsulfonyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-(difluoromethylsulfinyl)-5-(3,5-difluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;5-phenyl-2-(2,2,2-trifluoroethylsulfinyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-2-(1-fluorocyclopropyl)sulfonyl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(S)-difluoromethylsulfinyl]-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-5-phenyl-2-[(S)-trifluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-5-phenyl-2-[(R)-trifluoromethylsulfinyl]-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(R)-difluoromethylsulfinyl]-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-5-phenyl-2-[(S)-2,2,2-trifluoroethylsulfinyl]-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(R)-cyclopropylmethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-5-phenyl-2-[(R)-2,2,2-trifluoroethylsulfinyl]-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(S)-cyclopropylmethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo1,2b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-2-[(R)-isopropylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(R)-ethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;rac-(5S,7S)-7-fluoro-2-[(S)-isopropylsulfinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(S)-ethylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;rac-(5S,7S)-2-[(R)-tert-butylsulfinyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;3-[(5S,7S)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-5-yl]benzonitrile;(5S,7S)-5-(3,5-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;cis-3-[[(5S,7S)-7-fluoro-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol;(5S,7S)-7-fluoro-5-(4-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(4-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-2-[2-(difluoromethoxy)ethylsulfonyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,5-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chlorophenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(2-fluorophenyl)-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(1R,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile;cis-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile;trans-3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanecarbonitrile;(1S,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile;(5S,7S)-2-trans-[3-(difluoromethoxy)cyclobutyl]sulfonyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-cyclopropylsulfonyl-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-5-fluoro-phenyl)-2-(difluoromethylsulfonyl)-7-fluoro-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1R,2R)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(2,3-difluorophenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(5-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-5-(3-chloro-2-fluoro-phenyl)-7-fluoro-2-[(1S,2S)-2-fluorocyclopropyl]sulfonyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;2-(difluoromethylsulfonyl)-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(1R,2R)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile;(1S,2S)-2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclopropanecarbonitrile;2-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]ethanol;(5S,7S)-7-fluoro-2-(2-methoxyethylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;cis-(3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]sulfonyl]cyclobutanol;(5S,7S)-7-fluoro-2-trans-(3-fluorocyclobutyl)sulfonyl-5-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;(5S,7S)-7-fluoro-5-(3-fluorophenyl)-2-(oxetan-3-ylsulfonyl)-6,7-dihydro-5H-pyrrolo[1,2b][1,2,4]triazole;and,(5S,7S)-7-fluoro-2-(oxetan-3-ylsulfonyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;or, a pharmaceutically acceptable salt thereof.
 16. The compound ofclaim 1, having a RIP1 kinase inhibitory activity K_(i) of less than 100nM.
 17. A pharmaceutical composition comprising a compound of claim 1,or a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier.
 18. A method for the treatment of a disease ordisorder in a human, the method comprising administration to the humanof an effective treatment amount of a compound of claim 1, wherein thedisease or disorder is selected from the group consisting of Parkinson'sDisease, Lewy body dementia, multiple system atrophy, Parkinson-plussyndromes, tauopathies, Alzheimer's Disease, frontotemporal dementia,amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateralsclerosis, Huntington's disease, ischemia, stroke, intracranialhemorrhage, cerebral hemorrhage, muscular dystrophy, progressivemuscular atrophy, pseudobulbar palsy, progressive bulbar palsy, spinalmuscular atrophy, inherited muscular atrophy, peripheral neuropathies,progressive supranuclear palsy, corticobasal degeneration, anddemyelinating diseases.
 19. The method of claim 18, wherein the diseaseor disorder is Alzheimer's disease.
 20. The method of claim 18, whereinthe disease or disorder is multiple sclerosis.
 21. The method of claim18, wherein the disease or disorder is Parkinson's disease.
 22. Themethod of claim 18, wherein the disease or disorder is amyotrophiclateral sclerosis.
 23. The method of claim 18, wherein the disease ordisorder is Huntington's disease.
 24. The method of claim 18, whereinthe disease or disorder is spinal muscular atrophy.